L 1996 AUTHOR Indexaalavi, Author Index Â€¢1996 2101

lINDEXAalavi, 1996 AUTHOR

286P(ab)Aaron,A, 231P(ab)Akbunar, 3P(ab)Amanullah,M, 102P(ab)Atkins,H, 1023,1578,JR, 513, 676Aaron,AD, 1 289P(ab)Akerman,AT, 69P(ab),93P(ab),A, 72P(ab)Atkins,HL, 239, (ed).281P(ab)Baltimore,1591(ed), 1591 276P(ab)Abdel-Dayem,LA, 76P(ab)Akhtar,KK, 181P(ab),182P(ab)Amarenco, 209P(ab)Atsumi,MS, 1662,242P(ab),HM, 993Akhurst,M, 181P(ab)Attle,H, 24P(ab)Balza.D, 251P(ab),277P(ab), 131P(ab),132P(ab)Akinci,T, 1683, 1976Amato, P, 242P(ab)Aubert,JN, 238P(ab)Bandy,E, 301P(ab)Abdel-Nabi, 32P(ab)Ambrose,R, 1860Aubrey,B, 224P(ab)Bangard,D, 9P(ab),135P(ab),H, 289P(ab)Akisik,H, 6P(ab),193P(ab),KR, 174P(ab)Augustine,BA, 100P(ab),265P(ab)Bangerter.M, 136P(ab),238P(ab), 242P(ab),251P(ab),M, 202P(ab)Amdur, 90P(ab)Auinger,SC, 13S, 259P(ab)Abe, 277P(ab),301P(ab)Akizawa, 285P(ab)Amerenco,R, 241P(ab)Aung,Ch, 262P(ab)Banish.M, 1444Abe,H, 1976Amin, G, 174P(ab)Aureli,MT, I24P(ab)Banks,MR. 294P(ab)Abe,R, 7P(ab)Aktay,H, 993Amyotte,TM, 1883Aurengo,M, 1872, 1876. 146Bannerman,D, 955Abe,S, 1815Akyuz,R, 237P(ab)Anayat,G, 1773Austin-Lane,A, 847, 1578Banshai, J, 320Abella-Columna,Y, 139P(ab)Al-Bunny,C, 147P(ab)Anazawa,AR, 284P(ab)Avedon,JL, 150P(ab)Baquey,S. E,lllP(ab), 289P(ab)Al-Hallaq,A, 1460Anderson,Y, 46Avril, M, 863Bar, C, 132P(ab),136P(ab), 212P(ab)Al-Mohannadi,H, 805Anderson,BG, 99P(ab)Awata,N, 1815Bar-Sever,RS, 139P(ab)Abi-Dargham, 289P(ab)Al-Nabulsi,S, ab).71P(ab),CJ, 1294, 61 P( 410Awotwi-Pratt,S, 22P(ab),28P(ab),Z, 81, 33P(ab),285P(ab)Abitbol,A, 87P(ab)Al-Samrrai,I, 95P(ab),128P(ab), l48P(ab)Ayyangar,J, 292P(ab)Bar-Shalom, 121P(ab)Al-Za'abi,E, 201P(ab),302P(ab)Anderson, 90P(ab)Aziz,KM, 139P(ab)Baran,R, 23P(ab)Abraham,C, 289P(ab)Alaamer.AS,K, 277P(ab)Azizi,M, 242P(ab), 230P(ab)Baranowska-Kortylewicz,Y. 161P(ab)Abramovici,SA, 1832Alam, 1058, 107P(ab)Anderson,JH, 68P(ab)Azuma,N, J,315, 2017Abrams, J, 646Alarcon,MS, 227P(ab)Anderson,JR, 244P(ab)Baars,M, 150P(ab),13S,90P(ab). 1589Abrams,DN, 276P(ab)Alauddin,GS, 1336Andersson,PJ, 1331, 22SBarbaras,16S, 19S, 843Aburano,MJ, 107P(ab),193P(ab)Alavi,MM, 1519,2002Ando,P, 584Baas,JB, 172P(ab)Barbaries,LG, 44P(ab),291P(ab),T, 5P(ab), 781AndrÃ©-Fouet,H, 584Babain,P, 118P(ab)Barber,E, 292P(ab)Acampa, 92P(ab),114P(ab),A, 723, 147P(ab)Andreaco,X, 296P(ab)Babchyck,R, 53P(ab),301P(ab)Barbet,HB, 138P(ab),156P(ab),W, 117P(ab),130P(ab), 85P(ab),86P(ab)Andreas.J,M, 1760Babich,B, 159P(ab)Achong, 132P(ab),148P(ab), 33P(ab),I43P(ab),JW, 4P(ab), l29P(ab)Barclay,J, 1853, 267Achong,D, 165P(ab),176P(ab), 104P(ab)Andrews, 152P(ab),228P(ab), 1891Barclay,AB, 113P(ab),240P(ab)Ackerman,DM, 246P(ab),252P(ab), 157P(ab),260P(ab)Andrich,D, 239P(ab),240P(ab), 315Bardet,PD, 265P(ab),276P(ab), 269P(ab)Bacharach, 1853Bardies,S, 857Ackermann,C, 278P(ab),283P(ab), 34P(ab),253P(ab)Anesi,MP, 1731, 786,1557, SL, 690, 1853Bareille,M, 78P(ab),215P(ab)Adachi,RJ, 284P(ab),295P(ab), 25P(ab),39P(ab),1795, 863Bareket,R, 17N(7)Alazraki, 185P(ab)Angelberger,E, 93P(ab),99P(ab),60P(ab), 182P(ab)Barendswaard,Y, 263P(ab),296P(ab)Adam,I, 48P(ab),84P(ab),NP, 1575, 1931,5P(ab), P, 1480, 160P(ab),161P(ab), 1052Bares, E, 125P(ab),179P(ab), 251P(ab)Angeletti,20P(ab), 211P(ab),253P(ab)Bachen, l34P(ab),137P(ab),R, 27P(ab), P(ab)Adam,L-E, 221 293P(ab),307P(ab)Alberto, 1452Anjilvel,S, 140P(ab)Barker, 2024Adam,LE, 123P(ab)Annibale,S, 257P(ab),264P(ab),P, IP(ab)Barker,C, 21 36P(ab)Adamietz,M, 165P(ab)Alberts,R, 1452Anthony,B, 296P(ab)Bachmann, 157P(ab)Barker,FG II, 1942Adams,IA, 276P(ab)Albertson,KR, 270P(ab)Antonini,DC, 218P(ab)Badawi,R, 1795Barlow,WC, 1001Adams,BK, 1535AlbertusPiers,DA, 281P(ab)Aoyama,A, 73P(ab)Bading.JR,RD, 92P(ab)Barnes,R, 80P(ab)Adams,KF, 482Albin, C, 179P(ab)Appel,T, 107P(ab),155P(ab)Baetens, 81Barnes,PD, 121P(ab),137P(ab)Adelson,S, 164P(ab)Albright,RL, 265P(ab)Appelbaums,M, 275P(ab)Baro,WE, 263P(ab)Alderson,RE, 233P(ab)Aprile,FR, 91P(ab)Bag,J. 16Baron,ME, 269P(ab)Adelstein,PD, 5P(ab)Aleksandrova,PO, 185P(ab)Arai,C, 1662Bagheri,R, 95Baroni,J, 343,102P(ab),SJ, 315, IP(ab)Alexander,Y, 5 64P(ab),254P(ab)Araikum,T, 1819, 14P(ab),149P(ab)Bagnara,B, 238P(ab)Barre,S, 187P(ab),229P(ab), 158P(ab)Alexander,E, 95Barrett,L, 19S,ISAdiseshan,IOS, 16S, 1690Alexander,HR, 1323Araki.T,S, 243P(ab)Bahadur,MC, 53P(ab),63P(ab),HH, 276P(ab)Alexoff,RW, 1819,64P(ab),1551, 137P(ab)Bahr,S, 124P(ab),301P(ab)Barrett, 79P(ab)Adler,P, 1 P(ab)Alfano,D, 41 254P(ab)AraÃ±o, 1846Bahtiarian,A, 302P(ab)Adler,B, 260P(ab)Algozine,B, 7P(ab)Aras,Y, 22P(ab),74P(ab)BaidjnathEA, 117P(ab),H9P(ab),JA, 99P(ab)Affleck,LP, 1575,47P(ab),CA, 177P(ab),257P(ab),T, 1662, 129P(ab),151P(ab), 191P(ab)Afriyie,DJ, 84P(ab)Ali, 291P(ab)Araujo, 972Baidoo,Panday, RKL, 202P(ab),232P(ab)Barrington, 103P(ab),242P(ab)Agis,MO, 1356Alisauskus,SA, 926, 92P(ab),148P(ab),LI, 723, 189P(ab)Bailer,KE, 96P(ab)Alkan,R, 176P(ab)Arbab.AS, 115P(ab)Bailey,H, 87P(ab),282P(ab)Barrington,S, 5P(ab)Agnew,H, 184P(ab)Allada,M, 1819,64P(ab),1551, 873Bailey,AG, 104P(ab)Agresti,JE, 1717Allen,V, 254P(ab)Arbizu, 85P(ab),148P(ab),DL, 1771Barrio, SF, P(ab)Ahlberg,R, 251 HOP(ab),269P(ab),M, 93P(ab)Areeda,J, 271P(ab)Bailey, 79P(ab),107P(ab),JR. 37P(ab),58P(ab),AW, 301P(ab)Allen-Mersh, 81P(ab)Arildsen,J, 19SBair,NO, 147P(ab),l93P(ab)Barran, 150P(ab),177P(ab)Ahlman, 54P(ab)Almeida,T, 131P(ab)Arimizu,RC, 829Baje,HJ, 217P(ab)Aloj,P, 258P(ab),277P(ab)Arisaka,N, 622Baker,M, 162P(ab),272P(ab),B, 1519,2002Ahlstrom,H, 99P(ab),118P(ab),L, 1408, 198P(ab)Bakheet,RJ, 84P(ab), 292P(ab)Barrow, 1766Ahmad,H, 32, 199P(ab),203P(ab), 184P(ab)Aronochick,H, 26Bakheet,S, 198P(ab)Barsa,J,SA, 843, 69P(ab)Ahmad,A, 204P(ab),254P(ab)Alonso, 117P(ab)Aronsson,JM, 993Bakkaloglu,SM, 301P(ab)Bartell,251P(ab), 457Ahmed,K, 1519Arrighi,EF, 145P(ab)Bakker,A, 159P(ab)Bartenstein.KM, 993Ahn, M, 1919(le),266P(ab)Alper,O, 282P(ab)Arthur,JA, 67P(ab)Bakker,M, 22P(ab),157P(ab),P, 1 268P(ab)Ahn,BC, 258P(ab)Asenbaum,JE, 1388,190P(ab)Bal,WH, 108, 278P(ab)Barth, 252P(ab)Ahonen,SH, 289P(ab)Alpen,E, 159P(ab), 1931Ashburner,S, 218P(ab)Banlett,I, 22P(ab)Aicher,A, 33P(ab),125P(ab),NM, 950, 271P(ab)Ashby,J, 137P(ab)Baldassarri,CS, 39P(ab),93P(ab)Bartolic,ML, 1795, 463Aigbirhio,KP, 161P(ab),239P(ab), 203P(ab)Ashihara,CR Jr., 16SBaldwin, S, 141P(ab)Aigner,FI, 244P(ab)Aiston, 781Ashook,T, 2006Baldwin,D, 259P(ab)Bass,E, 1524Aioi,R, 191P(ab)Altieri,KL, 46Atahan,G, 11.32P(ab),33P(ab),RM, 61P(ab),128P(ab),LA, 51P(ab), H6P(ab)Aizawa,S, 565Altmann,P, 1956Atasever,L, 44P(ab),272P(ab), 201P(ab)Bassa, 12P(ab)Ajami,Y, 234P(ab),235P(ab)Alvarez,A, 139P(ab)Atay,T, 285P(ab)Balfore, 1472,261P(ab)Bassett,P, 931, 255P(ab)Akabani,K, 233Atkins,S, 254P(ab)Balkanci,J, G, 89P(ab),90P(ab), RD, 1491Amano, FB, 643, 1639Atkins, F, 291P(ab)Ballinger, LW, 269P(ab)

Author Index â€¢1996 2101 Bassingthwaighte, JB, Benali, H, 217P(ab) Berthele, A, 278P(ab) Blumenthal, RD, 96P(ab), 106P(ab) 106P(ab), HOP(ab), Benard, F, 130P(ab) Berthold, T, 441, 121P(ab) 102P(ab), 168P(ab), Bouchard, M, 723 146P(ab) Benari, B, 93P(ab), 180P(ab) Bertrand-Caix, J, 863 169P(ab) Boudreau, RJ, 142P(ab), Bastidas, D, 673, 1016, Benazzouz, F, 189P(ab) Besnard, J-C, 186P(ab) Blundell, P, 17P(ab) 189P(ab) 38P(ab), 152P(ab) Bencherif, B, 7P(ab)0 Best, S, 44P(ab), 272P(ab) Boazi, M, 186P(ab) Bourguignon, M, 217P(ab) Baudin, E, 912, 1830, Bender, H, 1496, 100P(ab), Better, N, 1618 Bobba, K, 47P(ab) Bourque, JP, 1031 20P(ab) 134P(ab), 138P(ab), Bettman, L, 103P(ab) Bobigny, CHU, 274P(ab) Bousser, MG, 1976 Bauer, B, 76P(ab) 236P(ab), 252P(ab), Beutler, JJ, 289P(ab) Bock, E, 248P(ab) Bouville, AC, 24N(12) Baum, H, 107P(ab) 265P(ab) Beyer, GJ, 51P(ab) Bock, F, 241P(ab) Bowen, WD, 7P(ab), Baum, JK, 74P(ab) Bendriem, B, 5, 118, 1557, Beyer, J, 104P(ab), 159P(ab) Bock, M, 296P(ab) 205P(ab), 267P(ab) Baum, RP, 362, 1942, 76P(ab), 154P(ab), Bhargava, K, 199P(ab), Bockisch, A, 103P(ab), Boxen, I, 1578 9P(ab), 121P(ab), 137P(ab) 170P(ab), 217P(ab), 244P(ab) 104P(ab), 144P(ab), Boy, C, 113P(ab) Baum, S, 854 226P(ab) Bhattathiry, MM, 306P(ab) 159P(ab), 209P(ab), Boyd, J, 136P(ab), 264P(ab) Baumeister, R, 25P(ab) Benjamin, C, 75P(ab) Bhatti, MA, 114P(ab) 233P(ab) Boyd, SJ, 744 Bausart, R, 258P(ab) Benkelfat, C, 113P(ab), Bhulya, T, 242P(ab) Bode, A, 154P(ab) Boz.A, 1916(le), 1917(le) Bautovich, G, 90P(ab) 284P(ab) Bi, Z, 197P(ab) Boden, JA, 868 Braams, JW, 897 Bavisotto, L, 140P(ab) Bennett, A, 1749 Bianchi, V, 13P(ab) Bodi, I, 287P(ab) Bracco, L, 278P(ab) Bax, JJ, 1631,59P(ab), Bennett, JA, 87P(ab), Biassoni, P, 243P(ab) Boer, GJ, 134P(ab) Brachman, M, 46 60P(ab), 176P(ab), 148P(ab) Biegon, A, 40P(ab) Boerman, OC, 1392, Bradley, LA, 276P(ab) 178P(ab), 184P(ab) Bennett, LR, 306P(ab) Bien, S, 463 169P(ab) Brady, F, 191P(ab) Bazzicalupo, L, 260P(ab) Bense, S, 99P(ab) Bier, D, 55P(ab) Boersma, LJ, 584 Brady, J, 289P(ab) Beanlands, RS, 174P(ab) Benti, R, 37P(ab), 230P(ab) Bierman, H, 46 Bogdanov, AA Jr., 198P(ab) Brady, LW, 65P(ab), Beattie, B, 53P(ab), 54P(ab) Benlourkia, M, 2040, 2046 Biersack, H-J, lOOP(ab), Bogers, AJJC, 748 265P(ab) Beauduin, M, 258P(ab) Benz, P, 209P(ab) 134P(ab), 138P(ab), Boggs, R, 226P(ab) Brady, M, 138P(ab) Beaumier, P, 144P(ab) Beppu, Y, 1444 236P(ab), 243P(ab), Bohuslavizki, KH, 4P(ab), Brady, TJ, 198P(ab) Bebe, M, 29P(ab) Bera, R, 249P(ab) 252P(ab), 265P(ab), 142P(ab), 246P(ab), Brancate, R, 967 Becherer, A, 1480, 254P(ab) Berardino, S, 13P(ab) 273P(ab), 280P(ab) 256P(ab), 257P(ab) Brandau, W, 1865, 1990, Beck, D, 225P(ab) Berdichevsky, D, 125P(ab) Biersack, HJ, 626, 1496, Boissier, B, 233P(ab) 49P(ab), 268P(ab) Becker, DV, 24N(I2) Berenl, S, 201, 163P(ab), 1962 Bok, B, 35P(ab), 101P(ab), Brandt, A, 142P(ab) Becker, J, 27P(ab), 200P(ab) 164P(ab) Bieszk, JA, 149P(ab) 113P(ab), 2l7P(ab), Brandt, T, 122P(ab) Becker, W, 362, 255P(ab) Berg, G, 1519 Bigio, E. 79P(ab) 231P(ab) Brannon, WL, 1595 Becker, WS, 829 Berg, GEB, 228 Biler, P, 284P(ab) Bol, A, 39P(ab) Braun, C, 13P(ab) Beckurts, KTE, H4P(ab) Berger, H, 261 P(ab) Billotey, C, 1773 Bolasco, P, 565 Braverman, LE, 991 Bednarczyk, EM. 198P(ab) Berger, R. 16P(ab) Biniakiewicz, DS, 752, Bom, HS, 67P(ab) Brcke.T, 1931 Beek, FJA, 289P(ab) Bergman, D, 1487, 135P(ab) 49P(ab), 188P(ab) Bomanji, J, 995 Brechbiel, MW. 152P(ab), Beekhuis, H, 482 Bergman, J, 51 P(ab) Binkert, B, 1995 Bomanji, JB, 1828 234P(ab) Beekman, FJ, 62P(ab), Bergman, JB, 387 Binkley, D, 86P(ab) Bombardieri, E, 250P(ab), Breeman, WAP, 108, 1388, 171P(ab), 213P(ab), Bergmann, SR, 1294, 1723, Biraben, A, 1946 251P(ab) 141P(ab) 216P(ab) 39P(ab), 83P(ab). Birnbaum, EH, 132P(ab) Bonab, AA, 33P(ab), Breier, A, 77P(ab) Beer, S, 172P(ab) 147P(ab), 221P(ab), Btschof-Delaloye, A, 228P(ab) Breithardt, G, 106P(ab) Beets, AL, 6P(ab), l66P(ab), 222P(ab) 245P(ab) Bonaduce, D, 13P(ab) Breitschwerdt, E, 200P(ab) 193P(ab).202P(ab) Bergstrom, KA, 45P(ab), Bishop, J, 1683 Bonasera, TA, 1009 Bremner, JD, 80P(ab) Begent,RHJ,868 76P(ab) Bisi, G, 26P(ab) Bone, D, 120P(ab), 208P(ab) Brennan, KM, 130P(ab), Behar,P,136P(ab) Bergstrom, M, 32, 1766 Bizais, Y, 57P(ab) Bongiovanni, J, 171 146P(ab) Behnke,A,257P(ab) Berk, AJ, 107P(ab) Biziere. K, 77P(ab) Bongiovanni, JA, 838 Brenner, L, 11 Behr,T,362,905,1504 Berkefeld, J, 121P(ab) Bjurling, P, 32 Boni, RAH, 441 Brenner, W, 4P(ab), Behr,TM, 829,9P(ab), Berkenboom, G, 83P(ab) Black, K, 146P(ab) Boniface, GR, 1942 142P(ab), 246P(ab), 43P(ab),44P(ab),96P(ab), Berlangieri, S, 1683 Black, P, 65P(ab), 263P(ab), Boning, G, 180P(ab) 256P(ab), 257P(ab) 102P(ab),168P(ab), Berlangieri.SU, 121P(ab), 265P(ab) Bonnin, F, 35P(ab), Brensing, A, 243P(ab) 169P(ab),231P(ab), 131P(ab), 132P(ab) Black, PMcL, 19S 113P(ab), 231P(ab) Bresnick, M, 119P(ab), 232P(ab), 243P(ab) Berlin, JA, 723 Blahd, WH, 53P(ab) Bonora, D, 22S 129P(ab), 232P(ab) Beintema. KD, 21P(ab) Berman, DS, 14P(ab), Blalock, JE, 276P(ab) BontÃ©,FJ, 79P(ab) Brezinski, DA, 174P(ab) Bekdik, C, 177P(ab), 59P(ab), 68P(ab), 69P(ab), Blank, E, 169P(ab) Booij, J, 65P(ab), !34P(ab) Brill, AB, 1583, 23N(6) 257P(ab), 291P(ab) 81P(ab), 93P(ab), Blankespoor, SC, 218P(ab) Boonstra, H, 263P(ab) Brill, D, 23N(6) Bekdik, CF, 1956 H6P(ab), 149P(ab), Blanksma, PK, 1631 Bordenave, L, 863 Briscoe, E, 926, 1356, Bekhechi, D. 229P(ab) l76P(ab), 180P(ab), Blasberg, R, 53P(ab), Borer, JS, 38P(ab), 93P(ab), 79P(ab) Belakhlef, A, 209, 1850, 181P(ab), 182P(ab) 54P(ab) l84P(ab) Britton, K, 1872 133P(ab) Berman, KF, 559, 79P(ab), Blasini, R, 126P(ab) Borgers, M, 26P(ab) Britton, KE, 96P(ab) Belezzuoli, EV, 92P(ab), 284P(ab) Blasl, C, 307P(ab) Borges-Neto, S, 14P(ab), Brix, G, 2024, 154P(ab), 182P(ab) Berman, RM, 315 Blastos, BP, 231 P(ab) 74P(ab) 221P(ab), 249P(ab), Belghili, J, U3P(ab) Berna. L. 631 Blatter, J, 265P(ab) Bormans, G, 767, 26P(ab), 266P(ab) Belgi, A, 302P(ab) Bernard, AM, 1946 Blaufox, D, 1876 54P(ab) Brizel, DM, 1438 Bellanova, B, 250P(ab) Bernard, B, 141P(ab) Blaufox, MD, 171,838, 1883 Borously, S, 48P(ab) Brochet, E, 275 Belldegrun. A, 14IP(ab), Bernard, BF, 1388 Blend, MJ, 252, 21 IP(ab), Borovicka, J, 245P(ab) Broderick, TM, 307P(ab) 267P(ab) Bernard, E, 34P(ab). 46P(ab) 217P(ab) Bosch, CMJ, 964 Brodin, LAA, 120P(ab) Bellcmann. ME, 2024, Bernard, HF, 190P(ab) Blessing, G, 166P(ab) Bossuyt, A, 718, 1346, 1605, Broglia, L, 255P(ab) 154P(ab), 22IP(ab), Bernard, X, 39P(ab) Blevins, WE, 197P(ab) 88P(ab), 211P(ab), Bronen, RA, 1749 249P(ab), 265P(ab), Bernas. M, 183P(ab) Blier, P, 113P(ab) 268P(ab) Bronster, DJ, 467 266P(ab) Bernatz, S, 262P(ab) Blijham, GH, 38, 244, 465, BÃ¶ttcher,HD, 1942 Brooks, DJ, 109P(ab), Beller, GA, 1398, 3P(ab), Bernstein, ID, 43P(ab), 1511 BÃ¶ttcher,M, 1626 27IP(ab) 69P(ab) 233P(ab) Block, P, 718 Botti, G, 665, 155P(ab), Brotchi, J, 53P(ab) Bellina, CR, 22S Bernuau, J, 113P(ab) Blohm, K, 170P(ab) 156P(ab) Broussard, WF, 32P(ab) Bello, S, 2l6P(ab) Berridge, MS, HP(ab), Bloomfield, PM, 85P(ab) Bottlaender, M, 5 Brown, A, 191P(ab) Ben-Haim, S, 39P(ab), 174P(ab) Blower, PJ, 166P(ab) Bottoncetti, A, 279P(ab) Brown, CV, 178 139P(ab) Berry, CR, 2011, 200P(ab) Blumenfeld, JD, 838 Botvinick, EH, 47P(ab), Brown, DJ, 109P(ab)

2102 The Journalof Nuclear Medicine Brown, JK, 218P(ab) Buzdar.AU, 931 129P(ab), 196P(ab), 136P(ab) Chili, A, 250P(ab), 251P(ab) Brown, JW, 302P(ab) Byars, LG, 155P(ab) 203P(ab), 211P(ab), Chang,F,190P(ab),203P(ab) Chittenden, S, 228P(ab) Brown, K, 818 Byrne, MJ, 379 234P(ab) Chang,S,1349 Cho, BK, 89P(ab), 274P(ab) Brown, KL, 57P(ab), Carretta, RF, 1903, 294P(ab), Chang,SM, 157P(ab) Cho, K, 304P(ab), 308P(ab) 244P(ab) Cabahug, C, 218P(ab) 25N(1) Chang,W, 207P(ab), Choe.YS, 1009, 179P(ab), Brown, ML, 1903 Cabahug, CJ, 239 Carrier, LK, 306P(ab) 210P(ab) 226P(ab), 275P(ab) Brown. PR, 288P(ab) Cabico, JA, 69P(ab), Carnero, MV, 665 ChangLai, SP, 295P(ab) Choi, CW, 248P(ab) Brown, RS, 1042, 1540, 182P(ab) GarriÃ³,1,631, 49P(ab) Channing, M, 204P(ab), Choi, NC, 950 64P(ab), 65P(ab) Cadiot, G, 275, 253P(ab), Carroll, FI, 109P(ab) 230P(ab) Choi, YB, 179P(ab), Browne, BJ, 292P(ab) 256P(ab) Carroll, T, 28P(ab), 119P(ab), Chapman, PT, 114P(ab), 226P(ab), 252P(ab), Browne, G, 31P(ab) Cadorette, J, 2040, 170P(ab) 129P(ab), 151P(ab), 128P(ab) 275P(ab) Browne, JA, 62P(ab) Caetano, D, 273P(ab) 202P(ab), 232P(ab) Chapman, WC, 131P(ab) Choi, YY, 252P(ab) Brownell, A-L, 65P(ab), Caillou, B, 1830 Carson, JM, 39P(ab), Chappell, D, 6P(ab) Chossat, F, 229P(ab) 66P(ab) Caixas, A, 631 93P(ab), 160P(ab) Charif, H, 296P(ab) Chou, J, 97P(ab) Brownell, GL, 66P(ab) CaÃame,W, 241 P(ab) Carson, RE, 690, 786, Charkes, ND, 57P(ab) Chou, KL, 27P(ab), Bruckbauer, T, 155P(ab) Calcagno, G, 238P(ab), 10P(ab), 77P(ab), 99P(ab), Charles, HC, 1438 125P(ab), 136P(ab), BrÃ¼cke,!, 1931 243P(ab), 297P(ab) 203P(ab), 230P(ab) Charney, DS, ll,32P(ab), 286P(ab) Brucker-Davis, F, 1690, CalderÃ³n, C, 287P(ab) Carter, EA, 239P(ab), 33P(ab), 44P(ab), 80P(ab), Chowdhury, S, 84P(ab), 15P(ab) Caldwell, JC, 106P(ab) 240P(ab) 272P(ab), 285P(ab) 142P(ab) Bruckner, JB, 140P(ab) Caldwell, JH, 70P(ab), Carton, H, 22P(ab) Charon, Y, 303P(ab), Choyke, P, 253P(ab) Bruels, MC, 229P(ab) 110P(ab), 146P(ab), Carvalho, PA, 158P(ab), 19S 306P(ab) Chrem, Y, 293P(ab) Brunken, RC, 177P(ab) 205P(ab) Casale, F, 256P(ab) Charrier, S, 922 Christian, PE, 18P(ab), Brunner, F, 108P(ab) Calguner, M, 290P(ab) Casati, R, 37P(ab) Chatal.JF, 1853, 72P(ab) 97P(ab), 124P(ab) Bruno, A, 37P(ab), 230P(ab) Callahan, RJ, 843, 198P(ab), Case, JA, 127P(ab), Chatziioannou, A, 8P(ab) Christopher, P, 273P(ab) Brust, P. 16P(ab) 228P(ab), 239P(ab) 153P(ab), 212P(ab) Chaudhuri, TK, 288P(ab) Chu, HB, 1545 Bubeck, B, 1883 Callahna, RJ, 2092 Casey, JL, 868 Chauvel, P, 1946 Chu, JMG, 83P(ab) Buchsbaum, DJ, 186P(ab) Callans, D, 14P(ab), Casey, M, 170P(ab) Chen, A, 279P(ab), 280P(ab) Chu, LS, 27P(ab), 262P(ab), Buchsbaum, M, 38P(ab) 149P(ab) Casey, ME, 85P(ab) Chen, B, 24P(ab) 286P(ab) Buchtel, HA, 270P(ab) Calnon, DA, 3P(ab) Caspani, S, 205P(ab) Chen, CC, 1740,2037, Chu.TS, 174P(ab) Buck, A, 441, 699, 146P(ab), Calsamiglia, G, 185P(ab) Castagna, A, 258P(ab) 15P(ab), 104P(ab), Chua, K, 104P(ab) 207P(ab) Calvitto, M, 55 Castellani, M, 37P(ab), 118P(ab) Chugani. DC, l45P(ab) Budinger, TF, 40P(ab), Calza, P, 47P(ab) 230P(ab) Chen, CH, 303P(ab) Chugani, HT, 51 P(ab), 51P(ab), 98P(ab), Camargo, ECS, 273P(ab) Castle, VP, 16 Chen, EO, 177P(ab) 145P(ab) 130P(ab), 131P(ab), Camargo, EE, 273P(ab) Castronovo. FPJr., 19S Chen, EQ. 1809, 276P(ab) Chui, C-S, 89P(ab) 146P(ab) Camaya, MV, 34P(ab), Catena, G, 88P(ab) Chen, F, 49P(ab) Chumpradil, S, l7P(ab) Buell, U, 140P(ab) 244P(ab) Cave, V, 182P(ab) Chen, G, 437 Chun. KJ, 838 Buga, K, 287P(ab) Camici, PG, 71P(ab), Caymaz, O, 184P(ab) Chen, GH, 245P(ab) Chung, J, 639, 978 Buhler, KR, 151P(ab) 106P(ab) CebÃ³n,J, 131P(ab), 132P(ab) Chen, J, 57P(ab) Chung, J-K, 28P(ab), Buijs, WCAM, 2072 Camp, V, 186P(ab), Ceccarelli, C, 606 Chen, JL, l40P(ab) 89P(ab), 100P(ab), Bujenovic, LS, 80P(ab) 191P(ab), 298P(ab) Cekirge, 5,291 P(ab) Chen, K, 224P(ab), 304P(ab) 248P(ab), 274P(ab), Buonocore, E, 279P(ab) Campbell, CE, 123P(ab) Cellar, J, 1749 Chen, KY, 136P(ab), 282P(ab) Buonomo, C, 22P(ab) Campisi, R, 82P(ab) Celler, A, 36P(ab), 120P(ab), 262P(ab) Chung, SW, 282P(ab) Buralli, S, 16S. 22S Camsari, G, 233 209P(ab), 219P(ab) Chen, M, 332 Chung, TS, 426. 551 Burchert.W, 521,2066 Caner, B, 177P(ab), Census, DM, 284P(ab) Chen, W, 1349 Chung, WS, 248P(ab) Burdette, JH, 215P(ab) 257P(ab), 291P(ab) Ceriani, R, 169P(ab) Chen, WL, 247P(ab) Chyatte. D, 276P(ab) Burg, M, 59P(ab) Cangemi, V, 35P(ab) Cerqueira, MD, 177P(ab) Cheng, J, 218P(ab) Chyr, JS, 286P(ab) Burger, C, 699, 146P(ab), Cannas, P, 35P(ab), 255P(ab) Cesani, F, 926, 1356 Cheng, KT, 83P(ab) Cid, E, 58P(ab) 207P(ab) Cannizzaro, G, 185P(ab) Cesaro, P, 274P(ab) Chengazi, V, 96P(ab) Cinotti, L, 147P(ab) Burke, D, 54P(ab) Cantin, J, 75P(ab) Cetin, S, 233 Cherif, A, 72P(ab), 86P(ab), Civelek, AC, 262P(ab) Burke, JF, 244P(ab) Canzi, C, 230P(ab) Chabriat, H, 1976 253P(ab), 264P(ab) Clack, R, 18P(ab), 120P(ab) Burns, HD, 307, 288P(ab) Cao, Z, 1740,2037 Chadhuri, TR, 235P(ab) Cherry, SR, 55P(ab), Claessens, RAMJ, 62, 1392, Burns, L, 66P(ab) Capa, G, 302P(ab) Chakrabarti, M. 62P(ab), 73P(ab), 85P(ab), 86P(ab), 72P(ab), l28P(ab), Burns, RJ, 1918(le) Capasso, I, 155P(ab) 196P(ab) 107P(ab), 130P(ab), 241P(ab) Burns, SM, 276P(ab) Caplan, R, 162P(ab) Chakrabarti, MC, 1384 147P(ab), 193P(ab) Clark, J, 225P(ab), 226P(ab) Burns, T, 39P(ab) Capobianco, D, 264P(ab) Chakraborty, PK, 5IP(ab), Chesnut, RW. 194P(ab) Clark. JC, 194P(ab) Burris, T, 222P(ab) Caraco, C, 138P(ab), 145P(ab) Chester, KA, 868 Clark, RD, 40P(ab) Bums, TG, 1575, 84P(ab), 156P(ab), l99P(ab), Challeton, C, 598 Chevillard, S, 233P(ab) Clark, RL. 124P(ab) 305P(ab) 254P(ab) ChalÃ³n, S, 186P(ab) Chi, DY, 275P(ab) Clark, S, 74P(ab) Burrows, BA, 1922 Cardei, S, 13P(ab), 178P(ab) Chaly.T, 209, 216, 1760, Chia, CY, 298P(ab) Clark, WS, 179P(ab) Bury, T, 260P(ab) Cardella, JF, 294P(ab) 1850, 133P(ab) Chiang, YH, 40P(ab) Clarke. CP, 121P(ab) Buscombe, JR, 104P(ab) Caride, VJ, 91P(ab), Champion, P, 36P(ab) Chiao, PC, 1923 Clarke, GA, 995 Bush, LR, 673, 775, 296P(ab) Champlin, RE, 234P(ab) Chiesa, R, 55 Clarke, SEM, 823, 1353, 204P(ab) Carles, MC, 144P(ab) Chan, B, 280P(ab), 283P(ab) Childers, SR, 87P(ab) 297P(ab) Bushnell, DL, 31P(ab) Carlson, G, 254P(ab) Chan, G, 131P(ab), 132P(ab) Childs, M, 114P(ab), Clausen, M, 4P(ab), Butler, J, 1789 Carlson, K, 86P(ab) Chan. JG, 121P(ab) 246P(ab) 142P(ab), 246P(ab), Butler, SP, 744 Carney, BI, 1643 Chan, KH, 77P(ab) ChillÃ³n, HM, 2092 256P(ab), 257P(ab) Butterworlh, E, 70P(ab) Camochan, P, 54P(ab), Chan, KW, 42 Chin, BB, 723 Clavo, AC, 502, 64P(ab), Buvat, I, 39P(ab), 161P(ab), 166P(ab), 191P(ab) Chan, Y-W, 204P(ab) Chin. CT, 267 253P(ab) 217P(ab) CarÃ³n, H. 237P(ab) Chandarlapaty, SKC, 798 Chingas, GC, 98P(ab) Clemenson, A, 922 Buxton, D, 767 Carpenter. S, 91 P(ab) Chandra, R, 1731 Chinol, M, l69P(ab), Cleveland, K, 259P(ab) Buxton, DB, 3P(ab) Carpinelli, A, I33P(ab) Chandramouli, B, 261P(ab) 195P(ab), 238P(ab) Cliffe, IA, H2P(ab) Buxton-Thomas, M, 195 Carr, AA, l08P(ab) Chandy, B, 489 Chiotellis. E, 188P(ab) Clinthorne, NH, 7P(ab), Buyck, D, 35P(ab), 113P(ab) Carr, RM, 141P(ab) Chang, CP, 27P(ab) Chiou, PF, 125P(ab) 119P(ab), 170P(ab), Buyukpamukcu, M, 139P(ab) Carrasquillo, JA, 1384, Chang, CS, 245P(ab) Chiou, RK, I3S l71P(ab) Buzdar, A, 86P(ab) 29P(ab), 62P(ab), Chang, CW, 27P(ab). Chirinos, RE, 238P(ab) Cloughesy, T, 146P(ab)

Author Index â€¢1996 2103 Cloutier, D, 117P(ah). 81P(ab), 148P(ab), Czernin, J, 1626, 82P(ab), Davison, A, 17P(ab), 161P(ab) 232P(ab) 176P(ab), 179P(ab) 130P(ab) 118P(ab) Delbeke, D, 131P(ab) Coates, D, 249P(ab) Cordero, GG. 287P(ab), Czitrom, D, 181P(ab) Daya, S, 159P(ab) Delforge, J, 5, 118, 70P(ab), Coenen, HH, 1865, 55P(ab), 307P(ab) De, D, 96P(ab), 162P(ab), 76P(ab), 226P(ab) D'Aiuto, G, 155P(ab), 279P(ab) Cordes. M, 22 240P(ab) Delgado, L, 266P(ab) Cohen, C, 159P(ab) Cordes, U, 159P(ab) 156P(ab) De Braud, F, 169P(ab) Delisle, M, 606 d'Amico, A, 133P(ab), Cohen, CL. 147P(ab) CordobÃ©s,MD, 189P(ab) deBruin.W, 213P(ab) Delle Fave, G, 1452 Cohen, D, ll8P(ab), Cornel, JH, 748, 1951, 258P(ab) De Cicco, C, 169P(ab) DeLong, DM, 174P(ab) D'Hondt, AM, 25P(ab), 289P(ab) 59P(ab), 176P(ab) De Cristofaro, MTR, Delpassand, ES, 32P(ab) Cohen, I, 14P(ab), 59P(ab), Correia, JA, 228P(ab), 126P(ab) 278P(ab) Delriego, J, 75P(ab). D'Souza, CD, 32P(ab), 68P(ab), 69P(ab), 239P(ab), 244P(ab) DeDreuille, O, 217P(ab) 267P(ab), 269P(ab) 116P(ab). !81P(ab), Corstens, FHM, 62, 1392, 33P(ab) De Geest, H, 767 Demaerel, P, 22P(ab) 182P(ab) 2072, 119P(ab), 128P(ab), Dachille, MA, 74P(ab), DeGeeter, F, 473, 718 DeMan, P, 81P(ab) Cohen. M, 14P(ab), 259P(ab) l69P(ab) 224P(ab) De Graff, WG, 1384 Demez, P, 261P(ab) Cohen, R, 45P(ab). 105P(ab). Corti, A. 238P(ab) Dacosta, M, 255P(ab) de Jong, BM, llP(ab), Demirkazik, FB, 1956 115P(ab), 284P(ab) Cosimi, AB, 293P(ab) Dadachova, E, 195P(ab) 21P(ab) Demonceau, G, 274P(ab) Cohen, SM, 13S Costa, DC, 995, 65P(ab), Dadparvar, S, 65P(ab), de Jong, M, 1388, 48P(ab), Demoor, D, 718 Cohen-Solai, A, 70P(ab), 134P(ab) 114P(ab), 163P(ab), 141P(ab), 190P(ab) Demus, DD, 14P(ab) 181P(ab) Costa, R. 243P(ab), 297P(ab) 259P(ab), 263P(ab), de Jong, PE, 482 den Harder, JM, 216P(ab) Coit, D, 138P(ab) Costa, WLS, 172P(ab), 265P(ab) de Klerk, JMH, 38, 244, 465, DeNardo, DA, 146, 1970, Colao, A, 159P(ab) 223P(ab) Dae, MW, 47P(ab), 106P(ab) 1511,289P(ab) 90P(ab), 232P(ab) Colas-Linhart, N, 101P(ab), Couette, J, 606 Daenen, F, 250P(ab), de Kraker, J, 237P(ab), DeNardo, GL, 146,451, 231P(ab) Counsel!, RE, 1540 261P(ab) 287P(ab) 1970,90P(ab), 128P(ab), Colchen D, 90P(ab), Coupland, DB, 36P(ab) Daghighian, F, 1052, 1557, de Labriolle-Vaylet, C, 129P(ab), 167P(ab), l50P(ab) Courey, MH. 1913(le) 25S, 29S 101P(ab) 170P(ab), 232P(ab) Cole. GM. 79P(ab) Cousins, C, 91 P(ab) Dagli, M, 91P(ab) de Latour, M, 922 DeNardo, SJ, 146,451, 1970, Cole, WC, 95P(ab) Couthon. HM, 105 Daher, E, 1783 de Leeuw, PW, 594, 1652 90P(ab), 128P(ab), Colella, AC, 255P(ab) Couturier, O. 57P(ab) Dahl, JR, 216 De Martin, M, 42P(ab) l29P(ab), 143P(ab), Coleman, RE, 498, 1438. Cowan, D, 926 Dahlbom, M, 8P(ab), de Montigny, C, 113P(ab), 167P(ab), 170P(ab), 1906,2011, 19P(ab), Cowan, RJ, 1535 73P(ab), 119P(ab), 284P(ab) l99P(ab), 232P(ab) 22P(ab), 74P(ab), Coxson. PG, 131P(ab), 170P(ab), 303P(ab) De Roo, M, 22P(ab), Denays, R, 274P(ab) l20P(ab). 154P(ab). 146P(ab) Dale, S, 120P(ab), 208P(ab) 26P(ab), 54P(ab), 91P(ab), Dence, CS, 108P(ab) l60P(ab), l74P(ab), Crabbe, D, 183P(ab) Dalery, K, 150P(ab) 175P(ab) Dendale, P, 718 200P(ab), 214P(ab), Cradduck.TD. 178 Dalhberg, ST, 212P(ab) De Sadeleer, C, 1346 DeNovo, R, 1846 216P(ab), 219P(ab), Craig. JC, 46P(ab) Dalrymple, GV, 13S, De Vathaire, F, 598, 606 Deo, Y, 362 295P(ab) Crane, PD, 1031, 117P(ab), 150P(ab) de Vries, DJ, 30P(ab), DePuey, EG, 13P(ab), Collares, M, 273P(ab) 151P(ab), 202P(ab), Damhaut, P, 21P(ab), 153P(ab) 48P(ab), 69P(ab), Collecchi. P, 16S 232P(ab) 53P(ab), 83P(ab) de Vries, EGE, 1571, 67P(ab) 105P(ab), 115P(ab), Collet, GJ, 259P(ab) Crankshaw, C, 51P(ab), Damphousse, DJ, 119P(ab), de Zeeuw, D, 482 116P(ab), 125P(ab), Collier, A, 274P(ab) 71P(ab), 247P(ab) 129P(ab), 151P(ab), Deacon, T, 66P(ab) 276P(ab) Collier. BD. 1285, 1903, Cremonesi, M, 169P(ab) 202P(ab) Deal, KA, 71P(ab) Der, MG, 10P(ab) 84P(ab) Crespo, E, 245P(ab) Dams, R, 1048 Dean, RT, 673, 775, 1016, Derbyshire, S, 74P(ab) Colnaghi, Ml, 665 Cristel, ME, 40P(ab), Danek, A, 122P(ab) 152P(ab), 204P(ab), Derebek, E, 302P(ab) Colombo, L, 236P(ab) 128P(ab). 201P(ab) Danforth, DN Jr., 99P(ab) 272P(ab) Dereniak, ES, 53P(ab) Comazzi. V, 188P(ab) Crocker, AC, 129P(ab), Dangas, G, 60P(ab) Dearling, JLJ, 166P(ab) Derenzo, SE, 85P(ab) Combs, MJ, 207P(ab) 151P(ab), 202P(ab), Daniel, GB, 1846 deBeco, V, 233P(ab) Deriso, GT, 798 Cornet. M, 229P(ab) 232P(ab) Daniel, J, 151P(ab) DeBruin, S, 97P(ab) Derksen, J, 270 Compierchino. A. 205P(ab) Crommelin, DJA, 1392 Daniel, MJ, 141P(ab) Debruyne, FMJ, l69P(ab) DeRogatis, A, 276P(ab) Connetl, JM, 6IP(ab), Crompton. N, 54P(ab) Danieli, R, 1452. 35P(ab), Dec, GW, 144P(ab) DeRook, F, 177P(ab) 95P(ab) Cronin, BF, 1771, 282P(ab) 255P(ab) deCosla, BR, 2021, Descamps, X, 685 Connolly, JL, 74P(ab) Croop, JM, 118P(ab) Dann, R, 231P(ab) 143P(ab), 187P(ab) Desisto, WC, 19S Connolly, LP, 81, 22P(ab), Crumrine, P. 269P(ab) Dannais, RF, 307, 6P(ab), Decristoforo, C, 1912(le) Detry, R, 258P(ab) 28P(ab), 292P(ab) Csaplar, K. 201P(ab) HP(ab), 33P(ab),41P(ab), Dederichs, B, 137P(ab) Deutsch, G, 88P(ab), Conrad, B, 278P(ab) Csernay, L, 273P(ab), 45P(ab), 47P(ab), 77P(ab), Deecke, L, 1931 l64P(ab), 277P(ab) Conrad, EU, l40P(ab) 287P(ab) 107P(ab), H2P(ab), Deenmamode, M, l48Pfab) Devillers, A, 1946 Conti, E, 88P(ab) Cuccia, A. 239 164P(ab), l92P(ab), DeFabritiis, A, 88P(ab) De Vito, R, 97P(ab) Conti, PS. 107P(ab), Cuccurullo, V, 156P(ab) 20IP(ab), 280P(ab), DeFerrari, GM, 37P(ab) Dewanjee, M, 96P(ab), 135P(ab), l40P(ab). Cukier, A, 294P(ab) 288P(ab) DÃ©frise,M, 120P(ab) 162P(ab), 240P(ab) l55P(ab), 193P(ab) Culbert, P, 174P(ab) Dansereau, RN, 143P(ab) DeGrado, TR, 2011, 94P(ab), Devous, Sr, MD, 1735, Contreras, S, 23P(ab) Cullom, SJ, 81P(ab), Daou, D, 253P(ab), 256P(ab) 160P(ab), 174P(ab), 22N(11) Conway, J, 873 l49P(ab), 176P(ab), Das, S, 5P(ab), 178P(ab), 200P(ab), 219P(ab) Dewhirst, MW, 1438 Conway, JJ, 287P(ab), 210P(ab), 214P(ab), 270P(ab) DegrÃ©,S, 83P(ab) Dewitte, O, 21P(ab) 20N(7) 215P(ab) DaSilva, JN, 202P(ab) Dehdashti, F, 87P(ab), Dey, D, 25N(9) Cook, GJR. 1353, 1359, Culp, R, 80P(ab), 210P(ab) Datz, FL, 97P(ab), 124P(ab) 99P(ab), 132P(ab), Dey, H. 80P(ab), 100P(ab) 27P(ab), 87P(ab), 297P(ab) Cumming, P, 55P(ab) Daube-Witherspoon, ME, 135P(ab) Dey, HM, 282P(ab) Cook, SA, 177P(ab) Cunha, ML, 273P(ab) 2087, 99P(ab) deKemp, RA, 174P(ab) Dhawan, RT, 1828 Cooke. CD, 48P(ab), Cunningham, B, 259P(ab) Dauplat, J, 922 del Rosario, RB, 1923, Dhawan, V, 209, 216, 1760, 97P(ab), l79P(ab) Cuocolo, A, 735, 13P(ab), Davenport, A, 104P(ab) 70P(ab). 192P(ab) 1850, 133P(ab), 281P(ab) Cool. V, 53P(ab) l59P(ab), 178P(ab) Davidson, P, 142P(ab) Del Sole, A. 42P(ab) Di Bartolo, N, 195P(ab), Cooper, JD, 5P(ab). 135P(ab) Curici, DT, 186P(ab) Davies, G, 37P(ab), 184P(ab) Del Vecchio, S, 665 196P(ab) Coppola, R, 2021 Cutler, PD, 1009, 73P(ab), Davies, M, 54P(ab) Del Vecchio, W, 156P(ab) Di Bella, EVR, 1891 Coppola, RC. 143P(ab), 87P(ab) Davila-Garcia, M, 6P(ab) Delahaye, N, 70P(ab), Di Carli, MF, 4P(ab) 187P(ab) Cygne, BV. 134P(ab) Davila-Roman, VG, 82P(ab) 181P(ab), 253P(ab) Di Gregorio, F, 156P(ab) Corbelli. C. 88P(ab) Cyr, JE, 673 Davis, BR. 171 Delaney, RC, 1749 Di Lieto, E, 264P(ab) Corbetl, JR. 1923. 70P(ab). Czech, T, 1931 Davis, CM, 60P(ab) DeLano, DA, 82P(ab), Di Luca,, 22S

2104 The Journal of Nuclear Medicine Di Paola, M, 847 Dubois,EA, 160P(ab) 232P(ab) Erdil, YT, 233 Farris, JS, 303P(ab) Di Paola, R, 147P(ab), Dubovsky,E,1876 Eersels.J. 184P(ab) Erdos, J, 33P(ab) Fashingbauer, P, 2006 217P(ab) Dubovsky,EV,588,293P(ab) Efange, SMN, 108P(ab), Erel, J, 93P(ab). l49P(ab), Fataar, A, 1001 Di Sacco, S, 22S Duca,MD, 14P(ab) 280P(ab) 180P(ab), 182P(ab) Faulhaber, PF, 99P(ab) Di Stefano, R, 22S Ducassou.D,863 Egan, GF, l21P(ab). Ergene, O, 302P(ab) Faulkner, DB, 305P(ab) Diamond, GA, l4P(ab), Duet,M, 1773 131P(ab), l32P(ab) Eriksson, B, 32 Fawwaz, RA, 5P(ab), 68P(ab), 116P(ab) duFour,R,306P(ab) Egashira, S, 781 Erlandsson, K, 159P(ab) 270P(ab) Diamond, JA, 60P(ab) Duggaraju,R,151P(ab) Egert, S, 94P(ab) Ernst, M, 45P(ab), 284P(ab) Fazio, F, 55, 967, 1655, DiBella, EVR, 153P(ab) Duke.JH,162P(ab) Eggli, DF, 294P(ab) Eronen, E, 387 42P(ab), 133P(ab), Diener, HC. 279P(ab) Duncan,D,252P(ab) Egholm, M, 203P(ab) Erwin, WD, 1970, 149P(ab) 205P(ab), 258P(ab) Dieterich, M, 122P(ab) Duncan,DB,429 Ehrenkaufer, RL, 281P(ab) Eshima. D, 1575. 46P(ab), Fazzini, PF, 26P(ab) DiFabrizio, L, 1662, Duncan,JR,118P(ab), Ehrhardt, GJ, 194P(ab) 47P(ab), 84P(ab), Feillel, V, 922 242P(ab) 201P(ab),302P(ab) Eichler, HG, 5P(ab) 186P(ab), 191P(ab), Fein, T, 142P(ab) Diggles, L, 1789, 230P(ab), Duncan.R,661,1946 Eichstadt, H. 22 222P(ab), 298P(ab), Feine, U, 463, 1468, 231P(ab) Dunleavy,T,136P(ab), Eidelberg, D. 209, 216, 1760, 305P(ab), 307P(ab) 134P(ab), 137P(ab) Diksic, M, 55P(ab). 264P(ab) 1850, 133P(ab),281P(ab) Eshima, LA, 1575, 46P(ab), Feinendegen, DL, 1841 H3P(ab), 284P(ab) Dunn,R,905,1504,9P(ab), Eilles, Chr, 248P(ab) 47P(ab), 84P(ab), Feinendegen. LE, 1841 DiLeo, C, 1655 43P(ab),44P(ab),96P(ab), Eisenberg, B, 57P(ab), 186P(ab). 191P(ab), Fcldman. DR, 1682 Dillehay, G, 878 102P(ab),168P(ab), 103P(ab) 222P(ab), 298P(ab) Feldmann. H, 157P(ab) Dilsizian, V, 690, 1795, 169P(ab),231P(ab), Eisenhut, M, 362, 6P(ab) 305P(ab), 307P(ab) Felix, R, 22 25P(ab), 39P(ab), 60P(ab), 239P(ab) Eisenstein, EL, 14P(ab) Eshuis, SA, 263P(ab) Fendrick.AM, HOP(ab), 93P(ab), l60P(ab), Dunn, RM, 829 Eising, EG, 247P(ab) Eskin, JD, 53P(ab), 301P(ab) lllP(ab), 158P(ab) 161P(ab) Dunn, WL, 1456, 243P(ab) Eisner, D, 104P(ab), Espasandin, J, 266P(ab) Feneley, M, 96P(ab) DiLuca, L, 16S Dunnwald, LK, 252P(ab), 159P(ab), 209P(ab) Esposito, G, 559, 79P(ab), Feng, D, 224P(ab), 227P(ab) Dimitrakopoulou-Strauss, A, 267P(ab) Eisner, RL, 1891, l74P(ab) 284P(ab) Feng, T, 207P(ab) 68P(ab), 147P(ab), Dunphy, C, 136P(ab), Eisold, J, 854 Esselstyn, CB, 1809,2000 Feng, YJ, 58P(ab) 257P(ab),264P(ab) 264P(ab) EKJ,, 533 Esser, JD, 1323 Feroze, H, 105P(ab) Ding,HJ,298P(ab) Dunphy, F, l36P(ab), El-Shirbiny, A, 102P(ab), Esser, PD, 273P(ab) Ferrant, A, 916 Ding,Y,554 264P(ab) 138P(ab) Estorch, M, 631 Ferrari, C, 230P(ab) Ding,Y-S,33P(ab),40P(ab), Dupont, JO. 861 Elahi, N, 1956, 177P(ab) Ethier, S, 75P(ab) Ferraro, M, 14P(ab) 44P(ab) Dupont, P, 22P(ab) Eidin, A, 105P(ab) Ethier, SP, 1042, 1540 Ferrili, K, l43P(ab), Dinh, L, 23P(ab) Durack, LD, 2030 Elgazzar, A, 16P(ab) Ettori, F, 1300 l52P(ab) Diril, H, 239P(ab) Durak, H, 302P(ab) Elgazzar. AH, 858, 60P(ab), Evans, AC. 222P(ab), Feske, WI, 140P(ab) DiSalvo, TG, 144P(ab) DuranCordobes, M, 233P(ab) 250P(ab) 223P(ab), 283P(ab) Fessier, JA, 7P(ab) Discepolo, A, 164P(ab) Durie, B, 267P(ab), 269P(ab) Elger, CE, lOOP(ab) Evans, J, 90P(ab). l02P(ab), Festa, A, 237P(ab) Ditlow, C, 49P(ab) Durski, JM, 135P(ab) Elhendy, A, 748, 1951 228P(ab), 229P(ab) Fetters, JK. 471 Divgi, C, 1922 Duryea, RA, 95P(ab) Eliashiv, SD, 101P(ab) Evans, K, 1331,1336 Fiasse, R, 916 Divgi, CR, 43P(ab) Duscha, BD, l74P(ab) EU, PJ, 995, 1828, 178P(ab), Everaert, H, 88P(ab), Ficaro, EP, 1562, 78P(ab), Dixon, M, 242P(ab) Dutka, D, 71P(ab) 26N(11) 21IP(ab), 268P(ab) 81P(ab), 98P(ab), Dlouhy, SR, 270P(ab) Dutschka, K, 1865 Eller, D, 46 Ezquerra, NF, 48P(ab), 148P(ab), 176P(ab), Dobelbower, RR. 90P(ab) Dwamena, BA, lllP(ab), Ellerhorst, J, 32P(ab) 179P(ab) 180P(ab), 2l5P(ab) Dobkin. JA. 1009 l41P(ab). 158P(ab) Ellis, G, 252P(ab) Ezuddin, S, 798, 293P(ab) Fiche. M, 1853 Dodd, LR, 95P(ab) Dwyer, KM, 1583 Elmaleh, D, 269P(ab) Fields, ALA, 237P(ab) Doerr, RJ, 135P(ab), Dykes. JA, 1846 Elmaleh, DR, 4P(ab), Faber,TL,41P(ab),97P(ab), Fields, SD, 554 238P(ab) Dykstra, CJ, 209P(ab) 33P(ab). 65P(ab), 66P(ab) 213P(ab) Fig, LM. 25P(ab), 285P(ab), Dogan, S, 302P(ab) Dyling, O, 167P(ab) Elmqvist, H, 120P(ab), Fadda,G, 633 306P(ab) Dohmen, BM, 140P(ab) Dynes, AM, 1771, 282P(ab), 208P(ab) Fagret, D, 229P(ab) Figlin, RA, l4IP(ab) Dole, MG, 16 Dzewas, B, 36P(ab) Elomaa, I, 256P(ab) Fahey, FH, 1639, 225P(ab) Filez, L, 54P(ab) Doli, J, 68P(ab), 154P(ab), Eiser, H, 362 Fahmy, A, 241P(ab) Filipchuk, NG. 93P(ab) 221P(ab), 265P(ab) Eagle, KA, 14P(ab) Eisinga, PH, 279, 1571, Fahrenkamp. A, 1990, Fimmers, R, 1962 Donald, PJ, 136P(ab) Early, T, 79P(ab) HP(ab), 71P(ab) 49P(ab) Fine, E, 1876 Donalh, A, 51P(ab) Eary, JF. 2030, 43P(ab), Emi, T, HOP(ab) Faigel, DO, 114P(ab), Fine, EJ, 838 Dondi, M, 1688, 1876, 67P(ab), 140P(ab), Emond, P, 186P(ab) 246P(ab) Finestone, H. 2098(le) 88P(ab) 233P(ab) Emslander, H-P, 36P(ab) Faivre-Chauvet, A, 1853 Fink, GR. 429 Donegan, M, 151P(ab) Easton, E, 249P(ab) Emter, M, 2066 Falcini, M, 278P(ab) Fink. M. 228 Dong, B, 958 Eberl, S, 128, 137, 90P(ab), Enas, JD, 40P(ab), 51P(ab) Falcone, A, 22S Finley, PA. 6P(ab). HP(ab). Donlevy, TM, 196P(ab) 147P(ab), 220P(ab) Endo, K, 273, 457, 1981, Fallanca, F, 264P(ab) 112P(ab). 20IP(ab), Donnelly, J, 151P(ab) Eben, M, 296P(ab) 159P(ab), 184P(ab), Fallani, F, 88P(ab) 279P(ab) Donnenfeld, H, 277P(ab) Ebinger, G, 88P(ab) 253P(ab) FallÃ³n,BA, 270P(ab) Finley, RJ, 36P(ab) Donohay, T, 50P(ab) Echemendia, E, 251P(ab), Endres, CJ. 77P(ab) Fanti, S, 1688, 88P(ab), Finn, R, 53P(ab), 54P(ab), Donohoe. KJ, 1903, 301P(ab) Engel, H, 441 250P(ab) 25S, 29S 172P(ab), 23N(6) Eckardt, A, 103P(ab) Engel, J, 101P(ab) Paraggi, M, 275, 181P(ab), Finn, RD. 1557 Dorcaralto, A, 238P(ab) Eckblade, MB, 89P(ab), Enomoto, K, 279 253P(ab), 256P(ab) Fiore, F, 260P(ab) Dortlemez, H, 184P(ab) 90P(ab) Enomoto, M, 641 Farahati, J, 286P(ab) Fioretti, PM, 748, 1951, Dortlemez, O, 184P(ab) Eckelman, WC, 1408, Ensing, G, l90P(ab) Farde, L, 76P(ab), 108P(ab), 59P(ab), 60P(ab). 176P(ab) Dose, J, 99P(ab) 10P(ab), 77P(ab), Ensing, K, HP(ab), 71P(ab), H2P(ab), 192P(ab), Firby, P. 1578 Dosik. D, 169P(ab) 118P(ab), 129P(ab), 108P(ab) 284P(ab) Firestone, L, 74P(ab) Dotlonni, ME, 236P(ab) 152P(ab), 197P(ab), Epenetos, A, 54P(ab), Farlow, MR, 270P(ab) Fischer, H, 200P(ab) Doudet, D, 230P(ab) 199P(ab), 203P(ab), 204, 238P(ab) Farman-Ara, B, 217P(ab) Fischer, KC, 5P(ab) Douillard, JY, 1853 254P(ab), 279P(ab) Ephron, VJ, 162P(ab), Farncombe. T. 219P(ab) Fischer, R, 218P(ab) Dowlati, A, 260P(ab) Eda, R, 296P(ab) 272P(ab) Farquhar, TH, 73P(ab) Fischman, A, 843 Downer, JB, 87P(ab) Edeline, V, 893 Erb, D, 9P(ab), 238P(ab) Farrell, E, 9P(ab), 198P(ab) Fischman, AJ, 950. 4P(ab), Dragotakes, SC, 240P(ab) Edell. SL, 74P(ab) Erbas, B, 145P(ab), Farrell.JJ, 1595 24P(ab), 33P(ab), 65P(ab), Drucker, MJ, 252P(ab), Edwards, DS, 29P(ab), 290P(ab), 293P(ab) Farrell, ML, 293P(ab) l25P(ab). 143P(ab), 267P(ab) 119P(ab), 129P(ab), Erdenli, I, 290P(ab) Parres, MT, 46P(ab) l52P(ab). 16IP(ab),

Author Index â€¢1996 2105 198P(ab), 228P(ab), Frackowiak, RSJ, 42P(ab) Fujino, S, 1622, l79P(ab) Garcia Bolao, I, 93P(ab) Gildehaus, F-J, 1990, 239P(ab), 240P(ab), Fragu, P, 1830 Fujishima, M, 275P(ab) Garcia Velloso, MJ, 93P(ab) 49P(ab) 244P(ab), 269P(ab) Frajewicki, V, 1371 Fujita, H, 12P(ab) Gardet, P, 598, 912 Gildersleeve, DL, 1923 Fisher, D, 43P(ab) Fraker, D, 253P(ab) Fujita, M, 1403, 1836, Gardin, I, 101P(ab), Giles, F, 267P(ab), 269P(ab) Fisher, GA. 1464 Fraker, DL, 1690 66P(ab), 95P(ab), 285P(ab) 217P(ab) Gillan, MM, 114P(ab), Fisher, MF, I6N(4) Franceschi, D. 446, Fujita, T. 374. 1365, 1600, Garg, PK, 2011, 200P(ab) 163P(ab), 259P(ab), Fisher, RS, 57P(ab). 238P(ab), 255P(ab) 2057, 76P(ab) Gariepy, J, 199P(ab) 263P(ab), 265P(ab) 244P(ab) Franceschi, M, 446, 133P(ab) Fujiwara, S, 1289, 181P(ab) Garini, P. 185P(ab) Gilland, DR, 154P(ab), Fisher, SJ, 1042, 1540, Franceschini, R, 169P(ab), Fujiwara, T, 761, 175P(ab) Garner, BA, 229P(ab) 212P(ab), 216P(ab) 75P(ab) 195P(ab) Fukuchi, K, 761, 1686, Carreau, L, 186P(ab) Gillispie, SB, 220P(ab) Fill, GJ, 121P(ab) Francese, C, 598, 606 l2P(ab), 94P(ab), 175P(ab) Galley, SJ, 554, 33P(ab), Gillooley. J, 242P(ab) Fitz, C, 269P(ab) Franchi, R, 88P(ab) Fukuda, H, 320, 410 44P(ab), 187P(ab), Gimelli, A, 735 Fixmann, T, 283P(ab) Francis, I, 289P(ab) Fukuda, T, lllP(ab) 203P(ab) Ginovarl, N, 108P(ab), FjÃ¤lling,M, 2002 Francis, IR, 158P(ab) Fukui, M, 21P(ab) Gatti, R, 297P(ab) H2P(ab), 192P(ab), Flamen. P, 88P(ab), Frangin, Y, 186P(ab) Fukuma, H, 1444 Gautherot, E, 1853, 129P(ab) 284P(ab) 2llP(ab), 268P(ab) Franke, W-G, 208P(ab), Fukumura, T, 21P(ab), Gay, R, 235P(ab) Ginsburg, M, 5P(ab) Flameng, W, 26P(ab) 283P(ab) 36P(ab), 133P(ab), Gay, S, 235P(ab) Gioia, G, 14P(ab), 149P(ab) Flanagan, FL, 99P(ab), Franken, PR, 718, 88P(ab), 271P(ab),275P(ab) Gebauer, H-D, 208P(ab) Gionfriddo, MA, 656 132P(ab), 135P(ab) 211P(ab). 268P(ab) Fukuoka,S,1824 Gebert, J, 87 Giordani, B, 201 Fleming, JS, 873, 1058, 1832 Franklin, J, 141P(ab) Fukushi,K,649 Gebhardt, M, 28P(ab) Giordani, BL, 163P(ab), Fleming, RA, 177P(ab) Franssen. EJF, 1571,2082, Fukuyama,H,1600 Geboes, K, 54P(ab) 164P(ab) Fiesher, JE, 41P(ab) 67P(ab), 71P(ab), 157P(ab) Fukuyama,T,781 Geleijnse, ML, 1951 Giorgetti, A, 735 Fleshman, JW, 132P(ab) Fratkin, MJ, 243P(ab) Fulham,MJ,128,137, Gelfand, MJ, 35P(ab), Giorgi, MCP, 294P(ab) Fletcher, A, H2P(ab) Frazzini, V, l3P(ab) 147P(ab),220P(ab) 287P(ab) Gisonni, P, 178P(ab) Fletcher, J, 878. 1876 Frederick, D, 17P(ab), Fulton,RR, 137,147P(ab), Gennari,D, 205P(ab) Giubbini, R, 1300 Fletcher, JW, 136P(ab), 66P(ab), 20IP(ab) 220P(ab) Genlilcore, R, 249P(ab) Gjedde, A, 223P(ab), 249P(ab), 264P(ab), Freedman, N, 786 Fung, C, 82P(ab) Georgiou, M, 798, 23P(ab), 283P(ab) 303P(ab) Freedman, NMT, 690, Furhang, EE, 89P(ab), 289P(ab) Gladden, KH, 288P(ab) Flint, A, 65P(ab) 99P(ab), 253P(ab) 102P(ab) Gerard, SK, 181P(ab) Glahn, DC, 284P(ab) Flores, LG II, 84, 308P(ab) Freedman, RS. 1545 Furmanski, P, 169P(ab) Gerber, B, 25P(ab), Glajchen, N, 297P(ab) Flores II, LG, 901 Freeman, LM, IOP(ab), FÃ¼rst,S, 138P(ab) 126P(ab), 39P(ab) Glaser, B, 1537 Florio, F. 92P(ab) 74P(ab) Furth, EE, 114P(ab), Gerdsen, I, 283P(ab) Glaser, C, 999, 1526, Flower, M, 54P(ab), Freeman, SJ, 241 P(ab) 246P(ab) Gerlach, L, 249P(ab), 266P(ab) 191P(ab) Freifelder, R, 276P(ab) Furudate, M, 71,955 264P(ab), 265P(ab), Glaspy, JA, 99P(ab) Floyd, CE Jr., 295P(ab) Frenkel. A, 103P(ab), Futami, S, 84, 901, 308P(ab) 266P(ab) Glass, D, 54P(ab), 114P(ab), Fluck, S, lOP(ab) 139P(ab), 245P(ab) Fulatsuya, R, 101P(ab) Germain, CJ, 61P(ab), l48P(ab) Fluks, L, 1571 Frey, A, 70P(ab) 95P(ab) Glass, EC, 53P(ab), 181P(ab) Flux, GD, 228P(ab) Frey, EC, 7P(ab), 30P(ab) Gacinovic, S, 65P(ab) Germann, C, 234P(ab), Glatting, G, 160P(ab), Hyod, BB, 242P(ab) Frey, KA, 1042. 21P(ab), Gaebel, W, 113P(ab) 235P(ab) 220P(ab) Fogarasi, M, 1655 109P(ab), 163P(ab), Gage, HD, 225P(ab), Germano, G, 81P(ab), Click, SJ, 18P(ab), 153P(ab) Foged. C, 76P(ab) 164P(ab), 270P(ab) 281P(ab) 149P(ab) Glikmanas, M, 275 Fogelman, I, 1353. 1359, Freyburger, G, 863 Gaggero, B, 238P(ab) Gerson, MC, 752, 49P(ab). Glover, DK. 1398, 3P(ab) 27P(ab), 87P(ab), 297P(ab) Freyer, R, 208P(ab) Gagnon, A, 75P(ab), 188P(ab) Go, KG, 157P(ab) Folks, RD, 46P(ab), 48P(ab), Frickhofen, N, 262P(ab) 150P(ab) Gerundini, P, 37P(ab), Go, RT, 1809, l77P(ab), 97P(ab), 179P(ab), Fried, M, 245P(ab) Gaillard. N, 1860 230P(ab) 276P(ab) 293P(ab) Friederici, A. 280P(ab) Gal, R, 178P(ab) Cervino, EV, 1618 Godbersen, GS, 4P(ab) Follansbee, WP, 149P(ab), Friedland, R, 11P(ab) Galle, P, 847 Geselowitz, DA, 233P(ab) Goes, E, 1346 176P(ab) Friedman, HS, 1438, 61P(ab) Galli, M, 735 Gestin, JF, 72P(ab) Goethals, P, 1048 Fommei, E, 1876, 1883 Friedman, JD, l4P(ab), Gallo, R, 152P(ab) Getz, TA, 307P(ab) Coin, J, 114P(ab) Fontaine, F, 598 59P(ab), 68P(ab), 69P(ab), Galt, JR, 214P(ab), 293P(ab) Gewirtz, H, 161P(ab). Coins, B, 1374 Fontanini, G, I6S 81P(ab), 93P(ab), Galynker, II, 2098(le) 213P(ab) Gokgoz, L, 184P(ab) Fonti, R, 665 H6P(ab), 149P(ab), Gambhir, SS, 1428, 1428, Geworski, L, 55P(ab), Golan, H, 513 Foo, M, 1828 180P(ab), 181P(ab), 107P(ab), HOP(ab), 279P(ab) Gold, DV, 169P(ab) Forrest, A, 198P(ab) l82P(ab) 147P(ab), 193P(ab), Geyer, BC. 7P(ab) Goldberg, SN, 1310 Forrester, JW, 31 P(ab) Friedman, M, 13P(ab), 269P(ab), 301P(ab), Geyskes, G, 1876 Goldenberg, DM, 829, 905, Forsher, C, 272P(ab) 2llP(ab) 303P(ab) Ghali, S, 33N(9) 1504, 9P(ab),43P(ab), Forssell-Aronsson, E, 2002 Friedman, NC, 275P(ab) Gan, MP, 306P(ab) Ghesani, M, 13P(ab), 44P(ab), 62P(ab), 96P(ab), Forst, T, 104P(ab) Friets, E, 100P(ab) Ganeies, A, 10P(ab) 116P(ab), 276P(ab) 102P(ab), 151P(ab), Forstrom, LA, 1456, PrisiÃ³n, K, 42P(ab) Gangopadhyay, S, 69P(ab) Ghetti, B, 270P(ab) 168P(ab), l69P(ab), 243P(ab) Friston, KJ, 27IP(ab) Gann, DS, ISP(ab) Chez, C, 281 P(ab) 231P(ab), 232P(ab), Fortsas, M, 178P(ab) Fritzberg, AR, 29P(ab), Gansow, O, 152P(ab), Ghilardi, FM, 281P(ab) 239P(ab), 243P(ab) Foss, J, 798 95P(ab), 166P(ab) 234P(ab) Giacalone, F, 1853 Goldfarb, CR, 2098(le) Foster, C, 166P(ab) FrÃ¶hlich,DEC, 140P(ab) Ganz, W, 798, 96P(ab), Giammarile, F, 912 Goldfine. SM, 38P(ab) Foster, NL, 163P(ab), Frohmann, JP, 138P(ab) 240P(ab), 293P(ab), Gianchandani, RY, 852 Goldman, CK, 234P(ab) 164P(ab), 270P(ab) Front, A, 245P(ab) 302P(ab) Gianolli, L, 205P(ab) Goldman, S, 21P(ab), Fotzsch, R, 283P(ab) Front, D, 530, 103P(ab), Gao, D-W, 106P(ab) Gibbons, G, 489 53P(ab), 83P(ab) Foulon, CF, 187P(ab), 139P(ab) Gao, P, 107P(ab) Giblin, MF, 96P(ab), Goldsmith, SJ, 1528 197P(ab), IS Frost, JJ, 41P(ab), 45P(ab) Garada, B, 17P(ab), 158P(ab) 198P(ab) Goldslein, DS, 170P(ab) Fountain. SW, 1275 Frouin, F, 147P(ab) Garada, BM, 19S Gibson, RE, 307, 288P(ab) Goldstein, S, 216P(ab) Fowler, JS, 554, 1609, Fry. D, I69P(ab) Garcia, EV, 41 P(ab), Gierada, DS, 5P(ab) Gomez, G, 631 33P(ab), 40P(ab), 44P(ab), Fujibayashi, Y, 729, 757, 48P(ab), 81P(ab), 97P(ab), Gifford, AN, 187P(ab), Gona, J, 135P(ab), 136P(ab), 45P(ab), 76P(ab), 281P(ab) 1403, 1836, 56P(ab), 125P(ab). 179P(ab), 203P(ab) 259P(ab) Fox, PS, 294P(ab) 95P(ab), l92P(ab), 213P(ab), 254P(ab), Gil, R. 33P(ab) Gong, GY, 252P(ab) Fox, PT, 223P(ab) 257P(ab) 305P(ab) Giladi, N, 245P(ab) Gonvers, JJ, 245P(ab) Fox, R, 131P(ab), 132P(ab) Fujii, K, 21P(ab) Garcia, JR, 1476 Guardi, MC, 205P(ab) Gonzalez, R, 302P(ab)

2106 The Journalof Nuclear Medicine Goodman,6P(ah).l86P(ab),MM. l51P(ab),239P(ab)Grimm, Hammersley, PAG. 235P(ab) Hata, T, 1836. 95P(ab) !91P(ab),222P(ab), 284P(ab)Gurney,RE, 283P(ab), Hamzeh, FM, 193P(ab) Halazawa, J, 12P(ab), 298P(ab),305P(ab)Goodwin, 144P(ab),233P(ab)Grivet-Fojaja,W, 823Gussak,S, Han, SH, 1511 HOP(ab), l65P(ab) 82P(ab)Gutzler.H, Hanaoka, NM, 273P(ab) Hattori, N, 1600, 1981, 1985, 2092Gordon,DA, I59P(ab),164P(ab)Grizzle,MR, 68P(ab)Guzman,F, Hanauske, A-R, 138P(ab) 2057, 101P(ab), 150P(ab), 307P(ab)Gordon,BM, 861Gwechenberger,R. Hancock. RD, 16P(ab) 175P(ab) 1336Gordon,I. 1331, 1491Groen,WE. 115P(ab)Gyulai, M, Handa, N, 242P(ab) Hauck, RW. 36P(ab) 307P(ab)Gorelick,L, l49P(ab),2IlP(ab),MW, 1970, 74P(ab)H.Muller,F, Hanelin, LG, 74P(ab) Hauser, M, 121P(ab) 45P(ab)Gorenberg,D, 216P(ab)Groen, Hanke, J, 1468 Haustermans, K, 54P(ab) 290P(ab),297P(ab)Corey,M, 67P(ab)Groeneveld.HJM, 584H\ojgaard,SH, Hankerson, J, 45P(ab) Hawk, TC, 22P(ab). 1316Groolhuis,ABJ, 261Haack, L, Hankins, D, 197P(ab) 219P(ab) 143P(ab),187P(ab),JG, 2021, 482Gropler, GMM, 87Haag,K, Hanks, JB. 158P(ab) Hawkes. DJ, 208P(ab) 281P(ab)Gorges, 82P(ab),83P(ab),RJ, 218P(ab)Haaparanta,S, Hanley, D, 905. 9P(ab). Hawkins, RA, 506 103P(ab).144P(ab),R, 161P(ab),222P(ab)Gros. 51P(ab).256P(ab)Haaxma-Reiche,M, 387, 168P(ab), 169P(ab), Hawkins, RE. 868 159P(ab)Goris, 239P(ab), 243P(ab) Hawkins, WG, 89P(ab), 211P(ab)Gormley,ML, 157P(ab)Groshar,M. 21P(ab)Habbab.N, H, Hanna, MG, 9P(ab) 90P(ab), 231P(ab) 119P(ab),170P(ab)Gosalbez,JE, 290P(ab),297P(ab)Grosmann.D, 1662Habbema, Hannah, A, 1683, 131P(ab), Hay, RV, 25P(ab) 19P(ab)Haber.JDF, 886, 132P(ab) Hayano, T, I36I 23P(ab)Goshen,R, 296P(ab)Gross,T, 74P(ab)Haberern,SB, Hanrahan, SM, 40P(ab) Hayashi, N, 251P(ab) 127P(ab)Goswami,E, 1778,15P(ab),MD, 852, 1540, l59P(ab)Haberkorn,G, Hansen, CL, 183P(ab) Hayashi. T, 1985, 150P(ab) 165P(ab)Goto,N, 27P(ab),l41P(ab),25P(ab), 68P(ab).147P(ab),U, 87, Hansen, HJ, 62P(ab), Hayashi, Y, 37P(ab) 10Gotti,R, 4 158P(ab),285P(ab), 154P(ab),234P(ab), 151P(ab), 239P(ab) Hayashida, K, I, 1824, 1575Gottlieb,NM, 306P(ab)Grossi, 235P(ab),249P(ab), Hansen, L. l7P(ab), 46P(ab), 277P(ab) 14P(ab),149P(ab)Gottschalk,C, 55Grossman,A, 257P(ab),264P(ab), 47P(ab), 190P(ab), Hayal, NJ, 48P(ab) 64P(ab),260P(ab),HB, 265P(ab),266P(ab)Haben, 191P(ab) Hayes, A, 57P(ab) 1313,1636Gottschalk,A, 577, 262P(ab)Grossman, Hanson, JM, 162P(ab) Hayes, MJ, 1275 165P(ab)Grossman,MI, 217P(ab)Habib,MO, Hanson, MW, 74P(ab), Hayles, SO, 140P(ab) 273P(ab)Gould,H, 76Grossmann,SJ, 35P(ab)Hachamovitch,MP, 154P(ab). 174P(ab) Haynor, DR. 2030 1701Gouliamos,KL, 1841Groth, K, 14P(ab).68P(ab),R, Harada, K. 189P(ab) Hayran, M, 1956, 257P(ab) 32P(ab)Govindan,A, 137P(ab)Grotta.W, 69P(ab),116P(ab), Harapanhalli, RS, l02P(ab) Hazenberg, MP, 108 62P(ab),151P(ab)Gown,SV, 272P(ab)Grover-McKay,J, 181P(ab),182P(ab)Hachiya.T, Harcke, HT, 23P(ab) He, XS. 2021, 143P(ab), 39P(ab)Groves, M, Hardoff, R, 1371. 245P(ab) l87P(ab) 267P(ab)Grabb,AM, 179P(ab)Gruenwald,B. 12P(ab)Hacken, Hardy. K. 45P(ab). 131P(ab). He, Z-X. 93P(ab), 178P(ab) 76Graf, BC, 138P(ab).252P(ab)Grunbaum,F, 230P(ab)Haddad,MT, 132P(ab) He. ZX, 58P(ab), 69P(ab). 76P(ab)Grafton,R, 178P(ab)Hagge,M, Harkness, B, 1639 126P(ab) 135P(ab),140P(ab)Graham,ST, 49P(ab)GrÃ¼nden,Z, 74P(ab)Hahn,RJ. Harkness, BA, 225P(ab) Heard, S. 275P(ab) 77P(ab)Grunder,G, 25P(ab),34P(ab),K, 1799. Harmon, W. 292P(ab) Heesters, MAAM, l57P(ab) 1557Graham,MC, 695, 112P(ab)GrÃ¼nwald,G, 56P(ab),156P(ab), Harolds, JA, 1517 Heiba, SI, 48P(ab) 2049,67P(ab),MM, 178, 1496,1962.F, 626, 236P(ab),252P(ab)Haider. Harrelson, JM, 1438 Heidendal, GAK, 1652 220P(ab),235P(ab)Graham, 134P(ab),243P(ab),100P(ab), Harrington, D. 218P(ab) Heifetz, L, 46 265P(ab),273P(ab)Gualdi, 144P(ab),175P(ab)Haim,N, Harrington, E, 272P(ab) Heil. W. 296P(ab) 143P(ab),152P(ab),W, Harrington, KJ, 54P(ab) Heilman, J. 142P(ab) 228P(ab)Grahman, 1452Guan,G, l39P(ab)Haines,N, Harrington, M, 272P(ab) Heine, J, 103P(ab) 221P(ab)Gralow,MM, 247P(ab)Gucuyener,SI, 79P(ab)Hajjar,JL, Harrington. WN. 241P(ab) Heineman, WR, 205P(ab) 252P(ab)Grana,JR, 1755Guenther,K, 144P(ab)Halama.RJ, Harris, AR, 29P(ab), Heinz, A, l43P(ab), 169P(ab)Granerus,C, 54P(ab)Guerchaft,I, 178Haie, JR, 232P(ab) 187P(ab), 281P(ab) 1876Graney,G. 274P(ab)Guha,M, 74P(ab)Haikar,CA. Harris. T, H9P(ab). 129P(ab) Heiss, W, 429 146P(ab).252P(ab)Granowska.W, 1643Guhlmann,S, ,Hall, RK, 293P(ab) Harrison, C, l81P(ab) Heiss, W-D. 76P(ab). 262P(ab)Guhlmann,A, 166P(ab)Hall,A, 54P(ab), Harrison, KA, 13S, 90P(ab) l22P(ab), 270P(ab) 96P(ab)Grant,M. 249P(ab)Guillaud,CA. 112P(ab).284P(ab)Halldin.H, 108P(ab), Harrison. RL, 172P(ab) Helbich, T, 254P(ab) 48P(ab)Grant,C, 188P(ab)Guilloteau,C, Harrop, R, 120P(ab), Held.J, 1468, 137P(ab) 293P(ab)Grapow,S, 186P(ab)Guimond,D, 76P(ab),108P(ab),C, 209P(ab), 219P(ab) Heller. GV, 14P(ab), 37P(ab), 138P(ab)Grassi,AS, 98P(ab)Guirao,A, H2P(ab),I92P(ab), Hart. E, HOP(ab) 58P(ab), 68P(ab), 42P(ab)Gratz.F, 80P(ab)Gulaldi.MA, 284P(ab)Halpern, Hartman. JJ, 1294, 39P(ab), 105P(ab). 149P(ab), 255P(ab)Graves,S, 290P(ab)Gulec,N, 92P(ab).182P(ab)Halson,SE. 83P(ab). 221P(ab) 150P(ab), l76P(ab). 295P(ab)Gravina,M, 238P(ab),255P(ab)Gullberg,SA, Hartman, L. 109P(ab) 177P(ab) 260P(ab)Graziano,A, 873Ham,P, Hartman, NG, 1578 Heller, SL, 838 162P(ab)Greco,FM, 8P(ab),18P(ab),GT, 1805Harnacher,HR, 1281, Hanmann, A, 273P(ab) Heilman, P, 1766 P(ab)Green,R, 25 1 97P(ab),206P(ab)Gulrajani,30P(ab), 41P(ab).I42P(ab)Hamad.K, Hasegawa, A, 3P(ab) Heilman. RS. 1285. 84P(ab) 107P(ab)Green,AL, Hasegawa, BH, 218P(ab) Heminway. SJ. H9P(ab). 1643Green,L, 4P(ab)Gunasekera,R, 138P(ab),252P(ab)Hamagami,K, Hasegawa, H, 30P(ab), 129P(ab). 151P(ab). 147P(ab)Green,LA, 91P(ab)Gunaydin,R, lllP(ab), 212P(ab) 202P(ab) 1294,51P(ab),MA, 1003, 184P(ab)Gunel.S, 1679Hamamoto,S, Hasegawa, S, 94P(ab) Hendel. RC, 14P(ab). 308P(ab)Green, 943GÃ¼nther,E, 180P(ab)Hamberg,K, Haseman. MK, 10P(ab). 81P(ab). 149P(ab), 204P(ab)Green,MV, 174P(ab)Guo,VJ, 950Hamblen,LM, IHP(ab), 132P(ab), l76P(ab), 2llP(ab), 293P(ab)Greenberg,N, 95P(ab)Gupta,LW, 61P(ab), 74P(ab),219P(ab)Hambye.AS,SM, I39P(ab) 216P(ab) 1589Greenes,CR, 12IP(ab)Gupta,N, 58P(ab), Hashikawa. K, l2P(ab). Hendershott, I, 249P(ab) 178Greenwald,RA, P(ab)Gupta,NC, 943, 261 175P(ab)Harnes. 242P(ab), 285P(ab) Hendi, P, HOP(ab), 1962Greer, F, 101P(ab).250P(ab),P, 75P(ab), 245P(ab)Hamill,W, Hashimoto, J, 30P(ab), 269P(ab), 30IP(ab) 154P(ab)GrÃ©goire.KL, 498, 267P(ab),269P(ab), 63P(ab)Hamill,J, 212P(ab) Hendrikse, NH, 1571 147P(ab)Grekin,MC, 272P(ab),273P(ab), 288P(ab)Hamilton,TG, 307. Hashish, AH, 873 Hendry, JH, 336 852Grierson,RJ, 301P(ab)Gupta, 1649Hamlin.D, Haskard. DO. l l4P(ab), Hengstler. JG. 233P(ab) 67P(ab),240P(ab)Griffiths.JR, 244P(ab)Gur,S, 151P(ab)Haniniami.DK, 128P(ab) Henkin, R, 15N(I) 554Gur,R, 26Hammami.M. Hassan, M, 35P(ab) Henkin, RE. 1903 GL, 62P(ab),96P(ab), RC, 1965, 283P(ab),284P(ab)Gur, MM. 993 Hasselquist, B. 142P(ab) Henneman. P. 1789

Author Index â€¢1996 2107 Hennessy, OF, 12!P(ab) Hirano, T, 273, 457, 1460 Hong, C, 283P(ab) Hundeshagen, H, 521,2066 261P(ab) Henry, JW, 1313, 1636 Hirose, Y, 1, 1824, 277P(ab) Hong, S-C, 127P(ab) Hung, JC, 84P(ab), 142P(ab) Inoue, Y, 183P(ab), 189P(ab) Henry,TR,41P(ab), Hirshfeld, A, 277P(ab) Honigman, S, 245P(ab) Hunter, GJ, 950 Intenzo, CM, 157P(ab), 222P(ab) HiÂ«,JM, 226P(ab) Hooper, PK, 128, 147P(ab), Hurley, D, 264P(ab) 260P(ab), 278P(ab) Henze, E, 4P(ab), l42P(ab), Hitzemann. R, 554 220P(ab) Hurwitz, RA, 286P(ab) Inugami, A, 12P(ab) 246P(ab), 256P(ab), Hilzemann, RJ, 1609, Hopkins, DM, lllP(ab) Huse, D, 286P(ab) lonna, F, 138P(ab) 257P(ab) 33P(ab). 44P(ab), 45P(ab), HÃ¶r,G, 1942, 9P(ab), Hussey, D, 202P(ab) losilevsky, G, 103P(ab) Henzlova, MJ, 60P(ab) 76P(ab) 121P(ab), 137P(ab) Hustinx, R, 250P(ab), Ine, T, 649 Heo. J, 14P(ab), 149P(ab), Hnatowich, DJ, 1655,2092, Hori, M, 1686, 183P(ab) 260P(ab), 261P(ab) Iriye, T, 975 150P(ab), 182P(ab) 152P(ab), 190P(ab) Horikoshi, S, 457 Hulchins, GD, 42P(ab), Irngartinger, G, 68P(ab) Hercovitch, P, 203P(ab), Hnatowski, DJ, 203P(ab) Horn, R, 273P(ab) 86P(ab), 270P(ab) Irvin. GL III, 798 230P(ab) Ho, D, 224P(ab) Horoszowski, H, 127P(ab) Hutchinson, RJ, 16 Irwin, AG, 92P(ab) Herda, SC, 1575, 84P(ab), Ho, MH, 85P(ab) Horowitz, M, 1643 Hutton, B, I915(le) Isaacs, RS, 136P(ab) 307P(ab) Hobson, D, 1589 Horowitz, S, 127P(ab) Hutton, BF, 137, 171P(ab), Isacson, O, 66P(ab) Herholz, K, 122P(ab), Hobson, LJ, 166P(ab) Horti, A, 6P(ab), HP(ab), 215P(ab) Isawa, T, 1460 270P(ab) Hock. JC, 167P(ab) 192P(ab), 208P(ab) Huysmans, DAKC, 2072 Ischise, M, 1591(ed), Herman, BE, 854 Hodgson, HJF, 114P(ab) Hosain, F, 105 Hwang, D-R, 118P(ab) 1591 (ed) Herman, SD, 14P(ab) Hoefler, G, 1524 Hoshi, H, 84, 901 Hwang, GJ, 469 Ishibashi, K, 244P(ab) Hermann, G, 297P(ab) Hoefnagel, CA, 584, 972, Hoshima, M, 1522 Hwang, SC, 303P(ab) Ishida, M, 12P(ab), 285P(ab) Hermus, ARMM, 2072 237P(ab), 287P(ab) Hoshizaki, H, 3P(ab), Hwang, T, 1595 Ishida, Y, 1, 1824, 277P(ab) Herrero. P, 1294, 1723, Hoekstra, A, 38 184P(ab) Hwang, YC, 118P(ab) Ishihara, M, 304P(ab), 39P(ab), 83P(ab), Hoekstra, HJ, 257, 984, Hosoda, S, 185P(ab) Hyun, H, 252 308P(ab) 147P(ab). 22IP(ab). 86P(ab) Hosokawa. R. 757, 1403, Hyun, IU, 89P(ab) Ishii, K, 123P(ab), l53P(ab), 222P(ab) Hoekstra, OS, 259P(ab) 1836 Hyun, IY, 28P(ab), 274P(ab) 220P(ab), 259P(ab) Herreros, J. 93P(ab) Hoeymans, PAJ, 1951 Hosokawa, T, 95P(ab), Ishii, S, 123P(ab), 215P(ab) Herrold, EM, 38P(ab) HotÃ¯er,PB, 11, 1749, 304P(ab) I.Syrbu, SI, 656 Ishii, Y, 192P(ab), 251P(ab), Herscheid, JDM, 38P(ab) 33P(ab), 44P(ab), Hosono, M, 304P(ab) Ichihara, T, 30P(ab), 257P(ab) Herschman, H, l07P(ab), 272P(ab), 285P(ab) Hou, N, 296P(ab) 212P(ab) Ishikawa.T, 209, 216, 1760, 147P(ab), 193P(ab) Hoffman, EJ, 52P(ab), Houle, S, 202P(ab) Ichikawa, A, l86P(ab) 1850 Herscovilch, P, 10P(ab) 73P(ab), 78P(ab), 130P(ab) Houlihan, MJ, 74P(ab) Ichimiya, A, 275P(ab) Ishikawa, Y, 5P(ab), Herskovic, T, 905, 9P(ab), Hoffman, JM, 41 P(ab), Houston, S, 32P(ab). 87P(ab) Ichise, M, 513, 8P(ab), 29IP(ab), 292P(ab) 168P(ab), l69P(ab), 19IP(ab), 222P(ab), Hove, M, 926 77P(ab), 280P(ab), Ishiwala, K, 279, 320, 239P(ab), 243P(ab) 298P(ab) Howard, RJ, 195 281P(ab) 123P(ab), 215P(ab), Hertel.A, l21P(ab), Hoffman, TJ, 61 P(ab), Howanh, DM, 1456 Ichiya, Y, 2IP(ab), 36P(ab), 259P(ab) 137P(ab) 185P(ab) Howman-Giles, R, 964, l33P(ab), 271P(ab), Ishizu, K, 374, 1600, 2057, Herz, M, 41P(ab), 99P(ab), Hofland, U, 24P(ab) 34P(ab). 46P(ab) 275P(ab) 101P(ab), 123P(ab) lllP(ab), 138P(ab) Hofmann, D, 296P(ab) Hoyes, KP, 336 Ichiyanagi, K, 1622, Isitman, AT, 1285, 84P(ab) Herzog, H, H3P(ab), Hofstaedter, F, 248P(ab) Hr, G, 1942 179P(ab) Iskandrian, AS, 794, 14P(ab), l66P(ab), 219P(ab), Hogendoorn, PCW. 270 Hsiau, HY, 27P(ab) Ido, T, 320 37P(ab), 58P(ab), 93P(ab), 222P(ab), 227P(ab), HÃ¶h,C, HOP(ab), 147P(ab), Hsu, H, 244P(ab) Iftikhar, I, 1306 149P(ab), 150P(ab) 283P(ab) 301P(ab) Hsu, L, 96P(ab) Iguchi, N, l85P(ab) l80P(ab), 182P(ab), Hess, EM, l2IP(ab) Hoh,CK,506.1428,1428, Hu, G, 85P(ab), 227P(ab) lida, H, l2P(ab), 110P(ab) 184P(ab) Hetherington, HP, 277P(ab) 1717,8P(ab),68P(ab), Hu, P, 127P(ab) lida, Y, 7P(ab) Isobe, H, 955 Hichwa, RD, 39P(ab), 99P(ab),l23P(ab), Huang, C. 437, 155P(ab) limura, O, 1679 Isobe, N, 184P(ab) 199P(ab), 221P(ab), 130P(ab).141P(ab), Huang, G, 207P(ab), lizuka. T, 184P(ab) Isono, K, 279 225P(ab), 226P(ab) l46P(ab),267P(ab), 210P(ab), 308P(ab) Ikeda, A, l01P(ab) Israel, O, 530, 103P(ab), Hickey, JJ, l44P(ab), 303P(ab) Huang, MH. 298P(ab) Ikeda, S, 1343 139P(ab). 297P(ab) l66P(ab) Hohenbcrger, P, 257P(ab) Huang, S, 506, 1717 Ikegami, T, 248P(ab) Issaq, E, 290P(ab) Hicks, K, 1472, 85P(ab), HolÃ¡n,V, 415 Huang, S-C, 55P(ab), Ikeno, E, 1289 Itami, J, 258P(ab) 227P(ab) Holdeman, KP, I3S 146P(ab), l63P(ab) Ikeoka, N, 641 Ito, H, 410 Hicks, KW, 931 Holden, JE, 421, 94P(ab) Huang, SC, 42P(ab), Ikota, N, 649 Ito, K, 271P(ab) Hider, R, l50P(ab) Holder, LE, 1740,2037, l09P(ab), 224P(ab), Ilgin, N, 45P(ab) Ito, Y, 66P(ab) Hierhol/er, J, 22 15P(ab), 104P(ab), 304P(ab) Im, J-H, 273P(ab) Itoh, K, 71,955, 16P(ab), Higashi, K. l7P(ab), 64P(ab). H8P(ab) Huang,WS, 247P(ab) Imahori, Y, 1673 239P(ab), 290P(ab), l22P(ab) Holgate, ST, 873 Huang,WT, 188P(ab) Imai, S, 680 291P(ab), 293P(ab) Higashi, T, 248P(ab) Holle, L, 615 Huang,Y,l45P(ab) Imamura, Y, 781 Itoh.T, 180P(ab) Higashi, Y, 246P(ab) Hollema, H, 67P(ab), Hubner,KF,l22P(ab), Imazeki, K, 258P(ab) Ilou, T, l53P(ab) Higazy, EE, 48P(ab) 263P(ab) 139P(ab),206P(ab), Imbert, B, 98P(ab) Ivancevic, V, 158P(ab) Higginbolham, C, 61P(ab) Hollenberg, M, 18IP(ab) 279P(ab) Imbriaco, M, 1528, 102P(ab) Ivanovic, M, 2l4P(ab) Higuchi, T, 273 Hollinger, EF, 210P(ab) HÃ¼bsch,P, 20P(ab) Inampudi, C, 89P(ab), Iwama, T, 277P(ab) Hildebrand, J. 21P(ab), Holman. BL, 178, 17P(ab), Hudson, HM, 171P(ab) 165P(ab), 277P(ab) Iwami, T, 1361 53P(ab) l58P(ab) Huerkamp, M. l91P(ab) Inanir. S, 184P(ab) Iwasaki. T, 680, 3P(ab), Hildcrson, JM, 857 Holmberg, ECV, 228 Huesman, MK, 146P(ab) Indolii, P, 256P(ab) 159P(ab) Hill, TC, 305P(ab) Holmberg, M. l20P(ab) Huesman, RH, 8P(ab), Ingels, M, 1605 Iwase, T, 304P(ab) Hilson, AJW, 92P(ab), Holmes, RA, H7P(ab). 130P(ah), 131P(ab), Ingvar, C, 622 Iwala, R, 1713 l()4P(ab) 232P(ab) 146P(ab), 155P(ab) Innis, RB, ll,32P(ab), lyo, M, 649 Hilton. E. l6IP(ab) Holschbach, M, 1841, Huggins, GS, 16IP(ab) 33P(ab), 44P(ab), 80P(ab), Izaki, M, 294P(ab) Hiltuncn. J, 76P(ab) H3P(ab), 142P(ab), Hughes, JMB, 1275 133P(ab), 134P(ab), Izzo, J, 29S Himi, T, H6P(ab) 20IP(ab), 283P(ab) Huisman, RM, 482 272P(ab),285P(ab) HiÃ±es,H. 53P(ab). 2IIP(ab) Holt, CS, 225P(ab) Hukuda, T, 3P(ab) Inobe,Y,80P(ab) Jabir, AM, 798 Hirai, J, 179P(ab), Hollinan, D, IIN(3) Hume, SP, I09P(ab), Inokuma,T,248P(ab) Jabre, A, 12P(ab) Hiraike, S, 1819 Horns, C. 4P(ab) 224P(ab) Inoue,O,66P(ab) Jackson, GE, 379 Hirakawa, K, 259P(ab) Homsy, Y, 23P(ab) Humm, J, 1052, 25S Inoue,T,457,931,1472, Jacob, T, 289P(ab) Hiraki, Y, 296P(ab) Honda, N, 304P(ab) Humm, JL, 78P(ab), 86P(ab), 159P(ab), Jacobs, A, 1605 Hirano, S, 123P(ab) Honda, T. 248P(ab) 102P(ab), 29S 184P(ab), 253P(ab), Jacobs, W, 293P(ab)

2108 The Journal of Nuclear Medicine Jacobson.AF, 117P(ab), Jones, R, 131P(ab), 132P(ab) Kao, PF, 288P(ab) Kemp.BJ, 2l3P(ab) 203P(ab) 177P(ab) Jones, T, 1275, 32P(ab), Kao,T, 172P(ab) Kempf.JS, 1662, 242P(ab), Kim, JH, 50P(ab), 305P(ab) Jacobson, GB, 1766 85P(ab), 191P(ab) Kapadia, KM, 114P(ab), 251P(ab), 277P(ab), Kim. JS, 305P(ab) Jacobsson, H, 1417 Jones, W, 85P(ab) 163P(ab), 259P(ab), 301P(ab) Kim, JY, 67P(ab) Jacquet, N, 250P(ab), Jones, WF, 86P(ab) 263P(ab), 265P(ab) Kengen, RAM, 91P(ab) Kim. KT. 248P(ab) 26IP(ab) Jones-Wilson, TM, 71P(ab) Kapadvanjwala, M, 96P(ab), Kennedy, J, 53P(ab), 78P(ab) Kim, M-K, 29P(ab), Jacquier-Sarlin, MR, 1413, Jons, P, 45P(ab) 162P(ab) Kerdraon, J, 1976 129P(ab), 203P(ab) 1694 Jonson, S, 99P(ab) Kaplan, MS, 2030, 223P(ab) Kes, S, 177P(ab) Kim. MS, 305P(ab) Jadali, F, 220P(ab), 269P(ab) Jordan, K, 1557 Kapp, OH, 279P(ab) Kessler, DB, 123P(ab) Kim. S, 28P(ab) Jagoda, E, 1408, 10P(ab), Jorfeldt, L, 208P(ab) Kappeier, C. 55P(ab), Kessler.J, 122P(ab) Kim, SE, 307, 179P(ab), 118P(ab), 152P(ab), Joshi, R, 53P(ab) 279P(ab) Kesteloot, D, 1048 226P(ab). 275P(ab) 197P(ab), 204P(ab), Joshi, V, ISOP(ab) Kapteijn, BAE, 972 Ketring, AR, 61P(ab) Kim, SM, 157P(ab). 254P(ab) Joubert, F, 188P(ab) Kapucu, LO, 1755, 139P(ab) Kettner, B, 20P(ab), 260P(ab). 278P(ab) Jahn, S, 51P(ab) Jousse, F, 39P(ab), 93P(ab), Karacay, H, 151P(ab) 158P(ab) Kim. SW, 312 Jain, D, 1783, 59P(ab) 160P(ab) Karaki, A, 116P(ab) Khalaf, AI, 48P(ab) Kim, T, 169P(ab) jailing, MF, 1519 Joyce, JM, 76 Karamoskos, P, 117P(ab) Khalkhali, I, 74P(ab) Kim. YC, 67P(ab) Jamadar, D, 288P(ab) Jung, TH, 268P(ab) Karayalcin, B, 1916(le), Khan, SH, 495 Kimes, A, 6P(ab), l92P(ab) Jamal, F, 147P(ab) Juptner, M, 279P(ab) 1917(le) Khandekar, S, 177P(ab) Kimiaei. S, 1417 Jamar, F, 916, 114P(ab), Jureidini, IM, 695 Karayalcin, G, 34P(ab), Khare,AB, 108P(ab), Kimmel, M, 4P(ab) 128P(ab), 258P(ab) Jurisson, SS. 96P(ab), 285P(ab) 280P(ab) Kimura, T, 248P(ab) Jana, S, 137P(ab) 165P(ab), 198P(ab) Karbe, H, 122P(ab) Khaw, BA, 4P(ab), 49P(ab), Kimura, Y. 153P(ab), Jang, S, 216P(ab) Juweid, M, 905, 9P(ab), Karlsson, P, 284P(ab) 50P(ab), l06P(ab), 220P(ab) Janicke, F, 99P(ab) 43P(ab), 44P(ab), Karp, JS, 1557, 19P(ab), 119P(ab), 144P(ab), King. K. 78 Janicki, C, 98P(ab) 168P(ab), 169P(ab), 130P(ab), 172P(ab), 175P(ab), 269P(ab) King, MA, 18P(ab). 30P(ab). Janier, MF, 147P(ab) 231P(ab), 232P(ab), 276P(ab) Khazaeli, MB, 1491. 63P(ab). 97P(ab), Jansen, F, 223P(ab) 239P(ab), 243P(ab) Karpman, HL, 82P(ab) 186P(ab) 127P(ab), 153P(ab), Jansen, H, 2082 Juweid, ME, 829, 1504 Kars, A, 1956 Kiat, H, 14P(ab), 59P(ab), 209P(ab), 212P(ab) Jansen, T, UP(ab), 71P(ab), Kasagi, K, 646 68P(ab), 69P(ab). 81P(ab), King. RB. 106P(ab) 108P(ab) Kabalka, GW, 194P(ab). Kaserer, K, 20P(ab) 93P(ab), ll6P(ab), King. SB III, 125P(ab) Janssen, AGM, 65P(ab), 279P(ab) Kashimada, A, 304P(ab) 149P(ab), l76P(ab), Kingstone, D, 92P(ab) 134P(ab) Kabasakal, L, 1285 Kashitani, N, 296P(ab) 180P(ab), 18IP(ab), Kinnala, A, 387 Jaszczak, RJ, 498, 120P(ab), Kachi, R. 126P(ab) Kashiwagi, T, 244P(ab) 182P(ab) Kinoshita, M, 712 154P(ab), 212P(ab), Kado, H. 12P(ab) Kasina, S, 29P(ab) Kido.Y, lllP(ab) Kinthaert, J, 1281 214P(ab), 216P(ab) Kadrmas, DJ, 7P(ab) Kassis,AI, 315, 343, Kiernan, FJ, 105P(ab) Kinuya. S. 44P(ab). 101P(ab) Jeanguillaume, C, 847 Kagan, M, 117P(ab), 102P(ab), 187P(ab), Kiesewetter, DO, 10P(ab) Kinzel, D, 157P(ab) Jenkin, B, 117P(ab) 119P(ab), 129P(ab), 229P(ab), IOS, 16S, 19S, Kigami.Y, 815, 1567 Kira. M, 80P(ab). 189P(ab) Jenkins, B, 66P(ab) 232P(ab) IS Kijewski. MF. 18P(ab). Kira, T, 80P(ab) Jeong, JM, 248P(ab), Kagetsu, NJ, 276P(ab) Kastis, GA, 301P(ab) 29P(ab), 77P(ab), Kirby, RJ, 96P(ab) 282P(ab) Kahan, BD, 292P(ab) Katayama, M, 975 I24P(ab), 153P(ab), Kirch, DL, 171P(ab), Jerabek, PA, 223P(ab) Kahn, D, 1583, 1876, Kathol, RG, 225P(ab) 158P(ab) 206P(ab) Jerusalem, G, 250P(ab) 31P(ab) Kato, C, 290P(ab), 291P(ab). Kijima, T, 304P(ab), Kirchner, PT,25N(1), 1815 Jewett, DM, 109P(ab) Kaji, T, 975 293P(ab) 308P(ab) Kirkby. BS, 79P(ab) Jinnouchi, S, 84,901, Kajiya, T, 37P(ab) Kalo, M, 271P(ab), 273P(ab) Kikuchi, K, 291P(ab), Kirkman, R, 186P(ab) 308P(ab) Kakishita, M, 101P(ab) Katoh, C, 16P(ab), 239P(ab), 292P(ab) Kirst, J, 252P(ab) Jochelson, M, 267P(ab), Kalaff, A, 280P(ab) 290P(ab), 291P(ab) Kilborne, R, 32P(ab) Kison, P. 98P(ab) 269P(ab) Kalaigian, H, 312, 1557 Katona, CLE, 65P(ab) Kilbourn. MR. 10P(ab), Kison, PV, 36P(ab), Joensuu, H, 256P(ab) Kaien, JD, 243P(ab) Katsetos, CD, 65P(ab), 21P(ab), l09P(ab) 260P(ab). 262P(ab) Johannsen, B, 16P(ab) Kalff, V, 117P(ab) 265P(ab) Kilgore, EJ, 1535 Kitano, H, 1600 Johanson, V, 2002 Kallenberg, CGM, 21P(ab) Katzenellenbogen, JA, 1009. Kilroy, K, 276P(ab) Kitschenberg. A, 273P(ab) Johansson, C, 1766 Kamada, T, 285P(ab) 28P(ab), 194P(ab) Kilts, C. 186P(ab). 191P(ab). KÃŒISÃŒOU.AN,1795, 25P(ab). Johansson, VJ, 1519 Kamal, T, 9P(ab) Kaufman, CI, 163P(ab) 298P(ab) 39P(ab), 60P(ab). 161P(ab) John, CS, 7P(ab), 205P(ab), Kamano, T, 304P(ab) Kaufman, GE, 275P(ab) Kim, AS, 1626 Kivlighn, S, 288P(ab) 267P(ab) Kamat. V, 69P(ab) Kaufmann. P. 922 Kim, BK, 978 Klain, M, 159P(ab) John,E,52P(ab),308P(ab) Kamiya, T, 572 Kaufmann, R, 137P(ab) Kim, BT, 179P(ab), Klein, GJ. 130P(ab), John,EK,489 Kamphuis, C, 62P(ab), Kawabe, K, 304P(ab) 226P(ab), 275P(ab) 131P(ab) Johnson,EG, 124P(ab) 171P(ab) Kawakami, Y, 955 Kim, C-G, 127P(ab) Klein, JL, 9P(ab), 97P(ab) Johnson,G III,l07P(ab) Kanagawa, M, 17P(ab) Kawano, S, 1824 Kim, CH, 268P(ab) Klein. S, 1789 Johnson,LL,50P(ab) Kanazawa, N, 184P(ab) Kawashima, R, 410 Kim. CK, 1487, 16P(ab), Klein. WP, 301 P(ab) Johnson,TK, 171P(ab), Kanegae, K, 71, 16P(ab), Kayden, D, 289P(ab), 60P(ab), 135P(ab), Klemm, E, lOOP(ab), 206P(ab) 239P(ab), 290P(ab), 302P(ab) 255P(ab), 268P(ab), 134P(ab), 138P(ab). Johnson, W, 97P(ab) 291P(ab) Kazumata, K, 1760, 1850, 297P(ab) 252P(ab), 280P(ab) Johnston, RE, 2079, 80P(ab) Kaneko, 5,291 P(ab), 133P(ab), 281P(ab) Kim, DI. 551 Kletter. K, 1480, 1872, Jolies, PR, 243P(ab) 292P(ab) Keast, RK, 212P(ab) Kim, EE, 931, 1472, 1476, 5P(ab), 46P(ab) Jolly, D, 55P(ab) Kang, X, 59P(ab), 81P(ab) Kee, JWM, 1023 72P(ab), 86P(ab), Klimke, A, 113P(ab) Jonas, M, 1865, 1990, Kanmaz, B, 233 Keep, PA, 868 127P(ab), 253P(ab). Kline, CM. l4P(ab) 49P(ab) Kanno, I, 137, HOP(ab), Kehoe, K, 140P(ab), 261P(ab), 264P(ab), Klinkowstein, RE, 61P(ab), Jones, AG, 17P(ab), 118P(ab) 165P(ab) 258P(ab) 296P(ab) 128P(ab) Jones, AKP, 74P(ab) Kanski, J, 293P(ab) Keil, R, 19IP(ab), 298P(ab) Kim, ES. lOOP(ab). 305P(ab) Klipper, R. 1374 Jones, DN, 1438 Kao, C, 437 Keir. ST. 61P(ab) Kim, EY, 2000 Klocke, FJ, 216P(ab) Jones, DW, 2021, 143P(ab), Kao, C-HK, 189P(ab) Kelham, SA, 302P(ab) Kim, H, 151, 136P(ab), Klok, R, 352 187P(ab), 281P(ab) Kao, CH, 145P(ab), Kellar, KJ, 6P(ab) 264P(ab) Klomp, H-J. 256P(ab) Jones, KL, 1643 l87P(ab), 188P(ab). Kelley. M, 249P(ab) Kim, H-J, 201P(ab), Kloos, RT, 1778, 15P(ab), Jones, LA, 128P(ab) 241P(ab), 245P(ab), Kelly. MJ, H7P(ab) 273P(ab) 158P(ab) Jones, M, 293P(ab) 292P(ab), 294P(ab), Kemeny. N, 25S, 29S Kim, HJ. 1965 Kloppenborg, PWC, 2072 Jones, PL, 343 295P(ab), 298P(ab) Kemerink, GJ, 1652 Kim, IS, 29P(ab), I29P(ab), Klumb. L, l51P(ab)

Author Index â€¢1996 2109 Knable, MB, 2021, 143P(ab), 2057, 95P(ab), 101P(ab), 268P(ab) Kuroki, T, 51,641 280P(ab) 187P(ab), 281P(ab) 123P(ab), 150P(ab), Krevsky, B, 818 Kurtaran, A, 1480, 5P(ab), Langen, K-J, 201P(ab) Knapp. FF Jr., 6P(ab), 175P(ab), 200P(ab), Krishna, L, 65P(ab), 20P(ab), 46P(ab), 251P(ab) Langhammer, HR, 36P(ab) l66P(ab), 184P(ab), 203P(ab), 248P(ab) 163P(ab), 259P(ab), Kuruc, A, 155P(ab) Langstrom, B, 32, 1766 186P(ab), 193P(ab), Konopka, LM, 275P(ab) 263P(ab), 265P(ab) Kusakabe, K, 185P(ab) Laniece, P, 303P(ab), 195P(ab), 202P(ab), Kool, W, 67P(ab) Krishnamurthy, GT, 35P(ab), Kusama, Y, 304P(ab), 306P(ab) 236P(ab) Koomans, HA, 289P(ab) 72P(ab), 95P(ab) 308P(ab) Lanman, T, 272P(ab) Knapp, WH, 114P(ab) Koops, HS, 257, 984, Kroger, LA, 451, 129P(ab), Kusano, S, 975 Lansimies, E, 45P(ab) Knecht, R, 1942 86P(ab) 167P(ab) Kushner, SA, 66P(ab), Lapela, M, 256P(ab) Knesaurek, K, 2l6P(ab), KÃ¶per,JW, 108 Krohn, KA, 2049, 43P(ab), 201P(ab), 219P(ab) Lapidus, A, 47P(ab) 38P(ab) Koplan, BA, 1398 49P(ab), 67P(ab), 70P(ab), Kusic, Z, 446 Lapke, J, 1516 Knight, J, 46P(ab) Koponen, H, 45P(ab) 106P(ab), HOP(ab), Kusuoka, H, 761, 1686, Laprovitera, A, 156P(ab) Knight, LC, 476, 775, 818, Koral, KF, 78P(ab) l46P(ab), 194P(ab), 66P(ab), 94P(ab), 175P(ab) Laragh, JH, 838 57P(ab), 244P(ab) Koray, Z, 145P(ab) 205P(ab), 235P(ab) Kuwabara, H, 55P(ab), LaRiccia, P, 278P(ab) Knight, RJ, 3P(ab) Korf, J, 2082 Krois, D, 20P(ab) 223P(ab) Larkin, R, 171P(ab) Knight, S, 121P(ab) Korkmaz, M, 931, 1472, Kroiss, A, 241P(ab) Kuwabara, Y, 21 P(ab), Larsen, RH, 197P(ab) Knoll, GF, I19P(ab), 1476 Kroker, B, 4P(ab) 36P(ab), 116P(ab), Larson, SM, 312, 695, 1052, 170P(ab) Korn, RL, 92P(ab), 132P(ab) Kroll, K, 49P(ab), 70P(ab), 133P(ab), 271P(ab), 1528, 1557, 43P(ab), Knollema, S, 2082 Kornblum, HI, 56P(ab) 106P(ab) 275P(ab) 78P(ab), 102P(ab), Knopp, MV, 296P(ab) Komek, G, 1480, 20P(ab) Kronauge, JF, 118P(ab) Kuwert, T, 268P(ab) 138P(ab), 25S, 29S Knust, El, 279P(ab) Kornhuber, J, 1931 Kronik, G, 115P(ab) Kuyama, J, 258P(ab) Larsson, SA, 1417 Kobashi, T, 304P(ab) Korobkin, M, 158P(ab) Kroode, HFJ, 1511 Kuyvenhoven, JD, 857 Lamelle, M, 32P(ab), Kobayashi, H. 29P(ab), Korupolu, G, 10P(ab) Kroon, BBR, 972 Kwan, W, 534 33P(ab), 272P(ab), 129P(ab), 185P(ab), Kosa, I, 126P(ab) Kropp, A, 6P(ab) Kwekkeboom, DJ, 108, 886, 285P(ab) 203P(ab) Kose, G, 1755 Kroser, JA, 246P(ab) 19P(ab), 141P(ab) Lasku, A, 238P(ab) Kobayashi. K, 51,641, Koshida, K, 44P(ab) Krouwer, HGJ, 465 Kwok, CG, 165,2062 Lassen, NA, 13P(ab), 66P(ab) Kosinski, AS, 125P(ab) Kruijer, PS, 38P(ab) Kwong, JS, 36P(ab) 164P(ab) Kobayashi, Y, 64P(ab) Koss, JE, 171P(ab), 206P(ab) Kruschke, C, lllP(ab) Lassmann, S, 246P(ab) L'Abbate, A, 735 Koch, P, 967 Koslakoglu, L, 1771, 1956, Krynyckyi, BR, 1995, Lastoria, S, 665, 138P(ab), Kocher, F, 249P(ab) 257P(ab), 282P(ab), 10P(ab), 162P(ab) La Rue, A, 79P(ab) 155P(ab), 156P(ab), Kodaira, S, 15P(ab) 291P(ab), 177P(ab) Krystal, J, 33P(ab), 285P(ab) Labarberra, J, 92P(ab) 199P(ab) Kodner, U, 132P(ab) Kosten, TR, 44P(ab) Krystal, JH, 11 LaBombardi, V, 242P(ab) Latour, Y, 69P(ab) Koenders, E, 169P(ab) Kosuda, S, 975, 260P(ab), Kuang, L-R, 72P(ab), Labrouche, S, 863 Lattanand, C, 252P(ab), Koenders, EB, 1392 262P(ab) 86P(ab), 264P(ab) Lacey, J, 232P(ab) 278P(ab) Koeppe, RA, 201, 10P(ab), Kotoo, Y, 26P(ab), 58P(ab), Kubo, A, 15P(ab), 30P(ab), LaCroix, KJ, 78P(ab), Laubenbacher, C, 99P(ab), 21P(ab), 109P(ab), l26P(ab), 185P(ab) 212P(ab) 80P(ab), 210P(ab) 114P(ab), 1918(le) 164P(ab), 285P(ab) Kotz, D, 11N(4), 20N(5), Kubota, K, 320, 1713, Lacy, JL, 52P(ab), 308P(ab) Lauchart, W, 200P(ab) Koeppel, JA, 225P(ab), 27N(5), 15N(6), 19N(9), 67P(ab) Lade, K, 233P(ab) Laureys, S, 88P(ab) 226P(ab) 19N(10), 21N(11), 17N(12) Kubota, R, 320, 1713 Ladner, RC, 152P(ab) Lavigne, GJ, 271P(ab) Koeter, GH. 265P(ab) Kotzerke, J, 2066, 160P(ab), Kudoh, T, 729, 1981, 1985, Lafair, J, 1537 Lawson, M, 224P(ab), Koffler, SP, 259P(ab) 249P(ab) 150P(ab), 175P(ab) Lagerwaard, A, 24P(ab) 304P(ab) Kofoed, KF, 3P(ab) Koutelou, M, 1306 KÃ¼hl,DE, 201, 10P(ab), Lago, G, 1919(le), 266P(ab) Lay Ergun, E, 291P(ab) Koga, S, 282P(ab) Kouyoumdji, JC, 233P(ab) 21P(ab), 109P(ab), Laguna, R, 287P(ab) Layfield, L, 1438 Kob, C, 639, 978 Kovanlikaya, A, 286P(ab) 163P(ab), 164P(ab), Lakkis, NM, 58P(ab), Lazewatsky, J, H7P(ab), Kob, C-S, 28P(ab), 89P(ab), Kowalsky, W, 1662 2l5P(ab), 270P(ab) 126P(ab) 119P(ab), 129P(ab), 100P(ab), 248P(ab), Koyama, H, 1522, 246P(ab) Kuhle, W, 767 Lally, KP, 162P(ab) 232P(ab) 274P(ab), 282P(ab) Koyama, K, 304P(ab) Kuikka, JT, 45P(ab), Lalush, DS, 63P(ab), Lazzarin, A, 258P(ab) Koh, W-J, 235P(ab) Koyama, M. 410, 12P(ab) 76P(ab), 1911(le) 80P(ab), 210P(ab) Le, D, 847 Kohlmyer, SK, 223P(ab) Koyanagi, T, 71 Kuker, RA, 255P(ab) Lambert, C, 167P(ab) Le, N, 1384, 29P(ab), Koike, S, 807, 248P(ab) Kozan, O, 302P(ab) Kukis, DL, 128P(ab), Lambert, R, 1368, 23P(ab), 129P(ab), 196P(ab), Koivislo, M, 22P(ab) Kozarek, RA, 57P(ab) 129P(ab), 167P(ab) 75P(ab), 180P(ab) 203P(ab), 234P(ab) Koizumi, K, 1551, 1819, Kozawa, S, 67P(ab) Kulago, A, 194P(ab) Lamberts, SWJ, 108, 886, Le Bouedec, G, 922 64P(ab), 254P(ab) Kraan, J, UP(ab), 7IP(ab), Kumar, V. 83P(ab) 19P(ab), 24P(ab) Le Doussal, JM, 129P(ab) Kojima, A, 80P(ab), 108P(ab) Kumazaki, T, 304P(ab), Lamberty, GJ. 225P(ab) Le Guludec, D, 70P(ab), 171P(ab), 189P(ab) Kramer. EL. 169P(ab) 308P(ab) Lamborn, KR, 1970, 181P(ab), 253P(ab), Kojima, K, 280P(ab) Krams, M, 55P(ab) Kume, N, 807, 1361 129P(ab), 170P(ab) 256P(ab) Kojima, S, 326 Krasenbaum, DN, 77P(ab), Kumita, S, 304P(ab), Lambrecht, RM, 1557 Le Poncin, M, 274P(ab) Kokote, H, 304P(ab) 112P(ab) 308P(ab) Lameire, N, 1048 Leach, C, 142P(ab) Kolachana, B, 77P(ab) Krasnow.AZ, 1285, 84P(ab) Kumpe, D, 295P(ab) Lamki, L, 162P(ab), Leahy, R, 155P(ab) Kolan, H, 151P(ab) Krause, BJ, 9P(ab) Kung, HF, 151,513, 1965, 272P(ab), 292P(ab) Lear, JL, 95P(ab), 295P(ab) Kolar, Z, 72P(ab) Krause, T, 218P(ab) 17P(ab), 66P(ab), Lammertsma, AA, 71P(ab), Leb, G, 1524 Kolb, FP, 55P(ab) Krausz, T, 1275 190P(ab). 201P(ab), 106P(ab), 109P(ab), Lebesque, JV, 584 Kolbcrt, K, 102P(ab) Krausz.Y, 1537 219P(ab), 281P(ab) 224P(ab) LeBlanc, JW, 170P(ab) Kole, AC, 86P(ab) Krawczynska, EG, 48P(ab), Kung, M, 151 Lamonica, D, 135P(ab) Lebtahi, R, 275, 253P(ab), Kolodny, GM, 103P(ab), 125P(ab), 179P(ab) Kung, M-P, 17P(ab), Lan, R, 187P(ab) 256P(ab) 172P(ab), 305P(ab) Krebs, D, 626 66P(ab), 190P(ab), Lanahan, MV, 128P(ab), Ledere, J, 912 Kolsky, K, 150P(ab), Kreis, JM, 95P(ab) 201P(ab) 201P(ab) Lecloirec, J, 1946 167P(ab) Kreissig, I, 137P(ab) Kung, MP, 1965 Landeau, B, 95 Lecomte, R, 2040, 2046, Komori, T, 263P(ab), Krems, B, 257P(ab), Kunst, E, 54P(ab) Lands, EL, 149P(ab) 170P(ab) 296P(ab) 264P(ab) Kunzi, G, 51P(ab) Lang, J, 287P(ab) Lee, B, 426 Kondoh.T, 180P(ab) Krenning, E, 748 Kurczak, S, 167P(ab) Lang, L, 1408, 118P(ab), Lee, D, 978 Koneru, S, 104P(ab) Krenning, EP, 108, 886, Kurita, T, 246P(ab) 197P(ab), 203P(ab), Lee, DS, 639, 28P(ab), Konishi, J, 374, 572, 646, 1388, 19P(ab), 24P(ab), Kuroda,T, 116P(ab) 204P(ab) 89P(ab), lOOP(ab), 729,757, 1365, 1403, 48P(ab), 60P(ab), Kurogane, H, 37P(ab) Lang, S, 999, 1526, 266P(ab) 248P(ab), 274P(ab), 1600,1836,1981,1985, 141P(ab), 190P(ab), Kuroki, M, 84 Langason, RB, 108P(ab), 282P(ab)

2110 The Journal of Nuclear Medicine Lee, H, 1016 53P(ab) 120P(ab),208P(ab)Line,Lindstrom, C, 269P(ab)Lopalco,R, 267P(ab), 250P(ab), 255P(ab). Lee, HH, 82P(ab) Levy,AV,41P(ab) 238P(ab)Lopresti.L, 272P(ab), 297P(ab) Lee, HK, 252P(ab), 273P(ab) Lewellen, B, 67P(ab) 117P(ab),143P(ab),BR, 87P(ab), 109P(ab),145P(ab)Lorberboym,B, Machecourt, J, 229P(ab) Lee, J, 268P(ab), 293P(ab) Lewellen, TK, 2030, 148P(ab),232P(ab)Line, Machida, K, 304P(ab) Lee, JD, 426, 469, 551 67P(ab), 172P(ab), 467,1487, M, 415, Machulla, H-J, 27P(ab), Lee, JR, 226P(ab) 223P(ab), 224P(ab), 281P(ab)Link,SW, 16P(ab),60P(ab),1528, 200P(ab) Lee, JS, 303P(ab) 235P(ab) 67P(ab),70P(ab),JM, 2049, 135P(ab),255P(ab), Maclntyre, WJ, 1809, Lee, JY, 305P(ab) Lewington, VJ, 1058 194P(ab),205P(ab)Link, 297P(ab)Lorenz, 177P(ab), 276P(ab) Lee, KB, 179P(ab), 268P(ab) Lewis, DH, 12P(ab) 9P(ab)Lorenz,M, Macke, HR, 29P(ab) Lee, KH, 639, 179P(ab), Lewis, DP, 80P(ab), 146P(ab)Linke,M, 110P(ab), 34P(ab)Lorenz,S, MacMullan, J, 100P(ab) 226P(ab), 275P(ab) 210P(ab) 56P(ab)Linse,R, 154P(ab),221P(ab),WJ, 2024, Macrae, IM, 661 Lee, KS, 551,2021, Lewis, J, 138P(ab) !66P(ab)Liow,KH, 249P(ab),266P(ab), Macrum, B, l81P(ab) 143P(ab), 187P(ab), Lewis, JS, 166P(ab) 227P(ab)Lipowska,J-S, 73P(ab), 296P(ab)Losman, Madar, I, 1428, 1428 281P(ab) Lewis, PJ, 100P(ab), 17P(ab),46P(ab),M, 62P(ab)Lottgen,MJ, Maddahi, J, 1428, 1428, Lee, L, 278P(ab) 271P(ab) 190P(ab),191P(ab)Lipp, 429Loucif,J, 68P(ab), 99P(ab), Lee, M, 978 Lewis,R,142P(ab) 129P(ab)Low,E, 141P(ab), 267P(ab), Lee, M-J, 273P(ab) Lexa,RN,210P(ab) 1524Lipszyc,RW, 1003Lowe,PS, 301P(ab) Lee, MC, 639, 28P(ab), Ley,A,152P(ab),205P(ab) 1016,38P(ab),H, 673, 136P(ab),249P(ab),VJ, Madras, BK, 17P(ab). 89P(ab), 100P(ab), Leyton,M, 113P(ab), 152P(ab),272P(ab)Lisbona, 264P(ab),303P(ab)Lowellen, 65P(ab) 248P(ab), 274P(ab), 284P(ab) Madsen, M, 39P(ab) 282P(ab), 305P(ab) Li,J,489,498,30P(ab), 1853Lister-James,A, 146P(ab)Lowenberg,TK, Maecke, H, 20P(ab) Lee, MT, 205P(ab) 151P(ab),205P(ab), 775,1016, J, 673, 19P(ab),268P(ab)Lu,B, Maecke, HR, 967 Lee, RJ, 1003 214P(ab) 138P(ab),152P(ab),20P(ab), Maeda, G, 1444 Lee, SH, 179P(ab) Li,N,61P(ab) 204P(ab),272P(ab)Little, 38P(ab)Lu,P, Maeda. T, 296P(ab) Lee, SK, 100P(ab), 194P(ab) Li,PY,665 227P(ab)Lubin,W, 85P(ab), Maekawa, M, 1673 Lee, WS, 551 Li,S,1480,92P(ab) 171P(ab),206P(ab)Liu,EP, 259P(ab)Lubushilzky,E, Maes, A, 767, 26P(ab) Lee, YJ, 248P(ab) Li,SR,20P(ab),251P(ab) I03P(ab)Lucht,R, Maffioli, L, 251P(ab) Leenders, K, 54P(ab) Li,X,227P(ab) 209P(ab)Liu,A, 221P(ab)Lucignani,R, Magata, Y, 572, 729, 1600, Lefebvre, F, 863 Li.Y,10P(ab),127P(ab) 89P(ab),165P(ab),HG, 88P(ab), 42P(ab),133P(ab),G, 123P(ab), 175P(ab), Legal, JD, 1860 Li,Z,106P(ab),HOP(ab), 235P(ab),276P(ab), 258P(ab)Ludlum, 192P(ab), 248P(ab) LeGuludec, D, 275 146P(ab) 277P(ab)Liu, 207P(ab)Ludwig,!,D, Magid, NM, 38P(ab) Lehikoinen, P, 256P(ab) Liang, P, 958 207P(ab)Liu,J, 154P(ab)Luger, Magnani, P, 967, 1655 Lehmann, WD, 362 Liang, Z, 218P(ab) 210P(ab),215P(ab)Liu,L, 81P(ab), 1931Lugo,A, Magoun. S, 1913(le) Lehner, H, 20P(ab) Liberzon, I, 285P(ab) 74P(ab)Lui,CE, MÃ¤he,M, 1853, 1970 Lehr, HA, 267P(ab) Licata, AA, 1809 1349Liu,R, 78, 332Lukasiewicz,W, Mahmarian, JJ, 1306, Lei, K, 190P(ab), 203P(ab) Lieh, LL, 1009, 226P(ab) 125P(ab),136P(ab),RS, 27P(ab), 17P(ab),148P(ab),R, 1 58P(ab), 69P(ab), 93P(ab), Leibenhaut, MH, 139P(ab) Licho, R, 127P(ab), 275P(ab) 172P(ab),262P(ab), 232P(ab)Lukinac, 126P(ab), 178P(ab) Leichner, PK, 89P(ab), Lidov, M, 467 286P(ab)Liu, 446Lumbroso,L, Mahmood, A, 17P(ab) 90P(ab), 231P(ab), 13S Lie, KI, 1631 119P(ab),129P(ab),S, 29P(ab), 912,20P(ab),J, 598, 893, Mahmood, K, 145P(ab) Leimer, M, 1480, 5P(ab), Liebeg, J, 211P(ab) 232P(ab)Liu, 52P(ab)Lumenta, Mahmoud. S, 289P(ab) 20P(ab), 251P(ab) Lieberman, J, 44P(ab) 1491Liu,T, 157P(ab)Lundkvist,C, Mahmud, AM, 1460 Leinenen, E, 45P(ab) Lieberman, R, 13S 308P(ab)Liu,Y-H,WG, l08P(ab),112P(ab),C, Mahoney, DW, 142P(ab) Leitha, T, 1526,46P(ab), Liebes, L, 169P(ab) 81P(ab)Liu, 192P(ab),284P(ab)Lung-Kurt, Mahraj, RPM, 294P(ab) 115P(ab), 254P(ab), Liedtke, AJ, 94P(ab) 196P(ab)Liu,YF, Mainenti, PP, 164P(ab) 266P(ab) Lieg, JL, 144P(ab) 62P(ab)Liu,YH, 615Luo, S, MainoltÃ¬,C, 260P(ab) Leitho, T, 999 Liegner, KB, 270P(ab) l07P(ab)Livingston,Z, 63P(ab)Luo,D-S, Mainlz, JBA, 213P(ab) Lelcuk, S, 259P(ab) Liem, IH, 972 252P(ab)Livni,DA, 193P(ab),202P(ab)Luong,H. 6P(ab), Maisey, MN, 1771, 27P(ab), Lemmens, JAM, 62 Lietzenmayer, R, 1468, 66P(ab)Lo,E, 65P(ab), 87P(ab), 208P(ab), Lenaers, A, 83P(ab) 134P(ab), 137P(ab) 188P(ab)Lobbezoo,JM, 513Luthra,A, 282P(ab) Leners, C, 916 Ligtenauer-Kaligis, EGR, 271P(ab)Lobmann,F, 109P(ab),191P(ab)Lutrin,SK, Maish, D, 151P(ab) LeonardJr., MH, 926 24P(ab) 104P(ab)LoBuglio,R, Majd, M. 1731,34P(ab) LeÃ³nidas, J, 34P(ab) Lillehei, C, 292P(ab) 1491Locati,AF, 139P(ab)Lutz,CL, Makihara, S, 296P(ab) Leonzi, O, 1300 Lim, BB, 7P(ab) 37P(ab)Lodewijks,EH, l22P(ab)Luxen.S, Makriyannis, A, 187P(ab) LepÃ³la, U, 45P(ab) Lim, J, 16P(ab) 268P(ab)Loeffler,H, 53P(ab)Luzi,A, Makuch, R, 1783 Leppo, JA, 160P(ab) Lim, JL, 282P(ab) 158P(ab)Loessner,JS, 633Lyster,S, Maldonado, A, 93P(ab), Lequen, H, 893 Lim, S, 131P(ab), 146P(ab), 252P(ab)Logan,A, 36P(ab),219P(ab)Lythgoe,DM, Malholtra, S, 115P(ab) Lerch, H, 106P(ab) 267P(ab), 269P(ab) 33P(ab),41P(ab),44P(ab),J, 554, Malholra, S, 105P(ab) Leskinen, S, 256P(ab) Lim, SK, 469 45P(ab),281P(ab)Logothetis, 1336M'Kacher,MF, 1331, Mali, WPThM, 289P(ab) Leslie, WD, 861, 1589 Lim, SM, 248P(ab) Malik, AB, 1545 1860Ma, R, Leung, A, 117P(ab), Limouris, GS, 32P(ab) 32P(ab)Loi, C, Malison, R, 201P(ab) 288P(ab) Lin.C, 1349 565Lombardi,G, 223P(ab)Maas,Y, 222P(ab), Malison, RT, 44P(ab), Leung,JY,1042.65P(ab) Lin, CH, 1749 159P(ab)Lommatzsch,G, 23P(ab)Macapinlac,K, 272P(ab) Leung,W, lOOP(ab) Lin, HM, 136P(ab) 236P(ab)Lomuscio,B, 1528,102P(ab)Macapinlac,H, MallÃn,W, 798 Levchenko,A,312 Lin, KP, 130P(ab) 236P(ab)Loncaric,G, Mallmann, P, 626, 265P(ab) Leveille,J,1368,75P(ab), Lin, Q, 6P(ab) 207P(ab),214P(ab)London,S, 29SMacaulay,HA, 25S, Malone, KM, 123P(ab) 180P(ab) Lin, W, 332 1826MacDonald,RD, Maloof, J, 943 Lever, JR, 193P(ab) Lin, WY, 145P(ab), 6P(ab),HP(ab),ED, 52P(ab),78P(ab),LR, Malveaux, E, 46P(ab), Lever, SZ, 189P(ab) 163P(ab), 234P(ab), 192P(ab),201P(ab), 119P(ab)Macey, 97P(ab), 191P(ab), Levi, H, 211P(ab) 288P(ab), 294P(ab) 279P(ab)Longford, 207P(ab).232P(ab),DJ, 1970, 298P(ab) Levi, L, 242P(ab) Lin, Z, 57P(ab) 194P(ab),279P(ab)Lonn,CPD, 234P(ab)Mach, Mamiya, T, 304P(ab) Levin, CS, 52P(ab), 78P(ab) Lindauer, M, 87 87P(ab),281P(ab)Machac,RH, Mammone, GL, 178 Levin, Z, 125P(ab) Lindholm, P, 256P(ab) 80P(ab),210P(ab)Lonneux,AHR, Mandai, AK, 118P(ab) Levine, A, 4P(ab) Lindner, KJ, 32 16P(ab),38P(ab),J, 415, Mandel, F, 209, 216, 1760 Levine, TB, 4P(ab) Lindroos, M, 51P(ab) 258P(ab)Looby,M, 60P(ab),152P(ab), Mandel, S, 278P(ab) Levivier, M, 21P(ab), Lindstedt, G, 1519 RJ, 29P(ab)Look, 216P(ab), Mandelkern, MA, 53P(ab).

Author Index â€¢1996 2111 79P(ab), 123P(ab) Martin, WG, 114P(ab) Matsushima, Y. 1613 McNeill, G, 183P(ab) Michiels, P, 91P(ab) Mandell, GA, 23P(ab) Martinez, M, 266P(ab) MatterÃ , JA, 81P(ab) McNerney.A, 167P(ab) Michigishi, T, 101P(ab) Mandell, L, 255P(ab) Martini, L, 88P(ab) Matters, J, 1783 McNulty, PH, 50P(ab) Michette, A, 88P(ab) Mandigers, CMPW, 270 Marionen. TB, 873 Mattes, MJ, 239P(ab) McPeck, M, 239 Middleton, ML, 171 Manetou, A, 32P(ab) Maruyama, I, 257P(ab) Matteucci, F, 22S McPherson, DW, 6P(ab), Miedema,AR, 1449 Manetti, C, 129P(ab) Marwin, S, 241P(ab) Matthew, E, 270P(ab) 186P(ab). 193P(ab), Miers. LA, 128P(ab), Mangner, TJ, 4P(ab), Marx, D, 2006 Matthews, DC, 233P(ab) 202P(ab) 129P(ab), 167P(ab) 5IP(ab), l45P(ab) Mandili. LG. 17P(ab). Matthews. WB, 107P(ab) Mdaka,T, 1323 Mignon, M, 253P(ab), Maniam, S, 80P(ab), 46P(ab), l90P(ab). Maublant, J, 922 Meadors, K, 86P(ab) 256P(ab) 210P(ab) 19IP(ab) Maunoury, C, 2037, Meares, CF. 451, 128P(ab), Mikami, Y, H6P(ab) Maniawski, PJ, 209P(ab). Marzullo, P, 735 104P(ab) 167P(ab) Miki, M, 1460 214P(ab) Masaki, H, 781 Maurea, S, 159P(ab), Mease, RC. 72P(ab), Mikuni, N, 101P(ab) Manil, L. 893 Masaki, K, 641 260P(ab) 167P(ab) Milan, E, 1300 Mankoff, DA. 2049, 67P(ab), Mascitelli, VA, 37P(ab), Maurer, AH, 476, 775, 818. Mechanick, JI, 1487. 1528, Milas, L, 72P(ab), 253P(ab) 140P(ab), 252P(ab), 177P(ab) 57P(ab), 244P(ab) 135P(ab) Milko, DL, 74P(ab) 267P(ab) Masdeu, J, 277P(ab) Mausner, LF, 72P(ab), Meegalla, S, 151 Millard, RW, 752, 49P(ab), Mann.JJ, 123P(ab), Mash, DC, 108P(ab) 128P(ab), l50P(ab), Meegalla. SK, 17P(ab) 188P(ab) 273P(ab) Mason. G, 1789, 277P(ab) 167P(ab), 195P(ab) Mehdorn, HM, 257P(ab) Miller, DD, 14P(ab), Mannino, T, lOOP(ab). Masone, M, 256P(ab) Maxted, D, 15P(ab) Mehling, R, 118P(ab) 68P(ab), 69P(ab) 305P(ab) Massarino, F, 243P(ab) May, A, 279P(ab) Mehta, BM, 312 Miller, JH, 286P(ab) Manolidis, S. 136P(ab) Mastrangelo, R, 237P(ab) May, CC, 304P(ab) Mehta, HH, l61P(ab), Miller, MA, 57P(ab), Mansi, L, 156P(ab), Mastrangelo, S, 237P(ab) Mayberg, HS, 223P(ab) 241P(ab), 285P(ab) 244P(ab) 256P(ab), 264P(ab) Maslrippolito, R, 303P(ab), Mayer, EA, 123P(ab) Meier, DA, 1745 Miller, MM, 63P(ab) Mantil.JC, H8P(ab) 306P(ab) Mazaika,T, 129P(ab), Meijer, S, 259P(ab) Miller, RF, 995 Mantwill, K, 142P(ab) Mastrofrancesco, P, 50P(ab) I51P(ab), 202P(ab). Meikle. SR, 128, 220P(ab) Miller, S, 31P(ab) Mar. W, 282P(ab) Masuda, I, 1985, 150P(ab) 232P(ab) Meinken, GE, 72P(ab), Miller, SD, 209P(ab), Maragliano, C. 243P(ab), Masuda. K, 815, 21P(ab), Mazza, SM, 193P(ab), 195P(ab) 214P(ab) 297P(ab) 36P(ab), I33P(ab), 282P(ab) Mekhmandarov, S, 259P(ab) Miller, TR, 63P(ab), Marcassa. C. 735 271P(ab), 275P(ab) Mazziotta, JC, 79P(ab) MÃªle,FM, 296P(ab) 217P(ab) Marcel, R, 160P(ab) Masuda. Y, 116P(ab) Mazzucchelli, L, 236P(ab) Melega, WP, 55P(ab), Milo, TJ, 275P(ab) Marchetti, D, 9P(ab) Masuyama, M. 1522 McAndrews, P. 46 109P(ab), 163P(ab) Minami, C, 1789, 230P(ab), Marchlinski, F. 14P(ab), Matlfias-Guiu. X. 631 McBride, BJ, 1016 Melhem, E, 12P(ab) 231P(ab) I49P(ab) Matalka, KZ, 343 McBride, JG, 4P(ab) Melin, J, 25P(ab), 39P(ab), Minard, TL, 259P(ab) Marcus, C, 230P(ab), Matheja, P, 268P(ab) McCallum, RW, 57P(ab) 126P(ab) Minn. H, 256P(ab) 231P(ab) Matheoud, R, 230P(ab) McCarron, JA, 112P(ab) Melissano, G, 55 Minosako, Y, 94P(ab) Marcus, CS, 1789 Mather, SJ. %P(ab), McCarthy, A, 34P(ab) Meiler, J, 255P(ab) Minoshima, S, 21P(ab), Mardirossian, G, 1583, 150P(ab) McCarthy, DW, 61P(ab), Meltzer, CC, 269P(ab), 163P(ab), 164P(ab), 190P(ab), 203P(ab) Matherson, KJ, 53P(ab), 71P(ab). 128P(ab) Meltzer, PC, 17P(ab) 2l5P(ab), 270P(ab), Marek, K, 133P(ab), 301P(ab) McCarthy, TJ. 40P(ab), Memsic, L, 250P(ab) 277P(ab), 278P(ab), 134P(ab) Mathews, WB. 307, 33P(ab), 108P(ab) MÃ©nard,JF, 1976 285P(ab) Marek, KL, 272P(ab) 41P(ab), 45P(ab), 47P(ab), McCarthy. WH, 964 Menard, S, 665 Minster, J, 136P(ab), Marek, MJ. 236P(ab) 112P(ab), 192P(ab), McCartney, WH, 80P(ab) Mendes, D, 116P(ab) 264P(ab) Marengo, M, 88P(ab) 288P(ab) McClellan, JM, 92P(ab), Meneghetti, JC, 294P(ab) Mintun, MA, 74P(ab), Maresca, K, 152P(ab) Mathias. CJ, 1003 148P(ab), 176P(ab) Menendez, LR. l40P(ab) 80P(ab), 109P(ab), Margcncau, WH, 61P(ab) Mathieu, JP, 229P(ab) McCool, D, 104P(ab) Menendez, M, 245P(ab) 145P(ab), 220P(ab), Margouleff, C, 209, 216, Mathis. CA. 109P(ab), McCormick, T, 263P(ab) Menzel, C, 1496, 1962, 224P(ab), 231P(ab), 1760, 1850 145P(ab), 231P(ab) McCowage, GB, 1438 100P(ab), 134P(ab), 269P(ab) Margouleff, D, 1850 Matoba, M, 1622 McCready, VR, 235P(ab) 138P(ab), 243P(ab), MiÃ³la,UJ, 1649 Mariani, G, 536, 47P(ab), Matoba, Y, 66P(ab) McCullough, SP, 232P(ab) 252P(ab), 273P(ab) Miotti, S, 665 238P(ab), 243P(ab), Matochik, J, 45P(ab) McDevitt, M, 78P(ab) Meredith, RF, 1491 Miraldi, F, HP(ab), 174P(ab) 297P(ab). 16S, 19S, 22S Matshall, BJ, 207P(ab) McDonough, E, 136P(ab), Merlet, P, 70P(ab) Mirick. GR, 451 Marienhagen, J, 248P(ab) Matsubara, S, 248P(ab) 264P(ab) Merlini, G, 185P(ab) Mirzadeh, S, 166P(ab). Marino, G, 256P(ab) Matsubara. T, 26P(ab). McDougall. IR, 2062 Merrick, MV, 42 195P(ab) Marinone, MG, 185P(ab) 58P(ab). 126P(ab), McElgin.W, 151 Mertz, JE. 189P(ab) Misaki, T, 646 Mariolli, S, 565 l85P(ab) McElgin, WT, 1965, Messa, C, 133P(ab), Mishani, E, 40P(ab) Markham. J, 1723 Matsuda, H, l7P(ab) 201P(ab), 219P(ab) 258P(ab) Mitchell, DA, 233P(ab) Markham.J. 1294 Matsui, R, 263P(ab), McEllin, K, 15P(ab) Mestas, D, 922 Mitchell, DS, 16 Markowilz, AL, 9P(ab), 296P(ab) McEwan, AJB, 237P(ab) Metroka, CE, 276P(ab) Mitchell, R, 42 169P(ab) Matsumori, A, 572 McFalls, EO, 2006 Mettler, L, l42P(ab) Mitsuoka, W, 781 Marks, DG, 53P(ab), Malsumoto, M, l2P(ab), McGhie, J, 748 Mettler, FH,24N( 12) Miura, H, 815 301P(ab) 242P(ab). 285P(ab) McGoron, AJ, 752, 49P(ab), Metz, CE, 160, 30P(ab) Miura, S, HOP(ab) Markstein, R, 113P(ab) Matsumoto, T, 807, 163P(ab) 188P(ab), 205P(ab) Metz, DC, 114P(ab), Miyahara, Y, 1343 Mannuse, JP, 253P(ab) Matsumura, K, 282P(ab) McGowan, DG, 237P(ab) 246P(ab) Miyamoto, C, 259P(ab), Marotta, G, 37P(ab), Matsumura, Y, 220P(ab) McGuffie, E, 1052 Meunier, J, 98P(ab) 263P(ab), 265P(ab) 230P(ab) Matsunaga. N, 807, 1361 McHarg, D, 90P(ab) Meyer. E, 42P(ab) Miyamoto, K, 1679 Marsden, PK, 73P(ab), Matsunari, I. 1622, 179P(ab), Mcllvain, TR, 29P(ab) Meyer, G, 34P(ab), 156P(ab), Miyamoto, S, 646 85P(ab) 180P(ab) McKay, RG, 105P(ab) 236P(ab) Miyaoka, RS, 2030, Marshall, RC, 149P(ab) Matsuno, K, 116P(ab) McKay, WJ, 1683, 121P(ab), Meyer, GJ, 521 172P(ab), 223P(ab) Marshall, RS, 273P(ab) Matsuno, N, 258P(ab) 131P(ab), I32P(ab) Meyer, MA, 226P(ab) Miyashita, K, 1824 Marlin, A, 79P(ab) Matsuno. Y. 26P(ab), McKusick, KA, 1906 Meyer, P, 1853 Miyatake. S. 200P(ab) Martin, CC, 206P(ab), 58P(ab), 126P(ab), McLean, S, 186P(ab) Meylaerts. SAG, 1449 Miyauchi. T, 36P(ab), 223P(ab) 185P(ab) McLeish.A, 131P(ab), Meyringer, R, 248P(ab) 64P(ab) Martin, GV, 49P(ab) Matsuo, H, 26P(ab), 58P(ab). 132P(ab) Michanek,A, 1519 Miyazawa, Y, 51 Martin, M, l29P(ab) 126P(ab), 185P(ab) McMahon, M, 105P(ab), Michanek, AMK, 228 Mizrachi, H, 169P(ab) Martin. MY, 276P(ab) Matsuo, 5,712 177P(ab) Michel, C. 39P(ab) Mizumura, S, 304P(ab),

2112 The Journalof NuclearMedicine 308P(ab) Morris, S, 58P(ab) 130P(ab)Munakata, 51Nakamoto,S, Newton, MA, 2l3P(ab) Mizunaga. M. 291P(ab) Monisti, PK, 271P(ab) 123P(ab)Munakata,JA, 200P(ab),203P(ab).Y, Ng, C, 282P(ab) Mochizuki, T, 180P(ab), Morrison, JC, 302P(ab) 304P(ab),308P(ab)Munch,K, 248P(ab)Nakamura, Ng, C-y, 171P(ab) 239P(ab), 290P(ab), Morrison, V, 302P(ab) 276P(ab)Nakamura.J, Ng, CK, 50P(ab), 80P(ab) 291P(ab) Morrissey, GJ, 197P(ab) 107P(ab)Mundler,G, 15P(ab)Nakamura.K, Nguyen, A, 136P(ab) Mochoviak, S, 11 Mortelmans, L, 767, 26P(ab), 1773Mundy,O, 712Nakao, Y, Nguyen, K, 75P(ab), Mock. BH. 40P(ab) 91P(ab) 54P(ab)MÃ¼nz,J, 150P(ab)Nakashima.K, 1985, 250P(ab), 272P(ab), Modorati. G. 967 Mortimer, JE, 99P(ab) 20P(ab),158P(ab),DL, 282P(ab)Nakashima,H, 273P(ab) Moeller.JR, 281P(ab) Morton, K, 1876 255P(ab)MÃ¼nz, 80P(ab)Nakaia,R, Nguyen, KN, 107P(ab) Moffat, FL, 238P(ab) Morion, KA, 46P(ab) 154P(ab)Murakami,F, 131P(ab), 1679Nakaia,T, Nguyen. N, 94P(ab), Moger, AS. 278P(ab) Morton, TE, 281 P(ab) 901Murakami,N. 263P(ab),296P(ab)Nakayama,Y, 107P(ab) Mohamadiyeh, M, 33P(ab), Mosca, F, 22S 1937Murakumo,T, Niccoli, L, 1300 164P(ab) Moser, E, 67P(ab), 218P(ab) 71Murano, M, 189P(ab)Nakayama.H. Nicholl, C. 6P(ab) Mohammadtaghi. S. 54P(ab), Moser, R, 156P(ab), 256P(ab)Murase,A, 189P(ab),200P(ab)Nallamolhu,M, Nichols, D, 16N(1), 20N(1). 91P(ab) 252P(ab) 180P(ab),223P(ab),K, 18N(8),34N(10),44N(11), Mohammed, A, 6P(ab) Moses, WW, 85P(ab) 2232Murata, 149P(ab),l82P(ab)Nally,N, 24N(12) Moin, K, 97P(ab) Mosesson, R, 255P(ab) 58P(ab),I26P(ab),I, 26P(ab), Nichols. K, 48P(ab), Molea, N, 297P(ab) Moshin, J, 723 185P(ab)Murata, 1876Namavari,J, 105P(ab), H5P(ab), Molenaar, WM. 257, 984 Moskovitz, B, 290P(ab) 1567Murata,K. 107P(ab),147P(ab).M, H6P(ab) Molinari, AS, 798 Mothe, G, 245P(ab) 1613Murayama,Y, 193P(ab)Namba, Nichols, TE, 74P(ab). Mollenstadt, S, 262P(ab) Motomura, N, 30P(ab), 36P(ab)Mure.S, 649Namba,H. 220P(ab). 224P(ab) Molloy, PT, 265P(ab), 212P(ab) 275Murman,A, 263P(ab)Namba,R, Nicholson, GL, 127P(ab) 286P(ab) Motta, C, 238P(ab), 270P(ab)Murray,DL, 200P(ab)Nampoory,Y, Nicholson. RL, 213P(ab) Molls, M, 157P(ab) 243P(ab), 297P(ab) 307P(ab)Murthy,DR, 289P(ab)Napolitano,MRA, Nickel, O, 209P(ab) Momen, A, 211P(ab) Moulopoulou, A, 32P(ab) 135P(ab)Musachio.S, 1487, 37P(ab)Nappi,C, Nickerson, LDH, 223P(ab) Momomura, S, 38P(ab). Mountz, JD, 276P(ab) 6P(ab),41P(ab).JL. l78P(ab)Narabayashi,A, 13P(ab), Nickles. RJ, 94P(ab), 82P(ab) Mounlz, JM, 88P(ab), 45P(ab),107P(ab), 263P(ab),296P(ab)Narayan,I, 206P(ab) Momomura. SI, 1937 89P(ab), 164P(ab), 112P(ab),192P(ab)Muswick, Nicolai, A, 178P(ab) Momose. M. 185P(ab) 165P(ab), 235P(ab), 1749Narayana,M, Nicolai. E, 13P(ab) Momose, T, l89P(ab), 276P(ab), 277P(ab) 685Mul, GJ, P(ab)Nariai,5,221 Nicolosi, A, 565 280P(ab) Mousa, D, 1649 266P(ab)Muto,F, 1919(le), 259P(ab)Narita,T, Niederle, B, 20P(ab) Monclus, M, 53P(ab) Movassaghi, N, 34P(ab) 155P(ab),156P(ab)Muzi,P, 138P(ab), HOP(ab)Naruki,Y, Niehoff, T, 1865 Monelli. N, 1688. 88P(ab), Moyer, BR, 673. 775. 1016. 246P(ab)Narula,Y. Nielson. JB, 199P(ab) 250P(ab) 204P(ab) 22IP(ab)Muzic,M, 220P(ab), 49P(ab),l06P(ab),J. 4P(ab), Niesen, A, 1942 Montane, B, 23P(ab) Moyers, C. 85P(ab), 86P(ab) HP(ab),174P(ab)Muzik,RF Jr., 685, l44P(ab),175P(ab), Nieweg, OE, 257, 972, 984, Monticciolo, D, 254P(ab) Mozley, LH, 283P(ab) 269P(ab)Naruse, 86P(ab) Monlplaisir, JY, 271P(ab) Mozley, PD, 151, 1965, 145P(ab)Myers,O. 4P(ab), 1783Nasci,H, Nijhof, MW, 128P(ab) Moody, T, 204P(ab). 66P(ab), 165P(ab), 1965Myers,AM, 266P(ab)Nassim,C, 999. Nikkeis, PGJ, 897 254P(ab) 201P(ab), 219P(ab), l48P(ab)Myers,M, 873Natale,MA, Nili, M, l03P(ab) Moog, F, 249P(ab), 262P(ab) 276P(ab), 278P(ab). 91P(ab)Myers,MJ, 1783Nativ,D, Nilsson, O, 1519,2002 Moon, DH, 99P(ab), 283P(ab), 284P(ab), lllP(ab),132P(ab),RW, 290P(ab)Naylor,O, Nishida. Y, 26P(ab), 58P(ab), l41P(ab), 267P(ab) 286P(ab) 139P(ab)Mzengeza. 6P(ab)Neal,I, 126P(ab), l85P(ab) Moore, A, 55P(ab) Mozzillo, N, I38P(ab) 55P(ab),284P(ab)Mzengezza,S, 74P(ab)Needle.CE, Nishide, H, 1622 Moore, E, 873 Msaki, P, 2040, 2046 265P(ab),286P(ab)Neff,MN, Nishigauchi, K, 807. 1361 Moore, MJ, 1578 Mu, M, 1965, 66P(ab), I13P(ab)Na, S, Nishigori, H, 326, 1698 Moore. SC, 18P(ab), 201P(ab) 92P(ab)Nekolla.S, 31P(ab), Nishiguchi. S. 51 29P(ab), 77P(ab), Muenz, LR, 1965 275P(ab)Nabi,DL, 70P(ab),131P(ab),SG, Nishijima, K, 1343 124P(ab), 153P(ab) Muenzing, W, 56P(ab) l98P(ab)Naddaf,H, 154P(ab),172P(ab), Nishikawa,J, 1937, 38P(ab), Morales, A, 240P(ab) Mugitani,T, 1522 242P(ab),251P(ab),S, 180P(ab),218P(ab)Nelleman, 82P(ab), 183P(ab), Morel, C, 51 P(ab) Muhlensiepen, H. H3P(ab). 277P(ab).301P(ab)Nader, 189P(ab), 280P(ab) Moresco, RM, 133P(ab) 20IP(ab) 53P(ab)Nellis,P, Nishikawa, M, 280P(ab) Morelli, JL, 233P(ab), Mukai, T, 374 ab)Nadkami,MA, 281 P( 94P(ab)Nelp,SH, Nishikawa, T, 64P(ab), 274P(ab) Mukherjec, J, 50P(ab), 162P(ab),240P(ab)Naeem,R, 1583Nelson.W, 122P(ab), 180P(ab) Moretti, M, 189P(ab) 193P(ab), 211P(ab) 174P(ab)Nelson,AD, 685, Nishimura,T, 1,761, 1686, Morey, SS, 35P(ab) Mukherji, SK, 2079 48P(ab)Nagai,M, 1031Nelson,CA, 1824, 12P(ab), 26P(ab), Morgan, HT, 209P(ab), Mukhopadhyay, SK, 70P(ab) 3P(ab)Nagamachi,R, 234P(ab)Nemoto,DL. 66P(ab), 94P(ab), 2IOP(ab), 214P(ab) Mulholland, GT, 40P(ab) 1626,308P(ab)Nagaoka,S, 84, 901, 280P(ab)Nello,M, l75P(ab), l83P(ab), Morgenroth, C, 268P(ab) Mullan. BP, 1456, 84P(ab). 288P(ab)Neuhold,ICV, 242P(ab), 277P(ab), Mori, H, 186P(ab) ll6P(ab) 3P(ab)Nagasawa,H, 20P(ab),251P(ab)Neumann,N, 285P(ab) Mori, M, 37P(ab) Mullani, N, 1701 244P(ab)Nagatsuka.M, Nishino, M. 246P(ab) Morimitsu, T. 1343 Muller, D, 158P(ab) 649Nagle, S. 1809,2000,177P(ab)Neumann,DR, Nishiooeda, Y, I, 1824 Morin, C, 237P(ab) Muller, E, 67P(ab) I7N(7)Nagren,CE, 1745, Nishiura, M, 66P(ab) Morishila, K, 94P(ab) Muller, H, 286P(ab) 256P(ab)Nahmias,K, 126P(ab)Neumann,FJ, Nishizawa, S, 374, 113P(ab), Morita, R, 815, 1567 Muller, NL, 36P(ab) 432Nair, C, 1408,62P(ab),RD, l23P(ab), 284P(ab) Moriwaki, H, l2P(ab), Muller. SP, 18P(ab), 29P(ab), 263P(ab)Naito,S, 118P(ab),228P(ab), Nizami, MA, 1001 242P(ab), 285P(ab) 55P(ab), 124P(ab), 244P(ab)Naito,M, 233P(ab),254P(ab)Neumann. Nobuyoshi, M, 26P(ab) Morozumi, T, 1686, l83P(ab) l53P(ab), 279P(ab) 1343Naito,T, Nofzinger, EA, 80P(ab) Morr, I, 87, 234P(ab), Muller-Berg. M. 137P(ab) 123P(ab)Nakada,Y, 283P(ab)Neumayr.A,U, Noguchi, J, 215P(ab) 235P(ab), 264P(ab), Muller-Ganner, HW, 200P(ab)Nakada,H, 241P(ab)Neumeyer, Noguchi, K, l2P(ab) 265P(ab) ll3P(ab), 20IP(ab), l6P(ab).239P(ab),K, 133P(ab)Neumeyer,J, 1760, Noguchi, S, 901 Morrell, AC, 276P(ab) 219P(ab), 222P(ab), 290P(ab),291P(ab)Nakagawa, 284P(ab)Neverve,JL, Noguera, C, 245P(ab) Morris, ED, l25P(ab) 227P(ab), 283P(ab) 218P(ab)Newell,J, Noguera, G, 245P(ab) Morris, G, 146 Muller-Schauenburg, W. 463, 282P(ab)Nakagawara,T, l2P(ab)Newhousc,DW, Nohara, R, 572, 729, 757, Morris, ID, 336 1468, 134P(ab), 137P(ab) 276P(ab)Nakahara,J, 182P(ab)Newport,H. 1403, 1836, l98l,95P(ab) Morris, JC, 1487. l35P(ab) Mumcuoglu, E, 86P(ab), H, 901,308P(ab)Nakajima, D, 85P(ab) Nonomura, A, 298P(ab)

Author Index -1996 2113 Nonoinura, K. 71 Ohashi, H, 26P(ab), 126P(ab) Otsuka, M. 271P(ab) Papos, M, 287P(ab) Pavics, L, 273P(ab), Nordman, E. 256P(ab) Ohlenschlaeger, U. 1841 Otsuka, S, 246P(ab) Pappas, N, 1609, 33P(ab), 280P(ab) Novak, S, 96P(ab), 162P(ab), Ohmori, Y, 1673 Ou, R, 54P(ab), 191P(ab), 44P(ab), 45P(ab), 76P(ab), Pawilan, Y, 224P(ab) 240P(ab) Ohnaka, Y, 815 228P(ab) 281P(ab) Pawlik, G, 429 Nowak, DJ, 1891 Ohnishi, H, 815, 1567 Otte, R, 100P(ab) Paracchi, A, 230P(ab) Payne, JK, 1735 Noz, M, l69P(ab) Ohnishi, T, 84, 901, 308P(ab) Otten, EW, 296P(ab) Paredes, A, 23P(ab) Pechmann, M, 156P(ab), Nozaki.T, 2l5P(ab) Ohshima, S, 3P(ab) Overall, J, 1609, 76P(ab) Parekh, JS, 158P(ab) 252P(ab) Nquycn, K, 267P(ab), Ohla, K, 76P(ab) Overbeck, B, 243P(ab), Parikh, A, 59P(ab) Peck, GE, 197P(ab) 269P(ab) Ohta, M, 258P(ab) 273P(ab) Park.CH, 157P(ab), Pecorale, A, 195P(ab) Nukiwa.T, 1460 Ohta, Y, 997 Overkamp, D, 463 260P(ab) Pecori, B, 156P(ab) Numala. H, IHP(ab) Ohlake. E. lllP(ab) Ovize, M, 147P(ab) Park, CY, 426,469, 551 Pedenovi, P, 26P(ab) Nunez, M, 266P(ab) Ohtake, T, 1937, 38P(ab), Ovunc, K, l77P(ab) Park, HM, 137P(ab), Pedley, B, 868 Nurmohamed, SA, 38P(ab) 82P(ab), 183P(ab), Owunwanne, A, 289P(ab) 236P(ab) Pedrini, L, 49P(ab), 88P(ab) Nusynowilz, ML, l44P(ab) 189P(ab) Oya, S, 190P(ab) Park, JM, 252P(ab) Peifer, JW, 97P(ab) Null, R, 85P(ab), 86P(ab), Ohtomo, K, 1444 Oyama, Y, 80P(ab) Park, KO, 67P(ab) Pelegrini, M, 217P(ab) 170P(ab) Ohyama, Y, 189P(ab) Oyen,WJG, 62, 1392, Park, R, 178P(ab) Pellier, P, 1853 Nutter, F. 200P(ab) Oian, J, 97P(ab) 119P(ab), 128P(ab) Park, S, 978 Peluso, P, 205P(ab) Nuulinen, J, 256P(ab) Okada, J, 258P(ab) Ozaki, S, 244P(ab) Park, S-G, 15P(ab) Pemberton, CC, 307P(ab) Nuyts, J, 767, 26P(ab) Okada. RD, 107P(ab) Ozbilek, E. 302P(ab) Park, YH, 137P(ab), Penney. BC, 21 IP(ab), Nyberg. S. l08P(ab) Okamura, T, 304P(ab) Ozdemir, S, 130P(ab) 236P(ab) 212P(ab) Okazawa, H, 374, 729. 1600, Ozker, K, 1285, 84P(ab) Parker, D, 166P(ab) Penninckx, F, 54P(ab) O'Brien, C, 964 2057, 101P(ab), 123P(ab) Ã–zyar,E, 1956, 257P(ab) Parker, JA, 178, 1618, 1906, Penllow, KS, 1557 O'Brien, JT, 195 Okazumi, S, 279 2087, 172P(ab) Perani, D, 42P(ab) O'Donnell, RT, 451, Okimura, T, 64P(ab), Paans, AMJ, 257, 279, 984, Parkes, SL, 744 Pereira, J, 273P(ab) 232P(ab) 122P(ab) 2082, HP(ab), 71P(ab), Parkman, HP, 57P(ab), Pereira, M, 905 O'Donoghue, JA, l02P(ab), Oku. N. 12P(ab). 285P(ab) 86P(ab), 157P(ab), 244P(ab) Perenboom, RM, 1392 3S Okuda, K, 757, 1403, 1836, 225P(ab), 265P(ab), Parmentier, C, 598, 606, 912, Pericak-Vance, MA, 79P(ab) O'Dowd, T. 211P(ab) 95P(ab) 306P(ab) 1860, 20P(ab), 52P(ab) Perkeges, JL, 57P(ab) O'Keefe, GJ, 121P(ab) Olalde, L, 301P(ab) Paberzs, A, 36P(ab) Parodi, O, 735 Perlman, SB, 162P(ab) O'Mara. RE, 1903 Old, LJ, 1052 Pace, L, 735, 178P(ab) Parra, LC, 124P(ab) Pemezky, G, 241P(ab) O'Neil, JP, 1009 Oliner, C, 37P(ab) Packard, AB, 270P(ab) Parsai, EI, 90P(ab) Perry, JR, 80P(ab) O'Reilly, P, 1872 Olinger, R, 208P(ab) Padhy.AK, l37P(ab) Partridge, EE, 1491 Perry, R, 2079 O'Sullivan, F, 220P(ab), Ollinger, JM, 226P(ab) Padurean, A, 152P(ab) Parwaresch, MR. 142P(ab) Perrymore, WD, 1517 221P(ab). 224P(ab) Olmos, RAV, 584 Paganelli, G, 55, 967, 1655, Pascani, K, 1609,45P(ab), Persson, M, 120P(ab) O'Tuama. LA, 12P(ab). Olshen.A, 221P(ab) 169P(ab), 195P(ab), 76P(ab) Pescatore, F, 1662 270P(ab) Olsson, RA, l42P(ab) 238P(ab) Pascual, M, 293P(ab) Pelegnief, Y, 256P(ab) Oates, E, 267, H3P(ab) Omar, WS, 242P(ab), Page, MPA, 195 Pascuavalca, D, 45P(ab) Pelerdy.AE, 861 Oberdorfer, F. 87, 341, 277P(ab) Pagliarulo, A, 78P(ab) Pasqualini, R, 107P(ab), Peler, BM, 14N(7) 68P(ab), 147P(ab), Ornata. M, 1937, 38P(ab), Paik, CH, 1384, 29P(ab), 188P(ab), 189P(ab) Pelers, AM, 54P(ab), 257P(ab), 265P(ab) 82P(ab) 129P(ab), 196P(ab), Pasquet, A, 25P(ab), 91P(ab), 114P(ab), Oberg, K, 32 Ommeslag, DJ, 857 203P(ab), 234P(ab) 126P(ab) 128P(ab), 148P(ab) Oberhausen, E, 615 Ongseng, F, 2098(le) Pajkrt, D, 24P(ab) Passath,A, 1524 Pelers, W, 4P(ab) Oberhofer, MT, l39P(ab) Onishi. Y. 374 Pak, C, 49P(ab) Pastan, I, 29P(ab), 129P(ab), Pelerson, J, 169P(ab) Obranovich, GT, 294P(ab) Ono, K, 1622 Pak, CYK, 175P(ab) 152P(ab), 203P(ab), Peterson, LM, 235P(ab) Obuchowski, NA. 1809 Ono. M, 7P(ab) Pak, KY, 119P(ab) 204P(ab) Pelerson, NP, 78P(ab) Odii, H, 51,641,304P(ab) Ono, S, 410 Palant, A, 224P(ab) Pastore, V, 264P(ab) Peliei.A, 101P(ab), 231P(ab) Ochoa, AV, 306P(ab) Onsel, C, 233 Palestre, CJ, 34P(ab), Pastores, G, 297P(ab) Pelil-Taboue, M, 95 Ochrymowycz, LA, 61P(ab) Onthank, DC, 151P(ab), 103P(ab), 161P(ab), Patel, B, 252 Pelrakis, I, 285P(ab) Oda, H. 26P(ab), 58P(ab), 202P(ab) 199P(ab), 241P(ab), Palei, D, 272P(ab) Pelras, S, 847 126P(ab), l85P(ab) Oohashi. H, 185P(ab) 242P(ab), 244P(ab), Patel, M, 241P(ab), Pelrella, M, 13P(ab) Oda. K, 1698, 123P(ab), Ooslerhof, GON, 169P(ab) 285P(ab) Palei, SL, 272P(ab) Petrosino, T, 155P(ab) 153P(ab), 215P(ab), Oosterwijk, E, 169P(ab) Palevsky, H, 295P(ab) Palhare, PM, 151P(ab) Petrov, A, 4P(ab), 175P(ab), 220P(ab) Oosterwijk-Wakka, JC, Palkovic, S, 268P(ab) Pathmaraj, K, 121P(ab) 269P(ab) Oehme, L, 208P(ab), 169P(ab) Palmedo, H, 626, 1496, Patlak, C, 209 Petligrew, Rl, 125P(ab) 283P(ab) Orduna, E, 287P(ab) 100P(ab), 134P(ab), Patsis, G, 188P(ab) Pellil.W, 31P(ab) Oei, HY, 1876, 19P(ab), Oren, R, 39P(ab), 138P(ab), 243P(ab), Palterson, GA, 135P(ab) Pezzullo, L, 138P(ab) 268P(ab) Oriuchi, N, 273, 457, 252P(ab), 265P(ab) Patterson, J, 661, 79P(ab) Pfaffendorf, M, 160P(ab) Oesch, F, 233P(ab) 72P(ab), 86P(ab), 264P(ab) Palmer, EL, 1310 Patterson, M, 81P(ab) Pfeffer, M, 1537 Oftbrd. R, 51P(ab) Orlandi, C, 37P(ab), 93P(ab), Palmer, J, 622 Patterson, R, 6P(ab) Pfluger, T. 34P(ab) Offord. SJ, 11. 112P(ab) 150P(ab), 184P(ab) Palmer. LB, 239 Palterson, RE, 1891, Pham, HL, 230P(ab), Ogawa. K, 30P(ab). Osada, H, 304P(ab) Palmon, S, 33P(ab) 174P(ab) 23IP(ab) 212P(ab), 215P(ab). Oser, U, 218P(ab) Pan,T-S, 18P(ab), 63P(ab), Palliilo, R, 182P(ab) Phaneuf,DC, 180P(ab) 225P(ab) Oshima, S, 680. l84P(ab) 97P(ab), 153P(ab) PailÃ³n, DD, 301P(ab) Phelps,ME, 506,1428, Ogawa, T, 12P(ab), 110P(ab) Osiecki.A, 215P(ab) Panaro, V, 238P(ab) PailÃ³n,JA, 31P(ab) 1428,1626,1717,42P(ab), Ogawa, Y, 291 P(ab), Osipova, TA, 52P(ab) Pancholy, S, l49P(ab) Pau, A, 238P(ab) 55P(ab),56P(ab),68P(ab), 292P(ab) Osman, AF, 81P(ab) Pandit, N, 415, 467 Paulesu, E, 42P(ab), 79P(ab),82P(ab),86P(ab), Ogihara-Umeda, l, 326, 1698 Osman, S, 109P(ab), Pang, IW, 301P(ab) 133P(ab) 99P(ab),107P(ab), Ogino, M. 1403, 1836, H2P(ab) Panico, MR, 260P(ab) Pauley, DR, 307P(ab) 109P(ab),HOP(ab), 95P(ab) Osmont, A, 95 Panther, R, 178P(ab) Paulik, SG, 249P(ab) 141P(ab),146P(ab), Oguchi, M. 64P(ab), Osorio, L, 169P(ab) Panyutin, I, 62P(ab), Paulus, M, 85P(ab), 86P(ab), 147P(ab),163P(ab), 122P(ab) Osier, Z, 218P(ab) 228P(ab) H9P(ab) 193P(ab),267P(ab), Ogunbiyi, OA, 132P(ab) Oster, ZH, 24P(ab) Papadopoulos, M, 188P(ab) Paulus, P, 250P(ab), 269P(ab),301P(ab), Ogura, S. 955 Ostertag, H, 221P(ab) Papageorgiou, S, 5 260P(ab), 261P(ab) 303P(ab) Oguz, A, 139P(ab) Osirem, JL, 79P(ab) Papatheofanis, FJ, 31P(ab) Pauwels, S, 916, 258P(ab) Phillips, E, 250P(ab) Oh-hori. K, 1679 Ota, T, 815, 1567 Papatheofanis, FP, 92P(ab) Pauza, CD, 162P(ab) Phillips, PC, 265P(ab),

2114 The Journalof Nuclear Medicine 286P(ab) Postiglione, A, 164P(ab) Rabilo, CA, 293P(ab) 71P(ab) Robbins, J, 1690, l5P(ab) Phillips, RL, 284P(ab) Postma-Tjoa, J, 748 Rabkin, G, 4P(ab) Reid, R. 8P(ab), 197P(ab) Robbins, R, l02P(ab) Phillips, WT, 1374, 247P(ab) Polena, MI, 665 Raderer, M, 1480, 20P(ab), Reid, WS, 279P(ab) Robert, A, 25P(ab), l26P(ab) Philpolt, GW, 61P(ab) Pounds, TR, lllP(ab), 251P(ab) Reidei, G, 157P(ab) Roberts, D. 271 P(ab) Picardi, V, 35P(ab), 255P(ab) 132P(ab), 136P(ab), Radosavljevic, I, 20P(ab) Reijs.AEM, 1951, 48P(ab), Roberts. TG, 279P(ab) Piccardo, P, 270P(ab) 139P(ab), 157P(ab) Raffel, DM, 1923, 70P(ab) 60P(ab) Robeson, W, 209, 216, 1850, Piccini, P, 109P(ab) Poussaint, TY, 270P(ab) Ragland, JD, 283P(ab), Reilly, RM, 199P(ab) 133P(ab) Piccolo, S, 155P(ab), Powe, J, 993 284P(ab) Reiman, E, 224P(ab), Robeson, WR, 1557 156P(ab) Powers, TA, 131P(ab) Ragland, T, 186P(ab) 304P(ab) Robidoux, A, 75P(ab) Pickering, AD, 195 Powers, WJ, 1668, 226P(ab) Rahi, S, 1946 Reiman, RE, 471 Robinson, R, 1749 Piepsz, A, 1281, 1346, 1805, Powsner, R, 12P(ab) Raijmakers, PGHM, 1316 Reiners, Chr, 286P(ab) Robson, L, 868 1883 Pozniakoff, TA, 273P(ab) Rain, JD, 1773 Reinhardt, CP, l60P(ab) Rocchisani, JM, 274P(ab) PierÃ ,J, 631 Prados, MD, 157P(ab) Raina, A, 182P(ab) Reinhardl, M, 67P(ab) Rocco, TP, 1618 Pieri, PL, 49P(ab) Prat, L, 49P(ab) Rajendran, J, 12P(ab), Reinhold, U, 138P(ab) Roche, A, 912 Piers, DA, 67P(ab) Prato, FS, 2I3P(ab) 117P(ab) Reisinger, I, 20P(ab), Roche, T. 141P(ab) Pierson, R Jr., 878 Pratt, JP, 95P(ab), 295P(ab) Rajopadhye, M, 28P(ab), 158P(ab) Rodrigue, S, 170P(ab) Pieri, M, 201, 27P(ab), Prauer, H, lllP(ab) 119P(ab), l29P(ab) Relyea, B, 577, 1636 Roelandl. JRTC. 748, 1951 200P(ab) Prekeges, JL, 103P(ab) Rajvanshi, P, 244P(ab) Rendi, J, 286P(ab) Roelants, V, 25P(ab), Pietrzyk, U, 122P(ab), Prenant,C, 341 Rakshi, JS, 271P(ab) Reno. JM, 29P(ab), 166P(ab) 126P(ab) l37P(ab), 155P(ab) Prescod, N, 823 Raleigh, MJ, 55P(ab), Renstrom, B, 94P(ab) Roelcke, U, 54P(ab) Pietzsch, H-J, 16P(ab) Prescott, DM, 1438 109P(ab), 163P(ab) Repp, R, 362 Rogers, BE, 95P(ab), Piga, M, 565 Press, OW, 43P(ab) Raltz, SL, 57P(ab) Resche, I, 32P(ab) 186P(ab) Pijpers, R, 259P(ab) Pretorius, HT, 263P(ab), Ramanna, L, 46 Reschini, E, 37P(ab), Rogers, JG, l61P(ab) Pike.VW, 112P(ab), 307P(ab) Rambaldi, PF, 156P(ab), 230P(ab) Rogers, WL, 7P(ab), 141P(ab), 191P(ab) Pretorius, PH, 97P(ab), 256P(ab), 264P(ab) Reske, SN, 160P(ab), 119P(ab), l70P(ab), Pimstone, N, 160 153P(ab) Rambaldi, R, 60P(ab) 220P(ab), 249P(ab), 17IP(ab) Pinchera, A, 606 Preumont, N, 83P(ab) Rammohan, R, 175P(ab) 262P(ab) Rogulski, MM. 301P(ab) Pinchuk,AN, 1540 Price, J, 145P(ab) Ramos, CD, 273P(ab) Reuland, P, 463 Rohe, RC, 77P(ab) Pinkert, J, 283P(ab) Price, JC, 690, 786 Ramos-Gabatin, A, 301P(ab), Reutens, DC, 42P(ab) Rohlen, DA, 283P(ab) Pinot, L, 303P(ab), 306P(ab) Price, JE, 264P(ab) 302P(ab) Reuler, S, 81P(ab) Rohrlich, P, 35P(ab) Pinson, CW, 131P(ab) Price, JP, 109P(ab) Rampy, MA, 1540 Reuuer, BW, 13IP(ab) Rolfes, RJ, 263P(ab) Pinto, CD, 301P(ab) Price, LH, 44P(ab) Ramsingh, KK, 263P(ab) Reveiz, MC, 199P(ab) Rolla, D, 243P(ab) PipÃ³lo, F, 40P(ab) Priori, SO, 37P(ab) Ramsingh, PS, 263P(ab), Reyes, GA, 126P(ab) Rolleman, E, 141P(ab) Pippin, J, 93P(ab), 184P(ab) Probst, R, 70P(ab) 307P(ab) Reynolds, JC, 1690, 15P(ab), Rolleman, EJ, 1388 Piriz, JM, 37P(ab), 58P(ab), Procaccini, E, 156P(ab) Rancure!, G, 1976 234P(ab) Romano, JE, 476 105P(ab) Pruckmayer, M, 999, 1526, Rank, BM, 294P(ab) Rezai, K, 1815 Rombach. M, 218P(ab) Pirker, W, 1931 115P(ab), 266P(ab) Ranner, G, 1524 Rezani, C, 177P(ab) Romeo, A, 88P(ab), 250P(ab) Pirmettis, I, 188P(ab) Pruim, J, 257, 897, 984, Rao, V, 71P(ab) Rhoden, S, 926 Romer, W, 36P(ab), 99P(ab), Pirotte, B, 21P(ab) HP(ab), 21P(ab), 71P(ab), Rapoport, E, 4P(ab), Rhodes, B, 1789 lllP(ab), l38P(ab) Pitt, SR, 81P(ab) 86P(ab), 157P(ab), 269P(ab) Rhodes, BA, 24P(ab) Rommelfanger, S, 94P(ab) Piwnica-Worms, D, 51P(ab), 263P(ab), 265P(ab), Rapun, R, 251P(ab), Rhodes, C, 106P(ab) Roncevic, S, 446 71P(ab), 247P(ab) 306P(ab) 301P(ab) Rhodes, CG, 1275, 71 P(ab), Roodenburg, JLN, 897 Plossl, K, 17P(ab) Prvulovich, EM, 995 Rasey, JS, 235P(ab) 106P(ab) Rooney, BC, 166P(ab) Plott, G, 1491 Puig, M, 631 Rashli, F, 1731 Ribbe, T, 120P(ab) Rosa, E, 312 Ploux, L, 303P(ab), 306P(ab) Puig, S, 266P(ab) Rasse, M, 999, 1526, Ribeiro, L, 223P(ab) Rosch, F, l66P(ab), 227P(ab) Plukker, JTM, 86P(ab) Pulawski, P, 1865 266P(ab) Ricard, M, 598, 1830, Rose, DJ, 152P(ab) Plutchok, J, 270P(ab) Puntieri, P, 264P(ab) Rassidakis, A, 32P(ab) 52P(ab) Rose, PA, 70P(ab), 81P(ab), Podoloff, DA, 931, 1472, Pupi, A, 278P(ab), 279P(ab) Raslad, J, 1766 Ricaurte, GA, 112P(ab) 148P(ab), 176P(ab) 1476, 32P(ab), 72P(ab), Puschel, W, 615 Rau, V, 308P(ab) Riccabona, G, 1912(le) Rosen, G, 272P(ab) 86P(ab), 127P(ab), Puskas, C, 49P(ab) Raubitschek, AA, 209P(ab) Ricci, S, 22S Rosen, PJ, 267P(ab) 207P(ab), 232P(ab), Put, E, 1605 Rauch, SL, 33P(ab) Rice, KC, 2021, 143P(ab), Rosenberg, JM, 280P(ab) 234P(ab), 253P(ab), Put, T, 1605 Rauth, AM, 1023 187P(ab) Rosenblatt, W, 33P(ab) 261P(ab), 264P(ab), Pyzalski, RW, 162P(ab) Ravad, GA, 182P(ab) Rieh, D, 80P(ab) Rosenlhal, L. 1872 296P(ab) Ravert, HT, 307, llP(ab), Rieh, DA, 282P(ab) RosÃ©s,AD, 79P(ab) Podreka, I, 1931 Qaim, SM, 166P(ab) 33P(ab),41P(ab), 45P(ab), Richards, JS, 277P(ab) Rosmuller, B, 236P(ab) Poewe, W, 22 Qazi, UA, 207P(ab) 47P(ab), 77P(ab), Richardson, DD, 1310 Rosner, D, 238P(ab) Pointon, O, 121P(ab), Qing, F. 1275 107P(ab), 112P(ab), Richardl, G, 107P(ab) Ross, R. 57P(ab) 131P(ab) Qu,T, 152P(ab), 190P(ab), 164P(ab), 192P(ab), Richenbacher, W, 39P(ab) Ross, SG. 8P(ab) Poldermans, D, 60P(ab) 203P(ab) 201P(ab), 280P(ab), Richie, JP, 315 RÃ¶ssler,K, 1431 Polgar, M, 287P(ab) Quadri, SM, 1545 288P(ab) Richmond, JCW, 225P(ab), Roszell, NJ, 49P(ab), Polla, BS, 1413, 1694 Quaife, RA, 179P(ab), Ravn, U, 51P(ab) 226P(ab) 188P(ab) Pollard, KR, 2030 295P(ab) Rawwas, JB, 16 Richter. JA, 93P(ab) Rola-Kops, E, 113P(ab), Polulak, D, 222P(ab), Querin, S, 1368 Raylman, RR, 1562, 36P(ab), Richter, WS, 22 283P(ab) 305P(ab) Quick, D, 32P(ab) 52P(ab), 98P(ab), I914(le) Riedl, M, 1931 Rolhfusz, BC, 293P(ab) Pomeranz, SJ, 263P(ab), Quin, GA, 852 Reba, RC, 279P(ab) Riese, K, 861 Rotman, M, 234P(ab) 307P(ab) Quinn, KB, 265P(ab) Reddy, NK, 279P(ab) Riggin, S, 276P(ab) Roltenberg, DA. 73P(ab), Pomper, MG, 41 P(ab) Quinn, MJ, 964 Redfern, MG, 142P(ab) Rigo, P, 250P(ab), 260P(ab), 227P(ab) Ponto, JA, 2092 Quinn, RJ, 744 RÃ©Ã©d.J, 85P(ab), 130P(ab) 261P(ab) Roubin, GS, 277P(ab) Ponto, LLB, 39P(ab), Quinn, TP, 96P(ab), 198P(ab) Reed, NL, 10P(ab) Rijntjes, M, 55P(ab) Rougier, P, 20P(ab) 199P(ab), 221P(ab), Quion, JV, 37P(ab) Reeves, F, 69P(ab) Ringelstein, JG, 275P(ab) Rouleau, D, 170P(ab) 225P(ab), 226P(ab) Quirijnen, JMSP, 244, 1511 Rehm, K, 227P(ab) Rini. JN, 243P(ab) Roussel, O, 283P(ab) Poppe, G, 767 Quirk, S, 197P(ab) Rehm, PK, 643, 1676 Rinne, D, 137P(ab) Rouvier, E, 1853, l29P(ab) Perenta, G, 178P(ab) Quyyumi, AA, 25P(ab) Reich, H, 278P(ab) Rilsema, GH, 594 Roy, LP, 46P(ab) Porter, D, 55P(ab) Reichan, B, 70P(ab) Riva, P, 49P(ab) Royal, H, 878 Porter, JK, 143P(ab) Rabin, MSZ, 212P(ab) Reichert, D, 16P(ab), Rizzo, G, 133P(ab) Royal, HD. 1903. 1906

Author Index â€¢1996 2115 Royal, HJ, 2087, 2092 Sakahara. H. 200P(ab), Salta, L, 565 Schoenberger, JA, 248P(ab) Semigran, MJ, l44P(ab) Royen, EA, 1449 203P(ab) Satyamurlhy, N. 107P(ab), Schofield, L, 50P(ab) Semmler, W, 257P(ab), Rozanski.A, l05P(ah), Sakamoto, H, lllP(ab) 193P(ab) Schomburg, A, 626, 1496. Sen, C, 415 H5P(ab) Sakamoto, K, 304P(ab) Saunders, AM, 79P(ab) 138P(ab). 243P(ab), Senda, M, 279, 1698, Rssler, K, 1931 Sakata, 1, 17P(ab) Saunders, R, 77P(ab) 252P(ab), 265P(ab), 123P(ab), l53P(ab), Ruhas. B, 21IP(ab) Sala-Trepat, M, 10IP(ab) Saunders, RC, 281 P(ab) 273P(ab) 215P(ab), 220P(ab), Rubin, A, 168P(ab), Salako, P, 146 Savelli, G, 250P(ab), Schomig.A, l26P(ab) 259P(ab) 169P(ab), 239P(ab) Salako, Q, 129P(ab), 251P(ab) Schonauer, M, 131P(ab) Senekowitsch-Schmidtke, R, Rubin. AD. 905, 9P(ab), 143P(ab), l67P(ab), Savi, A, 205P(ab) Schosser, R, 147P(ab) 41P(ab). l38P(ab). 43P(ab), 243P(ab) 199P(ab) Saxena, S, 79P(ab) SchrÃ¤g,A, 22 262P(ab) Rubin. PJ, 39P(ab), 82P(ab). Saleh. Z, 48P(ab) Sayed, ME, 48P(ab) Schramm, M, 142P(ab) Sennma. J. l79P(ab) l61P(ab). 221P(ab) Salensky, H. 48P(ab), Sayman, HB. 233 Schreij, G, 594, 1652 Seo, IS, 4P(ab) Rubin. RH, 843, 24P(ab), 105P(ab), 115P(ab). Scanlan, DR. 16IP(ab) Schrottle, W, 1799 Serafini, A, 798. 32P(ab), 33P(ab). 239P(ab) H6P(ab) Scarborough. E, 94P(ab) Schuller. M, l42P(ab) 96P(ab), l62P(ab), Rubin. S, 183P(ab) Salctnich, I, 633 Scarfone, C.498, 214P(ab). Schulz, C, 36P(ab) 238P(ab), 240P(ab), Rubinslein, M, 274P(ab) Salk. D, 252 216P(ab) Schulze, PE, 22 255P(ab), 302P(ab) Rubio, L, 93P(ab) Salman, HS, 48P(ab) Schabe!, Sl. 1682 Schulzer, M, 421 Sergeant, P, 26P(ab) Rubow. S, 283P(ab) Salman, UA. 247P(ab) Schackert, HK, 87 Schumaker, R, 78P(ab) Sema. FJ, 1828 Rubulolta, MR, 156P(ab) Salmassi. A, 142P(ab) Schad, D, lllP(ab), 154P(ab) Schuth, G, 222P(ab) Seto, H, 101P(ab) Rudas. M, 254P(ab) Salminen, E, 256P(ab) Schad, LR. 296P(ab) Schwabe, U, l42P(ab) Setyono-Han, B, 108 Ruddy, TD, 174P(ab) Salvador!, PA, 22S Schaefer, T, 137P(ab) Schwaiger, M, 1923, Seybold, S, 307P(ab) Rudello, F, 205P(ab) Salvatore, M, 665, 13P(ab). Schafer, H, l04P(ab) 36P(ab), 41P(ab), 70P(ab), Seymour, KM, 70P(ab) Rudoll'stifung, KA, 241P(ab) 138P(ab). 155P(ab), Schafers, M, 71 P(ab), 94P(ab), 99P(ab), Sfakianakis, G, 1876, Rueschoff, J, 248P(ab) 156P(ab). l59P(ab), 106P(ab), 268P(ab) l07P(ab), IHP(ab). 23P(ab), 96P(ab), Rufini. V. 633, 1464, 1778, l64P(ab). l78P(ab), Scharko, AM, 162P(ab) H4P(ab), l22P(ab), l62P(ab), 238P(ab), 237P(ab) 260P(ab) Scheff, AM, 74P(ab) l26P(ab), !31P(ab), 240P(ab), 255P(ab), Ruhlmann, J, 134P(ab), Salvatori. M, 633 Scheffel, U, 307, 6P(ab), 138P(ab). l54P(ab), 289P(ab), 293P(ab), 138P(ab), 252P(ab) Salzmann. JK. 112P(ab) HP(ab), 33P(ab), 41P(ab), 157P(ab), 172P(ab), 302P(ab) Ruiz. E, 245P(ab) Sambuceti, G, 735 l07P(ab), H2P(ab). 180P(ab), 2l8P(ab), Sfakianakis. GN. 798 Ruiz, M, 1398, 3P(ab) Samson, Y, 5, 1976, 76P(ab) 20IP(ab). 279P(ab) 262P(ab), 278P(ab), Sgouros. G, 695, 43P(ab), Ruotsalainen, U, 387, Samuel, A, 55 Scheidhauer, K, 137P(ab) 19l8(le) 78P(ab), 89P(ab), 96P(ab), 256P(ab) Samuels, RS, l03P(ab) Scheinberg, DA, 695, Schwarcz, TH, 230P(ab) l02P(ab) Rusckowski, M, 1655. San Pedro. EC. 88P(ab). 78P(ab) Schwanz, AM, 267P(ab) Shah. JH, 72P(ab), 95P(ab) 152P(ab), 190P(ab). 89P(ab). 165P(ab). Scheithauer, W, 1480, Schwartz, JG, 247P(ab) Shaker. R. 1285 203P(ab) 276P(ab), 277P(ab) 20P(ab), 25IP(ab) Schwartz. JR. 1826 Shalaby-Rana. E. 34P(ab) Rushton. HG, 1731 Sand. A, 2017 Scheiben, H, 767 Schwartz. M, 1826 Shan. YF, 308P(ab) RÃ¼ssel,FGM. 2082 Sandbank. J. 259P(ab) Scheiben, HR. 1626, 1717. Schwanz, PJ, 37P(ab) Shao, L. l32P(ab), 252P(ab) Russell. A, 105P(ab) Sandier. MP. 31P(ab), 3P(ab), 82P(ab) Schwanz, RB. 158P(ab) Shao, Y, 85P(ab), 86P(ab) Russell. C. 1876, 1883 l3IP(ab) Scheid. HH, 1990 Schwartzman, DS, 14P(ab), Shapiro. B, 633, 852. 1464, Russell, CD, 588. 1491, Sandrock, D. l58P(ab). Schelosky, L, 22 149P(ab) 1778, 15P(ab), 25P(ab), 293P(ab) 255P(ab) Schemman, F, 1942 Schwarz, SW, 61 P(ab), 141P(ab). l58P(ab), Russell. K, 114P(ab) Sanger, J, l69P(ab) Schenker, C, l6P(ab) 95P(ab) 288P(ab) Rust. M, l21P(ab) Sano, J, 308P(ab) Scheubeck. M, 286P(ab) Schwizer. W, 245P(ab) Shapiro, S, 197P(ab) Ruszkiewicz. JA, 74P(ab) Sano. M. 123P(ab) Scheunemann. C. l6P(ab) Sciagra, R. 26P(ab) Sharfstein, S, 107P(ab). Rutgers, DH, 38 Santoro. GM. 26P(ab) Schicha, H, 137P(ab) Sciuk, J, 1865, 1990, 147P(ab) Ruth, F, 262P(ab) Saoudi, A, 303P(ab) Schiepers, C, 767, 22P(ab), 55P(ab), 247P(ab), Sharkey, R, 1504 Ruth. TJ. 421 Saponaro. R, 185P(ab) 54P(ab) 279P(ab) Sharkey, RM, 829, 905. Ryan,A. 137 SarÃ¡n,F, 1942 Schiepers, CW, 306P(ab) Scopinaro, F. 1452, 35P(ab), 9P(ab), 43P(ab), 44P(ab), Ryan, J. 185 Sarda. L. 275, 253P(ab), Schierlinger, S, 172P(ab) 255P(ab) 96P(ab), 102P(ab), Ryan, JW, 2l2P(ab) 256P(ab) Schillaci, O, 1452, 35P(ab), Scott. A, 1052 168P(ab), 169P(ab), Ryan. PJ, 1353, 297P(ab) Sarfati. E, 1773 255P(ab) Scott. AM, 695, 1683, 231P(ab), 232P(ab), Ryhicki. F, l24P(ab) Sarti. G. 49P(ab) Schirmer. B. 57P(ab) 43P(ab), l2IP(ab), 239P(ab), 243P(ab) Ryu, JS, 252P(ab). 273P(ab) Sarwar, M. 457 Schlag. P, 257P(ab) l31P(ab), 132P(ab) Sharma, HL, 336 Ryu. YH. 551 Sasaki, M, 2IP(ab), 36P(ab). Schlom.J, 1491 Scott, JA, 1310 Sharma, S, 24P(ab) 133P(ab), 27IP(ab), Schlumberger, M, 598. 606. Scott-Moncrieff, C, 197P(ab) Sharma, V. 51P(ab). 7IP(ab) Saatci. U, 145P(ab) 275P(ab) 912, 1830, 1860, 20P(ab), Scovili. WA, 15P(ab) Sharp, JG, 13S Sacher, M, 415 Sasaki, T. 279, 326. 1698, 52P(ab) Scully, SP, 1438 Shaw, HM, 964 Sadalo, N, 123P(ab). 123P(ab) Schmall, B. 204P(ab) Seabold, JE. 1815 Shaw, U, 14P(ab). 68P(ab), l92P(ab), 25IP(ab), Sasaki, Y, 680, 1289, 1937. Schmidlin. P, 154P(ab). Sedelnikova, OA, 228P(ab) U6P(ab) 257P(ab) 38P(ab). 82P(ab), 221P(ab) Seeman, P. 113P(ab) Shaw, P, 34P(ab) Sadek. AH. l65P(ab), l83P(ab), 189P(ab), Schmidt, 5,615 Segal, D. 415 Shaw, SM, 197P(ab) 265P(ah), 278P(ab) 246P(ab), 280P(ab) Schmidt, U, 144P(ab) Segall, GM, 165 Shaya, E, 77P(ab) Sadik, A, 1662 Sasayama, S, 572, 729, 757, Schmid, T, 208P(ab) Seibyl, J. 33P(ab). 44P(ab), Shea, C, 203P(ab) Saenz, A, 1595 1403, 1836. 95P(ab) Schnakenberg, H, 167P(ab) 100P(ab), 133P(ab), Shedwick, LA, 231P(ab) Safer, JR. 176P(ab) Sassaman. M, 204P(ab) Schnakenberg, J, 222P(ab) 134P(ab). 246P(ab), Shefer, RE, 6IP(ab), Saffer, JR. 19P(ab) Sasso, D. 196P(ab) Schneider-Eicke. J, 126P(ab), 272P(ab). 305P(ab) 128P(ab) Saga, T, 179P(ab), 200P(ab), Sasso, DE, 656 l80P(ab) Seibyl, JP, 11 Sheff, K, l33P(ab), 203P(ab) Salake. S, 15P(ab) Schneidennan, GS, 6S Seidel, J, 204P(ab) 134P(ab). 272P(ab) Saha. GB. l77P(ab). Sato. J, 5P(ab). 291 P(ab), Schneiderman, MH, 13S, 6S Seike, Y, l2P(ab), 285P(ab) Shehata.AR, 14P(ab), 2276P(ab) 292P(ab) Schnitt, SJ, 74P(ab) Seitz, RJ, 2l9P(ab) 58P(ab). 177P(ab) Sahu, SK. l87P(ab) Sato, K, 410 Schnur. KC, 99P(ab) Seki, C, 280P(ab) Shelton. DK, 2l4P(ab) Sain, JD. 301P(ab) Sato, M, 410 Schober, O, 1865. 1990, Seki, H, 64P(ab), 122P(ab) Shelton, ME, 222P(ab) Saito, T, H6P(ab) Sato, S, l7P(ab) 49P(ab), 71P(ab), Sekito, Y. 276P(ab) Shen, MYH, 8IP(ab) Saito. Y. 291 P(ab) Satoh, H, 153P(ab) l06P(ab). 268P(ab) Seliskar. CJ. 205P(ab) Shen, S, 146. 1970, 90P(ab), Saitoh, M, 258P(ab) Satoh, T, 165P(ab) Schoder, H, 3P(ab) Selland. DG, 267 128P(ab), 232P(ab)

2116 The Journalof NuclearMedicine Shenk, RR, 99P(ab) Silver, S, 23N(8) Smith, MF, 212P(ab) 128P(ab), 150P(ab), Stoof, JC, 134P(ab) Sheridan, CM, 105P(ab) Silverman, DHS, 123P(ab) Smith, RJ, 19P(ab), 151P(ab), 167P(ab), Storck, M, 249P(ab) Sherman, ELC, 108P(ab), Silverman, DS, 99P(ab) 130P(ab), I32P(ab), 195P(ab) Storm, G, 1392 128P(ab) Silverman, ED, 854 172P(ab), 276P(ab), Srivastava, V, 252P(ab), Stout, DB. 109P(ab), Sherman, PS, 50P(ab) Silverman, J, 75P(ab) 283P(ab), 284P(ab) 295P(ab) 163P(ab) Shettar, S, 165P(ab) Silverman, RW, 85P(ab), Smith, SM, 307P(ab) Srur, S, 290P(ab) Stowe, LA, 306P(ab) Shi, B, 186P(ab), 298P(ab) 86P(ab) Smith, SV, 195P(ab), Stabin, M. 1995 Strassmann. G, 121P(ab) Shi, R, 127P(ab) Simakhodski, I, 283P(ab) 196P(ab) Stabin, MG, 538, 2079, Slratton, JR, 29P(ab) Shiba, K, 186P(ab) Simkin, P, 991 Smith, T, 1331, 1336 90P(ab), 162P(ab), Strauss, HW, 534, 1921 Shibasaki, H, lOlP(ab) Simon, AJ, 86P(ab) Smith, WS, 24N(9), 29N(10). 228P(ab), 229P(ab), Strauss, J, 23P(ab) Shibasaki, T, 457 Simons, M, 1618 34N(11), 30N(12) 231P(ab) Strauss, LG, 68P(ab), Shibazaki, T, 273 Simpson, G, 136P(ab) Smith, WH, 3P(ab) Stackhouse. M. 186P(ab) 147P(ab), 154P(ab), Shields, AF, 2049, 67P(ab), Simpson, LJ, 72P(ab) Smola, R, 207P(ab) Stadalnik, RC, 160, 1896, 257P(ab), 264P(ab) 240P(ab) Simpson, N, 109P(ab), Smylie, M, 237P(ab) 202P(ab) Stray, JE, 151P(ab) Shields, SC, 56P(ab) 145P(ab) Snow, BJ, 421 Stadier. E, 172P(ab) Striano, G, 42P(ab) Shiga, T, 276P(ab), 290P(ab), Simpson, NR, 231 P(ab) Snow, DA, 673 Stahlschmidt, A, 200P(ab) Strittmatter, W, 362 291P(ab), 293P(ab) Simsek, U, 289P(ab) Snow, GB, 352 Staib, L, 80P(ab) Strother, SC, 73P(ab), Shih, L, 151P(ab) Sinboku, H, 1343 Snyder, SE, lOP(ab), 21P(ab) Staib-Sebler, E, 9P(ab) 227P(ab) Shih, WJ, 1913(le), 230P(ab) Sinclair, RA, 121P(ab) So, Y, 28P(ab) Stallings, L, 83P(ab) Strotman. NA, 24P(ab) Shimada, S, 66P(ab) Singer, PA, 135P(ab) Soares, EJ, 30P(ab) Stalteri, MA, 96P(ab), Strul, D, 154P(ab) Shimizu, M, 10IP(ab) Singh, PR, 28P(ab) Soares, J Jr., 294P(ab) 150P(ab) Struttman, M, 61P(ab) Shimizu, T, 263P(ab) Sinnige, LGF, 21P(ab) Sohn, SK, 268P(ab) Stanowsky, A, 137P(ab) Stubbs. J, 102P(ab), Shimizu, Y, 304P(ab) Sinow, R, 1789 Soil, A, 245P(ab) Stanus, E, 21P(ab) 230P(ab), 231P(ab) Shimonishi. Y, 304P(ab) Sinusas, A, 1783 Solbach, M, 200P(ab) Starksen, NF, 47P(ab) Stubbs, JB. 151 Shimosegawa, E, 12P(ab) Sinusas, AJ, 62P(ab), Solin, O, 387, 51P(ab) Starzec, A, 189P(ab), Studebaker, R, 40P(ab) Shimotsu, Y, 1824 81P(ab) Solzabach, U, 218P(ab) 233P(ab) Studholme, C, 100P(ab), Shin. SA, 226P(ab) Sippel, C, 246P(ab), Som, P, 24P(ab) Stathis. M, 6P(ab), HP(ab), 208P(ab) Shinbata, H, 180P(ab) 257P(ab) Sommer, H, 156P(ab), 41P(ab), 201P(ab), Stumpf. MJ, 45P(ab) Shiomi, S, 51,641 Sisayan, R, 250P(ab) 252P(ab) 279P(ab) Stundzia. A. 8P(ab) Shiraishi, M, 55P(ab) Sisson, JC, 16,852, 1464, Somsen, GA, 160P(ab) Staub, A, 281 P(ab) Sturtz, GL, 105 Shirakami, Y, 94P(ab) 288P(ab) Song, HC, 67P(ab) Stauch, C, l42P(ab) Su, F-M, 144P(ab), 166P(ab) Shirazi, P, 275P(ab) Sitek,A, 120P(ab) Song, IS, 639 Staudenherz, A, 1526, Su, T, 77P(ab) Shoup, TM, 33P(ab), Skarulis, MC, 1690 Songini, C, 967 H5P(ab), 254P(ab), Sudati, F, 55. 967, 1655 222P(ab) Skibo, LK, 165 Sonmezoglu. K, 233 266P(ab) Suematsu, K, 276P(ab) Shreeve.WW, 1841 Skinner, RS, 25P(ab) Sonnenberg, F, 113P(ab) Stay ton. P, 151P(ab) Suetens, P, 767 Shreve, P, 15P(ab), 25P(ab), Skinner, RWS, 1540 Solicelli, A, 164P(ab) Steele, DL, 206P(ab) Sueyoshi, K, 263P(ab), 27P(ab) Skopicki, HA, 16IP(ab) Sostman, HD, 1438. 1906 Steele, PP, 171P(ab) 296P(ab) Shreve, PD, 36P(ab), Slade, SA, 191P(ab) Soucy, J-P, 98P(ab), Stefanini, S, 735 Suga. K, 807, 1361 141P(ab) Slaton, JW, 292P(ab) 271P(ab) Steffens, MG, 169P(ab) Sugawara, I, 15P(ab) Shuke, N, 5P(ab), 44P(ab), Slavin.A, 261P(ab) Soufer, R, 50P(ab), 59P(ab), Stegen, M, 274P(ab) Sugimoto, K, 251P(ab), 291P(ab), 292P(ab) Slivka.T, 149P(ab) 80P(ab), 282P(ab) Stein, PD, 577, 1313, 1636 257P(ab) Shulkin, BL, 16, 1464, Slizofski, WJ, 65P(ab), Soulen, M, 132P(ab) Steinbrenner, L, 135P(ab), Sub, JH, 551 288P(ab) 114P(ab), 163P(ab), SoÃ»lez,G, 1368 259P(ab) Suhonen-Polvi, H, 387 Sibomana, M, 258P(ab) 259P(ab), 263P(ab), Sparks. RB, 229P(ab) Steiner, B, 266P(ab) Sukekawa, H, 1289 Siccardi, AG, 967. 169P(ab), 265P(ab) Spath, G, 1496 Steinen, H, 441, 12IP(ab) Sulla, M, 245P(ab) 238P(ab) Slomka, PJ, 8P(ab), 25N(9) Spaulding, MB, 135P(ab), Steinstrasser, A, 362 Sullivan, K. 252 Siddiqui, A, 286P(ab) Slone, RM, 5P(ab) 136P(ab), 259P(ab) Stephens, S, 122P(ab) Sullivan, MJ, 174P(ab) Sides, K. 168P(ab) Sloof, GW, 184P(ab) Speckter, H, 209P(ab) Stephens, TS, 139P(ab) Sullo, P. 178P(ab) Sidoli, A, 238P(ab) Slooff, TJJH, 62 Speelman, JD, 134P(ab) Stephenson, MT, 118P(ab), Sumiya, H, 186P(ab). Siebert, R, 303P(ab), Slosky, JJ, 72N(2) Spelle, L, 5, 76P(ab) 202P(ab), 302P(ab) 298P(ab) 306P(ab) Slosman, DO, 1413, 1694 Spence, A, 221P(ab) Steuer, J, 11N(2), 15N(3) Summers, RM, 25P(ab) Sieckman, GL. 61P(ab), Smaldone, GC, 239 Spencer. RP, 105 Stevens, JS, 46P(ab) Sumner, A, 261P(ab) 185P(ab) Small, GW, 42P(ab), 79P(ab) Spencer, SS, lOOP(ab), Stevens, S, 206P(ab) Sun, K, 224P(ab) Siegel, A, 271 P(ab) Smarkey, S, 6P(ab) 305P(ab) Stevenson, A, 302P(ab) Sun, KT, 1626, 82P(ab) Siegel, AH, lOOP(ab) Smart, S, 1285 Sperling, B, 13P(ab) Stevenson, DA, 17P(ab), Sundaresan, SR, 135P(ab) Siegel, BA, 1906, 87P(ab), Smellie, JM, 823 Spetsieris, P, 216 66P(ab), l90P(ab) Sunder-Plassmann, L, 99P(ab), 132P(ab), Smilowitz, HM, 656 Spicer, KM, 83P(ab). Steventon, R, 285P(ab) 249P(ab) 135P(ab) Smit, EF, 67P(ab), 265P(ab) 208P(ab), 307P(ab) Stewart. JSW, 54P(ab) Sundin. A, 32. 1766 Siegel, J, 905, 9P(ab) Smith, AM. 155P(ab), Spies, H, 16P(ab) Stewart-Henney, PA. 60P(ab) Surkau. R, 296P(ab) Siegel, JA, 495, 9P(ab), 220P(ab) Spies, SM, 211P(ab), Stievenart, JL, 35P(ab), Surova-Trojanova, H, 44P(ab), 90P(ab), Smith, CR, 87P(ab), 216P(ab) 217P(ab), 113P(ab) 211P(ab) 102P(ab), 168P(ab), 281P(ab) Spies, WG. 216P(ab) Stillson, CA, 106P(ab) Sutherland, DR, 141P(ab) 231P(ab), 232P(ab) Smith, E, 191P(ab), 298P(ab) Spinks, TJ, 85P(ab) Stipp, VH, 230P(ab) Suto, Y, 997 Siegel, JS, 1504 Smith, EM, 288P(ab) Spitaels, SEC. 748 Stocklin, G, 41P(ab), Sutler. CW, 214P(ab) Siegel, S, 85P(ab), 86P(ab) Smith, EO, 1749, IOOP(ab), Spradau, TW, 28P(ab) 113P(ab), 142P(ab). Suzuki, H. 273. 457 Siemion, J, 279P(ab) 222P(ab) Springer, J, 65P(ab) 227P(ab) Suzuki. N, 17P(ab) Siewert, JR, H4P(ab) Smith, F, 301P(ab) Spyra, L, 218P(ab) Stodilka, R, 213P(ab) Suzuki, S, 1613 Siggelkow, H, 255P(ab) Smith, G, 554, l45P(ab). Squire, O, 25S Stoeter, P, 209P(ab) Suzuki, T, 680, 1567, 1981, Signorini, M, 42P(ab) 220P(ab) Sridhar, K, 255P(ab) Stoll, B, 245P(ab) 3P(ab), 184P(ab) Silbernian, A, 250P(ab) Smith, GS, 109P(ab), Srinivasan, A, 147P(ab), Stoller. M, 92P(ab) Suzuki, Y, 3P(ab) Silberstein, E, 881 231P(ab) 193P(ab), 420 Stollfus, J, 2l8P(ab) SwÃ¤hn,C-G, l08P(ab), Silberstein, EB, 185, Smith. GT, 1846, 122P(ab), Srinivasan, G, 1795, 25P(ab), Stollfuss, J, 180P(ab) H2P(ab), 192P(ab), 102P(ab), 23N(6) l39P(ab), 206P(ab), 39P(ab), 60P(ab), 93P(ab), Stone, CK, 94P(ab), 284P(ab) Sill, H, 1524 279P(ab) 160P(ab), 161P(ab) 206P(ab) Swailem, FM. 72P(ab) Silva, F, 287P(ab) Smith, KF, 4P(ab) Srivastava, SC, 72P(ab), Stone. D. 29P(ab) Swanson, DP, 2092,

Author Index â€¢1996 2117 23IP(ab) 123P(ab), 150P(ab), Terada. K, 101P(ab) 189P(ab) Tsuchida,T, 192P(ab), Swayne. AN, 168P(ab) 175P(ab), 239P(ab), Teras, M, 387 Tornita, K, 298P(ab) 251P(ab), 257P(ab) Swayne. LC, 905, 1504, 248P(ab), 276P(ab), Terauchi, T, 1444 Tomiyoshi, K, 457, 159P(ab) Tsuchiya, H, 298P(ab) 1826, 9P(ab), 168P(ab), 290P(ab), 291P(ab), Terra Filho, M, 294P(ab) Tomoike, H, 1289, 181P(ab) Tsui, BMW, 7P(ab), 30P(ab), 169P(ab), 243P(ab) 293P(ab) Terui, S, 1444 Tompkins, RG, 239P(ab), 63P(ab), 78P(ab), 80P(ab), Sweeney, TJ. UOP(ab) Tamamura. H, 122P(ab) Terzi, A, 1300 240P(ab), 244P(ab) 97P(ab), 210P(ab) Sweet, MP, 72P(ab), Tamarapalli, N, 293P(ab) Tesar, RD, lllP(ab), Tonami, N, 1622, 44P(ab), Tsuji, A, 80P(ab), 189P(ab) 167P(ab) Tamgac, F, 289P(ab) 132P(ab) lOlP(ab). 186P(ab), Tsuji, S, 186P(ab) Swirsky, D, 148P(ab) Tamir, A, 245P(ab) Teshima, T, 1460 291P(ab), 298P(ab) Tsukamoto, E, 16P(ab), Swischuk. LE, 1356 Tamura, M, 273, 457 Testa, T, 1872 Tondeur, M, 1281 239P(ab), 290P(ab), Sy, WM, 4P(ab) Tan, ES, 1631 Tetsuou, Y, 304P(ab) Top, LE, 234P(ab) 291P(ab) Sychra, JJ, 217P(ab) Tan, TX, 287P(ab) Tettenborn, B, 209P(ab) Topaloglu, R, 145P(ab) Tsukamoto, K, 1361 Syhre, R, 16P(ab) Tan, W, 278P(ab) Teule.GJJ, 1316, 1631, Torchilin, VP, 106P(ab) Tsukuda, K, 225P(ab) Synovec, RE, 205P(ab) Tanabe, H, 285P(ab) 38P(ab). 184P(ab), Torizuka,T, 1365, 64P(ab), Tsuyuguchi, N, 304P(ab) Syrola, A, 5, 118, 70P(ab). Tanabe, Y, 997 259P(ab) 248P(ab), 253P(ab) Tu, S, 32P(ab) 76P(ab), 170P(ab), TaÃ±ada,S, 180P(ab) Teusch, M, 140P(ab) Tornai, MP, 52P(ab), 78P(ab) Tulchinsky, M, 294P(ab) 226P(ab) Tanaka, F, 374, 1600, 2057, Thadani, V, 271P(ab) Tornesello, A, 237P(ab) Tuli, M, 289P(ab) Szabo. K, 33P(ab), 164P(ab) lOlP(ab) Thakur, ML, 489, 1789, Torniainen, P, 22P(ab) Tulli, MA, 294P(ab) Szabo, Z, 307, 33P(ab), Tanaka,H,1522,180P(ab) 151P(ab), 205P(ab) Torres, MA, 199P(ab), Tumeh, SS, 19S 47P(ab), 112P(ab), Tanaka,K,1365 Theobald, A, 341 242P(ab) Tung, HS, 247P(ab) l64P(ab), 262P(ab), Tanaka,S,1679 Theriault, R, 127P(ab) Toubert, ME, 1773 Turgut, B, 1755 288P(ab) Tanaka,Y,244P(ab), Thie.J. 122P(ab) Tourassi, GD, 295P(ab) Turjanski, N, 109P(ab) Szeimies, U, 156P(ab) 277P(ab) Thie, JA, 206P(ab) Touya, E, 266P(ab) Turkington, TG, 19P(ab), Szekely, C, 274P(ab) Tang, HR, 218P(ab) Thiel, A, 270P(ab) Towbin, RB, 269P(ab) 22P(ab), 74P(ab), Szonn, B, 256P(ab) Taniguchi, H, 1522 Thierens, H, 1048 Townsend, CE, 995 174P(ab), 219P(ab) Szulc, M, 38P(ab) Taniguchi, K, 3P(ab), Thijs, LG, 1316 Townsend, DW, 74P(ab) Turner, GT, 295P(ab) Szymanski, S, 112P(ab) 184P(ab) Thodtmann, R, 138P(ab) Towson, J, 90P(ab) Turoglu, HT, 1662, 242P(ab), Taniguchi, M, 122P(ab) Thomas, D, 121P(ab), Toyama, H, 1698, 123P(ab), 251P(ab),277P(ab), Tabuchi, K, 296P(ab) Tanihata, S, 26P(ab), 131P(ab), 132P(ab) 153P(ab), 215P(ab), 301P(ab) Tachibana. S, 263P(ab) 58P(ab), 126P(ab), Thomas, R, 155P(ab), 220P(ab), 259P(ab), Turpin, S, 1368, 23P(ab), Tada, M, 1713 185P(ab) 156P(ab) 282P(ab) 75P(ab), 180P(ab) Tadamura, E. 572, 729, 1981, Tanishima, Y, 1622 Thomashow, B, 5P(ab) Toyama, K, 1551, 1819, Turtle, J, 90P(ab) 1985, 150P(ab) Taniuchi, H, 192P(ab) Thomason, D, 249P(ab) 64P(ab), 254P(ab) Tutrone, RF, 315 Taddei. G, 238P(ab), Tansey, W, 1472, 72P(ab), Thome, M, 103P(ab) Toyama, S, 203P(ab) Tutumi, H, 244P(ab) 297P(ab) 86P(ab), 253P(ab) Thompson, C, 104P(ab) Toyama, T, 3P(ab), 184P(ab), Taguchi, A, 220P(ab) Tantayakom, S, 21 IP(ab) Thompson, JF, 964 244P(ab) Ãœberfuhr,P, 70P(ab) Tai, Y-C, 73P(ab), 130P(ab) Tapnio, P, 273P(ab) Thompson, NW, 852 Toyoda, H, 304P(ab) Uchida, Y, 258P(ab), Taillefer. R, 1368. 37P(ab), Tardif, CP, 1731 Thomsen, HS, 1883 Toyohara, J, 17P(ab) 277P(ab) 68P(ab), 69P(ab). 74P(ab). Tarditi. L. 169P(ab) Thrall, R, 196P(ab) Trampen, L, 615 Udelson, J, 69P(ab) 75P(ab), 93P(ab), Tarquini, A, 565 Thrall, RS, 656 Trask, DD, 132P(ab), Udelson, JE, I4P(ab) ISOP(ab). l80P(ab), Tateno, M. 680, 1981, 1985, Tian, J, 958 135P(ab) Ueda, S, 1673 l84P(ab) 150P(ab), 159P(ab), Tiblier, ES, 126P(ab) Trate, DM, 57P(ab), Ueda.T, 51,641 Taillon, LA, 104P(ab) 175P(ab) Tieku, S, 1942 244P(ab) Ueda, Y, 64P(ab) Tait, JE 29P(ab) Tatsch, K, 1799. 1965, Tiel-van Buul, MMC, Travagli, J, 598 Uehara, T, 1686, 285P(ab) Takada, A, 1522 25P(ab), 56P(ab), 24P(ab), 287P(ab) Travagli, JP, 912, 1830, Uema,T, 271P(ab) Takahashi, J, 320 156P(ab), 236P(ab), Tiihonen. J, 45P(ab), 76P(ab) 52P(ab) Uematsu, H, 251P(ab), Takahashi, M. 712, 80P(ab), 252P(ab) Tikofsky, RS, 273P(ab) Travin, MI, 14P(ab), 257P(ab) 189P(ab), 276P(ab) Tatsu, Y, 263P(ab), 296P(ab) Tiling, R, 156P(ab). 252P(ab) 105P(ab) Uematsu, M, 975 Takahashi, N, 160P(ab) Tatsukawa, K, 56P(ab) Tillet, I, 95 Trebossen, R, 170P(ab), Uemoto, S, 1365 Takahashi, T, 1522, 1713, Tatter. S, 66P(ab) Timar, E, 287P(ab) 217P(ab) Uemura, K, 165P(ab), 304P(ab) Taub, R, 46 Timmann, D, 55P(ab) TrÃªves,ST, 81, 22P(ab), 220P(ab) Takami, H, 15P(ab) Tauxe, WN, 180P(ab) Ting, G, 332 28P(ab), 270P(ab), Uezono, T, 7P(ab) Takano, K, 807 Tavolaro. R, 1452, 35P(ab), Tisell, LE, 1519 292P(ab) Ãœgur,Ã–,1956, 177P(ab), Takao, M, 1343 255P(ab) Tissingh, G, 134P(ab) Triana-Alexander, M, 291P(ab) Takarada, A, 37P(ab) Taylor, A, 1872, 1876, 1883 Titsch, U, 6P(ab) 276P(ab) Ugur, TM, 1956 Takashio, T, 5P(ab), Taylor, A Jr.. 881, 46P(ab), Tjuvajev. J, 53P(ab) Tricoire, H. 303P(ab), Umehara, I, 1613 291P(ab), 292P(ab) 17P(ab), 190P(ab). Tluczek, L, 50P(ab), 70P(ab) 306P(ab) Ungar, DR, 16 Takaloku, K, 66P(ab) 191P(ab), 293P(ab) TMzyar, E, 1956 Tripp, B, 23P(ab) Unlu, M, 1755, 139P(ab), Takayama, T, 291P(ab) Taylor, AT, 588, 1575, Tobes, MC. 4P(ab) Trisjono, F, 153P(ab) 184P(ab) Takeda. K, 282P(ab) 47P(ab), 84P(ab), Tochon-Danguy, H, Tristam, M, 1058 Uno, K, 258P(ab), 277P(ab) Takeda.T, 51,641 125P(ab), 307P(ab) 131P(ab), 132P(ab) Trivedi, MH, 1735 Urbain, J-L, 57P(ab), Takeishi, Y, 1289, 181P(ab) Taylor, C, 144P(ab) Tochon-Danguy, HJ, Troch, ME, 857 244P(ab) Takekawa, H, 955 Taylor, RJ. 13S 121P(ab) Trojan. H, 221P(ab), Uren, R, 34P(ab), 46P(ab) Takeuchi, A, 282P(ab) Taylor, SE, 146P(ab) Todd-Pokropek, AE, 2087 265P(ab) Uren, RF, 964 Takeyama. H, 296P(ab) Taylor, SF. 285P(ab) Toftdanl. DB, 261 Troncone, L, 633, 237P(ab) Uribe, J, 85P(ab), 227P(ab) Taki, J, 1622, 298P(ab) Teates, CD, 158P(ab) Tohyama, M, 66P(ab) Truckenbrodt, R, 41P(ab) Uslu, I, 233 Takikawa, S, 1850 Tehan. AM, l5P(ab) Tokcaer, AB, 1755 Trujillo, NP. 179P(ab), Utech, Cl, 307P(ab) Tal, I, 172P(ab) Teigen, EL, 1535 Tokuda, O, 807 295P(ab) Uysal, U, 1956, 177P(ab), Tall, J, 1639 Tellmann, L, 219P(ab) Tokunaga, M, 457 Tsai.CS, 187P(ab) 257P(ab), 290P(ab) Talusani, S, 295P(ab) Telsey, J, 38P(ab) Tolle, TR, 278P(ab) Tsai, S, 437, 513, 281P(ab), Uzal, D, 1956, 257P(ab) Tamagami. H, 649 Tempero. MA, 90P(ab). Toma, P, 297P(ab) Tsai, SC, 292P(ab), 298P(ab) Uzun, A, 233 Tamaki, N, 572, 729, 757, ISOP(ab), 13S Tomas, MB, 103P(ab), Tsai, Z, 332 1365, 1403, 1600, 1836, ten Bokum. AMC, 24P(ab) 242P(ab) Tsao, J, 8P(ab) v. Ammon, K, 54P(ab) 1981, 1985,2057, 16P(ab). TenCate. FJ, 1951 Tomassetti, P, 250P(ab) Tschabitscher, D, 241P(ab) V. de Beco, JL, 189P(ab) 95P(ab), lOlP(ab), Tennison. J. l42P(ab) Tomiguchi, S, 80P(ab), Tsoukalas, C, 188P(ab) Vaalburg, W, 257, 279, 897,

2118 The Journalof NuclearMedicine 984, 1571, 1631, llP(ab), van Gennip, A, 287P(ab) Vellante,237P(ab)Velu,C, I4IP(ab),190P(ab)Visser- Wallis.JW, 178, 63P(ab), 71P(ab), 86P(ab), van Gils, APG, 270 53P(ab)Vemulakonda,T, 217P(ab) 108P(ab), 157P(ab), van Ginkel, RJ, 257, 984 1639Vender, US, 108Vitola,Wisselaar, HA, Walsh, C, 17IP(ab) 225P(ab), 263P(ab), van Gog, FB, 352 265P(ab)Vento,J, 65P(ab), 131P(ab)Vlahos,JV, Walsh, TK, 35P(ab), 72P(ab), 265P(ab), 306P(ab) van Hagen, PM, 24P(ab) 196P(ab)Venugopal,J, 32P(ab)Voderholzer,L, 95P(ab) Vachiery, J-L, 83P(ab) Van Heertum, RL, 5P(ab), 205P(ab)Vera,R, 1799Voisin, WA, Wanet, PM, 2017 Vagg, RC, 168P(ab) 123P(ab), 270P(ab), 1896,202P(ab)Vera,DR, 160, 1860Volkert,P, Wang, G, 554 Vaidyanathan, G, 61P(ab), 273P(ab) 6IP(ab),185P(ab)Volkow,WA, Wang, G-J, 33P(ab),4IP(ab), 160P(ab), 191P(ab) van het Schip, AD, 38, 244, 35P(ab),I13P(ab),P, 1976, 44P(ab). 45P(ab), 76P(ab), Vaigneur, K, 85P(ab) 465, 1511 217P(ab)Verani, 1609,33P(ab),ND, 554, 281P(ab) Vainionpaa, L, 22P(ab) Van Horn, JD, 559, 79P(ab), 37P(ab),58P(ab),MS, 1306, 41P(ab),44P(ab),40P(ab), Wang, GJ, 1609 Valda Ochoa, A, 303P(ab) 284P(ab) 93P(ab),126P(ab),69P(ab), 76P(ab),187P(ab).45P(ab), Wang, H, 120P(ab), Valdes Olmos, RA, 972, van Horn, JR, 62 178P(ab),184P(ab)Verbeke, 203P(ab),281P(ab)Vollet, 214P(ab), 216P(ab), 237P(ab) van Isselt, JW, 289P(ab) 260P(ab) Valdivia, S, 97P(ab) van Kaick, G, 87, 68P(ab), 175P(ab)Verberckmoes,K, 49P(ab),268P(ab)VolontÃ©,B, 1990, Wang, J, 2057, 24P(ab), Valent, P, 5P(ab), 20P(ab) 147P(ab), 234P(ab), 91P(ab)Verbruggen,R, H4P(ab), 163P(ab), Valente, CM, 202P(ab) 235P(ab), 257P(ab), 91P(ab),175P(ab)Verdesca,A, 133P(ab)Volpi,MA, 259P(ab) Valentin, L, 303P(ab), 264P(ab), 265P(ab), 273P(ab)Volpino,JD, Wang, JK, 125P(ab), 306P(ab) 296P(ab) 50P(ab)Vergare,SA, 35P(ab)Volterrani,P, 172P(ab) Valentine, JD, 77P(ab) van KÃ¤mpen,A, 128P(ab) 138P(ab),156P(ab)Verhaar,E. 1883,225Voltini,D, Wang, KC, 89P(ab). Valerius, T, 362 van Kroonenburgh, MJPG, 37P(ab)vonF, 274P(ab) Valk, PE, lllP(ab), 1652 868Verhoeff,MJ, 247P(ab)vonder Ohe, MR, Wang, QJ, 1031 132P(ab), 136P(ab), van Leyen-Pilgram, K, 1449VerhÃ¶rst,NPLG, 70P(ab)vonScheidt, W, Wang, S, 332,437, 1003 139P(ab), 157P(ab) 270P(ab) 38P(ab)Verma,PMJ. 441,699,Schullhess, GK, Wang, SC. 5P(ab) Valkama, M, 22P(ab) van Lingen, A, 1631, 306P(ab)Vermeeren,RC, 121P(ab)Votaw, Wang, SJ, l45P(ab), Valkema, R, 19P(ab), 59P(ab), 60P(ab), 16N(2)Vermey,PC, 222P(ab),254P(ab),D, 163P(ab), 187P(ab). 48P(ab), 60P(ab), 268P(ab) 176P(ab), 178P(ab) 897Vermiglio,A, 298P(ab)Votaw, 188P(ab), 234P(ab). Vallabhajosula, S, 673, 1016, Van Mullekom, A, 498 1830Veronikis,F, 191P(ab),254P(ab),J, 241P(ab), 245P(ab), 38P(ab), 60P(ab), van Peski, J, 48P(ab), 991Vessella,IE, 298P(ab)Votaw, 288P(ab), 292P(ab), 152P(ab), 204P(ab), 60P(ab) 151P(ab)Vessotskie,RL, 222P(ab)Voute,JR, 41P(ab), 294P(ab), 298P(ab) 272P(ab) Van Renterghem, D, 473 201P(ab)Vessotskie,J, 237P(ab)Vreugdenhil,PA, Wang, X, 958, 149P(ab) van Baalen, JR, 23P(ab) van Rijk, PP. 38, 244, 465, 66P(ab)Veyre,JM, 594Vriesendorp,G, Wang, XY. 196P(ab) van Beek, JHGM, 38P(ab) 1511,23P(ab), 62P(ab), 922Vezina,A, 1545Vrolix, HM, Wang, Y, 6P(ab) vanBloois, L, 1392 216P(ab), 231P(ab), 197P(ab)Viale.W, 767Vural,M, WÃ¤ngberg,B, 1519,2002 van de Lagemaat, L, 289P(ab) 238P(ab)Viergever,G, 139P(ab)Vural,G, 1755, Ward, H, 2006 219P(ab) van Roermund, PM, 23P(ab) 62P(ab),213P(ab),MA, 175P(ab)Waack,I, 106P(ab), Warwick, T, 1916(le) vandeVen,MTP,2072 van Royen, EA, 65P(ab), 216P(ab)Viggiano, Washburn, LC, 752, 49P(ab) vandeVen,PJG,289P(ab) 134P(ab), 160P(ab) 148P(ab),176P(ab)Vignai,J, 122P(ab)Wachholz,M, Washino, K, 17P(ab) VandenAbbeele,AD, 315, Van Train, K, 81P(ab) 12)Wachsner,BW, 24N( Wasserheit, C, 169P(ab) 140P(ab),258P(ab), van Waarde, A, llP(ab), 1946Vignati,JP, 306P(ab)Wackers,RY, Wassmann, H, 268P(ab) 261P(ab), 305P(ab), 19S 71P(ab). 108P(ab) 236P(ab)Villa,A, 59P(ab),62P(ab),FJT, 1783, Watanabe, H, 285P(ab) van den Anker-Lugtenburg, van Zandwijk, N, 584 238P(ab),243P(ab)Villanueva-Meyer,G, 47P(ab), 81P(ab)Waddington, Watanabe, K, 84, 901, PJ, 19P(ab), 268P(ab) van Zwieten, PA, 160P(ab) 65P(ab)Wagenaar,W, 53P(ab), 308P(ab) van den Broek, WJM, 2072 Vanbilloen, H, 91P(ab) 926,1356, J, 305P(ab)Wagnberg,DJ, 178, Watanabe, N, 273, 457, van den Elsen, PA, 213P(ab) VanBrocklin, HF, 40P(ab), 79P(ab)Villar,74P(ab), 2002Wagner,B, H)IP(ab) van den Hoff, J, 521,2066 51P(ab) 272P(ab)Villegas,C, 46P(ab)Wagner,B, Watanabe, S, 26P(ab), van der Duin, LV, 2082 Vande Streck, PR, 294P(ab) 97P(ab)Villemagne,BJ, 262P(ab),11N(8),HN Jr., 58P(ab), 126P(ab), van der Graaf, WTA, 1571, Vandenberghe, R, 22P(ab) 6P(ab),UP(ab),V, 18N(10)Wagner, 185P(ab) 67P(ab) Vandermeiren, R, 175P(ab) 262P(ab)Villena-Heinsen, 121P(ab),137P(ab)Wagner,R, Watanabe, T, 189P(ab) van der Kleij, AJ, 287P(ab) vanDie, J, 465 615Vilmer, CE, Watanabe, Y, 761, I2P(ab), van der Linden, JGM, VanHagen, MP, 108 35P(ab)Vilner,E, 2066Wahl,TOF, 175P(ab) 72P(ab) Vannoy, SD, 172P(ab) 267P(ab)Vincent,BJ, 7P(ab), 432Wahl,L, Waters, D, 14P(ab), 37P(ab), van der Mark, TW, l IP(ab), Vanoverschelde, JL, 25P(ab), 302P(ab)Vincent,D, 1042,1540,RL, 371,502, 105P(ab), 195P(ab) 71P(ab), 108P(ab), 39P(ab), 126P(ab) 239P(ab)Vinci,J, 27P(ab),36P(ab),1562, Waters, DJ, 1003 265P(ab) Vansant, JP, 1575, 48P(ab), 47P(ab)Vines,P, 52P(ab),64P(ab),43P(ab), Waters, SL, 141P(ab) van der Meer, JWM, 1392, 84P(ab), 125P(ab), P(ab)Vingerhoets,D, 513, 281 75P(ab),98P(ab),65P(ab), Watkins, GL, 39P(ab), 128P(ab) 159P(ab), 213P(ab), 421Vini, FJG, HOP(ab),lllP(ab), l99P(ab). 225P(ab). van der Mey, AGL, 270 254P(ab), 307P(ab) 235P(ab)Vink,L, 141P(ab),253P(ab), 226P(ab) van der Pluijm, ME, 108 VanTol, H, 113P(ab) 38P(ab)Violon,A, 260P(ab),262P(ab), Watson, D, 69P(ab) van der Vliel, JA, 119P(ab) Vanzetto, G, 3P(ab), P(ab)Virgolini,P, 21 I914(le)Wainer, Watson. DD, 1398. 3P(ab) Van der Zee, AGJ, 263P(ab) 229P(ab) 5P(ab),20P(ab),I, 1480, 19P(ab)Wakabayashi,N, Watzlowik, P, 70P(ab) van derSchors, R, 352 Vargas, FS, 294P(ab) 251P(ab)Virzi, 259P(ab)Wakamatsu,S, Wawrzynski, PE, 81P(ab), van Deventer, SJH, 24P(ab) Vargo, JJ, 854 1655Visscher,F, l84P(ab)Wakasugi.S, 148P(ab), 176P(ab) van Dieren, EB, 38 Varkonyi, a, 287P(ab) 482Visser,CA, 179P(ab)Waki.T, Waxman.A. 75P(ab), van Dijk, A, 38, 244, 465, Varma, VM, 205P(ab) 38P(ab),59P(ab),CA, 1631, 192P(ab),251P(ab),A, 56P(ab), lOlP(ab), 250P(ab). 1511 Varrella, P, 138P(ab), I78P(ab)Visser,60P(ab), 257P(ab)Wakisaka, 267P(ab), 269P(ab), van Domburg, RT, 1951 156P(ab) ab),59P(ab),FC, 1631, 38P( 7P(ab)Wakita,K, 272P(ab), 273P(ab) van Dongen, AJ, 23P(ab) Varrone, A, 164P(ab) 60P(ab),176P(ab), 183P(ab)Waldmann,S, Waxman. AD, 46 van Dongen, GAMS, 352 Varvares, M, 136P(ab). 178P(ab),184P(ab)Visser, 234P(ab)Walicka,TA, Weaver, JP, 127P(ab), Van Don, ME, 50P(ab) 264P(ab) 229P(ab)Walker,MA, 275P(ab) vanDyck, CH, 1749, Vasconcelos, AG, 273P(ab) HP(ab),71P(ab),GM, 1571, 79P(ab)Walker,M, Webb, E, 285P(ab) 33P(ab), 272P(ab) Vaughan, SN, 265P(ab), 108P(ab)Visser, 65P(ab)Wall,S, Webb, S, 228P(ab) van Eijkeren, M, 1048 286P(ab) 352Visser,GWM, 46Wallace,F, Webber, KO, 29P(ab), van Es, PN, 1652 Vavrek, MT, 40P(ab) 1388,HP(ab),TJ, 108, 86P(ab).253P(ab),S, 72P(ab), 129P(ab), 152P(ab), Van Every, B, 117P(ab) Veening, MA, 1631, 60P(ab) 71P(ab),108P(ab), 264P(ab) 203P(ab), 204P(ab)

Author Index â€¢1996 2119 Weber, C, l59P(ab) Wiegner, R, 83P(ab), Wolters,EC, 134P(ab) Yamashita, I, 71 Yoshida, K, 1701 Weber, DA, 2l4P(ab) 208P(ab) Won, JH,426 Yamazaki,M, 277P(ab) Yoshida,M, 257P(ab) Weber, K, 87 Wieland, D, 70P(ab), Wong,CYO,l77P(ab), Yan,IT,25lP(ab) Yoshida, I, 2lP(ab), 36P(ab), Weber, W, 99P(ab), 11lP(ab), lO7P(ab) 276P(ab) Yang, A, 78 l33P(ab),27lP(ab), l38P(ab), l57P(ab) Wieland, DM, 16, 1923, Wong, DF, 77P(ab), Yang, CC, 298P(ab) 275P(ab) Weber-Luxenburger, G, SOP(ab),70P(ab), l92P(ab) lO7P(ab), 1l2P(ab), Yang, DI, 931, 1472, 1476, Yoshida,Y,37P(ab) l22P(ab) Wienhard, K, 76P(ab), 279P(ab), 280P(ab), 72P(ab), 86P(ab), Yoshino, E, 1673 Webner,P1,858,250P(ab) l22P(ab), l55P(ab) 283P(ab) 253P(ab), 26lP(ab), Yoshioka, N, l83P(ab) Weder, W, 121P(ab) Wiersema, AM, 1i9P(ab) Wong, FC, 127P(ab), 264P(ab) Yost, P. 249P(ab) Weemaes,AA, 1571 Wiersma, A, 2082 207P(ab), 296P(ab) Yang, I, 42P(ab), l46P(ab), Young,CS,307P(ab) Wegelius, U, 387, 256P(ab) Wierzbinski, B, l9l3(le) Wong, FCL, 931,1472, 303P(ab) Young,ET,53P(ab) Wehage, I, 181P(ab) Wiessler, M, 264P(ab) 1476,261P(ab) Yang, IY, 1398 Young,G, 293P(ab) Wehe,DK, 1l9P(ab), Wijers, AA, 306P(ab) Wong,JCH, 1771,208P(ab), Yang, Q, 20P(ab), 25 lP(ab) Young,H, 54P(ab),148P(ab) 170P(ab) Wikier, D, 2lP(ab), 83P(ab) 282P(ab) Yang, RC, 298P(ab) Young, I, 251P(ab), 3OlP(ab) Weichert, IP, 1540 Wilbur,DS, l5lP(ab) Wong, W, 931,1472,1476 Yang, S-O, 252P(ab), Young,I, 85P(ab),86P(ab) Weiland, FL, 294P(ab) Wilderman, SI, 119P(ab), Wong,W-H,261P(ab) 273P(ab) Young,K, 1846 Weiller, C, 55P(ab), 279P(ab) 170P(ab) Wong, WH, 85P(ab), Yang, ZY, 50P(ab), 193P(ab) Young, 5, 284P(ab) Weinbaum,DL,76 Wilk, M, l9P(ab) 227P(ab) Yao,R, 170P(ab) Young,SN, 1l3P(ab) Weinberger, DR. 559, 2021, Wilkinson, RA, 24P(ab), Woo, KS, 248P(ab) Yao,W, 506 Young, VR, 244P(ab) 79P(ab),l43P(ab), 240P(ab) Woolfenden, IM, 53P(ab), Yao,Wi, 68P(ab) Yu,D, 2lOP(ab) 187P(ab), 281P(ab), Wilkinson, RH Ir., 636 301P(ab) Yao, Z, 200P(ab), 203P(ab) Yu,MD, l97P(ab) 284P(ab) Willemsem, AIM, 2082 Worsley,DF, 36P(ab), Yasaka, Y, 37P(ab) Yu, SM, 286P(ab) Weinberger,J, 272P(ab) Willemsen, AIM, 984, 1631, 1l7P(ab) Yaster, M, 279P(ab) Yu,X, l55P(ab) Weiner, MF, 79P(ab) 225P(ab),265P(ab), Wp@, 533 Yasue, H, 80P(ab) Yu,Y-M, 244P(ab) Weiner, R, l96P(ab) 306P(ab) Wright, KL, 46P(ab) Yavascaoglu,I, 289P(ab) Yuan, A, 146, 1970, 90P(ab), Weiner, RE, 656 Williams, BB, 77P(ab) Wrobel, MC, 7P(ab) Ye,I, 218P(ab) 232P(ab) Weinheimer, Ci, 1723 Williams, CC, 307P(ab) Wu, A, 58P(ab) Yeh,5, 78, 1349,l38P(ab) Yuasa, K, 3P(ab), 64P(ab) Weinlaender, G, 1480 Williams, D, l97P(ab) Wu, C, 152P(ab) Yeh, SDJ, 102P(ab) Yueh,IC, l27P(ab) Weinreich, R, 54P(ab) Williams, I, 43P(ab) Wu,E, 178 Yeh, SH, 27P(ab), l25P(ab), Yuh,I,1567 Weintraub, BD, 1690, Williams, KA, 93P(ab), Wu,H,506, 1717 136P(ab),l72P(ab), Yukihiro, M, 1981, 159P(ab) l5P(ab) 104P(ab),lO5P(ab) Wu, HM, 68P(ab) 262P(ab), 286P(ab), Yun, LS, 224P(ab) Weintraub, WS, l25P(ab) Williams, LE, 209P(ab) Wu, HP,302P(ab) 303P(ab) Yung,TH, 247P(ab) Weinzapfel, BT,42P(ab) Williams, R, 57P(ab) Wu, KN, l27P(ab) Yeh, SI, 187P(ab) Yurekli, Y, 302P(ab) Weisman, MH, 242P(ab) Williams, SC, 304P(ab) Wu,L, 107P(ab) Yen,SH, l36P(ab),262P(ab) Yusen,RD, 5P(ab) Weismuller, 5, 82P(ab) Williams, W, 183P(ab) Wu, LC, l25P(ab), 136P(ab), Yen,I,78,1349 Yutani, K, 94P(ab) Weiss,M, 25P(ab) Williamson, PD, 100P(ab), 172P(ab), 286P(ab) Yeo, E, 286P(ab) Yuu,I,815 Weiss,Mi, 1799 271P(ab) Wu, S. 96P(ab), l62P(ab), Yeo,I, 978 Yves,N, 1773 Weiss, 5, 287P(ab) Willingham,MC, 1052 240P(ab) Yester, MV, 2087 Weissleder,R, 198P(ab) Wilson,AA,202P(ab) Wu,YH, 196P(ab) Yeung,DW,3lP(ab), Zabalegui, A, l69P(ab) Welch, A, 8P(ab), 18P(ab), Wilson, D, 202P(ab) Wunderlich, G, I 13P(ab) 92P(ab), l82P(ab), Zaers, I, 22lP(ab) l2OP(ab) Wilson, DW, 63P(ab), Wutz, W, l42P(ab) 242P(ab) Zaidi, H, 1421 Welch,MI, 1009,1294, 3OlP(ab) Wynne, I, 4P(ab) Yeung,H, 102P(ab), Zalcberg,J, l3lP(ab), l6P(ab),40P(ab),5lP(ab), Winek,R, 1516 138P(ab) 132P(ab) 6lP(ab),71P(ab),87P(ab), Winkle, W, 40P(ab), 86P(ab) Xia, W, 18P(ab), 97P(ab) Yeung,HW, 858 Zalutsky,MR, 2011,6lP(ab), 95P(ab), 99P(ab), Winkler, K, 261 Xing,A, 298P(ab) Yeung,HWD, 1528 l6OP(ab), l9lP(ab), lO8P(ab),118P(ab), Winn, HR, 12P(ab) Xiong, CY, 129P(ab), Yin, G, 2l4P(ab) 197P(ab), 200P(ab) 128P(ab) Winnick, 5, 312 l67P(ab) Ying, Z, 9P(ab), 168P(ab), Zamecnik, PC, 4P(ab), Weller,5, 27P(ab) Winter, E, 27P(ab) Xu, B,958 231P(ab) 269P(ab) Welsh, PC, l9lP(ab) Winter, PF, 1516, 307P(ab) Xu, IC,1896 Yipintsoi, I, llOP(ab), Zametkin, A, 45P(ab), Welt,S.1052 Wirth, M, 429 Xu,LC, 189P(ab) l46P(ab) 284P(ab) Wen, PYC, 195 Wise, M, l65P(ab) Xu, M, 1009, 108P(ab) Yokoi, F, 77P(ab), 112P(ab), Zamora, P0, 1962, 236P(ab) Wenger,DE, 1456 Wiseman, GA, 1456, 279P(ab), 280P(ab), Zanzi, I, 1760 Wenzel, R, 122P(ab) 116P(ab) Yaakob, W, 307P(ab) 283P(ab) Zanzonico, P, 1995, 38P(ab) Werner, E, 307P(ab) Wiseman, MB, 224P(ab) Yachiku, 5, 29iP(ab), Yokokawa,I, 975 Zanzonico, PB, 1921 Wernikoff, R, 2l3P(ab) Wishart, IM, 1643 292P(ab) Yokoyama, A, 757, 7P(ab), Zapf, A-O, 233P(ab) Wessell, D, 78P(ab) Wisner, ER, 202P(ab) Yadagar, I, 250P(ab) 56P(ab),192P(ab) Zardi, L, 238P(ab) West, DI, 823 Wisniewski, G, 1749, Yadav,S, 89P(ab),277P(ab) Yokoyama, H, 975 Zaret, BL, 59P(ab), 81P(ab) West, I, I81P(ab) IOOP(ab) Yamada, I, 1613 Yokoyama, 1, 1937, 38P(ab), Zasadny, KR, 371, 43P(ab), Westera,G, 699, l46P(ab) Witjes, IA, l69P(ab) Yamada, R, 304P(ab) 82P(ab), 280P(ab) 65P(ab),78P(ab) Wey, SP, 5 lP(ab) Witmeyer, PE, l47P(ab) Yamada, S, 320, 1713, Yokoyama, K, 44P(ab), Zea-Ponce, Y, 11, 44P(ab), Weyand, M, 1990,49P(ab) Witt, C, 20P(ab) 67P(ab) IOlP(ab) 272P(ab) Whatley, M, 15P(ab) Witte,C, l83P(ab) Yamamichi,Y,94P(ab) Yokoyama,R, 1444 Zelitt, D, 162P(ab) Wheeler, KT, 87P(ab) Wiue,M, l83P(ab) Yamamoto,I,815,1567, Yonekura, Y, 374, 572, 729, Zeng, GL, 206P(ab) Wheeler,RH, 1491 Wittry, MD, 303P(ab) 64P(ab), 122P(ab) 757, 1365, 1403, 1600, Zeng, SQ. l27P(ab) Whipple, C, 23N(l2) Woesler, B, 268P(ab) Yamamoto, K, 25lP(ab), 1985,2057,56P(ab), Zerauschek, F, 26P(ab) Whirrett, B, 87P(ab) Wohrle,H, 1468 257P(ab) 1OIP(ab),123P(ab), Zhang, I, 958, 108P(ab), White, CL III, 79P(ab) Wojno, K, 64P(ab) Yamamoto, 5, 56P(ab), 150P(ab),l75P(ab), 25S, 295 White,ID, 234P(ab) Wolf,FG, 829 l79P(ab) 192P(ab), 248P(ab), Zhang,II,3l2, 1528, White, M, 37P(ab) Wolf, H, 4P(ab), l42P(ab), Yamamoto, W, 5P(ab), 25lP(ab), 257P(ab) l57P(ab), 260P(ab), White, ML, 8lP(ab), 246P(ab), 256P(ab), 291P(ab),292P(ab) Yoo, TM, 29P(ab), 129P(ab), 278P(ab) 2lOP(ab),2l5P(ab) 257P(ab) Yamamura, Y, 1567 203P(ab) Zhang,M,200P(ab), White, I, 124P(ab) Wolfenden,PJ,1717 Yamanouchi, H, l23P(ab) Yoon, BW, 274P(ab) 203P(ab) Wichter, I, lO6P(ab) Wolkov,HB, l39P(ab) Yamanouchi, M, ll6P(ab) Yoon, K, 248P(ab) Zhang, N, 98P(ab) Wiegert, DA, 276P(ab) Wollenweber,SD,226P(ab) Yamaoka,Y, 1365 Yoshibayashi, M, 572 Zhang, Y, 7P(ab), 171P(ab), Wiegman,I, 225P(ab) Wolpers, HG, 521 Yamashina, I, 200P(ab) Yoshida,A, 37P(ab) 223P(ab)

2120 The Journalof NuclearMedicine Thao, HY, 308P(ab) Ziegler, M, 232P(ab) Zilleruelo, G, 23P(ab) Zoet-Nugteren,5, 748 Zuckerman, , 1323 Thao,QH,38P(ab),l52P(ab) Ziegler, P, 259P(ab) Zimmer, AM, 2l6P(ab) Zoghbi, 55, 32P(ab), Zuckier, LS, 1995, l62P(ab) Thao, XD, 78P(ab) Ziegler, 5, 94P(ab), 99P(ab), Zimmerman, RE, 17P(ab), 33P(ab), 44P(ab), Zuger, I, 249P(ab) Zhen, I, 308P(ab) lO7P(ab), I 1IP(ab), 29P(ab), 77P(ab), 272P(ab), 285P(ab) Zukerberg, BW, 132P(ab) Zheng, GL, 153P(ab) 122P(ab), 138P(ab), l58P(ab), 305P(ab), 195 Zollner, TM, l37P(ab) Zurakowski, D, 292P(ab) Zheng, L, I74P(ab) l54P(ab), lS7P(ab), Zinn,KR,235P(ab) Zonnenberg,BA,38,244, Zuurbier, C, l46P(ab) Zheng, M, 67P(ab) l8OP(ab),278P(ab) Zito, F, 967, l33P(ab), 465, 1511 Zwas, SI, I27P(ab) Zheng,Q-H,40P(ab) Ziegler, SI, 70P(ab), 258P(ab) Zubal, 1G. 9lP(ab), Zweit, I, 54P(ab),166P(ab), Zhou,FC,40P(ab) 13IP(ab), l47P(ab) Zivanovic, MA, 1058 lOOP(ab),246P(ab), l9lP(ab) Thou, Y, 146P(ab) Ziessman,HA, 643, 1639 Zoar, 5, 290P(ab) 305P(ab) Zwinderman,AH, 533 Thu. N, IIP(ab), I74P(ab) Ziffer, IA, l25P(ab) Zoboli,5, 88P(ab),l69P(ab), Zubieta, J, 152P(ab) Thu. YY, 47P(ab) Zitlo, UA, 8P(ab) 250P(ab) Zubieta, 1K, 45P(ab) Zhu,ZH, 196P(ab) Zilbovicius, M, 1976 Zoccarato, 0,1300 Zucker, I, 893

AuthorIndex â€¢1996 2121 1996 SUBJECT INDEX

Activated-platelet imaging, evaluation of Tc- pediatrie population, effects of renal Al receptor, potential use of "C-KFI5372 for P280, 775 pathology, 1331 Acupuncture, objective assessment of effects Aging detecting degeneration of presynaptic onbrain functions, Tc HMPAO SPECT abnormal, brain, radical-related disease, nuclear neurons. 1203 imaging, 278P(ab) medicine in, 56P(ab) Abdominal carcinoid tumors, accuracy of Acute myocardial infarction, reverse cerebral atrophy and, effects on cerebral blood somatostatin receptor scintigraphy in visualization of, "'In-pentetreolide redistribution of Tc-seslamibi How, 308P(ab) following PTCA, prediction of cerebral glucose metabolism and, atlention- SPECT, 1452 Absorbed dose. l-"C-glucose estimates in adults. successful revascularization and wall deficil/hyperaclivity disorder adults, motion status, 1289 changes related to, cortical blood How effects of hyperinsulineinia, 1668 Absorptiometry. dual-energy x-ray, Acute stroke, clinical utilization of SPECT activation response, l64P(ab) imaging and thrombolytic therapy, 1259 clinical management of very elderly patients. measurements of bone mineral Adenocarcinoma myocardial perfusion SPECT, 69P(ab) density, l03P(ab) gastrointestinal tract, '-"I VIP receptor scanning dopamine transporter imaging, comparative Abstracts, record number al SNM annual of. 20P(ab) nicrostriatal, 133P(ab) meeting, 27N(5) intestinal, binding of ';>l-labeled VIP-receptor effects on acetylcholine storage and release, ial- Acetate dialysate, effect on plasma renin activity antagonist in, 251 P(ab) MIB1 vesamicol receptor. 1192 and level changes, lung, relation between uptake ratios of 20ITI effects with |:'I ÃŸ-CIT.272P(ab) hemodialysis, l4SP(ab) SPECT, histopathological differentiation, cxtrastriatal dopamine D2 receptor availability Acetazolamide grade of Na-K ATPase staining, 955 and, 281P(ab) Te HMPAO brain perfusion SPECT enhanced Adenosine normal and pathological, comparison from point with, vertebrobasilar insufficiency Al. receptor antagonists, radiolabelcd, for PET of carbon dioxide patients. 88P(ab) and SPECT. l42P(ab) responsiveness. 165P(ab) assessment of vascular reserve in patients with potential use of "C-KF15372 as Al receptor normal and schizophrenic, PET studies of carotid artery disease, compared with ligand, PET, 1203 impaired Wisconsin card sorting, 79P(ab) dipyridamole SPECT, 1595 receptors, upregulation of, smooth muscle cells, normal process on striata! uptake values. I!'I-IPT effects of high flow on Tc-HMPAO uptake. comparison of Tc-HMPAO and '"Xe localization of atherosclerotic SPECT imaging of CNS dopamine lesions. 4P(ab) transporters, 1965 measurements of regional cerebral blood SPECT, fixed and reversible defects during. AIDS flow, SPECT, 1735 prior infarction patients, l81P(ab) see Acquired immunodeficiency syndrome one-day protocol for cerebral perfusion reserve, stress Tc sestamibi SPECT, early poststress Alagille syndrome, focal liver hyperplasia, Tc-ECD, 2057 imaging, 59P(ab) assessment with hepatoreceptor and PET evaluation of cerebral hemodynamics, stress lest, 99mTc-letrofosmin tomography and hepatobiliary imaging. 1365 chronic occlusive cerebral echocardiography, coronary artery ALCAPA syndrome, assessment by dobutamine arteries. 21 P(ab) disease, 178P(ab) stress M1TISPECT and Acetazolamide test Adhesion molecule, integrin as a target, wide- echocardiography, 748 Tc HMPAO SPECT and. dementia, 273P(ab) spectrum immunoscinligraphy, 200P(ab) Alcoholism, benzodiazepine receptors in, SPECT cerebral vascular reserve, quantification with "O Adrenal gland imaging of. 285P(ab) water, 282P(ab) incidentally discovered masses, cost- Aldosteronoma. depiction with NP-59 Acetylcholine, synthesis, tracer of, brain uptake effectiveness, l58P(ab) scintigraphy, adrenal infarction, 852 of "C choline, 283P(ab) mass, evaluation by FDG-PET for metastalic Aliasing artifact, SPECT imaging, optimal Acetylcholinesterase disease. 14IP(ab) number of views in 360-degree, 1740 "C CP-126 N998 studies of, 4IP(ab) nonhypersecretory adenomas, uptake and Alpha-2 receptor blocker, abnormal I MIlu ; delivery-dependent brain distributions, 10P(ab) retention of "C acetate, 15P(ab) early diagnosis of Alzheimer's disease using images in healthy subjects, diagnostic Adrenal infarction, depiction with NP-59 pitfalls related to sympathetic radioactive analog method, PET, 649 scintigraphy. aldostcronoma, 852 activity, 1686 Achalasia. idiopathic. nolulinum toxin efficacyin. Adrenergic denervation. discrepancy in dual- Alpha-particle emitting radionuclide. preclinical scintigraphy. 57P(ab) tracer autoradiography. experimental characterization, 78P(ab) ACNP, see American College of Nuclear myocardial infarctions. 680 Alveolar permeability Physicians Adrenergic innervation compartmental model for lung clearance of Acquired immunodeficiency syndrome arrhythmogenic right ventricular disease pertechnegas, 2066 "'Ga imaging of pericardial lymphoma, 995 brain lymphoma in, -'"'TISPECT detection patients. 106P(ab) degree of damage in cirrhosis, 437 norepinephrine release, isolated rat Alzheimer's disease of, 258P(ab) heart. 107P(ab) see also Dementia dementia Adrenergic receptors i:'I IMZ distribution volume, as a measure of peptide T and glucose metabolism, FDG- "F RS-15385-FP. PET, 40P(ab) neuronal loss, 164P(ab) PET, 1177 PET ligand, distributed nonlinear modeling Tc HMPAO, absolute and relative quantitation differential diagnosis of cerebral toxoplasmosis with, 278P(ab) and CNS lymphoma. '"TI SPECT, 1ISO of, 106P(ab) Alpha-Adrenergic receptors, synthesis of "F automated classification of neural networks in dual-isotope methods in diagnosis of, 302P(ab) atipamelzole. 51P(ab) brain SPECT, 195 inlracranial lesions in, '"'Tl chloride and Te Adult respiratory distress syndrome carbon dioxide responsiveness, stereotaxic sestamibi SPECT comparison differentiating from hydrostatic pulmonary comparison, 165P(ab) in, 277P(ab) edema, "Ga pulmonary leak index, 1316 cerebral oxygen and glucose metabolism, lymphoma or infectious intracranial lesions in. early detection, [CAM-1, 196P(ab) uncoupling of, 275P(ab) SIT1 SPECT for differentiation. 276P(ab) Advanced differentiated thyroid cancer, high- comparison of Tc-HMPAO and Tc-ECD sequential thallium and gallium chest scans. dose radioiodine therapy, '"I-Nal, 1496 images, 1749 opportunistic infections, 1662 Adverse reactions, prevalence in nuclear discriminant value of semiquantitalive untreated Pneumocystis corinti pneumonia, medicine, 185 SPECT, 404(le) diagnosis with gallium Aebersold Award, development of novel earliest metabolic reduction, PET scintigraphy. 293P(ab) radiopharmaceuticals, Kenneth study, l63P(ab) Acquisition, optimization of. performance of ""Te Krohn, 22N(9) early detection. PET strategies. 79P(ab) brain SPECT, 273P(ab) Aerosol deposition measurement, three- early diagnosis using radioactive analog method Acromegaly. octreotide in, growth hormone dimensional description using and PET. 649 response and '"In pentetreotide uptake mullimodalily imaging, 873 FDG-PET scanning for evaluation of, 270P(ab) in. l59P(ab) Age-dependency, biokinetics of Tc-DMSA in glucose transport and phosphorylation

2122 The Journal of Nuclear Medicine 4/!SVS^Â«S^

delermined by FDG-PET, 201 E-3174, pharmacological potency and ATI SPECT, 165P(ab) mapping AChE in human brain, PET and "C receptor occupancy of, 288P(ab) Aplastic anemia, bone marrow scinligraphy in PMPusc in, 21P(ab) impulse response function, validation hÃ©matologiedisorders, Tc- metabolic impairment in, assessment with '"F of, 288P(ab) antigranulocyte antibody. 978 FDG-PET. 275P(ab) Angiotensin-II. hypertensive chemotherapy, PET Appendicitis, atypical acute, "*"TcMN3Fab' SPECT and histopathologic correlation, cerebral imaging to measure blood How of fragment of anli-granulocyle antibody blood tlow, 79P(ab) hepatic tumors. 1522 in, 162P(ab) study of medial temporal oxygen metabolism, Angiotensin-II receptors, in vivo labeling with Appetite, glycÃ©mieresponse, gastric emptying in PET, 1159 "C-L-159.884. 307 NIDDM, postprandial hunger, 1643 vesamicol receptor, '-'!I MIV affinity Angular sampling, value in clinical ARA-C HD. see cytarabine. high dose for. l86P(ab) SPECT, 1915(le) Aromatic amino acid decarboxylase. endocrine Ambulatory renal monitoring, renal scan and, Annexin V. recombinanl. Tc radio labeling of. pancreatic tumors, in vivo enzymatic renal function after combined kidney and arterial thrombus imaging, 29P(ab) activity, PET, 32 pancreas transplant, 293P(ab) Anterior cruciate ligament Arrhythmias American Board of Science in Nuclear SPECT bone scintigraphy outcome in. left ventricular end-diaslolic Medicine, 20th anniversary, 30N(5) knee injury, 1353 volume relations, l49P(ab) American College of Nuclear Physicians, tears, knee bone scintigraphy with ventricular, outcome prediction using SPECT ACNP/SNM government relations SPECT, 297P(ab) perfusion imaging. 14P(ah) update, 20N(I) Anti-carcinoembryonic antigen antibody Arrhythmogenic right ventricular disease, Amino acid infusion, reduction of renal tubular '"I-labeled, radioimmunotherapy. 168P(ab) cardiac adrenergic activity in. l06P(ab) reabsorption of radioconjugates, 837(ed) """Tc-labeled, tumor uptake with, l5IP(ab) Arterial input function, measurement, high Amino acids treatment of medullary thyroid cancer. 243P(ab) temporal resolution, dynamic as PET tracer, breast cancer, 86P(ab) tumor targeting, radioimmunotherapy, 169P(ab) PET, 266P(ab) transport, concentration effects on "F FDOPA Anti-granulocyte antibody, """'TcMN3Fab Arteriography. detection and treatment of uptake, PET. l09P(ab) Anti-intercellular adhesion molecule-1 renovascular HTN, meta-analysis of transporters of. '-'I IMT and OMIMT, SPECT, antibody, detecting early inflammation. costs, sensitivities, and specificities, 171 brain tumors, 20IP(ab) "'In, 656 Arteriovenous malformation, spontaneous uptake, glucose metabolism and. brain Anti-macrocycle antibodies, response to regression on PET, 1673 tumors, 268P(ab) radiometal chelating agents, Arthrography Amphetamine, acute, effects on striatal dopamine lymphoma. 451 nuclear system, 163P(ab) Anti-platelet agents. E5510. effects on platelet combined scinligraphy and radiography for Amygdala-hippocampus, lesions, neonatal and deposition in atherothrombotic lesions, delecting hip prosthesis loosening. 62 adult, '-"I ÃŸ-CITand L!'I1BZM SPECT, '"In assessment, 242P(ab) radiographie primate, 281 P(ab) Anti-TAC dsFV diagnosis of total hip prosthesis loosening, 62 Amyloidosis. myocardial, detection wilhTc "F FMB-labeled. hydrolyzable linkers Artifacts, wrap-around lung in 180 degree cardiac aprotinin. l85P(ab) with, 204P(ab) studies, SPECT. 1891 Anatomic standardization, depression *Ga-Iabeled, biodistribution and Artificial neural networks, automated diagnosis of Alzheimer's disease, brain Androgen receptor, evaluation of "F-labeled calabolism, l52P(ab) ligands in baboons, prostate cancer, 1009 Tc MAG3-labeled, renal uptake and, 29P(ab) SPECT. 195 Anesthesia, during PET. binding of raclopride and Antibiotics, trovafloxacin, "F measurement. PET Aitatine-Zii NMSP. mouse brain. 279P(ab) study of E. co//-infected biotin conjugale labeled with, preparation and Angina pectoris. calcium blocker effects on rabbits, 239P(ab) binding properties, 197P(ab) outcome, 149P(ab) Antibody, predictive doses from therapy using human neuroblastoma xenograft model, athymic Angiography tracer studies, "'I, 1970 mice, 6IP(ab) biplane. 3D coronary artery trees from, Antibody labeling, proteins, role of Tin- Astrocytoma. visualized by Tc-ECD perfusion SPECT, 97P(ab) 117, 195P(ab) SPECT, 273 coronary Antigranulocyte immunoscintigraphy. prostate Atherosclerosis myocardial perfusion imaging and, 3D-fusion cancer metastasis to bone, differential carotid. Te P280 clinical studies. 272P(ab) image of, 218P(ab) difficulties of superimposed localization of, upregulation of adenosine rest-stress myocardial perfusion imaging osteomyelitis, 999 receptors on smooth muscle cells, 4P(ab) comparison to, l82P(ab) Aiilhmosili antibody macrophage density, FDG-PET imaging nuclear, multiwire proportional gamma camera radiolabeled, detection of myocardial of, 38P(ab) for, 52P(ab) injury, 38P(ab) myocardial insulin resistance related to, insulin radionuclide VI-V3 specific, genetically engineered single- resistance syndrome patients. 38P(ab) improvement in left ventricular ejection chain Fv of, mammalian proliferating smooth muscle cells in, '"In NC- fraction and cardiac volume after bypass system. l44P(ab) Z2D3imaging of, 49P(ab) surgery, 93P(ab) Antimyosin liposome membrane sealing Attenuation, identification of gastrointestinal quantitative analysis of gated blood-pool therapy, preservation of hypoxic bleeding despite presence of barium, images, 93P(ab) cardiomyocyte viability, lagged RBC scan. 643 Angioplasty myocardium. 106P(ab) Attenuation correction -'"'TImyocardial perfusion, reversibility in "Tc-sestamibi SPECT to detect Antipsychotic agents, striatal dopamine restenosis, 1300 receptors, temporal binding patients with regional carotid, semiquantitative diamox rCBF brain characteristics and receptor dyssynergy, 148P(ab) SPECT, 89P(ab) occupancy. 11 -"TI myocardial SPECT, dual-headed SPECT coronary. SPECT use in assessment of Antisense probes system, 30P(ab) results. 126P(ab) Tc N-myc. human breast tumor hosted in ""Tc sestamibi SPECT, cardiac, 81P(ab) versus bypass surgery, thallium quantitative SCID mice, 269P(ab) """Te sestamibi uniformity with, low likelihood SPECT. 125P(ab) """Tc-labeled. imaging myocardial MRNA of for coronary artery disease. 148P(ab) Angiotensin converting enzyme (ACE) heat shockprotei-70 after bypass, accurate, without transmission inhibitor, renography for detecting pig, 96P(ab) measuremenls, 18P(ab) renovascular hypertension, consensus Antistage-specific embryonic antigen-1. imaging analytical nonuniform, truncated fan-beam report, 1876 inflammatory diseases, neutrophils. 1789 cardiac SPECT imaging. l8P(ab) Angiotensin receptors Aortic valve stenosis, "C acetate planar imaging automated model, functional PET brain imaging dietary sodium as a regulator of. imaged with of, 38P(ab) studies, 42P(ab) "CL-159, 884, 47P(ab) Aphasia, primary progressive. Te HMPAO breast size and shape, defect contrast in

Subject Index â€¢1996 2123 myocardial perfusion SPECT, 216P(ab) lUdR, 6S(4) study, 643 cardiac SPECT, tasi iterative reconstruction safety evaluation of radiolabeled lUdR, 13S(4) Bartter's syndrome, renal scintigraphyas algorithms for. 63P(ab) strategies for selective targeting, tumor baseline and after caplopril administration. Battler's syndrome, 1688 clinical cardiac -""'TISPECT perfusion cells, 3S(4) imaging. 212P(ab) tumor targeting in bladder cancer, *IUdR. 315 Bayesian estimation, imagereconstruction, combined scatter correction, evaluation with use of 5-';'MUdR in treatment of colorectal cardiac PET, 130P(ab) simultaneous transmission/emission cancer with liver mÃ©tastases, Beclomethasone, inhaled,depositionof, Tc SPECT system, 209P(ab) pharmokinetics and dosimetry, 29S(4) labeling method for, l42P(ab) comparison of supine and prone, Tc sestamibi Auger electrons Benign exertional headache, frontal myocardial perfusion SPECT, 8IP(ab) SeeAuger electron emitters hypoperfusion demonstrated by Tc- compensation of map errors, Tc sestamibi decay, double-stranded DNA breaks induced HMPAO SPECT, 1172 downscalter with '"Gd transmission by, 229P(ab) Benzamides, brain D2 tracer,first-passextraction, scanning. 2l5P(ab) improved lumor-to-marrow radiation dose by brain. 279P(ab) defect size, location, and contrast effects, clinical use of l:5I-A33, 1052 Benzodiazepine receptor cardiac SPECT. 21OP(ab) Automatic contour detection, in vivo estimation analysis of "C-iomazenil cerebral binding effect on delect reversibility, regional dyssyn- of receptor biochemistry, Tc-NGA kinetics, 699 ergy patients, l75P(ab) kinetic modeling, 1896 brain effects on Tc letrofosmin SPECT. detection of Automatic motion correction, in vivo estimation quanlitation, using partial saturation method, of receptor biochemistry, '""Tc-NGA viable myocardium. ISOP(ab) PET, FMZ, 5 emission contamination. SPECT scanning line kinetic modeling. 1896 concentration, PET image after partial- source transmission data. 19P(ab) Autonomie neuropathy saturation "C-FMZ injection, 76P(ab) enhanced contour finding method. PET brain gastric emptying in patients with NIDDM, 1643 distribution, chronic cerebrovascular disease, myocardial abnormality of '-''I-MIBG in diabetic emission images. l72P(ab) evaluation of neuronal cell fast quantitative measurement. patients, cardiac denervation, 1985 loss, 133P(ab) SPECT, 217P(ab) Autonomous thyroid nodule, radioiodinctherapy quantitative assessmentof. iomazenil image performance, simultaneous in patients with or without visible SPECT, 374 transmission/emission image extranodular activity, 401(le) SPECT imaging of, alcoholics, 285P(ab) system, 2IOPIab) Autoradiography visualization of, '"I NNC I3(long dash)824l improper, effect on accuracy of SPECT tumor comparison of "F-Phe with "C-MET in tumor SPECT, 76P(ab) imaging, 21 IP(ab) imaging, 320 Beta-Adrenergic receptors interaction, myocardial SPECT perfusion distribution of tritiated-FDG in breast cancer, first delineation of, PET, brain, 1IP(ab) imaging. l49P(ab) correlation between glut-1 expression in vivo imaging and quantifying compared to in iodine contrast media effects, quantitative and FDG uptake, 1042 vitro radioligand binding, pulmonary SPECT with emission/transmission dual tracer measurement, cardiac oxidative density using PET, 1275 imaging systems, 2l8P(ab) metabolism. 95P(ab) measurement of concentration, "F iterative filtered backprojeclion algorithm for, dual-isotope, middle cerebral artery occlusion, fluorocarazolol PET. 174P(ab) SPECT with fanbeam rats, 282P(ab) thoracic. '"F fluorocarazolol PET use in. 7IP(ab) collimation, 2l4P(ab) usefulness of r"ln-DTPA-Arg' substance P to Beta-Ray camera, surgical,gamma-ray Mel/, intrinsic method, performance in visualize SPR+ processes, 108 background lor, 78P(ab) parameter estimation tasks, l8P(ab) Autoradiolysis. ""Yimmunoconjugates,l43P(ab) Bicarbonate dialvsate, effect on plasmarenin PET scans, transmission to emission Avidin. biochemicalmodificationfor two-step activity and level changes, transformation in projection imaging and therapeutic procedures, in hemodialysis. l45P(ab) space. l55P(ab) vitro and in vivo analysis, Bifunctional chelating agents photon attenuation, correction of, myocardial streptavidin, 1380 4-ICE, synthesis of, 72P(ab) perfusion imaging, l76P(ab) Avidin-antibody conjugate, radiolabelcd for radioimmunotherapy, l67P(ab) postinjection transmission measurement. biolinand. targeting of xenografled improvement in, 72P(ab) neurological FDG-PET, 128 intraperitoneal tumor using, 200P(ab) Bifunctional ligand. antibodyconjugationand reconstruction for, Tc sestamibi cardiac Avidin/biotin. tumor pretargclingand direct stable """Tc labeling, kit formulation. 362 SPECT, 81P(ah) antibody labeling in uveal melanoma, Biliary atresia. differentiationfrom neonatal scanning line source method for. using an quantitative comparison, 967 jaundice, Tc disofenin anthropomorphic phantom, 21IP(ab) Avidin/indium-lll-biotin, scintigraphyto delect cholescintigraphy in, 288P(ab) scatter and iterative, modified Wiener filter prosthetic vascular graft infection, 55 Biochemical validation study, measurementof method for nonslationary resolution Avidin/streptavidin. anlibody-dependenlsignal cortical AchE activity in Alzheimer's recovery. 21OP(ab) amplification, tumor targeting, 343 disease. 649 scatter compensation and, '"'Tl SPECT. 80P(ab) Award winners, 1996 SNM fellowships,20N(5) Biodistribution short AsF transmission CT for, cardiac Azidothymidine, labeled,for imagingcell '"In and ""Y-labeled human IgM, intrapcritoneal SPECT. 210P(ab) proliferation. 240P(ab) administration in mice with short transmission scans in. whole-body carcinomatosis. 1545 biotinylated antibody FAB' fragment, co- PET. 172P(ab) transmission emission tomography, myocardial localization with streplavidin, ISIP(ab) perfusion imaging comparison, 97P(ab) B three-dimensional fusion imaging in multidrug uniformity in cardiac phantom, increasing levels B-cell lymphoma. LYM-I therapyfor, l70P(ab) resistant tumors, 312 of liver activity. l76P(ab) ÃŸ-CIT.visuali/ation of ischemie insult in caudate Biokinetics. of """Tc-DMSA in children,effectsof using patient scatter body outlines, bone putamen. dopamine transporter renal pathology and age SPECT, 127P(ab) changes, 1214 differences, 1331 with transmission image segmentation, whole- Backprojectors, valid matrices,iterativere BiomÃ©dicalcyclotron, productionof high specific- activity MCu,6IP(ab) body PET. 8P(ab) construction. 206P(ab) Attenuation histogram, noisereductionin "F- Bacterial endotoxin test, for Biotin FDG-PET, 786 radiopharmaceuticals, evaluation :"Al conjugate-labeled, preparation and binding Auditory activation studies. PET, cochlear of, 305P(ab) properties, 197P(ab) implantation and hearing Balloon test occlusion, assessmentof MCu 13N4-macrocycle conjugates, radiolabeling subjects, l23P(ab) neurological deficits, HMPAO and radiotracer kinetic studies, Auger electron emitters SPECT. 551 rats, 166P(ab) applying in vitro approach to in vivo cancer Barium, positiveTc-RBC gastrointestinal antibody-dependent signal amplification in therapy strategies, i;lI-IUdR and 'â€¢''!- bleeding scan after small-bowel tumor xenografls. avidin or

2124 The Journal of Nuclear Medicine streptavidin, 343 evaluation of, 27P(ab) uptake and retention, 72P(ab) radiolabeled, targeting of xenografted mÃ©tastases Bone scan intraperitoneal tumor using, 200P(ab) "Sr effects on adriamycin toxicity in application in sports medicine, 17N(12) streptavidin and avidin biochemical treatment, 32P(ab) ABG-arthroplasty, hip, bone mineral density modification for two-step imaging and combined radionuclide therapy for after, 103P(ab) therapeutic procedures, in vitro and in treatment, 32P(ab) changing prostate-specific antigen levels related vivo analysis, 1380 diagnostic difficulties with superimposed to, prostate cancer patients, 296P(ab) Bispecific antibody, '"I-labeled bivalent hapten osteomyelitis, prostatic cancer, 999 diabetic renal osteodystrophy patients, 28P(ab) Bisphosphonate dose escalation of 186Re-HEDP in breast diagnosis of spinal mÃ©tastases,in cancer Tc-labeled conjugate of MTX, targeted cancer patients, 244 patients, 250P(ab) delivery of antineoplastics to bone osseous mÃ©tastases,pharmacoeconomic granulocyte scintigraphy, detection of tumors, 105 benefits of 89Sr therapy, 31P(ab) mandibular mÃ©tastases,266P(ab) effect on bone scintigraphy, 401 (le) relief of pain with 186Re-etidronate, prostate heparanase or collagenase activity correlation Bladder cancer cancer patients, pain assessment with, breast cancer patients, 127P(ab) diagnosis and tumor targeting of bladder cancer diary, 1511 hot spots in, confirmation of osseous tumor with 5-iodo-2~-deoxyuridine, 315 skeletal mÃ©tastases spread and, 266P(ab) FDG-PET preliminary study in, 260P, 262P(ab) clinical outcome of "Sr therapy, 31P(ab) preoperative assessment, mandibular invasion in intravesical administration of *IUdR, 315 therapy with "Sr or "'Sm EDTMP, hepatic oral cancer, 137P(ab) intravesical infusion of 5-'"I-IUdR, 16S(4) toxicity after, 31P(ab) Bone scintigraphy BLIP upgrade, status report, 167P(ab) SPECT Tc-sestamibi, assessment of osseous tumor Blood flow attenuation correction for, using patient scatter spread, 1526 cerebral, see Cerebral blood flow body outlines, 127P(ab) chronic recurrent multifocal osteomyelitis, cortical, activation response, aging related comparison to MRI in detection of vertebral physeal involvement in, changes, 164P(ab) mÃ©tastases,975 children, 23P(ab) myocardial. see Myocardial blood flow tumors, targeted delivery of antineoplastics, concomitant lung and gastric uptake of Tc- PET imaging to evaluate sensitivity of hepatic 99mTc-labeled gem-bisphosphonate MDP, sarcoidosis, 1530 tumor to hypertension chemotherapy, conjugate of MTX, 105 diagnosing and staging Langerhans' cell angiotensin-II., 1522 Bone and son-tissue tumor. Te MIBI histiocytosis, 1456 soft-tissue vascular anomalies, direct puncture scintigraphy, "Ga comparison within extensive photopenic osteomyelitis, septic scintigraphy, 183P(ab) subject, 298P(ab) arthritis, 1676 Blood sampling, quantitation of cerebral glucose Bone marrow hungry bone syndrome following utilization, FDG-PET, 221P(ab) imaging paralhyroidectomy, 1371 Blood vessels, wall, radiation dosimetry, 229P(ab) TcLLl,239P(ab) procedure guidelines for, 1903 Blood-brain barrier, changes in, RMP- sulfur colloid, filtration effects, 240P(ab) quantitative, leg length discrepancy, congenital Tinjection, dynamic SPECT mÃ©tastases growth disorders, 23P(ab) after, 252P(ab) detected by '"I scintigraphy, insular thyroid usefulness and limitations of three-dimensional Blood-pool imaging cancer, 633 images, volume-rendering technique and automated assessment of left ventricular noninvasive evaluation of, 982(ed) SPECT, 1567 ejection fraction and volumes by, versus regional dosimetry, measured relative Book reviews gatedMRI,218P(ab) depression in skeletalTc Atoms, Radiation and Radiation Protection, 2nd gated uptake, 232P(ab) ed., 707 FDG-PET comparison, assessment of left scanning, granulocyte scintigraphy, detection of Cancer Therapy with Radiolabeled ventricular function, 39P(ab) mandibular mÃ©tastases.266P(ab) Antibodies, 194 kit prepared ""Te DMP-HSA and Tc- toxicity, in radioimmunotherapy, different Clinical Nuclear Cardiology, 707 labeled-red blood cells, 175P(ab) predictive measures, 43P(ab) Combined Scinligraphic and Radiographie sensitivity dependence on region dosimetry Diagnosis of Bone and Joint definition, l49P(ab) regional variability of marrow-localizing Disease, 194 mathematical cardiac torso phantom for, volume antibody, 695 Medical Effects of Ionizing Radiation 1995, 707 and ejection fraction scintigraphy Nuclear Medicine: Diagnosis and determination, 97P(ab) evaluation of bone marrow status in Therapy, 1922 radionuclide analyses of, response to vasoactive hÃ©matologiedisorders, """Tc- Nuclear Medicine, 1921 drugs, hepatic lobular antigranulocyte antibody, 978 Principles of Nuclear Medicine, 1922 dynamics, 244P(ab) toxicity Radiation Protection in the Health synthetic copolymer kit for, 198P(ab) "*Re-HEDP in metastatic breast cancer, Sciences, 1921 Your Heart â€”An Owner's Manual, 22N(2) time-activity curve extraction, FDG-PET studies thrombocytopenia, 244 in small hearts, derivation of input Bone mineral density Bradykinin, RMP-7 agonist of, measurement of function, 1717 chronic dialysis effects, different changes in blood-brain barrier, use of Tc-labeled liposomes, compared with methods, 104P(ab) SPECT, 252P(ab) Tc-red cells, 1374 comparison, athletic and non-athletic Chinese Brain BMIPP, metabolic fate after etomoxir male adolescents, 298P(ab) "C p-CIT-FP and "C ÃŸ-CIT-FEuptake, PET administration, canine diabetic polyneuropathy effects, 104P(ab) examination of, 284P(ab) myocardium, 1836 dual-energy x-ray absorptiometry, 3D versus 2D PET, subjective image quality Bone measurements, 103P(ab), 13N(10) comparison. 74P(ab) Te MDP SPECT, diagnosis of lumbar spine femoral neck, lumbar spine comparison, with abnormal aging, radical-related disease, nuclear lesions,, l27P(ab) suspected osteoporosis, 103P(ab) medicine in, 56P(ab) allograft reconstruction, osteosarcoma after, testosterone treatment effects, young males with abscess, immunoscintigraphy for, 24IP(ab) skeletal scintigraphy use in. 28P(ab) delayed puberty, 103P(ab) activation benign and malignant masses, evaluation with Bone pain median and phrenic nerve. Te ECD SPECT FDG-PET, 140P(ab) malignant, absorption of stannous and MRI with image registration, 8P(ab) diseases, 99mTc MDP scans in neurofibroma, diphosphonates to patterns in motor sequence learning, plexiform neuroma and hydroxyapatite, 72P(ab) PET, 281P(ab) neurofibrosarcoma, Von metastatic, correlation of marrow suppression prediction of recovery in poststroke aphasia, Recklinghausen's with marrow absorbed dose of Sn- FDG-PET, 122P(ab) neurofibromatosis, 1778 117m(4+) DTPA, 102P(ab) activation response, aging related graft, viability, total hip replacement, FDG-PET normal and metastatic, Sn-117m(4+) DTPA changes, 164P(ab)

Subject Index â€¢1996 2125 antioxidative ability tumors mammogram, scintimammography glutalhionc localization with TC-WIMO- 12'IIMT SPECT compared with "F FDG- for, 269P(ab) HMPAO, 1698 PET, 157P(ab) detection with Tc-MIBI atrophy, aging and cerebral blood Tc HMPAO localization of, 263P(ab) scintimammography, 626 flow, 308P(ab) after radiotherapy, 2"'TI uptake and retention diagnosis with ""Tc alpha-fetoprotein and blood blood (low. see cerebral blood flow index value in, 255P(ab) pool activity subtraction, 148P(ab) cerebral glucose metabolism and peptide T in amino acid analogs IMT and OMIMT as dynamic '"In-pentetreotide scintigraphy, 622 AIDS dementia, 1177 SPECT tracers for, 201P(ab) evaluation of preoperalive chemotherapy using cerebral perfusion abnormalities in Sturge- blood-brain barrier permeability changes, FDG-PET, 931 Weber syndrome, 81 intra-arterial RMP7,""Ga EDTA PET FDG-PET and scintimammography, 265P(ab) dopaminc transporter, '"F-labeled ÃŸ-CIT-FPfor study of, 146P(ab) FDG-PET for distinguishing between benign PET. 192P(ab) childhood, -""TIavidity as an outcome and malignant masses, 99P(ab) energy metabolism, pH, and vascular reactivity, predictor, 270P(ab) FDG-PET, quantitative image analysis, 99P(ab) mitochondria] FDG-PET, local histology and prognostic imaging, prone or supine, comparison of encephalomyopathy. 123P(ab) value, 21P(ab) sensitivity, FDG-PET, 99P(ab) epileptic loci, contralateral cerebellar F-Dopa as an amino acid tracer in detection indeterminate mammograms, uptake, 426 of, extrapyramidal symptoms. 1180 scintimammography or contrast- fluid spaces, compartments and reaction glucose metabolism and amino acid uptake enhanced MRI use in, 156P(ab) volumes, 126(ed) in, 268P(ab) L-1-"C tyrosine as PET tracer for, 86P(ab) frontal area vascular response, orthostatic primary, "C THY, 157P(ab) limited-angular-view ML-EM pinhole SPECT hypotension, 1 SPECT and MRI comparison in assessment for, 214P(ab) Ili-mule cortication in, plasticity of the of, 272P(ab) localization of '"In MX-DTPA humanized BrE- corticostriatal pathway after, 56P(ab) thalium uptake indexes, comparative 3MAB in, 169P(ab) hypometabolism, epilepsy, FDG-PET, 41P(ab) evaluation, 157P(ab) mammoscintigraphy with Tc-sestamibi, 926 imaging visualization of grade II astrocytoma, **"Tc- metastatic, response to tamoxifen, PET ester-derivatized TcO mixed ligand complex ECD SPECT, 273 assessment of, 99P(ab) for, 188P(ab) volume imaging head PENN-PET scanner, ultra nuclear medicine use in studies, simulation tool ethical clinical practice guidelines, 1256 high resolution, 276P(ab) for modeling cost infarction Brain and head dosimetry model, revised effectiveness, 301P(ab) cerebral ischemia with, Tc BMS-181321 anthropomorphic representations, 1226 palpable and nonpalpable, Tc sestamibi detection of. 272P(ab) Brain injury, metabolic consequences and role of scintimammography in, 259P(ab) prediction after subarachnoid hemorrhage. PET, 1170(ed) pathologic features of, â„¢"Tcsestamibi uptake CBF with12'! IMP SPECT, 12P(ab) Breast cancer correlation with, 267P(ab) mapping, ECAT ART, 74P(ab) "F FDG-PET qualitative and quantitative recurrent or metastatic, whole-body FDG-PET metabolism. Te ECD, properties of enzyme to assessment, 254P(ab) accuracy in, 99P(ab) catalyze, 189P(ab) "F FTX PET with, 86P(ab) recurrent, whole-body FDG-PET in evaluation mid-saggital plane, Tc ECD SPECT images in Te M1BI and MRI comparison in detection of, 252P(ab) odegrees of freedom, 8P(ab) of, 75P(ab) scintimammography acccuracy, patient age and perfusion Te MIBI scintimammography monitoring of lesion histology effects, 254P(ab) cellular basis of ECD retention, "mTc- treatment, 156P(ab) sensitivity of imaging with a new receptor- HMPAO, 1694 ""Te recombinanl human alpha-fetoprotein for binding radiopharmaceutical, 199P(ab) extraction and retention of Tc-ECD, SPECT diagnosis, 87P(ab) sigma-2 receptors as potential biomarkers and "O-water PET studies, 1600 ""'Tc scintimammography, SPECT for, 87P(ab) SPECT-HMPAO accuracy in normal state, and, 252P(ab) small scintillation camera with photodiode observations in pathological situations Tc sestamibi detection readout for imaging of tumors, 52P(ab) and redox state alterations, 1413 "*Re-HEDP dose escalation in patients with staging of the axilla, FDG-PET use in, 307P(ab) PET activation studies bone mÃ©tastases,244 stereotactic coordinates from ECT sinograms, "O water, classic conditioning of flexor accuracy of, 74P(ab) radionuclide-guided biopsy, 1562 reflex, 55P(ab) axillary lymph node involvement, 75P(ab) suspected, Te MDP scintimammography language function, left-handed histopathologic correlation, 75P(ab) accuracy in, 155P(ab) subjects, 55P(ab) scintimammography, response to chemotherapy SUV-lean and Glut-1 expression, FDG- quantitation of benzodiazepine receptors using Tc tetrofosmin scintimammography use in PET, 65P(ab) partial saturation, 5 diagnosis, 156P, 255P(ab) suspicious mammographie findings, CEA-scan radionecrosis. functional brain imaging with advanced, early response to therapy, evaluation and histopathological results, 238P(ab) Te HMPAO, 259P(ab) by"C methionine PET, 256P(ab) tumor, human, hosted in SCID mice, Tc N- SPECT axillary lymphadenopathy and, """Te sestamibi mycantisense for imaging of, 269P(ab) cerebral blood flow in depressed patients in evaluation of, 252P(ab) Breast carcinoma, distribution of tritiated-FDG, detected with Tc-HMPAO SPECT, axillary node imaging, Tc sestamibi and'"In correlation between glut-1 expression electroconvulsive therapy, 1075 pentelreotide imaging, 251 P(ab) and FDG uptake, 1042 clinical utilization of in acute ischemie stroke, benign and normal tissue, FDG uptake Breast tumors thrombolysis, 1259 in. 249P(ab) investigations with "F-FDG and SPECT, 615 dipyridamole stress in evaluation of cerebral benign tumor, Tc sestamibi uptake correlation uptake of Tc-sestamibi, lymph nodes, 922 blood (low reserve, carotid artery with histologie characteristics Breast uptake, nonbreastfeeding thyroid cancer stenosis, 1595 in, 250P(ab) patients, radioiodine, 26 determination of dopamine receptor occupancy biological disposition and imaging of Breastfeeding by anlipsychotic RWJ-37796, striatal radioiodinated alkylphosphocholine in dose from after thallium-201 activity, 1!'I IBZM, 11 rodents, 1540 administration, 2079 evaluation of patients with pure photosensitive biopsied, sigma receptor binding sites radioiodine uptake, 26 epilepsy, Tc-HMPAO. 1755 in, 267P(ab) Brown tumor, hungry bone syndrome following impact on clinical management decision, 1070 CEA-scan in diagnosis and staging, 238P(ab) parathyroidectomy, bone perfusion scans, visual interpretation in comparison of four radiopharmaceuticals used scintigraphy, 1371 conjunction with statistical image in, 75P(ab) Buprenorphines, role in treatment of drug analysis, 275P(ab) correlation of heparanase activity with bone dependence, cerebral perfusion traumatic injury, SPECT imaging scan findings. 127P(ab) defects, 2098(le) after, 275P(ab) detection in dense breasts after negative

2126 The Journalof Nuclear Medicine analysis use in, 42P(ab) kinetics in normal human heart, 70P(ab) Carbon-11-DOPA,in vivo demonstrationof Carbon-11raclopride Calcium blockers, effects on outcome,angina decarboxylation, pancreatic tumors, 32 binding potential, estimation of, 280P(ab) pectoris, l49P(ab) Carbon-11doxepin, PET,artificialneural biodistribution and dosimetry, 231P(ab) Camera systems network decomposition of, 164P(ab) PET studies, dopamine microdialysis data and, gamma camera devices, computer using real Carbon-11flumazenil, distributionvolume dopamine D2 receptors, 77P(ab) time signal processing estimate bias, non-immediate equilibrium Carbon-11RTI-121, PET,quantificationof software, 206P(ab) state, 226P(ab) dopamine transporter, 109P(ab) myocardial perfusion studies, Carbon-11FMAU, preclinicalstudies,PET Carbon-11SKF 82957, dopamineDl agonist, ectomography, 208P(ab) indicator of tumor evaluation for PET studies, 202P(ab) Cancer proliferation, 107P(ab) Carbon-11THY, detectionof primarybrain see also specific type or site Carbon-11FMZ tumors, 157P(ab) "C-thymidine metabolites, PET imaging, 290 detection of viable neurons, ischemie Carbon-11thymidine enhanced FDG-PET imaging, emission penumbra, 76P(ab) for imaging cell proliferation, 240P(ab) computed tomography, 371 partial saturation injection, determination of monitoring of tumor response to recurrent, assessment with FDG and L- benzodiazepine receptor chemotherapy.67P(ab) methionine, 67P(ab) concentration, 76P(ab) Carbon-11tyrosine Cancer therapy Carbon-11-glucose,radiationabsorbeddose evaluation of cytotoxic therapy, lung development of growth factors as diagnostic and estimates in adults, effects of cancer, 265P(ab) therapeutic hyperinsulinemia, 1668 groin mÃ©tastasesin vulvar cancer radiopharmaceuticals, 197P(ab) Carbon-11-HED,PETimagingof patients, 263P(ab) Carbon-11urea, synthesisfrom "Ccarbon lutetium-177 radioisotope for, reactor neuroblastomas, 16 production of, 166P(ab) dioxide, 51P(ab) Cannabinoid receptors, '"IAM251bindingto, Carbon-11HDMI, forcardiacnorepinephrine transporter, 50P(ab) Carbon-11-methionine brain, mouse, 187P(ab) Carbon-11-hydroxyephedrine,functionalstatus Carbon-11-verapamil,PETimagingof P- Captopril of cardiac sympathetic neurons, "C- glycoprotein in tumors, "C-daunorubicin, baseline and post ACE-inhibition renal blood phenylephrine, PET, 1923 multidrug resistance, 1571 flow measurements, renovascular Carbon-11indomethacin, synthesis,brainstudies Carbon-13 urea breath test, diagnosisof//. hypertension, 1652 of cyclo oxygenase, 192P(ab) pylori, [L2]246P(ab) transplant renography investigations, Carbon-11-iomazenil,modelingalternativesfor Carbon-14 aminopyrine breath test, prediction interpretation using neural network, 1649 cerebral kinetics, 699 of liver function, postoperative Captopril radionuclide renography, renalartery Carbon-ll-KF15372, potentialuse as adenosine lethality, 114P(ab) aneurysms, pregnancy-related Carbon-14 L-DOPA,binding,';!IÃŸ-CIT AI receptor ligand, PET, 1203 comparison, Parkinson's disease, 66P(ab) factors, 1368 Carbon-11L-159,884 Captopril renography, detectionandtreatmentof impulse response function of, validation Carbon-14 urea breath test renovascular HTN, meta-analysisof of, 288P(ab) breath samples, simple liquid scintillation costs, sensitivities, and specificities, 171 potential PET tracer, in vivo labeling of counter for analyzing, 207P(ab) Carbon dioxide, metabolitesin tumorimaging, angiotensin II receptors, 307 diagnosis of H. pylori, replacement of "C-thymidine, PET, 290 Carbon-11McN 5652, loss of serotonin endoscopie biopsy, 246P(ab) Carbon-11 transporters, PET visualization diagnosis, Helicobacter pylori high-affinity ligands, PET imaging, pulmonary of, 112P(ab) gastritis, 114P(ab) cholinergic receptors, 108P(ab) examination of fasting stale, 1916(le) Carbon-11 MDL 100907, suitability as aserotonin Carborundum pneumoconiosis,*'GaandTc neuronal nitric oxide synthase labeled with, PET radiotracer, kinetic analysis, study, 201P(ab) baboon, 145P(ab) DTPAassessment of, lung Carbon-11 ÃŸ-CNT,PET,serotoninanddopamine Carbon-11methadone, PET,baboon scintigraphy, 294P(ab) transporter sites, brain, 40P(ab) studies, 40P(ab) Carcinoembryonicantigen Carbon-11acetate Carbon-11methionine radioimmunotherapyof medullary thyroid adenosine and dobutamine combination, cardiac compared with "F-FDG in detection of cancer, 905 radioimmunotherapywith '"I-NP-4F(ab, 1504 stress, 307P(ab) malignant tumors, PET, 1472 clearance, nasopharyngeal carcinoma, 136P(ab) comparison with "F-Phe for tumor imaging, 320 radiolabeled antibodies to, detection of compartmental model and, quantification of FDG comparison, residual or recurrent medullary thyroid cancer with, 9P(ab) myocardial perfusion, PET, 83P(ab) malignant tumor detection, 261P(ab) tumors expressing, radioimmunodeteclion and measurement of oxygen consumption, high uptake in brain radiation necrosis, epileptic therapy in, 9P(ab) myocardial, 222P(ab) activity, 1174 Carcinogenesis,riskestimatesanddosimetryof metabolic changes in hypertrophie parathyroid accumulation in radioiodine therapy, multinodular cardiomyopathy,PET, 572 hyperparathyroidism,PET, 1766 goiters, 2072 PET, aortic valve stenosis, 38P(ab) PET Carcinoid simple method of production, 341 delineation of cerebral glioma with, 259P(ab) myocardial uptake of labeled somastatin analog, simple preparation of l-"C-acetate, 341 evaluation of early response to therapy, carcinoid syndrome, 275 Carbon-11alpha-methyl-tryptophan advanced breast cancer. 256P(ab) somatostatin-receptor scinligraphy,bronchial kinetics, estimation of serotonin synthesis rate, potential as tracer for measuring liver protein tumor with mÃ©tastases,1537 brain, 145P(ab) synthesis, PET, 279 Carcinoid tumor PET, serotonin synthesis inhuman brain uptake in PET studies to detect brain tumors, 5-hydroxyindole acetic acid, urinary screening, measured by, 113P(ab) "F-Dopa, 1180 scintigraphy and hislopathology of Carbon-11carbon dioxide, synthesisof'C urea Carbon-11MHED hormonally active, 270 from, 51P(ab) metabolites of, measurement, 205P(ab) jugulo-tympanic region, methods of Carbon-11 CH, 3!, gas phaseproduction reinnervation, orthotopic heart diagnosis, 270 melastatic, high-dose1"!M1BGtherapy of, 194P(ab) transplant, 70P(ab) Carbon-11cholin, brainuptakeof, PET,283P(ab) in, 237P(ab) transport capacities and volumes, PET, during visualization of myocardial metastasis, '"In- Carbon-11 CP-126,998, studiesof catecholamine stimulation, 70P(ab) acetylcholinesterase,41P(ab) Carbon-11-N-methylspiperone,PETimagingof pentetreotide and fusion imaging, 1528 Carbon-11-daunorubicin,PETimagingof P- Cardiac abnormalities, SPECTmyocardial glycoprotein in tumors, "C-verapamil, neuroreceptors, typical and atypical perfusion imaging, """"Tc-sestamibi,1285 neuroleptics, 1122 Cardiac glycosides, """TC-Q12and;"'T1extraction multidrug resistance, 1571 Carbon-11PHEN, sensitivityto Carbon-11deprenyl, PETstudies,cluster neuronalmonoamineoxidase activity.

Subject Index â€¢1996 2127 and retention, effects of ouabain, 752 Cerebellum, semi-quantitativeanalysis,brain Cerebral perfusion Cardiac studies, transmissionsmoothing,effects SPECT imaging, 273P(ab) defects, improvement after buprenorphines, of attenuation in PET, 690 Cerebral angiography, assessmentof drug dependence, 2098(le) Cardiac sympathetic nervous system. neurological deficits during balloon test imaging, frontal vascular response, with raise- myocardial imaging with l:'I-MIBG, occlusion, HMPAO SPECT,551 up test in orthostatic hypotension, Tc- right ventricular pressure overload, 1343 Cerebral artery, stenosis,diamoxSPECT HMPAOSPECT, 1 Cardiomyopathy assessment of, 274P(ab) preoperative test occlusion of ICA, HMPAO '-"I-MIBGimaging in pheochromocytoma, Cerebral blood Mow brain SPECT,415 excessive catecholamine effect on heart Tc HMPAOSPECT, systemic lupus reserve and lungs, pulmonary edema, 1361 erythematosus patients, 163P(ab) combined transcranial Doppler and brain auto-antibodies in, sarcoplasmic reticulum age versus cerebral atrophy effects, 308P(ab) SPECT, 88P(ab) calcium ATPaseinhibited by, 144P(ab) carotid imbalance effects, "O water PET double-injection protocol with acetazolamide, development of, hypoxia effects on, imaging, 221P(ab) Tc-ECD. 2057 hamster, l75P(ab) change during executive function and vasodilatory stress, Tc ECD stress, 88P(ab) dilated declarative memory, "O water Cerebrospinalfluid shunt, radionuclide ÃŸ-blockadetherapy in, 1;

2128 The Journalof Nuclear Medicine hepatic uptake of Tc hepatobiliary kinetics of Tc-IDA Copper-62-PTSM DISIDA. 245P(ab) analogs, linear systems theory, 1323 assessment of regional myocardial perfusion, ventilation and alveolar permeability,TC- Compartmentalmodel analysis, FDG,rate PET, 1294 DTPA,437 constants in. cerebral blood volume detection of electron transport failure, Clinical applications, appropriatenessof estimation, 220P(ab) occlusion-reperfusion injury, 192P(ab) functional brain imaging, ethical clinical Compartmentalmodeling. Parkinson'sdisease, PET,colorectal liver mÃ©tastases,54P(ab) practice, 1256 combined FDOPAand 3OMFD PET quantitation of cerebral perfusion, three- Cocaine, bindingsites, on dopaminetransporter, studies, 209 compartmcntal model. 1089 PET imaging of, 65P(ab) Compartmentalmodels triple-isotope technique to trace, 206P(ab) Cognitive stimulation, genderdifferencesin cerebellar data, serotonin-2 receptor binding use as a myocardial PET perfusion tracer cerebral blood flow. PET.559 potential. PET,95 compared with "NH^, 729 Coincidence imaging, dual-headedgamma correlation between reaction volume and Coppcr-64 camera, 223P(ab) molecular lipophilicily. 118 anti-colon cancer monoclonal antibody, long- Colchicine. biodistributionevaluationusing Compartments,reactionvolume,brainfluid term studies of. 61P(ab) whole-body quantitative spaces, 126(ed) bis(diphosphinc)complexes, biological autoradiography.multidrug resistant Compressivegoiter, radioiodineriskestimates evaluation. l66P(ab) tumors, 312 and dosimelry, carcinogenesis, 2072 carrier-free, isolated from *'Gawaste, use in Collapse, left lowerlobe, pseudosignversusstripe Computer simulation, metalion spcciulionin PET and therapy. l95P(ab) sign on perfusion scan, blood plasma. 379 dosimetrie evaluation of, in "Cu in "1Cu-2IT- emphysema, 1682 Computer-assistedimage processing, neural BAT-Lym-l,radioiminunotherapy. 146 Cantautori networks to diagnose Alzheimer's high specific activity, production using a 511 keV,physical evaluation of, WWW disease, brain SPECT, 195 biomedicai cyclotron. 6IP(ab) resource. 305P(ab) Computers retention of. clearance organs and. 71P(ab) characteristics, intluence on quantification in case-based reasoning system, automated Copper-64 13N4-macrocycle.hiotinconjugales, SPECT, 1832 interpretationof myocardial perfusion radiolabeling and radiotraccr kinetic design, optimization by computer simulations imaging. 178P(ab) studies, rats, l66P(ab) of, 2l3P(ab) diagnosis assisted by, lung scans for pulmonary Copper-64 BAT-2IT-NR-LU-10Fab, PET electronic single-photon imaging device, embolism, 124P(ab) imaging and radioimmunotherapy theoretical performance limits, H9P(ab) local density functional methods. Te with, 95P(ab) pinhole computational chemistry, l89P(ab) Copper-64TETAoctreotide. radiotherapy improved scintimammography.78P(ab) Macin PET software application, 303P(ab) studies of, tumor-bearing rats. l28P(ab) positron and single photon emitter modeling software. State Space Modeler Copper-67 using. 215P(ab) (SSM). 303P(ab) clinical doses of, radioassay.presence of "Cu rotating slant-hole SPECT camera, phantom real-time signal processing software, building a impurity,gamma speclrometry, l99P(ab) experiments with. l20P(ab) gamma camera in, 206P(ab) dosimetrie evaluation of "Cu in, testing, focusing quality of commercial fan- simulation tool for modeling cost effectiveness, radioimmunolherapy, 146 beam collimator, 207P(ab) nuclear medicine in lung and breast measurement in presence of MCucontaminant Colon cancer, metastaticto liver,stagingwith cancer studies. 301P(ab) using dose calibrator, 302 FDG-PET, 131P(ab) simulations, optimization of collimator Copper-67 21T-BAT-LYM-1,efficacy and Colon transit design. 213P(ab) loxicity of, mice implanted with Burkilt's effects of opioid and opioid-like drugs measured software, package for PET lymphome, 128P(ab) by scintigraphy. 818 quantification, 304P(ab) Coronary artery disease -""'Tland Tc sestamibi comparison. subtypes of prolonged colonie transit, colon V/Q scanning, for directing pulmonary transit scintigraphy in differentiation angiography, 294P(ab) women. 69P(ab) of, 247P(ab) World Wide Web '"Tl reverse redistribution, clinical Colorectal cancer digital department moves to. 172P(ab) correlation. 735 advanced primary and recurrent. FDG-PET role virtual reality markup language extensions Tc sestamibi SPECT.gating and, l49P(ab) in. 132P(ab) and. cardiac SPECT and PET. 172P(ab) 3D coronary artery trees, from biplane FDG-PET Congenital growth disorders, leg length angiography, perfusion SPECT,97P(ab) comparison with CT, l32P(ab) discrepancy,accurate prediction of. adenosine stress test, Tc tetrofosmin diagnostic accuracy and cost- children, 23P(ab) tomography and effectiveness, 132P(ab) Congenital heart disease, false positive echocardiography, 178P(ab) validation with surgical pathology, l3IP(ab) ventilation perfusion scan in patient with .11Inn.ninneand dobutamine stress testing, imaging with """Te88BV59. totally human complex congenital heart disease. 1359 comparison withTc sestamibi monoclonal antibody,9P(ab) Congress SPECT, l77P(ab) intra-arterial infusion of 5-i;'I-IUdR in liver NRC and challenging issues, ACNP/SNP catheterization, post-nuclear testing referral mÃ©tastases,22S(4) update, 34N(10). 44N(1I) to, 68P(ab) recurrence, whole-body FDG-PET for response to NAS-IOM report, 25N(7) cavity dilatation, versus elevated lung heart evaluation of, 258P(ab) Consensus reports, on renalimaging,1872, ratio, exercise SPECT thallium, 183P(ab) recurrent, whole-body FDG-PETdetection 1876. 1883 detection during dobutamine stress test, of, 261P(ab) Constipation simultaneous perfusion tomography and treatment with hepatic artery infusion of 5-':

Subject Index â€¢1996 2129 cardiac serum markers, spontaneous dog study, 216P(ab) Depression angina, 58P(ab) Crossed cerebellar hyperperfusion. increased glucose metabolism in brain, during REM nonreversible defects, cardiac risk and. uptake of Te HMPAO on ictal brain sleep, 80P(ab) diagnostic population, IS2P(ab) SPECT, 426 limbic and prefontal hypoperfusion in normal rest ECG patients, SPECT in, I l6P(ab) CT, evaluation of squamous cell carcinoma psychiatric patients. SPECT, 410 patients at risk for cardiac death, SPECT mÃ©tastases,comparisons with other relapse, cerebral metabolic correlates for, FDG- strategy for identification, economics methods of assessment, 897 PET, 80P(ab) of. l4P(ab) Cyclooxygenase, inhibition by indomethacin, Diabetes postoperative tachyarrhythmia in, innervation inflammation imaging, brain, 192P(ab) cardiac denervation in, |;'I MIBG for assessment and perfusion mismatch as indicator Cystography, neonatal hydronephrosis, 287P(ab) of, 150P(ab) of, l84P(ab) Cytarabine, high dose, HMPAO SPECT scan foot lesions, "F FMISO PET scan assessment revascularization, -""'TIrest-redistribution abnormalities, children, 35P(ab) of, 27P(ab) SPECT in prediction of Cytokines, enhancement of radioiodine uptake in metabolic fate of "C acetate, rat improvement, l78P(ab) cultural thyroid cancer cells, 646 myocardium, 50P(ab) ROC analysts. Te MIBI SPECT and "'Rb Cytosine deaminase, gene therapy, in vitro MIBG imaging in silent myocardial ischemia, PET. 160P(ab) studies using 5-fluorocytosine, 87 evaluation of sympathetic SPECT evaluation, women, 182P(ab) innervation, 712 treadmill exercise first-pass left ventricular regional abnormality of |:'I-MIBG, assessment ejection fraction, diagnostic value of cardiac denervation, autonomie of. ISOP(ab) D neuropathy, 1985 vascular surgery, preoperative risk stratification D2 receptors, i;ll-epidepride SPECT in pituitary renal osteodyslrophy, bone scan findings in, UP(ab) adenomas, dopamine, 1931 in, 28P(ab) venous and arterial bypass grafts, attenuated Deadtime, multihead anger cameras, '"I dual- viable myocardium in, FDG-PET identification coronary vasodilatory capacity and flow energy-window acquisition of, 39P(ab) reserve, 82P(ab) mode, 78P(ab) Diabetic polyneuropathy, effects on bone wall motion in, rest motion analysis in gated Decision analysis, cost-effectiveness and accuracy mineral density, 104P(ab) SPECT, H5P(ab) of FDG-PET in non-small-cell lung Diagnosis, I!1-IBZM SPECT, therapy in Parkinson's disease, 1112 Coronary artery stenosis, resting perfusion and. cancer staging and management, 1428 detection of ischemia with FDG- Deconvolution, energy spectral, Compton-scatter Diagnostic imaging, simplified deoxyglucose PET, l74P(ab) correction in SPECT, 171P(ab) utilization rate analysis, FDG-PET, 950 Coronary flow reserve Deconvolution analysis, suitability of Dialysis, chronic, effects on bone mineral hyperlipidemia. angiographically normal renography, 403(le) density, 104P(ab) coronary arteries, 82P(ab) Deep venous thrombosis Diastereomers, improved method for maximal microvascular dilator capacity, "N TC-P280 as thrombus imaging agent, 775 radioiodination of '"I-IQNB, ammonia PET assessment of, l61P(ab) companion leg xenon imaging, part of routine SPECT, 2021 PET studies in familial hypercholesterolemia, V/Q scanning, 302P(ab) Diazepam, effect on skeletal muscle uptake of "F- dipyridamole, 1937 detection with Tc P280-labeled FDG, PET, 1127 simplified PET protocol, ":Rb and "N- peptide, 95P(ab), 294P(ab) Differential diagnosis, lung uptake on bone scan due to Wegener's vasculitis, 857 ammonia, 1701 lung scanning in diagnosis of pulmonary sympathetic neuron effects, heart transplant embolism, 165 Differentiated thyroid cancer, procedure patients, 4P(ab) scintigraphic detection with Tc modified rt- guideline for extended scintigraphy, 1269 Coronary reperfusion, acute, comparative PA, 744 Diffuse brain injury, cerebral hemodynamics and analysis of **Â°Tcsestamibi and metabolism measured by PET, 1166 Deferoxamine, gallium complex, different Diphosphines, "i'u. biological thallium, 160P(ab) concentrations and incubation Coronary stent conditions, l99P(ab) evaluation, 166P(ab) implantation, scintigraphic evaluation Degeneration, of dopamine transporters, age- Dipyridamole of, 126P(ab) induced, 554 brain SPECT SPECT assessment of results, l26P(ab) Delayed gastric emptying, right lateral and evaluation of cerebral blood flow reserve, Cost-effectiveness upright positioning in pediatrie patient, carotid artery stenosis, 1595 decision tree sensitivity analysis, FDG-PET Tc-sulphur colloid, 1356 correlation of â„¢T1SPECT with hemodynamic staging and management of non-small- Delayed graft function, renal allograft, Tc indices of myocardial dysfunction, 723 cell lung carcinoma, 1428 MAG3 clearance and, 292P(ab) myocardial blood flow at rest and during diagnostic accuracy and, FDG-PET. colorÃ©ela! Delayed imaging, diagnostic utility of SPECT loading dose, PET in familial cancer, 132P(ab) and 48-hour scanning in neuroblastoma, hypercholesterolemia, 1937 diagnostic management strategies, adrenal l:'I-MIBG, 1464 myocardial perfusion imaging, patient weight incidentaloma. l58P(ab) Delivery protocol, applying in vitro approach to effects, 177P(ab) FDG-PET, management of solitary pulmonary in vivo cancer therapy strategies, '"I- stress induced by, *;Rb PET studies, anesthetized nodule patients, HOP(ab), lllP(ab) lUdR and '!'I-lUdR, 6S(4) canine, kinetic studies, 146P(ab) patients at risk for cardiac death, SPECT Dementia Disseminated intravascular coagulation, in strategy for, 14P(ab) Tc HMPAO SPECT, acetazolamide test metastatic prostate cancer, 401 (le) PET, staging of small-cell lung cancer, 110P(ab) and, 273P(ab) Distribution volume preoperative risk stratification, vascular surgery cerebral oxygen and glucose metabolism, estimate bias, from non-immediate equilibrium patients, 14P(ab) uncoupling of, 275P(ab) state, flumazenil kinetics, 226P(ab) somatostatin receptor scintigraphy. 19P(ab) diagnosis orientation in. Te ECD brain in vivo ligand-receptor interaction modeling, stress echocardiography, versus nuclear SPECT, 274P(ab) reaction volume, 118 myocardial perfusion imaging. 174P(ab) functional brain image database system Diuresis renography, standardized approach to stress myocardial perfusion imaging, stable in, 164P(ab) investigating the dilated upper urinary angina, women, 68P(ab) regional rate constants, dynamic FDG-PET tract, TC-MAG3, 1872 Cost efficacy, detection and treatment of studies in Parkinson's disease, 1115 Diving illness, detection with Tc-HMPAO renovascular HTN. meta analysis, 171 Densitometers, impact on nuclear medicine, SPECT and texture analysis, 1154 CP96345, specific binding, substance Preceptor screening for osteoporosis with DEXA DMP444. potential thrombus imaging expression with "'In-DTPA-Arg', imaging, 13N(10) agent, 151P(ab) substance P. 108 Department of Energy, privilization of National DNA Cross-talk correction method, dual-isotope Lab, 21N(11) damage protection, double-stranded breaks acquisition, myocardial perfusion SPECT induced by decay of MI,229P(ab)

2130 The Journal of Nuclear Medicine single-strand breaks PET, psychostimulant-induced dopamine release '"I treatment for differentiated thyroid cancer, sile-specific detection, MCF7 cells, 233P(ab) and, 281P(ab) risk due to exposure, 1860 synthesis of DNA-protective vesamicol receptor binding sensitive to, intact '"I, radiation dose to spinal cord, 90P(ab) proteins, 233P(ab) striatum. 280P(ab) Tc DMSA, tissue and cellular distribution, rat transfer into lymphoma cells, TlOl-biotinylated- Dopamine D3 receptors, design of, 193P(ab) kidney, 231 P(ab) avidin-polylysineantibody Dopamine D4 receptors '""â€¢Sn(4+)DTPA, correlation of marrow complex, 62P(ab) living primary brain, 113P(ab) suppression with marrow absorbed triplexes, targeting of auger electron emitters, YM-43611 as potential radiotracer for, 50P(ab) dose, 102P(ab) potential for cytotoxic therapy, 3S(4) Dopamine metabolism, compartmental analysis, "F-FDOPA DNA-level dosimetry, treatment of colorÃ©ela! kinetics of OMFD in blood, striatum, bladder wall radiation dose, PET, 1850 cancer with liver mÃ©tastases,1BI- PET, 432 3D quantitative, colloidal phosphorus-32, lUdR, 29S(4) Dopamine receptors Bremsstrahlung SPECT, 90P(ab) Dobutamine occupancy by antipsycholic RWJ-37796, biodistribulion and MITImyocardial scintigraphy, left bundle branch continuous ':1I IBZM infusion, SPECT "C raclopride, 231 P(ab) block patients, 177P(ab) imaging, 11 Tc NOET, normal humans, 229P(ab) evaluation of simultaneous changes in left sensitivity, changes in synaptic TcP748, 231P(ab) ventricular function and perfusion, dopamine, 203P(ab) Te P829, 90P(ab) 99mTc-sestamibi, 1306 SPECT imaging , clinical utility of, 1591(ed) cobalt-55, 2082 SPECT combined with, diagnostic Dopamine terminals, low activity. Lesen Nyhan cobalt-57. 2082 accuracy, 58P(ab) disease, PET study, 45P(ab) comparisons of Tc-HYNIC-IgG with "'DTPA- stress Tc sestamibi uptake, magnitude of Dopamine transporter sites, I3'I-IACFTSPECT IgG, 843 ischemia, dogs with coronary in patients with Parkinson's determination of therapeutic activity, stenoses, 3P(ab) disease, 1197 radioimmunotherapy, 43P(ab) stress echocardiography Dopamine transporters dopamine transporter imaging, IPT, SPECT, 151 '-''I FP-CIT pharmacokinetics and dosimetry for FDG-SPECT versus, function after dose from breastfeeding after thallium revascularization, 59P(ab) evaluation, 65P(ab) 201, 2079 functional assessment of ALCAPA i;'I-IPT SPECT imaging of, effects of aging on in newborns, FDG-PET, 387 syndrome, 748 striata! uptake values, 1965 intralesional radionuclide therapy, mullimodality stress testing I!'I IPT SPECT measurement, nonhuman imaging and mathematical comparison with 99mTc sestamibi primates, 66P(ab) modeling, 228P(ab) SPECT, 177P(ab) 1!'I IPT SPECT, Parkinson's disease, 273P(ab) marrow, hÃ©matologietoxicity in, different myocardial assessment during peri-infarction '"I IPT uptake values, SPECT, predictive measures, 43P(ab) and remote ischemie event, 20ITI primates, 201P(ab) patient-specific SPECT, 1951 "F-labeled ÃŸ-CIT-FPfor, PET, 192P(ab) '"InT'Y-labeled monoclonal antibody Timing of thallium injections during altered densities, social phobia patients, 45P(ab) CC49, 90P(ab) dobutamine imaging, 193(le) changes after ischemie insult in caudate 3D, Monte Carlo approach, 89P(ab) Dopa-decarboxylase, putamenal, levodopa effects putamen, visualization with ÃŸ-CIT,1214 quantitative SPECT imaging and 3D-DFT on, Parkinson's disease, 55P(ab) cocaine binding sites on, PET imaging convolution, 89P(ab) Dopamine of, 65P(ab) platelet count, relationship between bone l:'I-epidepride SPECT, D2 receptor imaging in cocaine cogener for, SPECT exploration marrow absorbed dose and toxicity. pituitary adenomas, 1931 of, 186P(ab) Rhenium-186-HEDP, MIRD model, 38 asymÃ©trienigro-striatal function, sleep bruxism, comparative imaging with l!'I-ÃŸ-CIT-FPSPECT potential, minimal residual disease, radiolabeled ial IBZM SPECT, 271 P(ab) and "F-FDOPA-PET, Parkinson's antibodies, 44P(ab) comparison of l!'I-epidepride and U'I-IBZM, disease, 1760 radiation brain SPECT, 1589 decline with age, PET, 554 evaluation of "Cu in s'Cu-2IT-BAT-Lym- endogenous, synaptic concentration, SPECT dosimetry of IPT, SPECT, 151 1,146 measurement, resting state, 32P(ab) imaging agents, Tc-labeled trepanes as, 17P, '"I sodium iodide marker of Parkinson's disease process, 216 298P(ab) safety concerns with dialysis, 229P(ab) psychostimulant-induced release, PET studies of measurement using l:3I-ÃŸ-CITSPECT, trachea. 228P(ab) dopamine D2 receptors, 281 P(ab) evaluation of neuropsychiatrie biodistribution and, effects of Lym-1 antibody receptor occupancy by antipsychotic agent disease, 222 preload on, lymphoma patients. 90P(ab) RWJ-37796, continuous '"I IBZM methylphenidate induced high and, 44P(ab) estimates for PET radiopharmaceuticals using infusion, SPECT determination, 11 quantification of, "C RTI-121 and primates,"C arachidonic acid, 230P(ab) release, amphetamine-induced, aging effects, PET, l09P(ab) estimates for positron radiopharmaceuticals SPECT and1" IBZM, 33P(ab) receptors and, SPECT measurement in used in drug development, 228P(ab) transporter sites, '-'I ÃŸ-CITand |;'IIBZM alcoholics, 33P(ab) estimates in primates for humans for SPECT, primate, 281P(ab) SPECT imaging of '"I-ÃŸ-CIT,1129 DMP444, 232P(ab) Dopamine agonists, '"I-IB/.M binding in SPECT imaging, comparative exposure to staff from patients having Parkinson's disease, L-Dopa, 1112 nicrostriatal, 133P(ab) vascular surgery, 230P(ab) Dopamine Dl agonists, "C SKF 75670 and SKF SPECT measurement, in schizophrenia, 33P(ab) irradiation of '"I, 305P(ab) 82957, evaluation for PET sustained cocaine abstinence, SPECT imaging, organ S values for individual studies, 202P(ab) |;'I ÃŸ-CIT,44P(ab) patients, 232P(ab) Dopamine D2 receptors synthesis, imaging with "F-labeled PET measurements of "*YEDTMP "C raclopride PET studies, dopamine FECT, 191P(ab) uptake, 227P(ab) microdialysis data and, 77P(ab) Dosage escalation, ""Re-HEDP in breast cancer regional bone marrow, measured relative availability, integrity in Parkinson's disease, i;'l patients with bone mÃ©tastases,244 depression in skeletal Tc iodolisuride SPECT, 22 Dose calibrator, measurement of "Cu in presence uptake, 232P(ab) availability, opiate addicts, during naloxone of "Cu contaminant, 302 regional quantitation based on precipitated withdrawal, 45P(ab) Dose uptake ratio, simplified deoxyglucose SPECT, 232P(ab) binding, with '"I IBF SPECT, 281P(ab) utilization rate analysis, FDG-PET, 950 wall of blood vessels, 229P(ab) extrastriatal, availability, aging effects, 281P(ab) Dosimetry radioimmunodetection and therapy, CEA- NCQ-298, first-pass extraction, brain, 279P(ab) '"In-CYT-356, labeled monoclonal antibodies, expressing tumors, 9P(ab) occupancy measurements, using no input prostate cancer, 1583 risk estimates of radioiodine therapy. function, 77P(ab) '"I anti-CEA antibodies, red marrow dose and compressive goiter, 2072 myelotoxicity relations, 43P(ab) risk versus benefits in '"I-MIBG therapy, 1058

Subject Index â€¢1996 2131 small-scale alpha, red hone marrow, using determination with mathematical cardiac torso receptors, 6P(ab) histolÃ³gica!images, 231P(ab) phantom for bloodpool imaging, 97P(ab) Epidepride. dopamineI>j>receptorimagingin tumor, radioimmunotherapy of CEA-expressing measured by """Tetetrofosmin gated pituitary adenomas, SPECT, 1931 cancers, 231P(ab) SPECT, 179P(ab) Epidermal growth factor, use in imagingof Double-injection protocol, cerebralperfusion normal children, 286P(ab) breast cancer. 199P(ab) reserve with Acetazolamide,""'Tc- radial distribution of myocardial count rale Epiglottitis, scintigraphyusing'"In-WBCin ECD, 2057 density for measurement, 211P(ab) unsuspected cases, 76 Double-phase scanning, nodularthyroid reproducibility from stress versus rest gated Epilepsy malignancy,""Tc-sestamibi, 1919(le) perfusion SPECT, H5P(ab) defection of foci on iclal scan, crossed Drug dependence, roleof buprenorphinesin tomographic MUGA comparison to planar cerebellar hyperperfusion,426 treatment, improvement in cerebral techniques, 92P(ab) evaluation of Tc-ECD SPECT as perfusion defects, 2098(le) treadmill exercise first pass radionuclide investigational tool, pediatrics, 1106 Dual-energy x-ray absorptiometry bone mass ventriculography.93P(ab) extralemporal lobe measurementsfor osteoporosis. 13N myocardial wall motion and, gated FDG-PET interictal brain SPECT in, 271P(ab) Dual-isotope acquisition examination of. 226P(ab) localization of seizure foci, """TeECD enhanced cross-talk correction technique for, resting left ventricular, first-pass M'T1 SPECT, 100P(ab) myocardial perfusion SPECT dog venlriculography. 18IP(ab) hypometabolism, localization of, brain, FDG- study. 216P(ab) lomographic, severely hypoperfused PET,41P(ab) positron and single photon emitter, using myocardium, image ictal and inlericlal """Tc-bicisatebrain SPECT, gamma camera and pinhole enhancement. 105P(ab) pediatrie population, 1101 collimator. 215P(ab) treadmill exercise first pass, detection of ictal cerebral blood flow, temporoparieto- Dual-isotope imaging coronary artery disease, l80P(ab) occipital junction seizures, SPECT, 1946 impaired fatty acid metabolism and dyskinesis Elbow, lymphnode visualization.I913(le) iclal SPECT,Tc HMPAOor ECD. 100P(ab) in hypertrophie cardiomyopathy, 1UI- Electroconvulsivetherapy, assessmentof imaging regional cerebral blood flow at high BMIPP, 1679 cerebral blood flow in depressed now levels, HMPAO,661 evaluation of AIDS patients. 302P(ab) patients, Tc-HMPAO SPECT, 1075 intractable, surgical outcome, electrode data simultaneous evaluation of metabolic state and Electron transport chain, initochondrial. and, 100P(ab) myocardial perfusion, heart detection of failure with ":Cu partial seizures, SPECT localization for transplantation. 1990 PTSM. 192P(ab) postsurgical followup and invasive Dual-tracer autoradiography, ~'"TIand l:'I- Emission computed tomography electrode data, l01P(ab) MIBG, uptake discrepancy in breast cancer partial, associated with vascular malformations, experimental myocardial infarctions, 680 stereotactic coordinates from ECT sinograms, FDG-PET evaluation. 100P(ab) Dubin-Johnson syndrome, kineticchole radionuclide-guided biopsy, 1562 pedialric, comparison of FDG-PET, SPECT, and scinligraphy in evaluation of, 247P(ab) enhanced FDG-PET tumor imaging, 371 MR1in, 269P(ab) Dynamic chulescintigraphy.inducingand fatty acid uptake in ischemie heart disease in temporal lobe, presurgical localization of foci, describing gallbladder emptying, ejection patients without prior MI, |:'I- ';'IIMZ SPECT for, 101P(ab) fraction,261 BMIPP. 1981 Esophageal cancer Dynamic imaging. '"In-pentelreolidescintigraphy Emphysema staging, FDG-PET, 135P(ab) in breast cancer. 622 lung volume reduction surgery, V/Q scans for tumor imaging, :'"T1SPECT imaging Dynamic study, pulmonarySPECTof '"Xe evaluation, 5P(ab) of, 248P(ab) washout. 807 preoperalive assessment, V/Q Esophageal scintigraphy. optimizingresultswith Dyskinesis, hypertrophiecardiomyopalhy, scintigraphy,5P(ab) ROC analyses, esophageal motility, 1799 metabolic imaging with '-"I-BMIPP.1679 scintigraphic perfusion defect stripe sign versus Esophagitis. perfusionimaging,identifyinga pseudostripe sign, lobar collapse, 1682 noncardiac cause of chest pain. 1285 Encephalomyopathy,initochondrial,cerebral Esophagus, reflux esophagilis. quanlilative energy metabolism, pH, and vascular salioscintigraphies in, 245P(ab) E reactivity in, l23P(ab) Estrogen, receptor-positivetumor,evaluationwith ECATART, researchin cerebral Endocrine pancreatic tumors, decarboxylalion, '"In DTPAestradiol, 264P(ab) activation, 74P(ab) in vivo demonstration of enzymatic Estrogen receptors Kctopicparathyroid adenomas, localisationwith activity observed with PET,32 DNA single-strand breaks, site-specific Tc-MIBl scintigraphy,631 Endocrine tumors, '"In-pentetreolideuptake, detection, MCF7 cells, 233P(ab) Education lymphoma, 916 gallium-chelating ligands for, l94P(ab) and research as investment in the future, 17N(7) Endoprosthesis, hip, bone mineraldensityafter, Ethanol, percutaneousinjection,radioiodine continuing medical, 16N(4) lime-course of, l03P(ab) therapy comparison, Effective dose, radiationdosimetryof """Tc- Endothelial cells, re-appraisalof qualitycontrol hyperthyroidism, 255P(ab) DMSA in pediatrics. 1336 of radiolabeled granulocytes, 863 Ethylenedicysteineisomers, comparisonin rats Effective dose equivalent. Tc-DMSA. Endotoxemia. gram-negative,pulmonary and healthy volunteers, 46P(ab) Etomoxir. metabolicfateof '-''I-BMIPP,canine dosimclry in children, 1336 migration of granulocytes. granulocyte- Effective half-life, hyperlhyroidismtreatment colony stimulating factor effects, 24P(ab) myocardium, 1836 with '"I. 228 Endotoxins. problemsin FDG imaging,199P(ab) Euthyroid. '-''Iuplake.stabilityof values. 805 Effective renal plasma flow Energy spectrum, estimationof, mullispectral Expectation maximization with ordered camera-based determination, complete dynamic- images, SPECT, 17IP(ab) subsets, whole-bodyFDG-PET scan data, 91P(ab) Enhanced contour finding method, attenuation improvement with. 130P(ab) glomcrular filtration rale and. simultaneous correction. PET brain emission Expert systems estimation with"""'TcEC. 91P(ab) images, l72P(ab) interpretation, myocardial perfusion Enzyme replacement therapy. Gaucher's radionuclidcs in nephrology.Committee on imaging, 48P(ab) interpreting cardiac -*'"TISPECT studies, Renal Clearance report. 1883 disease, scinlographic monitoring Ejection fraction of, 297P(ab) comparison with physician comparison of planar and SPECT gated blood- Epibatidine training, l79P(ab) pool studies, 1795 "C N-methylated analogs of, synthesis of high External radiotherapy, treatmentof melastatic left ventricular specific activity, 192P(ab) thyroid cancer, 598 automated calculation, gated perfusion analog of Extracellular fluid, solutedistributionin, 9IP(ab) tomography. 213P(ab) central nicotinic acetylcholine Extrapyramidal effects, temporalbinding cardiac volumes and. improvement after receptors, 108P(ab) characteristics, receptor occupancy, bypass surgery.93P(ah) radiotracer for studies of nicotinic cholinergic antipsychotic agents, 11

2132 The Journal of Nuclear Medicine Extremity edema. ""Tc-albumin colloid Fluorine-18 DOPA high uptake in brain radiation necrosis, epileptic lymphoscintigraphy, postoperative examination of F-Dopa model, normal and activity, 1174 lymphocele discovered incidentally, 1517 Parkinsonian subjects, 432 histogram sharpening method to reduce FDG-PET and, multiple system atrophy and transmission noise, PET, 786 Parkinson's disease, 271P(ab) hyperparathyroidism after resection of PET imaging to detect brain tumors, Parkinson's parathyroid carcinoma, '"""Tc-sestamibi- disease, 1180 SPECT, 2000 F-DOPA, combined PET studies, Parkinson's statistical parametric mapping of, 271P(ab) inhaled drug deposition, labeling of fluticasone disease, 3OMFD, 209 uptake, amino acid transport effects, 109P(ab) propionate particles in, 141P(ab) Fab' fragments, reduction of renal uptake of Fluorine-18 epibatidine analog interpretation of myocardial PET scans in monoclonal antibodies by amino acid radioligand for imaging of, 1IP(ab) hyperglycemia, 1713 infusion, 829 SPECT imaging of nicotinic acetylcholine L-methionine, assessment of cancer recurrence Factor analysis, FDG-PET studies in small receptors, baboon brain, 1IP(ab) with, 67P(ab) hearts, derivation of input function, 1717 Fluorine-18 FCAP, assessment of ACE activity, liver mÃ©tastases,discordance with MRI Factor analysis of dynamic structure (FADS), spontaneously hypertensive rat, 118P(ab) scans, 253P(ab) combination with SPECT for detection Fluorine-18 FECT, dopamine transporter management of lymphoma, 139P(ab) of abnormal parathyroid glands, Tc- imaging with, monkey, l91P(ab) metabolic changes in hypertrophie sestamibi, 1773 Fluorine-18 FHPG, synthesis, imaging of viral cardiomyopalhy. PET, 572 Familial hypercholesterolemia, myocardial infection and gene therapy, middle cerebral artery occlusion, viable and blood flow measurements with PET, PET. 193P(ab) ischemie regions, rats, 282P(ab) dipyridamole. 1937 Fluorine-18 fluoroacyclovir, probe for gene monitoring response of soft-tissue and Fan-beam collimator, commercial, focusing expression, PET, 193P(ab) musculoskeletal sarcoma to neoadjuvant quality of, 207P(ab) Fluorine-18 flurodeoxyglucose (FDG) therapy, PET, 1438 Fatty acid metabolism "C methionine comparison, residual or recurrent myocardial, comparison of viability focal accumulation of ':1I-BMIPP in malignant tumor detection, 261P(ab) studies, l77P(ab) liposarcoma, 997 |;'I BMIPPA comparison, uptake in ischemie myocardial uptake of, comparison of PET and impairment in hypertrophie cardiomyopathy, heart disease. 184P(ab) SPECT in dyssynergic metabolic imaging with I!>I-BMIPP, '-'I IMT SPECT compared with, evaluation of myocardium, 1631 dyskinesis, 1679 brain tumors, 157P(ab) neural development studies, conscious infant metabolic fate of '-'I-BMIPP in myocardium abnormal colonie accumulation in primates, 55P(ab) after etomoxir administration, canine pseudomembranous colitis, 1683 neurologic, signal-to-noise ratio in, comparison study, 1836 adrenal masses, evaluation for metastatic of reconstruction algorithms, 220P(ab) Fatty acids disease, l41P(ab) neurological PET, postinjection transmission 3R-BMIPP isomer, heart uptake of, 6P(ab) brain measurements of attenuation metabolic activity, myocardial function and, image misregistration, limites of visual correction, 128 recovery in postperfusion analysis, 208P(ab) non-small-cell lung cancer, 259P(ab) parameters, monitoring of non-Hodgkin's myocardium, 37P(ab) quantitative evaluation of 3D PET, 219P(ab) metabolism, myocardial cancer dual study with "'I whole-body lymphoma, 138P(ab) serial change in utilization, acute scanning, 1468 PET MI, 185P(ab) cerebral glucose metabolism in HIV-1 compared to """Tc-MIBI SPECT, evaluation of single injection of '='! BMIPP, 185P(ab) seropositive subjects, PET, 1133 musculoskeletal sarcomas, 1476 myocardial, PET and "C palmitate detection in cerebral glucose utilization, during derivation of input function, studies in small cardiomyopathy patients, 39P(ab) physiological stimulation, 223P(ab) animal hearts, 1717 radiolabeled to predict functional outcome after changes in function and regional glucose estimated radiation dose in neonates, 387 myocardial infarction, 718 uptake, stunned porcine myocardium, evaluation of preoperative chemotherapy in Fibromyalgia syndrome, abnormal CSF PET, 2006 breast cancer, 931 substance Pin, low Te HMPAO uptake compared to sestamibi SPECT, localization of glucose uptake by tongue and pharyngeal and, 276P(ab) parathyroidism adenomas, muscles, 1918(le) Filtering, fast quantitative measurement of hyperparathyroidism, 1809 imaging of neuroblastomas, 16 attenuation map, SPECT, 217P(ab) compared with "C-MET in detection of position of photon-emitting objects in emission Flow tracers, lipophilic cationic, detection with malignant tumors, PET, 1472 scanner, stereotactic coordinates, ECT microelectrode sensors, 205P(ab) comparison of "F-Phe with "C-Met in tumor sinograms in breast biopsy, 1562 Flumazenil. FMZ affinity and benzodiazepine imaging, 320 preliminary study, bladder cancer receptor concentration estimates using detection and treatment of ocular patients, 260P(ab) partial saturation method, 5 melanoma, 137P(ab) primary renal cancer visualization with. I lunai i/ini. Moyamoya disease, improved diagnosis of malignant melanoma, comparison correlation with histopathological cerebral perfusion following therapy, with scintigraphy. 137P(ab) data. 64P(ab) "MTc-HMPAO, SPECT, 84 dual-isotope probability of malignancy in solitary pulmonary Fluorine-18 myocardial viability, 261P(ab) nodules, PET, 943 5a-dihydrotestosterone, evaluation of 18F- single acquisition SPECT, correction for response to hyperthermic isolated limb labeled androgen receptor ligands in downscatter, 137P(ab) perfusion for soft-tissue sarcoma, baboons, prostate cancer, 1009 endotoxins in, 199P(ab) PET, 984 5-Fluorouracil. biodistribulion and metabolism, evaluation of therapy on transplanted VX2 liver routine estimation of regional cerebral PET and MRI study tumor, 296 metabolic rates of glucose, 147P(ab) comparison, 249P(ab) focal pulmonary abnormalities. 36P(ab) sarcoma, tumor glucose metabolic rate and mapping of dopamine transporters, PET and gastroesophageal cancers, preoperative differential uptake ratio in, l40P(ab) SPECT, 298P(ab) staging, 135P(ab) simplified deoxyglucose utilization rate pinhole SPECT, brain, Monte Carlo head and neck cancer analysis, PET, 950 study, 120P(ab) chemotherapy response in, 136P(ab) skeletal muscle uptake, effect of oral radiolabeled transferrin, iron metabolism in cell value in preoperative workup, 136P(ab) diazepam, 1127 proliferation, tumor localization, 1408 whole-body staging by, 136P(ab) SPECT versus PET. cardiac, determination of I Inorine-IS altanserin, use in quantitative head and neck tumors, benign or myocardial viability. 60P(ab) imaging of serotonin receptors, 109P(ab) malignant, 304P(ab) staging of high-risk cutaneous Fluorine-18 atipametzole, synthesis, high-energy slit aperature and pinhole SPECT, melanoma, 137P(ab) staging, Hodgkin's disease, 139P(ab) biodistribution in rats, 51P(ab) correcting aperture penetration, 7P(ab)

Subject Index â€¢1996 2133 statistical parametric mapping for assessment of, before and after placebo infusions, pneumoconiosis, 294P(ab) brain, clinical validation of, 42P(ab) PET, 1142 prediction of response, after chemotherapy in detection of brain tumors, Parkinson's thoracic and upper abdominal tumors, 36P(ab) lymphoma, 139P(ab) tumor uptake disease, 1180 pulmonary leak index in differentiating chronic hyperglycemia. 253P(ab) enhanced PET tumor imaging, emission hydrostatic pulmonary edema from hyperacute changes after stereotactic computed tomography, 371 ARDS, noninvasive, 1316 radiosurgery, 257P(ab) PET radiolabeled liposomes for tumor imaging, 326 uptake determination of regional cerebral glucose radiopharmaceutical tumor targeting with correlation of Glut-1 in pancreatic utilization, 394 receptor-mediated endocytosis, 1003 tumors, 248P(ab) Fluorodopa, Parkinson's disease, PET data scintigraphy, somatostatin receptor comparison, distribution of Iritialed-FDG in breast cancer, analysis, 421 malignant lymphomas, 268P(ab) correlation between glut-1 Focal liver hyperplasia, assessment with with different deferoxamine concentrations and expression, 1042 hepatoreceplor and hepatobiliary incubation conditions, 199P(ab) expression of Glul-1 and, colon imaging, Alagille syndrome, 1365 Gallium-67 citrate carcinoma, 248P(ab) Folate binding protein hilar uptake, after CHOP chemotherapy for non- normal head and neck structures, 251P(ab) concentration of GP38 in ovarian cancer, 665 Hodgkin's lymphoma, 140P(ab) proliferating cell nuclear antigen and. non- radiopharmaceutical tumor targeting via uptake, benign hyperplasia, after chemotherapy small cell lung cancer, 64P(ab) receptor-mediated endocytosis of "Ga- for lymphoma, children, 256P(ab) Wortmannin effects on glucose DF, 1003 Gallium-67 hydroxyaryl derivatives, agents for utilization, 94P(ab) Folate receptor, concentration of FBP-GP38 in lymphoma diagnosis, 196P(ab) uptake and retention kinetics in rat hearts, ovarian cancer, 665 Gallium-67-citrate sympathetic nerve terminals, 2011 Forensics, appropriateness of functional brain comparative study thallium versus gallium uptake in laryngeal muscles, speech-related imaging, ethical clinical practice, 1256 scintigraphy in lymphoma subgroups, visualization with PET, 1771 Fractionated cold kits, reduced stability, quality uptake according to tumor grade, whole-body, staging of malignant control, 1913(le) type, 46 melanoma, 138P(ab) Free thyroxine estimate, correction of, 144P(ab) scintigraphy for noninvasive detection of early whole-body PET, physiological and artifactual Frontal area, vascular response of orthostatic tumor development, non-Hodgkin's versus pathological accumulations, 441 patients, I lymphoma, 1524 Fluorine-18-riuorophenylalanine. feasibility for Frontal lobe, cerebral blood flow, gender sequential thallium and gallium chest scans, tumor imaging compared with "C- differences as a function of differentiating kaposi sarcoma from Met, 320 cognition, 559 lymphoma and opportunistic infections Fluorine-18 fluoroproline, tracer for collagen Fulminant hepatic failure, monitored by "â€¢Tc- in AIDS, 1662 synthesis, 41 P(ab) GSA, 641 Gallium-68 EDTA, brain tumor blood-brain Fluorine-18 FMISO Functional indices, assessment and diagnosis barrier permeability changes, intra- imaging kit, hypoxic tissues, 72P(ab) Furosemide, standardized approach to arterial RMP7, 146P(ab) PET, assessment of diabetic foot investigating the dilated upper urinary Gamma camera lesions, 27P(ab) tract, TC-MAG3, International accuracy of ""Tc-MAGS clearance uptake, evaluation of tumor hypoxic fraction Consensus Committee on diuresis measurements, heart curve, 1281 using tumor: muscle ratios, 235P(ab) renography, 1872 building of, computer using real-time signal Fluorine-18 FQNPe, preparation and processing software, 206P(ab) biodistribulion of, 193P(ab) Compton scatter camera design, medical Fluorine-18 FTHA. fatty acid tracer retention, imaging of myocardial ischemia and radiopharmaceuticals, 77P(ab) hypoxia, 94P(ab) Gadolinium-3, computer simulation of metal ion dual-head Fluorine-18 FTX, PET, breast cancer, 86P(ab) speciation, MRI contrast agents, 379 Tc MAGj clearance measurements Fluorine-18 holo-transferrin, dynamic 3D-PET Gadopentate, interference with"Ga, tumor with, 91P(ab) and, measurement of transferrin receptor imaging, 198P(ab) coincidence mode imaging with, 223P(ab) kinetics, liver, 203P(ab) Gallbladder, morphine-augmentation in diagnosis SPECT/PET, initial coincidence imaging Fluorine-18 misonidazole, PET, localization of of acute cholecystitis, pericholecystic rim with, 53P(ab) liver hypoxia with. 200P(ab) sign, 267 high resolution miniaturized, bone tumor Fluorine-18-OMFD, plasma to striatum forward Gallbladder emptying, dynamic localization during surgery, 303P(ab) transport rate, comparlmental cholescintigraphy, ejection fraction, 261 mobile tomographic, acute perfusion studies in analysis, 432 Gallium emergency room or intensive care Fluorine-18 orthocarborane, preparation, PET ligands for, estrogen receptor, 194P(ab) unit, 120P(ab) imaging of new boron neutron capture scintigraphy multiwire proportional, murine nuclear therapy agents, 194P(ab) diagnosis of acute osteomyelitis, spine and angiography with, 52P(ab) Fluorine-18 PFBG sacroiliac, 297P(ab) positron and single photon emitter using, PET, imaging of pheochromocytoma, diagnosis of untreated Pneumocystis carinii simultaneous acquisition technique dogs, 200P(ab) pneumoniain AIDS patient, 293P(ab) for, 215P(ab) Fluorine-18 RS-15385-FP, PET, alpha- thallium and, disseminated mycobacterium renal uptake of """Te MAGj interobserver Iadrenergic receptor radioligand avium complex, 242P(ab) variance, 293P(ab) for, 40P(ab) Gallium-67 Ganglioneuroblastoma, "In-pentetreotide Fluorine-18-setoperone, alteration of 5-HT2 :'"T1 comparison, imaging of pediatrie imaging in children, 893 receptors in unlesioned cortical areas, Hodgkin's disease, 285P(ab) Gastric antral vascular ectasias, diagnosis with stroke, 1976 anular DSFV fragment, biodistribution and Tc-labeled red cell scans, case Fluorine-18 trovalfloxacin, pharmacokinetics, report, 854 PET study of E. a>//'-infected catabolism, 152P(ab) compared to :"'T1 imaging in salivary gland Gastric bleed sites, amplitude images for rabbits, 239P(ab) disorders, Tc, 1819 detection of, 246P(ab) Fluorocytosine, conversion to 5-fluorouracil, computer simulation of metal speciation in Gastric emptying gene therapy with cytosine blood plasma, MRI contrast agents, 379 antral motility and, alterations in men and deaminase, 87 evaluation of "F-labeled transferrin, tumor women, dynamic antral Fluorodeoxyglucose (FDG) localizing agent, 1408 scintigraphy, 244P(ab) breast tumor investigations with whole-body gadopentate interference with, tumor effects of gastric acid suppressant drugs on, acquisition and SPECT, 615 imaging, 198P(ab) dynamic antral scintigraphy, 57P(ab) cerebral glucose metabolism, reliability of scans lung scintigraphy, assessment of carborundum effects of opioid and opioid-like drugs measured

2134 The Journal of Nuclear Medicine by scintigraphy, 818 hepatoma cells, 234P(ab) Gertsmann-Straeussler-Scheinkerdisease estimation of antral motility, new uptake of specific substrates, for HSV patients, PET study of, 270P(ab) method, 57P(ab) thymidine kinase, hepatoma individual tissues, quantitative FDG-PET gastric pacing effects, patients with cells, 235P(ab) imaging, 68P(ab) gastroparesis, 57P(ab) Generator myocardial, dichloracetate effects, 3P(ab) in early NIDDM, glycÃ©mieresponse, 1643 T produced by, preparation of clinically useful sensitivity of dynamic FDG-PET in Parkinson's management of patients with gastrointestinal radioconjugates, 195P(ab) disease, 1115 disorders, 245P(ab) radioisotope, based on microfiltration ofY/^Sr simplified deoxyglucose utilization rate peristalsis and, scintigraphic imaging microfiltration, 194P(ab) analysis, FDG-PET,950 of, 56P(ab) Genetic risk, assessmentafter I skeletal muscle uptake of "F-FDG , effect of postprandial glucose and insulin level relations, exposure, 612(ed) oral diazepam, 1127 hypertensive subjects, 247P(ab) Geometric asymmetries, in circular Wortmannineffects on, FDG uptake time, untreated Parkinson's disease photomultipliers, PET block measurement of. 94P(ab) patients, 245P(ab) detector, 227P(ab) Glucose transport, Alzheimer'sdisease, dynamic Gastric function, calculationmethodsof solid Gertsmann-Straeussler-Scheinkerdisease. FDG-PET, 201 gastric emptying lag phase, 1639 glucose metabolism in. PET Glucose transport proteins Gastric motility, new methodfor study, 270P(ab) feasibility of targeting for tumor imaging, 1031 estimation, 57P(ab) Glioblastoma, transfectionwithCD gene, in vitro targeting for tumor imaging, controversial Gastric pacing, effects on gastricemptying, studies using 5-fluorocytosine, 87 issues, 1038(ed) patients with gastroparesis, 57P(ab) Glioblastoma multiforme Glucose uptake Gastric physiology, calculationmethodsof solid '"FBPA-Fkinetics, PET,279P(ab) by tongue and pharyngeal muscles, FDG- gastric emptying lag phase, 1639 boron neutron capture therapy in, PET PET, I918(le) Gastritis, bile refluxduringSPECTmyocardial determination of, 235P(ab) degree estimated by PET, stunned porcine perfusion imaging, identifying Glioma myocardium, LV function, 2006 noncardiac cause of chest pain, 1285 MITIscintigraphic localization, histological Glucose-transporter 1 gene Gastroenteropancreatictumors evaluation and proliferation FDG uptake and somalostatin receptor scintigraphy in, 253P(ab) markers, 265P(ab) colon cancer, 248P(ab) staging and management, octreotide scans delineation with "C methionine PET,blood flow pancreatic cancer, 248P(ab) for, 20P(ab) measurement and, 259P(ab) histological differentiation in thyroid Gastroesophagealcancer, preoperativestaging, detection with "C THY PET, 157P(ab) neoplasms, 248P(ab) "F FDG-PET, l35P(ab) FDG-PET in Glucosylifosfamide,biodistribution,prostate Gastroesophageal reflux clinical grading scale, 263P(ab) adeno carcinoma, 264P(ab) assessment of pediatrie gastric emptying, right local histology and prognostic value, 21P(ab) Glut, facultativeandsodiumdependent,mRNA lateral and upright positioning, 1356 high-grade, high-dose focal radiotherapy, expression in nude mice tumor gastric emptying studies in, 245P(ab) SPECT/CT-guidedstereotactic biopsy xenografls, 254P(ab) Gastrointestinal adenocarcinomas, I \ I[' after, l58P(ab) (.lui-1 expression, distributionof triliated-FDG compared to "'In-CYT-103 low-grade, presurgical speech-activated FDG- in breast cancer, correlation to FDG immunoscintigraphy, 1480 PET in, 270P(ab) uptake, 1042 Gastrointestinal tract hemorrhage,"Tc-RBC malignant, therapy trial with *T-biotin, l69P(ab) Glutathione. regionallocalizationin brain,use of scintigraphy,clinical utility despite novel PET tracer for, evaluation of gene """Tc-mej-o-HMPAOas an imaging presence of barium, 643 therapy,53P(ab) agent, 1698 Gated blood-pool scintigraphy, robust proliferative capacity of, ;'"T1proliferating cell GlycÃ©miecontrol, gastricemptyingin patients myocardial edge detection, left nuclear antigen and "Ki use in, 65P(ab) with NIDDM, postprandial hunger, 1643 ventricular ejection fraction, 685 recurrent malignant, !"'T1and Te MIBI Goiter, differentialdiagnosis. 1745 Gaucher's disease SPECT in, 260P(ab) Government relations, 16N(I), 20N(1), 34N(IO), enzyme replacement therapy in, scintigraphic recurrent, from radiation necrosis, FDG-PET in 44N(11), 24N(12) monitoring of, 297P(ab) differentiation of, l57P(ab) ACNP and SNM, endorsement of lipid deposits in bone marrow.Tc sestamibi Glomerular filtration rate institute of medicine report. 18N(8) scintigraphy for evaluation, 297P(ab) "Cr EDTAestimation, comparison in clinical GP38, quantitationof FBPin ovariancancer,665 Gemcitabine, metaboliceffects, prostateadeno practice, 92P(ab) GPIIb/IIIa receptor, use of Tc-P280 as carcinomas, rat, 265P(ab) radionuclides in nephrourology.Committee on thrombus imaging agent, 775 Gender differences Renal Clearance report, 1883 Grade of differentiation, relationshipbetween alterations in gastric emptying and antral use of single-sample adult technique in Na-K ATPasestaining and uptake ratios motility, dynamic antral children, 1805 of MT1SPECT,adenocarcinoma of scintigraphy, 244P(ab) Glucose lung, 955 in cerebral blood flow, role of cognitive state utilization, cerebral Granulocyte colony-stimulating factor, with PET, 559 graphical analysis of FDG double thyrotoxicosis induced by contrast prognostic value of stress, *""Tcsestamibi injection, 223P(ab) media, metastatic thyroid cancer, 1532 SPECT, 14P(ab) quanlitation in FDG-PET without blood Granulocytes, pulmonarymigrationof, gram- serotonin synthesis, reduction in plasma sampling, 221P(ab) negative sepsis, granulocyte-colony tryplophan, 284P(ab) Glucose metabolic rate, tumor,sarcoma,use of stimulating factor effects, 24P(ab) SPECT,evaluation of coronary artery disease in FDG in, 140P(ab) Graphical analysis, corticaldata,serotonin-2 women, 182P(ab) Glucose metabolism receptor binding potential. PET,95 Gene expression Alzheimer's disease, dynamic FDG-PET,201 Graves' disease imaging, living animals, PET reporter and peptide T in AIDS dementia complex, effective halt-life measurements of 1311,228 gene/reporter probe technology, 107P(ab) FDG-PET, 1177 rapid thyroid 1311turnover, probe for, "F fluoroacyclovir use in, 193P(ab) cerebral hyperlhyroidism, 1815 Gene therapy aging effects, attention-deficit/hyperactivity Growth factors, developmentof, diagnosticand cytosine deaminase acativity, in vitro studies disorder adults, 284P(ab) therapeutic using 5-fluorocytosine, 87 during REM sleep, depressed radiopharmaceulicals, 197P(ab) evaluation, novel PET tracer for, 53P(ab) patients, 80P(ab) GSO, scintillation detectors distributed on HSV-TK,gamma camera imaging of, 53P(ab) systemic lupus erythematosus, 21P(ab) spheroid surfaces, PET brain imaging of viral infection and, synthesis of "F uncoupling of, dementia, 275P(ab) imaging, 1219 FHPG synthesis, 193P(ab) detection of hexokinase activity in tumor metabolic effects, HSV thymidine kinase, cells, 192P(ab)

Subject Index â€¢1996 2135 H Helicobacter pylori whole-body PET-FDG staging of, 139P(ab) "C breath samples, simple liquid scintillation Holmium-166 DOTMP, uptake, bone marrow Half-time hepatic excretion, extraction efficiency and excretion rate of Tc-mebrofenin, counter for analyzing, 207P(ab) ablation trial, 234P(ab) diagnosis, "C urea breath test use in, 246P(ab) HSV-tk, gene expression, gamma camera imaging hepatobiliary study in dogs, 1846 gastritis, diagnosis with "C urea breath with '"I FIAU, 53P(ab) HAMA, see Human anti-mouse antibody test, 114P(ab) Human anti-mouse antibody (HAMA), antibody Head and neck cancer ""Re-MAb conjugates for clinical Helium-3, magnetic resonance imaging, human responses to macrocyclic chelators, lungs, 296P(ab) lymphoma, 451 radioimmunotherapy, 352 Human breast tumor, Tc-sestamibi uptake, chemotherapy response, evaluation with FDG- Hemangioma hepatic, ""Te RBC imaging in, 114P(ab) correlation with multidrug resistance PET, 136P(ab) visualization on '"In-octreotide scan, gene expression, 286 differentiation, SUV and time SUV curve on somatostatin receptors, Beckwith- Human IgM, '"In and "'Y-labeled, intraperitoneal FDG-PET, 304P(ab) Wiedemann syndrome, 1516 administration in mice with immunoresponsive cell infiltration in, FDG HÃ©matologiedisorder, evaluation of bone carcinomatosis, 1545 uptake, 264P(ab) marrow status using Tc- Human immunodeficiency virus normal structures, FDG uptake, high resolution antigranulocyte antibody cerebral glucose metabolism in subjects with PET, 251P(ab) preoperative workup, FDG-PET value scintigraphy, 978 and without dementia, 1133 Hematoporphyrin derivative, Tc-labeled, FDG-PET imaging of lymph nodes in, 162P(ab) in, 136P(ab) squamous-cell carcinoma, detection of potential tumor imaging agent, 17P(ab) Hungry bone syndrome, increase in bone uptake Hematotoxicity, high-dose radioiodine therapy, mÃ©tastaseswith PET-TYR, MRI, and following parathyroidectomy, bone advanced differentiated thyroid cancer, scintigraphy, 1371 CT, 897 '"I-Nal, 1496 squamous-cell, study of new tumor marker, Hydrazinonicotinamide Hemodialysis, plasma renin activity, active renin Tc labeling of, optimization of mannitol CYFRA21.1, 145P(ab) staging, whole-body PET-FDG level changes and, 145P(ab) formation, 143P(ab) Hemodynamics, indices of myocardial Tc-labeled, pyridinethiols and imaging. l36P(ab) dysfunction, associated scintigraphy pyrimidinethiols asco-ligands Head and neck neoplasms, radiation treatment planning, Tc-labeled monoclonal findings, 723 for, 152P(ab) Heparanase, activity, correlation with bone scan Hydrocephalus, radionuclide shuntogram, shunt antibodies, SPECT. 1942 findings, breast cancer patients, I27P(ab) patency, 406 Health Care Financing Administration. Hepatic cancer, "Y-lipiodol as potential Hydronephrosis physician guidelines, 24N(9) therapeutic agent, 332 diuresis renography Health Care Financing Administration Hepatic extraction efficiency, Tc-mebrofenin, two-point postural drainage with, 46P(ab) (HCFA), proposed rule for 1997 hepatobiliary study in dogs, 1846 neonatal, cystographic investigation, 287P(ab) physician fee schedule. Hepatic infusion, use of 5-':'I-IUdR in treatment Hydrostatic pulmonary edema, differentiating Medicare, 29N(10) of colorÃ©ela!cancer with liver from ARDS, 67Gapulmonary leak Health insurance, portability bill, 29N(10) mÃ©tastases,25S(4) index, 1316 Health Physics Society, position on low doses of Hepatic metabolism, in vivo study of lipid Hydroxyamamide-based tetradentate ligand, radiation, 25N(7) metabolism with isomers of labeled fatty Tc chelates with, HPLC Heart acid analogs, pPPA and oPPA, 1841 analysis, 189P(ab) adrenergic activity, arrhythmogenic right Hepatic receptor imaging Hyperbaric oxygen therapy, combined"1! MIBG ventricular disease patients, 106P(ab) assessment of focal liver hyperplasia in Alagille therapy, recurrent neuroblastoma, detection of myocardial metastasis of carcinoid tumor, '"In-pentetreotide and fusion syndrome, 1365 children, 287P(ab) fulminant hepatitis monitored by Tc- Hyperglycemia imaging, 1528 failure, sympathetic activity after long-term GSA, 641 chronic, tumor FDG uptake in, 253P(ab) Hepatobiliary imaging influence on interpretation of myocardial FDG- overload, 160P(ab) assessment of focal liver hyperplasia in Alagille PET images, 1713 imaging agent, Te Q compounds enhanced by syndrome, 1365 PET tumor tracers of, 64P(ab) ligandester groups, 188P(ab) extraction efficiency and excretion rate, Tc- Hyperlipidemia, coronary flow reserve in, oxidative metabolism, dual tracer mebrofenin canine study, 1846 angiographically normal coronary auloradiographic measurement, 95P(ab) perfusion and metabolism studies, short-axis monitoring of graft and native liver functions arteries, 82P(ab) post transplantation, 847 Hyperparathyroidism angle selection effects, 160P(ab) Hepatocellular carcinoma Tc-pertechnetate uptake by a parathyroid PET adrenoceptor ligand, distributed nonlinear angiotensin-H-induced hypertension adenoma, 861 modeling of, l06P(ab) chemotherapy, PET imaging to measure bone scintigraphy in hungry bone syndrome, regional energy spectrum, in multispectral hepatic blood flow. 1522 brown tumor, 1371 images, SPECT, 171P(ab) therapy management. FDG and "C ethanol FDG-PET and sestamibi-SPECT in recurrent regional oxygen consumption "O kinetics, dog, HOP(ab) PET, 68P(ab) postoperative parathyroid cancer, 2000 estimation by single-breath inhalation of "O, Hexokinase. activity, tumor malignancy relations, localization of mediastinal parathyroid detection with glucose adenoma, 1535 PET study, 146P(ab) metabolism, 192P(ab) parathyroid "C-methionine accumulation, respiratory motion in imaging, compensation High-resolution tomography, new approach PET, 1766 for, l30P(ab) for, 306P(ab) parathyroidectomy guided by SPECT-MIBI and SPECT and PET, World Wide Web and virtual High-dose iodine-131-sodium iodide therapy, parathyroid measurements, 798 reality markup language extensions advanced differentiated thyroid preoperative assessment with Te MIBI in, 172P(ab) carcinoma, 1496 scinligraphy, 15P(ab) transplantation, see Transplantation Hilar uptake, *'Ga imaging, after CHOP Hypertension uptake and retention of MIBG, specific activity chemotherapy, 140P(ab) determination of, correlation of slope of hepatic effects, 160P(ab) Hip prosthesis uptake of ""Tc DISIDA, 245P(ab) Heart transplantation, evaluation of fatty acid orthopedic patient with polycystic kidney and functional abnormalities in, gated metabolism and myocardial perfusion, dual-isotope study, explanted heart. 1990 liver disease, scintigraphic SPECT, 115P(ab) Heat shock protein-70. imaging of, Tc-labeled findings, 2062 rapid gastric emptying in, postprandial glucose loosening, diagnosed with nuclear and insulin level relations, 247P(ab) antisense probes, 96P(ab) Heating techniques, ""'Tesulfur colloids, lung arthrography, 62 renovascular, diagnosis with captopril Hodgkin's disease scinligraphy, 291P(ab) uptake of, l97P(ab) pediatrie, 2"'TI and "Ga comparison, 285P(ab) spontaneous, "F FCAP assessment of ACE

2136 The Journalof Nuclear Medicine activity, rat, 118P(ab) resolution, quantitation of cancer patients, l98P(ab) Hyperthermic isolated limb perfusion, neuroreceptors, 1911(le) Indium-lll-leukocyte, correlationwithbone evaluation of soft-tissue sarcoma with Immunoconjugates.two-steptargeting, marrow scan in Paget's disease, 858 FDG-PET,984 xenografted tumors, 203P(ab) Indium-Ill NC-Z2D3, imagingof proliferating Hyperthyroid, |:1Iuptake,stabilityof values, 805 Immunoglobulin, imaginginfectionand smooth muscle cells, atherosclerotic Hyperthyroidism inflammation with ""Tc-liposomes, lesions, 49P(ab) '"I treatment, effective half-life Stealth,1392 Indium-111-octreotide measurements, 228 Immunoreactivity.preventionof radiolysis cost effective analysis of somalostatin receptor Plummer's disease, percutaneous ethanol during labeling, monoclonal antibody imaging, 886 injection or radioiodine protection, 1384 somalostatin receptor scintigraphy compared therapy, 255P(ab) Immunoscintigraphy with conventional imaging in medullary rapid thyroidal '"I turnover, 1815 '"In CYT356, patterns of metastalic prostate thyroid cancer, 912 Hypertrophiecardiomyopathy cancer determined by, 10P(ab) Indium-111-oxinate-labeledgranulocytes, re impaired fatty acid metabolism and dyskinesis Tc HIG, bone infection after orthopedic appraisal of quality control, Tc- in, l:'I-BMIPP, 1679 surgery and trauma, 127P(ab) HMPAO, 863 primary metabolic impairment in, PET,572 Te S12 Fab', localization of giant Indium-Ill pentetreotide Hypoxia, in solid tumors,evaluationof ""Tc- cellarteritis, 242P(ab) axillary node imaging, breast cancer. 251P(ab) labeled 2-nitroimidazole as a detection of brain abscess, 241P(ab) comparison marker. 1023 inflammatorybowel disease, monoclonal "'I MIBG, neuroblastoma patients, 34P(ab) antibody against E-selectin, 1l4P(ab) comparison with Te MDP,neuroblastoma monoclonal antibody BC-1, directed against patients. 34P(ab) oncofetal fibronectin, 238P(ab) detection of radiation pneumonitis, 584 three-step, evaluation of immunological dynamic imaging in breast cancer, 622 Image comparison, dataobtainedat different response after, 238P(ab) myocardial uptake in carcinoid syndrome, 275 times with different modalities, SPECT tissue distribution of CD4 lymphocytes, 24P(ab) scintigraphy in children with neuroblast-derived andPET,137 wide-spectrum, integrin as a target of, 200P(ab) tumors. 893 Image coregistration Implanted ports, injectionof *"Sr- somatostatin-receptor scintigraphy. metastasis intra-study alignment effects, dynamic chloride, 400(le) from bronchial carcinoid, 1537 neuroreceptor ligand images, 220P(ab) Impotence, pharmacologietreatmentplanningin. SPECT accuracy of somalostalin reccplor multi-modal, using external fiducial role of nuclear penogram, 288P(ab) scintigraphy. abdominal carcinoid markers, 219P(ab) In vivo imaging, biochemicalmodificationof tumors. 1452 PET-MRI,automatic and accurate streptavidin and avidin, 1380 tumor staging, neuro-endocrine and method, 224P(ab) Indium-Ill gastroenteropancrealic. 250P(ab) Image fusion incubation with In-111-octreotide, 2002 uptake |:'I MIBG, MR1and, integrated diagnosis of internalization of in human endocrine benign hyperplasia, after chemotherapy for abdominal tumors, pediatrie, 34P(ab) tumors, 2002 lymphoma, children, 256P(ab) lymphocyte scintigraphy,staging method for growth hormone response and to octreotide multimodality, automated system for, l25P(ab) non-Hodgkin's lymphoma. 258P(ab) Image processing technique, calculationof and, in acromegaly, 159P(ab) amplitude images, gastric bleed planar and SPECT imaging, quadruple energy uptake in endocrine tumors and lymphoma, 916 sites, 246P(ab) window algorithm use in. 207P(ab) visualization of myocardial metastasis, carcinoid Image quality radiolabeled immunoglobulin therapy, heart disease, 1528 decomposition of images, pinhole imaging intraperilonealadministration in rodents Indium-Ill platelets, anti-plateletagent system, 63P(ab) with peritoneal carcinomatosis, 1545 E5510effects, platelet deposition in list-mode likelihood. 124P(ab) radiolabeled liposomes for tumor imaging, 326 atherothrombolic lesions, 242P(ab) maximum-likelihood image reconstruction, from role of ICAM-1 in inflammatory process, 656 Indium-Ill polyclonal IgG. comparisonwitlV'Ga list-mode data, 124P(ab) versus T, anli-tac monoclonal antibodies scintigraphy, focal siles of infection and Image reconstruction, decreasingartifactsin labeled with, biodistribulion of, 234P(ab) inflammation, 239P(ab) SPECT.optimal number of views in 360- Indium-Ill biotin. ""Yand.dual-isotopecounting Indium III Stealth liposomes, biodistribution degree imaging, 1740 method, pretargeted cancer and pharmacokinclics, solid Image registration therapy. 144P(ab) tumors. 54P(ab) automated algorithm for, brain SPECT,98P(ab) Induim-lll-colloid. combinedscintigraphyand Indium-111WBC automatic radiology for detecting hip prosthesis scinligraphy. fever of unknown origin. l6IP(ab) intensity scaling and, SPECT brain loosening, 62 epiglottitis detected by HIIn-WBC images, 213P(ab) Indium-Ill DTPA, polypeptides,hepalocyte scintigraphy, 76 median and phrenic nerve brain activation metabolism of, 202P(ab) Indium-1 Urn localization of radionuclides in with Tc ECD SPECT and MRI, 8P(ab) Indium-lll-DTPA-D-Phe'-octreotide. system lestis, transferrin. 336 automatic 3D, with nonframe-based headholder, therapy in midgul carcinoid Indomethacin. "C-labcled.inflammation PET and MRI, 303P(ab) syndrome, 1519 imaging, brain studies of dosimetry for intralesional radionuclide Indium-Ill DTPA-estradiol.evaluation,estrogen cyclooxygenase, l92P(ab) therapy. 228P(ab) receptor-positivetumor, 264P(ab) Infection interpretation of MRI and FDG-PET images, Indium-lll-DTPA-IgG, biodistributionand E. coli, pharmacokincticsof "F trovafloxacin, dosimetry of Tc-HYNIC-IgG, PET study of rabbits, 239P(ab) known or suspected brain '""'Tcleukolaclic neplide, synthetic, 24P(ab) tumors, 22P(ab) comparisons, 843 multimodality,aulomated system for, 125P(ab) Indium-Ill ICAM-1. earlydetectionof lung Tc-MIBl scintigraphy, pulmonary Image resolution, artifactsand,investigationin injury, l96P(ab) tuberculosis. 233 3D PET, 73P(ab) Indium-Ill IgG Tc WBC imaging, comparison with '"I Image segmentation, multimodality,automated comparison with "7Gascinligraphy,focal sites of NWBC imaging. 204P(ab) system for, 125P(ab) infection and inflammation. 239P(ab) bone, after orthopedic surgery and trauma. "Tc Imaging intraperiloneal retention of. peritonitis, different HIG immunoscinligraphy in. l27P(ab) comparison of IJ'I-VIPreceptor scinligraphy and extent of fibrin formation, 2241P(ab) fever of unknown origin. '"In WBC '"In-CYT-103 immunoscinligraphy, scinligraphic detection of inflammation and scintigraphy in. l61P(ab) localizing intestine adenocarcinomas and infection, """Tc-Stealth-liposomes,1392 locomotor system, evaluation with '"In IgG melastatic spread, 1480 scintigraphy.evaluation of infections in the scintigraphy, l28P(ab) evaluation of the dopamine system of the locomotor system, 128P(ab) osteomyelitis, localization with recomhinanl human brain. PET, 1242 Indium-Ill KC-4G3, EDTAeffects on, prostate interleukin-8scintigraphy,25P(ab)

Subject Index â€¢1996 2137 peritonitis, different extent of fibrin formation evaluation of sympathetic nervous metabolism, reflection of possible in, IP retention of "'In IgG, 2241P(ab) system in pulmonary hypertension, 1343 ischemia, 95P(ab) platelet factor 4, 99mTc-P483H,673 Intestinal lymphangiectasia, intestinalleakageof myocardial uptake, abnormal metabolic prosthetic vascular graft, Tc HMPAOefficacy """Tc-MDP,unexpected during bone switching, fasting condilion, 175P(ab) in, 163P(ab) scintigraphy, 639 single injeclion, evalualion of myocardial radiodiagnoslic agent for, |;'I lUdR role Intestine, chronicinflammation,accumulationof perfusion and fally acid in. l87P(ab) Tc chemotactic peptides in, 239P(ab) melabolism, l85P(ab) scintigraphic detection of inflammation, Tc- Intra-arterial infusion, tumortargetingwith5- uptake and washout kinetics, rat hearts, 94P(ab) labcled Stealth liposomes, 1392 i;'I-IUdR in patients with liver Iodine-123 BMIPPA, 'Â»FFDGcomparison, scintigraphic findings in orthopedic patient with mÃ©tastasesfrom colorectal uptake in ischemie heart polycystic kidney and liver disease, 2062 cancer, 22S(4) disease, 184P(ab) use of slreptavidin and labeled biotin in Intraoperative detection Iodine-123 fatty acid, evaluationof fattyacid pretargeting approach, differentiated thyroid cancer, use of '"I melabolism and coronary perfusion, osteomyelitis, 1655 in, 52P(ab) dual-isotope study during cardiac viral, imaging of, synthesis of "F FHPG ion-implanted-silicondetector based probe. transplantation, 1990 synthesis, 193P(ab) detection of beta emitters, 52P(ab) Iodine-123 FP-CIT, evaluationof dopamine Inflammation, scintigraphicdetectionof Intraoral squamous-cell carcinoma, bone transporter system, 65P(ab) infectious process, """Tc-labeledStealth SPECT assessment of mandibular Iodine-123-5-iodo-6-nitroquipazine,use as tracer liposomes, 1392 invasion, 42 for in vivo study of serotonergic neurons, Inflammation imaging Intraperitoneal administration, "'Inand*"Y- SPECT, 1207 '"In polyclonal IgG, comparison wilh"Ga labeled human IgM. mice bearing Iodine-123-HuM195,bone marrowdosimetry, scinligraphy, 239P(ab) carcinomatosis, 1545 regional variability,695 Tc HMPAO labeled white blood cell scans, luti attuimi al delivery, ultrasound-guided Iodine-123 IBZM, SPECT,asymmelricnigro- detection of appendicitis in radiotherapy with "Y-glass microspheres, striatal dopaminergic function in sleep women, 241P(ab) liver cancer. 958 bruxism, 271P(ab) arthritis, '"In anti-E-selectin monoclonal Intratumoral injection, braintumor Iodine-123 IDAB, scintigraphy,visualizationof antibody, 128P(ab) administration of 5-':'I-IUdR, 19S(4) ocular malignant melanoma, 268P(ab) Inflammatory bowel disease Intravesical instillation, locoregional Iodine-123-iodo-lisuride,imagingstriata! immunolocalizationof, monoclonal antibody administration of 5-'!iI-IUdR in bladder dopamine D2 receptors in parkinson's against E-selectin, 114P(ab) cancer, 16S(4) disease, 22 leukocyte scintigraphy to assess disease Inulin, measurementof solutedistribution,in Iodine-123-iodobenzamides,tracersforthe activity,400(le) extracellular fluid, 91P(ab) detection of melanotic melanoma, 1865 pediatrie, assessment with Tc HMPAO labeled lodination. monoclonalantibody,forovarian Iodine-123-iodobenzamine,bindingin with leukocytes, 287P(ab) cancer, 142P(ab) Parkinson's disease, treatment with Inflammatory diseases, imagingwithTc- lodini'-120 MIBG. production and labeling. dopamine agonists, 1112 SSEA-l.neutrophils, 1789 newPET radiotracer, 19IP(ab) Iodine-123-iomazenil,quanlilaliveassessmentof Information superhighway, contacting Iodine-123 benzodiazepine receptors, SPECT, 374 specialists via the information diagnostic accuracy, differentiated thyroid Iodine-123 IMP superhighway,Newsbriefs, 24N(l ) cancer, 236P(ab) autoradiography,regional cerebral blood flow Inhalation injury, detectionbyTc DTPA evaluation of thyroid cancer, comparison with measurement, scatter compensation radioaerosol. lung scintigraphy, 294P(ab) Tcsestamibi for, 276P(ab) Institute of Medicine PK11195labeled with, high affinity ligand for CBF with, prediction of cerebral infarction after IOM study supports state, not NRC, regulation PET and SPECT, 6P(ab) subarachnoid hemorrhage, 12P(ab) of medical isotopes, 23N(2) safely evaluation of radiolabeled lUdR, 13S(4) hepatic distribution of blood flow, portal recommendations met with mixed sodium iodide capsules, thyroid uptake and streamlining, scintigraphy,51 reviews, 28N(6) dissolution, 197P(ab) Iodine-123 IMT, SPECT,evaluationof Insular carcinoma, comparativeradionuclide SPECT studies, serotonin transporter, 186P(ab) braintumors, 157P(ab) imaging, Tc-(V)DMSA, 78 uptake, stability of values over years, 805 Iodine-123 IMZ Insular thyroid carcinoma, bone marrow Iodine-123 ÃŸ-CIT benzodiazepine receptor distribution, chronic mÃ©tastasesdetected by "'I whole-body aging effects with, 272P(ab) cerebrovascular disease, evaluation of scintigraphy.633 binding, with clomipramine, striatum, serotonin neuronal cell loss, 133P(ab) Insulin resistance, myocardial,coronary dopamine interaction, 66P(ab) receptor imaging, as a measure of neuronal loss atherosclerosis and, 38P(ab) calculation of measures of dopamine in Alzheimer's disease, 164P(ab) Integrin, potentialas a target,wide-spectrum transporters, SPECT, 222 SPECT immunoscintigraphy,200P(ab) SPECT imaging of dopamine transporters, 1129 ischemie cerebrovascular disease, 12P(ab) Intercellular adhesion molecule-1. Iodine-123AM251. bindingto cannabinoid presurgical localization of foci, temporal lobe Biodistributionof '"In-labeled antibody, receptors, brain, mouse, 187P(ab) epilepsy, 10IP(ab) early detection of inflammation, 656 Iodine-123 BMIPP Iodine-123 interferon gamma, inhalation Interferon-a-2b. tumoruptakeof radiolabeled ECG-gated SPECT, myocardial, ischemie heart scinligraphy, 5P(ab) monoclonal antibodies and, l51P(ab) disease patients, 304P(ab) Iodine-123 IPPA Interleukin. localizationof infection, evaluation of myocardial viability in """Teseslamibi comparison, myocardial osteomyelitis, 25P(ab) canines, 1403 perfusion imaging in coronary Intermodality registration, automatedimage fatty acid uptake in ischemie heart disease. palienls, 37P(ab) technique for SPECT and PET, 137 patients withoul prior MI, 1981 myocardial viabilily assessment, observer Internal dosimetry focal accumulation in liposarcoma of the variability, 184P(ab) Tc-DMSA in children, effective dose thigh, 997 SPECT equivalent, 1336 heart uptake, rats, 6P(ab) fasling and nonfasling, deleclion of revised anthropomorphic model of the adult left ventricular hypertrophy, disturbed myocardial viability, 150P(ab) head and brain. 1226 myocardial fatty acidmetabolism prediction of left ventricular function after Internet in, l84P(ab) coronary revascularization, 37P(ab) case-based leaching files, 178 metabolic imaging in hypertrophie Iodine-123-IPT, SPECTimagingof CNS nuclear medicine review manual on, 304P(ab) cardiomyopalhy,impaired fatly acid dopamine transporters, effects of aging World Wide Web, physical evaluation of metabolism and dyskinesis, 1679 on striata! uptake values, 1965 collimatore, 305P(ab) melabolism and kinetics of, in canine myo Iodine-123-IQNB, improvedmethodfor Interventricular septum. '-'I-MIBGimaging. cardium, 757 radiiinHlinalinii of, 2021

2138 The Journal of Nuclear Medicine Iodine-123 It tropane. use as imaging agent, scintigraphy compared to :'"T1 whole-body scans lodohippuric acid, metabolism, lysosomes. presynaptic dopamine transporters, 151 in differentiated thyroid cancer, diagnostic and therapeutic Iodine-123 VIP, receptor scanning, concordance and discordance rates, 1487 purposes, 7P(ab) adenocarcinomas and endocrine tumors, therapy lohexol, contrast nephrotoxicity, renal gastrointestinal tract, 20P(ab) thymic uptake in the anterior scintigraphy. vascular occlusion versus Iodine-124, PET mediastinum, 991 ATN, 1828 ludhu--124 U ilk. imaging of tumor thyroid cancer, radiotoxicity after, IQNP proliferation, 54P(ab) micronucleus assay, 101P(ab) isomers of, stereochemistry, 186P(ab) Iodine-125 treatment Z-(R, R)-, imaging of muscarinic receptors, auger-electron emitting, positional changes, absorbed dose to salivary glands in thyroid brain and heart, 202P(ab) strand breaks on plasmid DMA patients, 102P(ab) Iron metabolism, role in cell proliferation, "F- after. I02P(ab) thyroid cancer in children and labeled transferrin, 1408 localization of radionuclides in testis. adolescents, 236P(ab) Iron-52 transferrin. whole-body imaging with.

Subject Index â€¢1996 2139 PET scanner comparison with dual- neural networks, 220P(ab) hypertrophy headed gamma camera, l48P(ab) new muscarinic cholinergic ligand, coronary artery disease and. radionuclide Iron-59, localization of radionuclides in testis, PET, IOP(ab) ventriculography and SPECT, 93P(ab) transferrin, 336 receptor concentration, dynamic PET coronary artery disease with, myocardial Ischemia data, l46P(ab) perfusion SPECT for, l82P(ab) detection of Tc-nitroimidazole in myocardial tracer, effect of increased vascularity, 207P(ab) disturbed myocardial fatty acid metabolism tissue, 761 Kinetic rate constants in, I84P(ab) Alzheimer's disease, dynamic FDG-PET, 201 experimental, reperfusion damage and, myocardial perfusion and, automated method dynamic FDG-PET studies in Parkinson's evaluation with Tc glucarate and for assessment, 179P(ab) PYP, H9P(ab) disease, 1115 normal limits, from myocardial perfusion visualization of insult in caudate putamen, n'I- Knee SPECT, bone scintigraphy of anterior imaging, 105P(ab) ÃŸ-CIT,1214 cruciate ligament injury, Tc- perioperative cardiac events, risk stratification Isotopes MDP, 1353 of, gated SPECT, 116P(ab) commercial production of, 21 N( 11) Koposi sarcoma, sequential thallium and gallium planar and SPECT blood-pool studies, ejection production, transition metal analysis, 195P(ab) chest scans, differentiating from fraction. 1795 lymphoma and opportunistic infections, quantification, both -'"'TIand Tc sestamibi AIDS, 1662 gated SPECT, 104P(ab) Krohn, Kenneth, Aebersold Award, 22N(9) wall motion, severe coronary artery disease, rest Krypton-Sim, determining regional pulmonary motion analysis in gated Janus, origin of, I272(le) abnormalities in patients on mechanical SPECT, 115P(ab) Jugular venous reflux, superior vena cava ventilators, 239 Lesen Nyhan disease, low dopamine activity in, syndrome, diagnosis and functional PET study, 45P(ab) assessment with radionuclide Leukemia venography, 1460 acute, bone marrow transplant, '"I anti-CD45 antibody regimen prior to, 233P(ab) L-l-["C]-tyrosine, PET evaluation of squamous regional dose variability of bone marrow- cell carcinoma mÃ©tastases,comparisons localizing antibody, 695 K with other methods of assessment, 897 Leukocytes Kaiman Filter, 3D, enhancement of SPECT L-Arginine. platelet thrombus reduction by. Te HMPAO labeled with, pediatrie patients images, brain, 208P(ab) during cardiopulmonary bypass, pig with inflammatory bowel Kidney model. 240P(ab) disease, 287P(ab) Te DMSA. tissue and cellular distribution, L-Dopa, |:1I-IBZM binding in Parkinson's disease, """Tc HMPAO scans, detection of appendicitis in rat, 23IP(ab) reduction by dopamine agonists, 1112 women, 24IP(ab) cancer, correlation with histopathological data Labeled fatty acids, lipid metabolism in the liver, TC-P483H, developed from platelet factor 4 to with FDG-PET imaging, 64P(ab) pPPAandoPPA. 1841 detect infection, 673 chronic dialysis, effects on bone mineral Labeling damage, monoclonal antibody loss of labeled scintigraphy, evaluation of Charcot density, 104P(ab) immunoreaclivily, prevention of, 1384 joint, 241P(ab) extraction, *""Tc,role of protein binding Lag phase, quantification for solid gastric labeling agent for, """Tc phenylcne imine phenol in, 47P(ab) emptying studies, 1639 in, 188P(ab) function Langerhans' cell histiocytosis, role of bone radiolabeling of complete dynamic scan data for camera-based scintigraphy in diagnosing and absence of plasma and erythrocytes, 84P(ab) determination. 9IP(ab) staging, 1456 stabilized Tc HMPAO use in, 84P(ab) radiopharmaceuticals for evaluation, 17P(ab) Language processing. Te ECD SPECT study Levodopa. effects on putamenaldopa- functional mass, renal scarring effects of, 280P(ab) decarboxylase activity, Parkinson's on, 290P(ab) Laryngeal muscles, speech-related visualization disease, 55P(ab) functional response, acelylcholine inhibition, of, "F-FDG-PET, 1771 Ligand tracer, binding, anesthesia effects, mouse scleroderma patients. 290P(ab) Larynx, uptake of "F FDG by muscles, speech brain, 279P(ab) intermittent hydronephrosis, modified lasix and, 282P(ab) Limb salvage surgery, homografl scintigraphy in, renogram, children, 23P(ab) Learning disability, abnormal cerebral glucose pediatrie, 286P(ab) measuring function of. in children and adults. metabolism and, children, PET study Limbic system, hypoperfusion in psychiatric TC-MAG3. 588 of, 286P(ab) illness, SPECT, 410 normal function, clearance of '""Te MAG3 Left bundle branch block, septal metabolic Lipid metabolism 293P(ab) mismatch. I918(le) assessment of myocardial viability, |:

2140 The Journalof Nuclear Medicine hypoxia, imaging with 18Fmisonidazole systems with synthetic discriminant Lyme disease, perfusion abnormalities in, **Tc PET, 200P(ab) function, 124P(ab) HMPAO brain SPECT detection lobular dynamics, blood pool changes in scintigraphy of, 270P(ab) response to vasoactive drugs, 244P(ab) guidelines for pulmonary embolism, 1906 Lymph node mÃ©tastases detection of superior vena cava clot, collateral FDG-PET imaging, in HIV patients, 162P(ab) discordance between FDG-PET and MRI flow to liver, 1826 involvement in the pona hepatis, papillary scans, pre and post therapy, 253P(ab) severe trauma, accumulation of Tc thyroid cancer, 993 FDG-PET imaging of, 250P(ab) chemotactic peptides in, 240P(ab) tumor-involved, size limitations in detection of tracers used to assess protein synthesis, ventilation 2D and 3D PET, 98P(ab) PET, 279 dynamic pulmonary SPECT, 133Xe uptake of Tc-seslamibi, breast tumors, 922 experimental studies with "O and washout, 807 visualization in elbow region, 19I3(le) PET, l47P(ab) incidence of abnormalities in cirrhosis, 437 Lymphangioscintigraphy, transport index in, measurement, ISOwater and PET, Lung cancer evaluation of peripheral dogs, 244P(ab) Tc MIBI imaging, CT and FDG-PET lymphedema. 183P(ab) Liver cyst, febrile patient with polycystic kidney comparison, 260P(ab) Lymphedema and liver disease and hip assessment of mediastinal involvement with peripheral, evaluation using a transport index, prostheses, 2062 Tc-sestamibi SPECT, 938 lymphangio scintigraphy, 183P(ab) Liver malignancy, ultrasound-guided internal cytotoxic therapy, evaluation with "C tyrosine upper extremity, classification via radiotherapy using *"Y-glass PET, 265P(ab) lymphoscintigraphy, 261P(ab) microspheres, 958 differentiating benign from malignant lesions, Lymphocele, Tc-albumin colloid Liver mÃ©tastases,tumor targeting by intra-arterial FDG-PET, 12IP(ab) ,122P(ab) lymphoscintigraphy, evaluation of limb infusion of 5-'"I-IUdR, colorectal FDG-PET, simplified deoxyglucose utilization edema, 1517 cancer, 22S(4) rate analysis, 950 Lymphocytes Liver perfusion scintigraphy, hilar and mediastinal lymph node mÃ©tastasesin, CD4, tissue distribution, determination with transjugularintrahepatic portosystemic Tc MIBI evaluation, 263P(ab) immunoscintigraphy, 24P(ab) shunts, compared with surgical shunts, in mediastinal lymph node mÃ©tastasesand, FDG- labeling, damages induced by "*â„¢Tc hypertension, 243P(ab) PET in the detection of, 122P(ab) HMPAO, 101P(ab) Liver tumors, new treatment approaches, 963(ed) mediastinal staging, FDG-PET, 121P(ab) Lymphoma Liver-heart artifact, early and delayed non-small cell "'In-pentetreotide, endocrine tumors, 916 myocardial SPECT imaging, Tc- "F FDG-PET staging of, 259P(ab) "Ga hydroxyaryl derivatives, agents for tetrofosmin, 1622 FDG uptake with proliferating cell nuclear diagnosis, l96P(ab) Lobar, collapsed left lower lung, differential antigen, Ki-67 and DNA ploidy after chemotherapy, prediction of response by diagnosis of stripe sign in perfusion scan, pattern, 64P(ab) "Ga scintigraphy, I39P(ab) emphysema, 1682 nodal staging with FDG-PET and antibody responses to macrocycles, 451 Localization CT, 121P(ab) B-cell, enhanced retention of radionuclides by, glutathione in brain, use of Tc-meso-HMPAO preoperative nodal staging and detection with *"Y-labeled monoclonal as an imaging agent, 1698 FDG-PET, 249P(ab) antibody, 151P(ab) pattern of ictal perfusion in seizures originating staging, PET and CT comparison, 260P(ab) BCL1, radioimmunotherapy with bispecific in the posterolateral cortex, SPECT, 1946 nuclear medicine use in studies, simulation tool antibodies and"'I-labeled bivalent Locoregional administration for modeling cost haptens, 129P(ab) auger emitters, i;'I-IUdR and 125I-IUdR, effectiveness, 301P(ab) brain, AIDS patients, ;'"TI SPECT detection preclinical animal cancer studies, 10S(4) patient management with whole-body FDG- of, 258P(ab) intra-arlerial infusion of 5-l;'I-IUdR in patients PET, 121P(ab) comparison of a"7I and "'Ga scintigraphy. 46 with liver mÃ©tastasesfrom colorectal primary FDG-PET for management of, 139P(ab) cancer, 22S(4) Tc tetrofosmin SPECT in, 264P(ab) malignant intravesical infusion of 5-l:'I-IUdR in patients detection with Tc tetrofosmin, 35P(ab) somatostatin receptor and "Ga scintigraphy with bladder cancer, 16S(4) primary and metastatic, ="'71and Tc MIBI comparison, 268P(ab) Lorazepam SPECT of, 296P(ab) whole-body FDG-PET in detection of extent regional brain metabolic responses to, sequential follow-up PET FDG scanning, after of, 262P(ab) non-Hodgkin's reproducibility for, 76P(ab) radiation treatment, 261P(ab) reproducibility of regional brain metabolic small cell FDG-PET parameters for monitoring changes, 1609 chemotherapy, Tc sestamibi as predictor of of, 138P(ab) Lossy compression, effect on parameter response, 67P(ab) hilar uptake on "Ga citrate after CHOP estimation, PET, 125P(ab) iodinated bombesin analogues, 185P(ab) chemotherapy, 140P(ab) Lung mÃ©tastasesand, somatostatic receptor low grade, !Â°'TIscintigraphy in, 258P(ab) concomitant lung and gastric uptake in bone scintigraphy in diagnosis, 20P(ab) somatostatin receptor scintigraphy in staging scintigraphy, sarcoidosis, 1530 solitary lesion of, 19P(ab) disease, "FDG imaging of, 36P(ab) W'TISPECT differentiation of benign and stage with "'In lymphocyte endobronchial stem implantation, by V/Q malignant, 268P(ab) scintigraphy, 258P(ab) scanning, quantification of, 36P(ab) Tc MIBI, Te DMSA and-""Tl pediatrie, MIBI scintigraphy in, 139P(ab) low probability scans, review of six-month comparison, 268P(ab) pericardia! imaging in AIDS, "7Ga, 995 mortality in, 117P(ab) staging, CT and FDG-PET scans for, 249P(ab) radiolabeled I un L biodistribution and nodules SUV-lean and Glut-1 expression, FDG- radiation dosimetry of, 90P(ab) Tc sestamibi to distinguish malignant from PET, 65P(ab) Lymphoscintigraphy benign, 35P(ab) tumor imaging, preliminary SPECT study of Id Tc colloidal albumin, sentinel node ""Te tetrofosmin utility in, 11IP(ab) UMP, 248P(ab) identification, 259P(ab) Lung uptake, Tc-MDP bone scan in Wegener's FDG-SPECT diagnosis of, 36P(ab) Tc dextran 70 for, 143P(ab) solitary, FDG-PET, cost-effectiveness vasculitis, 857 Tc sulfur colloid for, 84P(ab) of, HOP(ab), lllP(ab) Lung uptake assessment, '"In-pentetreotide, Tc sulfur colloid, reduced particle pulmonary angiograms with and without scans, detection of radiation pneumonitis, 584 size, 301P(ab) comparison of lung scan criteria Lutetium-177, reactor production of, cancer Tc-sulfur colloid, preparation parameters, and, 118P(ab) therapy, 166P(ab) particle size distribution and respiratory gated FDG-PET, thoracic and upper Lutetium-177-CC49, intraperitoneal stability, 1575 abdominal tumor imaging, 36P(ab) radioimmunotherapy of ovarian classification, upper extremity scans, pulmonary embolism, pattern recognition cancer, 1491 lymphedema, 26IP(ab)

Subject Index â€¢1996 2141 drainage lo triangular intermuscular space myocardial falty acid melabolism, 1-"C- MÃ©tastases nodes, melanoma. 964 palmitate, 1723 squamous cell carcinoma, deteclion of evaluation of limb edema, Tc-albumin colloid, Maxillary sinus, sinusitis, involvement in melaslases wilh PET-TYR, MRI, and lymphocele, 1517 nasopharyngeal carcinoma, FDG-PET CT, 897 lymphatic mapping in cutaneous melanoma, 972 in, 262P(ab) ihyroid cancer, treatment with radioactive iodine melanoma, sentinel node identification, Te MDX210, "Tc-labeling of bifunclional and external radiotherapy, 598 sulfur colloid, 307P(ab) ligands, 362 Metastasis, lymph node involvement in Ihe porta Media, focus on Alzheimer's diagnosis with noninvasive long-term followup, after lymph hepatis, papillary thyroid cancer, 993 vessel transplant, 25P(ab) PET, 33N(5) Metastatic liver cancer, angiotensin-II-induced with sulfur colloid, identification of sentinel Medial temporal lobe, decreased oxygen hypertension chemotherapy, PET metabolism in Alzheimer's disease, node in malignant melanoma, 138P(ab) imaging to evaluate hepatic blood Lysine PET, 1159 flow, 1522 favorable effects of, biodistribution of Tc Mediastinal lymph nodes, assessment with 'Ir Methotrexate, anlineoplaslic delivery to bone dsFv, 129P(ab) sestamibi SPECT, lung cancer, 938 tumors, *â„¢Tclabeled gem- pharmacokinetics of, effects on I2'Ianti-Tac Mediastinum, thymic uptake of "'I, 991 bisphosphonate conjugate, 105 dsFv antibody accumulation, Medicare, impact of HCFA's proposed rule for Methyl iodide, "C, gas phase produclion kidney, 203P(ab) 1997 physician fee schedule, 29N(10) of, 194P(ab) reduction of renal uptake of '"In-DTPA- Medicare reform, SNM response to budget Mibolerone, "F androgen receptor ligands in octreotide, sodium malÃ©ate.1388 cuts, 16N(1) baboons, prostate cancer, 1009 Medullary thyroid cancer Micronucleus, radiotoxicity after'"! Iherapy, bispecific antibody and '"I-labeled bivalent thyroid cancer, 101P(ab) hapten dosimelry, two-slep largeling, Midgut carcinoid, '"In-DTPA-D-Phe'-octreotide, M small-cell lung cancer, 1853 systemic radionuclide Iherapy, 1519 MAM25, Tc-labeling of bifunctional comparison of oclreotide scintigraphy and Migraine, sponlaneous, PET rCBF studies ligands, 362 conventional imaging, 912 in, 279P(ab) Macrocyclic chelators, antibody response in treatment with '"I-labeled anti-CEA Mild head injury, one-year follow-up, predictive lymphomas., 451 anlibodies, 905 capacity of Tc-HMPAO SPECT, 1605 MAG3, captopril transplant renography, Melanoma Minimal degree, renographic characteristics of i:

2142 The Journalof Nuclear Medicine imaging, staging recurrent prostate PET imaging agents of, 51P(ab) acid utilization during, 185P(ab) cancer, 10P(ab) PET imaging of P-glycoprotein in tumors, "C- acute, assessment of salvaged myocardium by iodinated, or ovarian cancer, 142P(ab) daunorubicin and "C-verapamil. 1571 Tc tetrofosmin, l26P(ab) MOvlS protein associated with, """Te sestamibi as a adenosine sestamibi SPECT in, implications of in vitro quantitative autoradiography, transport substrate of, 247P(ab) fixed and reversible defects, 181P(ab) concentration of FBP-GP38 in ovarian tumors, accumulation of ""Te M1BI, 118P(ab) coronary angioplasty, reverse redistribution of cancer, 665 Multidrug resistance associated protein, Tc Tc sestamibi after. 181P(ab) myelosuppression and therapeutic potential of sestamibi uptake mediated by, cancer cell dobutamine :'"T1-SPECT for assessment of peri- "Y, colonie cancer xenograft lines, 233P(ab) infarction and remote ischemia, 1951 models, 168P(ab) Multimodality imaging, three-dimensional dual-tracer autoradiography. '-'I-MIBG and prevention of radiolysis during labeling, 1384 description of pulmonary deposition of *"T1, 680 prostate cancer staging, 11N(4) aerosols, 873 functional risk area, assessed by Tc radioimmunoscinligraphy in patients with Multinodular goiter, dosimetry and risk tetrofosmin, 58P(ab) malignant melanoma, staging, 252 estimates of radioiodine therapy, recovery of fatty acid metabolic activity and radioimmunotherapy and chemotherapy, "'I- carcinogenesis, 2072 function, postperfusion labeledMN-14 IgG anti-CEA MAb, Multiple energy radionuclides, multiple energy myocardium. 37P(ab) colon cancer, 169P(ab) reconstruction, SPECT, 171P(ab) SPECT with pinhole collimator, rats, l59P(ab) radioimmunotherapy of medullary thyroid Multiple sclerosis, white matter lesions in, FDG- Myocardial ischemia -'"'TIand Tc-(etrofosmin uptake comparison, cancer, 905 PET, 22P(ab) radioimmunotherapy with '"I-NP-4 F(ab'>2 anti- Muscarinic receptors severe systolic dysfunction and low CEA antibody, small-volume improved method for radioiodination of 1231- flow, 1398 tumors, 1504 IQNB, SPECT, 2021 amlodipine effects, angina patients, ambulatory reduction of renal uptake by amino acid kinetic analysis, PET, 10P(ab) left ventricular function infusion, 829 ligand binding, molecular modeling monitoring, 59P(ab) successful radioimmunotherapy, micro and of, 279P(ab) assessment of reperfused myocardium, Tc occult mÃ©tastases,SCID mouse myocardial, upregulation of, heart denervation HL91 use in, 94P(ab) model, 44P(ab) and, 70P(ab) changes in function and regional glucose T lOl -biotinylated-avidin-polylysine complex, preparation and biodistribution of "F uptake, stunned porcine myocardium, transfer of DNA intolymphoma FQNPe, 193P(ab) PET, 2006 cells, 62P(ab) SPECT imaging, '"I QNB for, 143P(ab) detection. "S homocysteine thiolactone, 49P(ab) vesicular internalization, enhancement of Z-(R, RJ-IQNP imaging, brain and fatty acid tracer retention during, radiation dose to nucleus, 1052 heart, 202P(ab) comparison, 94P(ab) Monte Carlo simulations, analysis of scatter Muscles, effect of oral diazepam, '"F-FDG- gated SPECT, FDG SPECT contributions, PET, 2024 PET, 1127 comparison, 60P(ab) Monte Carol approach, patient-specific Mycobacterium avium complex, disseminated, identification by i;'I BM1PP, 95P(ab) dosimetry, 89P(ab) review of gallium and thallium scans and quantitative FDG-PET detection of, 174P(ab) Morphine, augmentation, normal gallbladder autopsy findings, 242P(ab) swine model, Tc glucarale uptake in, 50P(ab) ejection fraction and, after intravenous Myelodysplastic syndrome, bone marrow Myocardial metabolism sincalide, 113P(ab) scintigraphy in hÃ©matologiedisorders, impairment in hypertrophie Motion correction Tc-antigranulocyle antibody, 978 cardiomyopathy, 572 cardiac creep, rest/stress myocardial perfusion Myeloma interpreting cardiac FDG-PET images, influence studies, 131P(ab) Te MDP in evaluation of, diffuse marrow of blood glucose, 1713 multihead SPECT, 214P(ab) increase, 267P(ab) Myocardial perfusion ouabain effects on Tc-Q12 and â€¢'"'TIextraction respiratory, compensation for, cardiac Tc-sestamibi uptake, 1001 imaging, 130P(ab) evaluation, Te MIBI characteristics and retention, 752 volumetric approach, "N ammonia cardiac in, 269P(ab) three-dimensional spillover and recovery PET, 131P(ab) Myocardial blood flow correction, PET, 767 Motor stimulation, patterns of brain activation, "C acetate and, compartmental model Myocardial perfusion imaging "O water PET, 281 P(ab) and, 83P(ab) i:ll IPPA and Tc seslamibi comparison, in Moyamoya disease assessment with generator-produced "Cu-PTSM coronary patients, 37P(ab) assessment of cerebral perfusion following and PET, 1294 "N ammonia therapy with flunarizine, 84 changes in, contractile reserve and, 82P(ab) data fitting, parameter estimation evaluation of posterior circulation, Tc- collateral, downscatter correction for dual stability. 224P(ab) HMPAO SPECT and MRI, 1613 isotope SPECT imaging, 216P(ab) motion correction in, volumetric- comparisons of *-'Cu-PTSM with "NH3 as PET pediatrie, evaluation of surgical outcome with approach, l3IP(ab) diamox SPECT, 89P(ab) perfusion tracers, 729 "O water, use of factor analysis in, 147P(ab) MRI, see Magnetic resonance imaging estimates, "O water PET, 221P(ab) Â»Tl a-MSH, see Peptides idiopathic dilated cardiomyopathy. reduced attenuation and scatter compensation Multidrug resistance coronary vasodilatory capacity in, 80P(ab) Tc sestamibi hepatic clearance, genetic factors in, 82P(ab) attenuation correction effects on defect in, 262P(ab) measurement with "N ammonia PET, 174P(ab) reversibility, 148P(ab) **Â°TcTcN-NOET and sestamibi uptake, cancer PET studies in detection of familial combined attenuation correction and scatter celllines sensitive and resistant to hypercholesterolemia, correction for, 30P(ab) chemotherapy, 189P(ab) dipyridamole, 1937 phantom studies, small-lesion detectability breast tumor cells reproducibility of "N-ammonia PET in, 213P(ab) Tc-tetrofosmin as substrate for P- measurements of, resting and hyperemic results of attenuation and scatter correction glycoprotein, Tc-MIBI, 1578 states, 1626 in, 212P(ab) development in breast tumor cells, Tc- venous and arterial bypass grafts, attenuated simultaneous acquisition of transmission and sestamibi, 286 coronary vasodilatory capacity and flow emission data, 80P(ab) â€¢'"'Tland Tc sestamibi comparison, coronary identification in tumors using "C-CHC, three- reserve, 82P(ab) dimensional fusion imaging, 312 Myocardial imaging, bile reflux during, artery disease, women, 69P(ab) P-glycoprotein expression, solid tumors, identifying noncardiac cause of chest a"Tl versus dobutamine echocardiography, evaluation withTc sestamibi, 67P(ab) pain, 1285 chronicleft ventricular P-glycoprotein overexpression, chemotherapy Myocardial infarction dysfunction, 126P(ab) failure, cancer patients, 71P(ab) acute phase of reperfusion, serial change in fatty Te Q12, rat hearts during hypoxia, acidosis,

Subject Index â€¢1996 2143 and ischemia reperfusion, 49P(ab) image acquisition, 8P(ab) metabolism """Te sestamibi comparison with Tc left ventricular hypertrophy patients, coronary '-"I BMIPPA comparison with '"F tetrofosmin, uptake, 48P(ab) artery disease in, 182P(ab) FDG. 184P(ab) Tc sestamibi SPECT mobile lomographic gamma camera, emergency fasting condition, negative uptake of IUI anterior defect location with, l4P(ab) room or intensive care unit use, 120P(ab) BMIPP, 175P(ab) gating and, detection of coronary artery motion correction, for cardiac creep, l31P(ab) metabolism and kinetics of '"I-BMIPP in canine disease. l49P(ab) nonreversible defects, cardiac risk and, tissue, 757 prognostic value of stress in, gender diagnostic population, 182P(ab) necrotic, subcellular distribution of Tc differences, 14P(ab) normal limits of left ventricular glucaratein, 175P(ab) Tc sestamibi, automated method for function, 105P(ab) oxygen consumption, "C acetate for assessment of left ventricular rest-stress, comparison to coronary measurement of, 222P(ab) function, l79P(ab) angiography, 182P(ab) quantitative polar map of, correction for partial Tc SPECT, correlation with cardiac serum resting Tc sestamibi SPECT, post injection volume effeclin, 153P(ab) markers, spontaneous angina, 58P(ab) times, 48P(ab) thickening, reversible ischemia, gated ""re-labeled compounds, uptake in human risk assessment, patients with submaximal tomographic polar map Fourier breast cancer cell lines, 190P(ab) exercise, 182P(ab) amplitude images, l05P(ab) adenosine stress Tc sestamibi, early post- rotating planar projection views, interaction thorax phantom, dynamic functional stress imaging, 59P(ab) with attenuation correction, 149P(ab) SPECT, 219P(ab) automated interpretation of, case-based scanning line source method, using an uptake and distribution of j:'I MIBG, long reasoning system, 178P(ab) anthropomorphic phantom, 211 P(ab) QTsyndrome patients, 37P(ab) blood flow and coronary endothelial function, simultaneous evaluation, perfusion and fatty viability after hear transplant, 83P(ab) acid metabolism, 185P(ab) '"I IPPA prediction of left ventricular function cavity dilatation, versus elevated lung heart SPECT after coronary revascularization, 37P(ab) ratio, l83P(ab) clinical management of very elderly ;"'TI and '"F FDG SPECT assessment comparison, attenuation correction, 97P(ab) patients. 69P(ab) of, 39P(ab) coronary angiography and correction of photon attenuation in, 176P(ab) Tc sestamibi SPECT and histology 3D-fusion image, 218P(ab) stress Tc sestamibi/rest !"'T1,regional correlation, 26P(ab) coronary artery disease evaluation, dyssynergy patients, 175P(ab) accuracy of thallium defects, 25P(ab) women, 182P(ab) stress, stable angina in women, cost analysis assessment with gated SPECT Tc cross-talk correction method, dual-isotope of, 68P(ab) tetrofosmin during dobutamine acquisition, 216P(ab) TcN-NOET, metabolite analysis, after injection administration, 116P(ab) defect contrast in, effect of breast size and in rats, 188P(ab) attenuation correction effects on Tc shape, 216P(ab) ventricular arrhythmias, life-threatening, tetrofosmin SPECT, 180P(ab) detection of coronary artery disease, end-stage outcome prediction, 14P(ab) comparison of *"T1and Te MIBI reinjection renal disease patients, 69P(ab) versus stress echocardiography, cost- tomography in, 308P(ab) dipyridamole for, patient weight effectiveness, 174P(ab) comparison of Tc sestamibi, tetrofosmin, effects, 177P(ab) with ectomography, collimator design, 208P(ab) and stress reinjection mTl for, 26P(ab) dipyridamole/rest Tc tetrofosmin, assessment wrap-around lung effect, attenuation artifacts in detection with '-"I IPPA SPECT, 150P(ab) of coronary artery disease, 58P(ab) SPECT, 1891 diabetes mellitus patients, FDG-PET dobutamine :"'TI, left bundle branch block Myocardial SPECT, early and delayed Tc- identification of, 39P(ab) patients, l77P(ab) tetrofosmin imaging, liver-heart dual-isotope simultaneous acquisition with dual-isotope, downscatter correction for, study artifact, 1622 Tc tetrofosmin and "F FDG, 60P(ab) of collateral circulation, 216P(ab) Myocardial stunning, changes in LV function FDG cardiac SPECT versus PET, 60P(ab) effect on diagnostic and clinical and regional glucose uptake, 18-FDG- image quality of FDG SPECT after managemcni, 1618 PET, 2006 glucose, 60P(ab) errors due to partial volume effects, contractile Myocardial uptake, of labeled somatostatin long-chain fatty acid l:'I PHIPA 3â€” movement and, 215P(ab) analog in carcinoid syndrome, 275 10, 49P(ab) exercise-induced ischemia, chronic left Myocardial viability multicenter trial of Tc lelrofosmin ventricular dysfunction patients, 25P(ab) comparison between FDG-PET and FDG- SPECT, 26P(ab) expert system interpretation. 48P(ab) SPECT, dyssynergic myocardium, 1631 observer variability in assessment with '"I extracardiac activity on, scatter correction and evaluation of perfusion and metabolic state, IPPA, 184P(ab) attenuation correction in, 214P(ab) isotope study, 1990 post-redistribution reinjection of :Â°'TI false-positive, obese male patients, 178P(ab) evaluation with l:'I-BMIPP in canines, 1403 for, 47P(ab) fully automatic processing system, knowledge- predictions of functional outcome, BMIPP and stress-redistribution-reinjection :'"TI based image understanding. 97P(ab) sestamibi scinligraphy, 718 SPECT, 179P(ab) gamma camera images, "*Tc NOET kinetics, Myocardial viability assessment, discussion of ischemie myocardium at rest. 107P(ab) complex and unresolved issues, state-of- gated the-art technologies, 794 both "TI and Tc seslamibi, quantification Myocardium N of left ventricular function, l04P(ab) '-'I BMIPP uptake and washout kinetics, N-Acetyl aspartate, NMR spectroscopic maps of, hypertensive patients, functional rat, 94P(ab) cerebral ischemia measured by, 277P(ab) abnormalities, 115P(ab) amyloid involvement, detection with Tc Na-K ATPase, relation between grade of perioperative cardiac events, risk stratification aprotinin, 185P(ab) histopathological differentiation, uptake of, H6P(ab) blood flow, see Blood flow ratios of ^'Tl SPECT in adenocarcinoma poslexercise, rest motion analysis in, 115P(ab) collateral circulation, downscatter correction for of lung, 955 stress versus rest, reproducibility of left dual isotope SPECT imaging, 216P(ab) Narcolepsy, semiquantitative rCBF brain SPECT diabetic, metabolic fate of "C acetate in, ventricular ejection fraction in, l65P(ab) from, ll5P(ab) rat, 50P(ab) Nasopharyngeal carcinoma tomographic ejection fraction, severely flow reserve, sympathetic neuron effects on, "C acetate clearance in, 136P(ab) hypoperfused myocardium, 105P(ab) heart transplant patients, 4P(ab) evaluating primary disease and differentiating inferior wall evaluation, full versus empty glucose metabolism, dichloracetate residual/recurrent disease from therapy stomach, 19l6(le) effects, 3P(ab) changes, -"'Tl and Tc-sestamibi interpretation, physician training level injury, aortic rÃ©gurgitation,antimyosin antibody- SPECT, 1956 effects. l79P(ab) mediated detection, 38P(ab) maxillary sinus involvement from sinusitis, kinetic parameters, input function shape and FDG-PET in, 262P(ab)

2144 The Journalof Nuclear Medicine prÃ©and post therapy,Te sestamibi arKF'TI Neuronal death, changein thedopamine marker of sympathetic neurons in cardiac evaluation, 257P(ab) transmitter after insult in caudate tissue, 1923 National Atomic Museum, Exhibitplannedfor pulamen, ÃŸ-CIT,1214 Normal data files, quantificativeanalysisof nuclear medicine at the National Atomic Neuropeptide receptor imaging, of SPECT images, !1"T1,Tc-sestamibi, Museum, 15N(1) schwannoma, 1272(le) Tc-telrofosmin, and """Tc- Neck ultrasonography, detectionof recurrenceor Neuroreceptoroccupancy, PETmeasurements furifosmin, 1783 metastasis in differentiated thyroid of, typical and atypical NP-59 scintigraphy. simultaneousdepictionof carcinoma, 446 neuroleptics, 1122 aldosteronoma and adrenal Needle biopsy, stereotacticcoordinatesfromECT Neuroreceptors,quantitationof. needto increase infarction, 852 sinograms, breast cancer, 1562 imaging resolution, 1911(le) NRC, See Nuclear Regulatory Commission Neonatal cholestasis, hepatobiliarykineticsof Neurotransmitters. Nuclear arthrography, radiographyand '""Tc-IDAanalogs, linear systems comparison of l:'I-epideprideand I!'I-IBZM, scintigraphy to diagnose loosened hip theory, 1323 dopamine receptor imaging, 1589 prosthesis, 62 Neonates, estimatingradiationdose, FDG- evaluation of the dopamine system of the Nuclear Education in Medicine Association, PET. 387 human brain, PET, 1242 proposed standard for residents, 33N(9) Neoplasms Neutrophil Nuclear medicine "F-labeled transferrin, iron metabolism in cell imaging inflammatorydiseases, antistage- clinical function, impact of turn-key proliferation, localizing tumors. 1408 specific embryonic antigen-1, 1789 PACS,208P(ab) FDG uptake in soft-tissue sarcomas, PET, 257 inhibition by 1-arginine.normothermic commentary of 100thanniversary,evaluation of Nephrotoxicity cardiopulmonary bypass, l62P(ab) radiation research, 18N(10) contrast-induced, role of radionuclide renal NHS-BATester, antibodyconjugationandstable experiment design, optimal image sampling scan, vascular occlusion versus Tc labeling, 362 schedule, 227P(ab) ATN, 1828 Nicotine acetylcholine receptors issues in nuclear technology assessment. 000 therapy with radiometal-conjugated MAb imaging, brain, baboon, UP(ab) European organizations, 26N(11) fragments, peplides and. 96P(ab) PET ligand for study of, epibatidine review manual on the Internet, 304P(ab) Neural development studies, FDG-PET, analog, 108P(ab) robotics, remote preparation of radioactive consciousinfant primates, 55P(ab) radioligand for imaging of, 1IP(ab) doses, 205P(ab) Neural networks Nicotinic receptors therapeutic, with ""Sror '"Sm EDTMP,skeletal decomposition of "C doxepin PET image binding, PET measurement of, 1IP(ab) mÃ©tastases,31P(ab) sequences, 164P(ab) SPECT radiotracer for, analog of Nuclear oncology, advances in 1996, 885 interpretation of captopril transplant renography, epibatidine, 6P(ab) Nuclear Regulatory Commission, Institute of renal artery stenosis, 1649 studies with "C n-melhylated analogs of Medicine study supports state regulation generation of parametric images with, 220P(ab) epibatidine, 192P(ab) of medical isotopes over NRC, 23N(2) Neuroactivation studies, working Nigrostriataldopaminergic function, FDOPA memory, 284P(ab) and 3OMFD PET, combined studies in Neuroblastoma Parkinson's disease, 209 '"In penletreotide Nitric oxide, neuronal,"C-labeled,PET O comparison with '"I M1BG,34P(ab) study, 201P(ab) Obesity, effects on false positivescans, comparison with Te MDP,34P(ab) Nitrogen-13 ammonia myocardial perfusion imaging, 178P(ab) '"In-pentetreotide imaging in children, 893 cardiac PET,motion correction in. volumetric Occipital meningioma. discordantuptakeon "'I MIBG and '"I MIBG imaging, approach, l31P(ab) brain SPECT images, Tc-HMPAO and children, 35P(ab) PET, measurement of myocardial blood flow, Tc-MIBI, 1183 '"I MIBG therapy, survival after, 237P(ab) age and oxygen consumption Octreotide scans '"I MIBG. followup, 34P(ab) effects, 174P(ab) human xenograft model, athymic mice, '"At staging and management, gaslroenteropancreatic simplified PET protocol for determining tumor patients, 20P(ab) in, 61P(ab) coronary flow and flow reserve, subcutaneous cavernous hemangioma PET hydroxyephedrine imaging, 16 ":Rb, 1701 visualization, Beckwith-Wiedemann recurrent, combined "'I MIBG therapy and use as a myocardial PET perfusion tracer syndrome. 1516 hyperbaric oxygen, children, 287P(ab) compared with ':Cu-PTSM, 729 Oligodeoxyribonucleotides.[L2)'^[-labeled. SPECT and delayed planar imaging, '"I- Nitroimidazole, statusof hypoxiain solid tumors. radiotoxicity in mammalian MIBG, 1464 Tc, 1023 cells, 228P(ab) stage 4, treatment with '"I MIBG and Noise reduction, histogramsharpeningof Oligonucleotides, augerstrategies,potentialfor chemotherapy combined, 237P(ab) attenuation images. "F-FDG-PET. 786 cytotoxic therapy, 3S(4) Neuroendocrine tumors Non-Hodgkin's lymphoma. transitionfrom Opiates, addiction,dopamineD2 receptor cost effective analysis of somatostalin receptor orbital pseudotumor,"Ga-citrate availability during naloxone precipitated imaging, 886 scintigraphy, 1524 withdrawal, 45P(ab) diagnosis, '"I MIBG compared with Non-small-celllung carcinoma, decisiontree Opioid drugs, effects on whole-guttransit '"IMIBG, 243P(ab) analysis for cost-effectiveness in staging measured by scintigraphy, 818 internalization of In-111 in humans, 2002 and management, FDG-PET Opioid receptors, mu. binding,in cocaine staging, value of '"In pentetreotide in, 250P(ab) accuracy, 1428 abusers, SPM, 45P(ab) Nonisotopicexchange, l:'I-iodobenzamidesfor Neurofibroma,Te MDPbonescans, Opportunistic infections, differentialdiagnosis neurofibromatosis, 1778 the detection of melanotic with sequential thallium and gallium Neurofibromatoses,type 1,pediatrie,FDG- melanoma, 1865 chest scans, kaposi sarcoma, lymphoma PET. 265P(ab) Nonisotropicspatial resolution, improved in AIDS, 1662 Neurofibrosarcoma.Te MDPbone scans in collimator design, SPECT and planar Oral cancer, preoperativeassessment,roleof neurofibromatosis, 1778 scintigraphy, 1417 bone scanning in. l37P(ab) Neuroimaging, comparisonof l!'I-epideprideand Nonstationary. scattersubtraction-restorationin Orbital pseudotumor, transitioninto lymphoma, I2'I-IBZM,dopamine receptors, 1589 high-resolution PET, 2040 "Ga-cilrale scintigraphy, 1524 Neurological illnesses., evaluationof the Norepinephrineanalog, "CMHED,PET, Orthostatic hypotension dopamine system of the human brain, presynaptic sympathetic nervous cerebral hypoperfusion, denervated PET, 1242 function studies, 205P(ab) myocardium,"""Tc-HMPAObrain Neurology Norepinephrinetransporter SPECT, 1824 pediatrie, utility of FDG-PET use in, 286P(ab) cardiac, "C HDMI as potential radiotracer maladaptation of frontal vascular response. 1 postinjection transmission measurements for for, 50P(ab) Osseous metastasis, procedureguidelinefor attenuation correction, FDG-PET, 128 evaluation of "C-phenylephrine, MAO-sensitive treatment of bone pain, 881

Subject Index â€¢1996 2145 Osseous tumor, mÃ©tastases,hot spots in bone measuring changes in cerebral blood hyperparathyroidism, 159P(ab) scintigraphy and, 266P(ab) now, 283P(ab) Parathyroid hormone measurements, combined Osteoarthritis. induced,Tc pertechnetate. vascular tracer activity effects, 280P(ab) with Tc-MIBI SPECT as guide to uptake mechanism of, rat, 298P(ab) presurgical speech-activated FDG-PET, low parathyroidectomy,798 Osteoarthropathy, infectedversus grade gliomas, 270P(ab) Parathyroid hyperfunction, Tc-MIBI noninfecled, 706 quantitative imaging, 226P(ab) scintigraphy to identify functional Osteomyelitis autonomy,565 acute, spine and sacroiliac, gallium scintigraphy Parathyroid hyperplasia, functionalautonomyin of, 297P(ab) secondary hyperparathyroidism, Charcol joint, labeled leukocyte/marrow identification with Tc-MIBI scintigraphy in, 24IP(ab) P-glycoprotein, Tc-sestamibi imagingfor scintigraphy,565 chronic recurrent multifocal, physeal diagnosing multidrug resistance, breast Parathyroid scintigraphy, increasedaccuracy involvement in. children. 23P(ab) tumor cells, 286 with "Tc-MIBI, FADS,and infection imaging with streptavidin and "'In- PACS,see Pictureandarchivingcommunication SPECT, 1773 biotin, prelargeting, 1655 system Parathyroidectomy interprctalional confusion, "'In-WBC uptake Paget's disease guided by SPECT-MIBIand parathyroid correlation with bone marrow scan in diagnosis with '"In-leukocyte and Tc-sulfur measurements, 798 Page!'s disease, 858 colloid uptake, 858 increase in bone uptake, bone scintigraphy in recombinant interleukin-8 scintigraphy, FDG-PET appearance of, 27P(ab) hungry bone syndrome, 1371 localization of infection, 25P(ab) FDG-PET differentiation from osteoblastic Parkinson's disease Osteoporosis mÃ©tastasesof prostate, 27P(ab) 3OMFD, combined PET studies in Parkinson's bone mass measurement, impact of Pain disease, 209 densitometers on nuclear medicine, acupuncture and, effects on brain functions, '-'I IPT SPECT dopamine transporterimaging DEXA, I3N(10) Tc HMPAOSPECT imaging, 278P(ab) in, 273P(ab) suspected, bone mineral density measurement in bone mÃ©tastases,'"Sm EDTMP as a palliative "C L-DOPAbinding, l:5IÃŸ-CIT femoral neck or lumbar spine, 103P(ab) agent, 32P(ab) comparison, 66P(ab) Osteosarcoma central processing of, in trigemina! clinical significance of striata! DOPA after allografl reconstruction, skeletal neuralgia, 278P(ab) decarboxylase activity, PET, 216 scintigraphy use in, 28P(ab) Pain response, effectivenessof '"Re-etidronatein combined FDOPAand 3OMFD PET effect of chemotherapy, :'"T1scintigraphic metastatic bone pain, daily pain diary studies, 209 assessment, 1444 kept by patients with prostate comparative dopaminergic imaging, '"I-ÃŸCIT- Ovarian cancer cancer, 1511 FP SPECT and "F-FDOPAPET, 1760 '"I-labeled MN-14 IgG anti-CEA MAb. Painful osseous mÃ©tastases,radiopharmaceutical comparison of cocaine congeners as imaging radioimmunotherapy with, 168P(ab) dosage and response, 249(ed) probes for dopamine terminals, imaging with """'Te88BV59, totally human Palmitate. quantitationof myocardialfattyacid PET, 1186 monoclonal antibody,9P(ab) metabolism, PET, 1723 determination of regional rate constants, intraperitoneal radioimmunotherapy,"7Lu- Pancreas dynamic FDG-PET, 1115 CC49, 1491 cancer, classification by FDG-PET, 140P(ab) differentiation from progressive supranuclear iodinated monoclonal antibody for, 142P(ab) in vivo enzymatic activity of endocrine tumors, palsy, I2'IÃŸ-CITbasal ganglia Ovarian carcinoma PET, 32 distribution in, 133P(ab) concentration of FBP-GP38. in vitro Panda and lambda signs, sarcoidosis,4P(ab) dopamine transporters in quantitalion autoradiography,665 Paragangliomas, diagnosisof can-moidtumorin 1!'IÃŸ-CITbrain SPECT in, 134P(ab) unexpected pleuroperitoneal migration of "P- jugulo-tympanic region, 270 SPECT imaging, '"I use in, 133P(ab) chromic phosphate therapy.636 Parallel-hole collimators, improvedspatial F-Dopa PET in detection of brain tumors, 1180 Oxidation. PETquantitationof myocardialfatty resolution. SPECT and planar fluorodopa PET data analysis, nigrostriatal acid metabolism, l-"C-palmitate, 1723 scintigraphy, 1417 dopaminergic function, 421 Oxygen, cerebral,uncouplingof, Parameter estimation, loss compression kinetics of '"I iodolisuride, striatal binding, 22 dementia, 275P(ab) effectson, PET, 125P(ab) multiple system atrophy and, "F DOPAand Oxygen-15 Parathyroid, FDG-PETandsestamibiSPECT FDG-PET use in, 271P(ab) clinical studies, dual-PET system for comparisons, hyperparathyroidism, 1809 neural degeneration and graft survival, PET and noninvasive quantification, IlOP(ab) Parathyroid adenoma. Tc-sestamibi SPECT MRS use in, primate model, 66P(ab) kinetics, estimating regional oxygen localization, 1535 preparation and biological evaluation of 12SI- consumption, canine heart, 110P(ab) Parathyroid carcinoma, FDG-PETand IACFT for SPECT imaging, 1197 single-breath inhalation, estimation of regional sestamibi-SPECT, putamenal dopa-decarboxylase activity in, oxygen consumption, human heart, PET hyperparathyroidism, 2000 levodopa effects on, 55P(ab) study, 146P(ab) Parathyroid gland striatal signal in, 1BIFP-CIT SPECT use Oxygen-15 butano! Tc pertechnetate/sestamibisubtraction, dual- in, 134P(ab) cerebral blood flow studies compared with, phaseTc sestamibi, and SPECT treatment with dopamine agonists, '"I-IBZM motor activation, 219P(ab) comparison, ISP(ab) binding, SPECT, 1112 kinetics, PET neuroactivation studies, 222P(ab) Tc sestamibi detection of pathology, in untreated, gastric emptying time and gastric Oxygen-15 water hyperparathyroidism, 158P(ab) motility in, 245P(ab) cerebral blood flow studies compared with, dual versus single isotope imaging, 16P(ab) Partial volume correction motor activation, 219P(ab) binding potential measurements, "C raclopride detection of brain tumors, Parkinson's evaluation of primary and secondary hyperparathyroidism,""Te sestamibi PET, 283P(ab) disease, 1180 scintigraphy,243P(ab) MRI-based, for brain FDG-PET factor analysis, myocardial perfusion assessment hyperparathyroidism,preoperative assessment images, 42P(ab) with, l47P(ab) wilhTc MIBI scintigraphy, 15P(ab) Partial volume effect kinetics. PET neuroactivation studies, 222P(ab) lesion localization, SPECT versus planar correction for metabolism, depletion of vascular reserve imaging, preoperative, 242P(ab) including contractile movement, myocardial effects, 277P(ab) nodules, Tc tetrofosmin and MIBI imaging SPECT,215P(ab) PET of, 159P(ab) quantitative polar map of investigation of panic disorder, 225P(ab) PET and "C-methionine accumulation, myocardium, 153P(ab) liver perfusion studies, 147P(ab) hyperparathyroidism, 1766 MRI-based correction for, PET, 154P(ab) measurement of regional hepatic blood scintigraphic detection of pathology, Mueller-Gaertnercorrection, brain flow, 244P(ab) histopathology and, in PET, 225P(ab)

2146 The Journalof Nuclear Medicine reducing effect of, activity quantitation with therapy and hyperbaric oxygen, 287P(ab) Peritonitis, see Infection OS-MLEM SPECT, 153P(ab) thymic hyperplasia, '"In pentetreotide and "'Ga Permeability surface area product. Tc-ECD Particle deposition, use of Tc-DTPA in citrate uptake in, lymphoma, 256P(ab) extraction and retention, dynamic determining regional abnormalities in tumors, MIBG scintigraphy in, 288P(ab) SPECT and "O-water PET. 1600 ventilated patients, 239 urinary tract infection, renal outcomes Permeability-surface area product, brain Particle size distribution, ""Tc-sulfur colloid for after, 46P(ab) perfusion SPECT, correction for lymphoscintigraphy, preparation Penicillin, induced focal seizures in rats, HMPAO nonlinear relationship of tracer flow and parameters, stability, 1575 as cerebral blood flow tracer, 661 uptake, 1237 Pathology, evaluation of fatty acid metabolism Penis, hemodynamic impotence, radioisotope Pertechnegas and myocardial perfusion, heart penile plethysmography role in, 292P(ab) compartmental model for alveolar clearance transplantation, 1990 Penogrant, nuclear, role in treatment planning for of, 2066 Patient management, utility of cerebral SPECT impotence, 288P(ab) transition from technegas, 1917(le) imaging impact on clinical Pentetreotide PET, see Positron emission tomography decisions, 1070 biodistribution and dosimetry, 230P(ab) PET transmission noise, histogram sharpening Patlak method, TcMAG3 renal uptake, somatostatin receptor-positive method to reduce noise in PET, "F- scimigraphy, 291P(ab) tissues, 141P(ab) FDG, 786 Pediatrie acute pyelonephritis, Tc-DMSA Peptide nucleic acid, Tc-labeled, hybridization Pharmacokinetics renal SPECT in diagnosing and of, 203P(ab) DMP444, potential thrombus imaging monitoring, 1349 Peptide T, and glucose metabolism in AIDS agent, 151P(ab) Pediatrie gastric emptying, right lateral and dementia complex, FDG-PET, 1177 ofcobalt-55, 2082 upright positioning, ""'"sulphur Peptides ofcobalt-57, 2082 colloid, 1356 a-MSH, receptors in melanoma, imaging Pharmacologie stress, reproducibility of "N- Pediatrics with, 19IP(ab) ammonia PET measurement of '"In-pentetreotide scintigraphy, neuroblast- ""Rh-tetrathiamacrocycle conjugate, bombesin myocardial blood flow, resting and derived tumors, 893 analogue, 61 P(ab) hyperemic states, 1626 '"I MIBG and '-'I MIBG imaging, '"In DTPA octreotide and others, delivery to Pharmacological challenge, reproducibilily of neuroblastoma, 35P(ab) lysosomes, liver, kidneys, and target regional brain metabolic changes. Tc-DMSA studies in urinary tract tissues, 302P(ab) lorazepam induced responses, 1609 infection, 823 '"In DTPA polypeptides, hepatocyte metabolism Pharmacology, evaluation of the dopamine abdominal tumors, integrated diagnosis, I of, 202P(ab) system of the human brain, PET, 1242 MIBG, MRI and image fusion, 34P(ab) Tc leukotactic, novel approach to infection Phenyltropane, PET, serotonin and dopamine assessment of renal uptake of Te DMSA, imaging, 24P(ab) transporter sites, brain, 40P(ab) planar posterior-view method, 291P(ab) Te P748, biodistribution and Pheochromocytoma biokinetic behavior of Tc-DMSA, effects of dosimetry, 231 P(ab) "'I-MIBG dosimetry in cancer therapy, 1058 renal pathology and age Te P829, biodistribution and malignant, high-dose '"I MIBG therapy differences, 1331 dosimetry, 230P(ab) in, 237P(ab) chronic recurrent multifocal osteomyelitis, "Tc-labeled PET imaging, "F PFBG use in, dogs, 200P(ab) physeal involvement in, based on ternary ligand system, 29P(ab) suspected, MIBG scintigraphy in, l58P(ab) scintigraphy, 23P(ab) comparison to challenge with tumor characterization and effects of excessive estimating glomerular filtration rate, using cysteine, 150P(ab) catecholamines on heart and lungs, '"I- single-sample adult technique in inflammation imaging, 152P(ab) MIBG imaging, 1361 children, 1805 bombesin Phobia, social, altered dopamine transporter evaluation of renal parenchyma, TcMAG3 iodinated analogues, small cell lung densities in, 45P(ab) SPECT, 23P(ab) cancer, 185P(ab) Phospholipid synthesis, study of PET tracers to high risk neonates, Te ECD brain SPECT radioiodinated analogue, as a potential assess liver protein synthesis, 279 in, 22P(ab) radiotherapeutic agent, 1SdÃ¬'iah i Phosphorous-32-phosphate pleural ictal and interictal Tc-bicisale brain SPECT chemotactic, Tc radioactivity, unexpected migration of identification of epileptogenic foci, 1101 accumulation in chronic intestinal intraperitoneal therapy for ovarian inflammatory bowel disease, **"TcHMPAO inflammation, 239P(ab) carcinoma, 636 labeled with leukocytes, 287P(ab) accumulation in lung, severe trauma Photic activation. Tc-HMPAO brain SPECT, intermittent hydronephrosis, modified lasix effects, 240P(ab) evaluation of patients with pure renogram, 23P(ab) potential use of Tc-P587 and Tc-P829 as photosensitive epilepsy, 1755 learning disability, abnormal cerebral glucose radiotracers for detection of SSTR- Photodiode detectors, Sherbrooke Avalanche metabolism and, PET, 286P(ab) expressing tumors, 1016 Photodiode PET Scanner, performance left ventricular ejection fraction in, 286P(ab) radiolabeled, canine model of Â¡ntra-arterial of, l70P(ab) leg length discrepancy, accurate prediction of, thrombus, 152P(ab) Photopenic osteomyelitis, bone scintigraphic congenital growth disorders, 23P(ab) rhenium-bound hormone, structure and findings, septic arthritis, 1676 limb salvage procedures, homograft function, 96P(ab) Physiological accumulations, differentiating scintigraphy, 286P(ab) synthesis, radiolabeling of polypeptide uptake pattern in muscles from lymphoma, MIBI scintigraphy in, 139P(ab) sequences during, 198P(ab) pathological lesions, whole body PET moyamoya disease, evaluation of surgical Percutaneous transluminal coronary scans. 441 outcome with diamox SPECT, 89P(ab) angioplasty, reverse redistribution of Picture Archiving and Communication Systems noninvasive quantification of renal function, Tc-sestamibi, with SPECT imaging, on-line teaching-reference tile, filmless nuclear gamma camera using ""MTc-MAG3, 71 prediction of artery patency and wall medicine department. 307P(ab) primitive neuroectodermal CNS tumors, motion status, 1289 turn-key, nuclear medicine clinic function somatostatin receptor Perfusion, pseudostripe sign in lobar collapse, and, 208P(ab) scintigraphy, 286P(ab) differential diagnosis, emphysema, 1682 Pinhole collimator, high-resolution thyroid pyelonephritis, cortical lesions in, Tc-MAG3 Pericardia! lymphoma. "Ga imaging, AIDS, 995 tomography, SPECT, 2017 and Tc GH comparison in, 287P(ab) Peripheral nerve neoplasms. Te MDP bone Pinhole magnification. Tc-DMSA scimigraphy radiation dosimelry of Tc-DMSA, effective scans, neurofibromatosis, 1778 to detect pyelonephritis in piglets, dose equivalent, 1336 Peripheral vascular disease, flow characteristics, comparison of planar and SPECT radionuclide salivagram, pulmonary disease and evaluated by direct puncture imaging. 1731 medical conditions predisposing to scintigraphy, 183P(ab) Pituitary adenomas, dopamine D2 receptor aspiration, 22P(ab) Peristalsis, gastric, scintigraphic imaging imaging, l:'I-epidepride and recurrent neuroblastoma, combined '"I MIBG of, 56P(ab) SPECT. 1931

Subject Index â€¢1996 2147 Pituitary glands. "'In-DTPA-octreolide uptake, totherapy, advanced breast anesthetized canine, 146P(ab) SPECT. 1449 cancer, 256P(ab) l-"C-acetate, simple method of production, 341 PK receptor ligand, high affinity, PET and "C PMP, mapping AChE in human brain, l-"C-glucose, absorbed dose estimates in adults, Alzheimer's disease. 2IP(ab) SPECT. 6P(ah) hyperinsulinemia, 1668 Placebo, cerebral glucose metabolism during "C raclopride 2D and 3D, tumor-involved lymph nodes, size pharmacologie studies, paired FDG-PET correction for partial volume effects on limitations indetection of, 98P(ab) scans. 1142 binding, 283P(ab) 2D- and 3D-, detectability of small Planar collimator. improved spatial resolution in estimation of binding potential. 280P(ab) lesions, 220P(ab) SPECT and planar scintigraphy, 1417 '-"'IMIBG. production and labeling, 19IP(ab) 3D "O water brain activation studies, scatter Planar imaging "N ammonia correction for, 227P(ab) comparative methods for quantifying thyroid data fitting, parameter estimation 3D whole-body volume, SPECT. 1421 stability, 224P(ab) 2D comparison, image quality, brain, 74P(ab) SPECT and delayed 48-hour scanning in myocardial blood flow measurement, age and acquisitions parameters for, 73P(ab) neuroblastoma. '-'"I-MIBG. 1464 oxygen consumption relations, 174P(ab) activity outside the FOV, signal-to-noise Planar-concave collimator. improved spatial "N ammonia assessment of maximal loss, 73P(ab) resolution, SPECT and planar microvasculardilator capacity, coronary FDOPA scans for, with scatter scintigraphy. 1417 disease, 161P(ab) correction, 73P(ab) Plasma volume, measurement with *-'Cu-HSA- "O study, regional oxygen consumption, human resolution and artifacts in. 73P(ab) DTS, regional HCT to assess cerebral heart. 146P(ab) 5-fluorouracil biodistribution and metabolism, circulation, 1080 "O water comparative animal study, 249P(ab) Platelet count, relationship between absorbed estimation of myocardial blood activation studies dose and toxic dose of '"Re-HEDP. 38 flow. 221P(ab) "O water, classic conditioning of flexor Plethysmography. penile, evaluation of penile investigation of panic disorder, 225P(ab) reflex, 55P(ab) hemodynamic impotence, 292P(ab) measurement of regional hepatic blood language function, left-handed Pleural effusion How, 244P(ab) subjects, 55P(ab) patterns on V/Q lung scans. 296P(ab) motor task activation of cerebral activation/deactivation patterns, brain, SPM95 ventilation/perfusion scan interpretation for cortex, 273P(ab) sensitivity to, 41P(ab) acute pulmonary embolus. 1310 patterns of brain activation in motor sequence adenosine and dobutamine combination, cardiac Pneumocystis carini!, localization difficulty, learning. 281 P(ab) stress, 307P(ab) Alzheimer's disease detecting infection and inflammation quantitative imaging. 226P(ab) with Tc-Sleallh-liposomes, 1392 vascular tracer activity effects, 280P(ab) decreased medial temporal oxygen Poisson noise, accurate treatment of, visual selective attention to orientation and metabolism, 1159 reconstruction of brain SPECT, 218P(ab) spatial frequency. 306P(ab) glucose transport and phosphorylation, 201 Polar map. myocardium, correction for partial "O, cerebral blood flow change during analysis of binding kinetics, "C-iomazenil, 699 volume effect in, 153P(ab) executive function and declarative analysis of scatter contributions, Monte Carlo- Polyethylene glycol memory, 284P(ab) based calculations, 2024 ""Tc-labeled liposomes for blood pool imaging, "OCO") steady-state method compared with appropriateness of functional brain imaging. ventriculography, 1374 SPECT, use of permeability-surface ethical clinical practice, 1256 delecting acute infection and intlammation with model for nonlinear correction of brain assessment of regional myocardial perfusion, """Tc-liposomes, Stealth, 1392 perfusion, 1237 Â«Cu-PTSM and PET, 1294 Polypeptides, radioiodination of, diagnosticand "F BPA-F, kinetics, glioblastoma, 279P(ab) attenuation correction of, brain emission therapeutic purposes, 7P(ab) "F DOPA, statistical parametric mapping images, 172P(ab) Porta hepatis, metastasis of papillary thyroid of, 271P(ab) auditory activation studies, cochlear cancer. 993 "F FDHT staging, prostate cancer, 87P(ab) implantation and hearing Portal streamlining, mapping of hepatic blood "F fluorocarazolol, measurement of beta- subjects, 123P(ab) flow distribution by scintigraphy, '"I adrenergic receptor automated interstudy image, registration IMP, 51 concentration, 174P(ab) method, comparison of dataseis with Positron camera, 2D/3D acquisition capability, "F misonidazole, localization of liver hypoxia SPECT, 137 isotropie spatial resolution and, with, 200P(ab) automated search for significant elements evaluation of, 170P(ab) '"F orthocarborane, imaging of new boron in, 209P(ab) Positron emission tomography (PET) neutron capture therapy agents, 194P(ab) autoradiography and, binding studies of 5-HT2 receptors, post-stroke changes in "F transferrin, biodistribution in nude mice serotonin receptors, human and unlesioned cortical areas. PET, 1976 models, 118P(ab) monkey, 112P(ab) "C ÃŸ-CIT-FPand "C ÃŸ-CIT-FEuptake, human "F-FDG bladder wall radiation dose, "F-FDOPA, 1850 brain, 284P(ab) derivation of input function, small animal block detector technology, for SPECT "C acetate hearts. 1717 imaging, 119P(ab) cardiac, heart transplant patients, 161P(ab) determining regional cerebral glucose block detector, circular pholomultipliers in, uptake and retention, adrenal determination, 394 geometric asymmetry effects, 227P(ab) adenomas, 15P(ab) imaging of soft-tissue sarcoma, 257 brain "C COP 12177 and HED, hypertrophie "F-FDG and Tc-MIBI SPECT, comparison of FMZ, pons, noninvasive quanlitation of cardiomyopalhy assessed by, 71P(ab) diagnostic accuracy in musculoskeletal benzodiazepine receptors, 5 "C deprenyl, cluster analysis use in, 42P(ab) sarcomas, 1476 hydroxyephedrine imaging of "C doxepin. artificial neural network "F-FDG uptake by laryngeal muscles, speech- neuroblastoma, 16 decomposition of, 164P(ab) related visualization. 1771 measurement of AchE activity in Alzheimer's "C DTBZ and, equilibrium versus "F-FDG, estimated radiation dose to disease using radioactive analog compartmental analysis, l09P(ab) newborns, 387 method, 649 "C HED uptake, ischemia-induced inhibition. "F-labeled ÃŸ-CIT-FP,for dopamine Mueller-Gaertner partial volume correction isolated rat heart, 107P(ab) transporter. 192P(ab) in, 225P(ab) "C MDL 100, 907 "F-Phe versus "C-Met in tumor imaging, 320 regional radioactivity quantitation in blood cerebral serotonin receptor "Cu BAT-2IT-NR-LU-10 Fab as an agent flow. 222P(ab) occupancy, H2P(ab) for. 95P(ab) serotonin receptors in, 108P(ab) imaging cerebral serotonin *"Ga EDTA study, blood-brain barrier camera for high temporal and spatial resolution, receptors, 112P(ab) permeability changes, brain design aspects, 85P(ab) "C melhadone, baboon studies, 40P(ab) tumor, 146P(ab) cardiac, Bayesian image reconstruction "C methionine, evaluation of early response "!Rb studies, dipyridamole-induced stress. for, 130P(ab)

2148 The Journalof Nuclear Medicine carrier-free "Cu, isolated from potential, "F-setoperone, 95 imaging atherosclerotic macrophage density "Gawaste, 195P(ab) evaluation of "C-phenylephrine, MAO-sensitive by, 38P(ab) CBF studies, spontaneous migraine, 279P(ab) marker of sympathetic neurons in cardiac immunoresponsive cell infiltration and, head central processing, vestibular system, stimulus- tissue, 1923 and neck cancer, 264P(ab) induced differences of, 122P(ab) evaluation of "F androgen receptor ligands in impact of image registration, brain cerebral blood flow baboons, prostate cancer, 1009 tumors, 22P(ab) evaluation of cerebral hemodynamic and evaluation of hepatic blood flow, angiotensin-Il- liver mÃ©tastases,250P(ab) metabolic status, carotid artery induced hypertension locally recurrent and metastatic thyroid disease, 429 chemotherapy, 1522 cancer, 135P(ab) gender differences as a function of evaluation of preoperative chemotherapy in lung and breast cancer, 65P(ab) cognition, 559 breast cancer patients, FDG, 931 lymph nodes, HIV patients, 162P(ab) cerebral glucose metabolism in HIV-1 F-Dopa as an amino acid tracer for detection of management of lymphoma, 139P(ab) seropositive subjects, AIDS dementia brain tumors, extrapyramidal management of solitary pulmonary nodule complex, 1133 symptoms, 1180 patient, HOP(ab), lllP(ab) changes in LV function and regional glucose fast iterative image reconstruction, performance mediastinal staging of lung cancer, 121P(ab) uptake, myocardial stunning in porcine evaluation, 154P(ab) metabolic impairment in Alzheimer's studies, 2006 FDG disease, 275P(ab) monitoring non-Hodgkin's coincidence imaging, dual head gamma cerebral glucose metabolism, reliability of camera, 53P(ab) scans before and after placebo lymphoma, 138P(ab) comparative nigrostriatal dopaminergic imaging infusions, 1142 monitoring of tumor response to in Parkinson's disease, SPECT, 1760 enhanced tumor imaging, emission computed chemotherapy, 67P(ab) comparison of "F-FDG and "C-MET, malignant tomography, 371 myocardial viability assessed by, 39P(ab) tumor detection, 1472 "C ethanol and, hepatocellular myocardial wall motion and ejection comparison with dual-headed gamma camera, carcinoma, 68P(ab) fraction, 226P(ab) whole-body imaging with'Te 2D- and 3D comparison, 226P(ab) nasopharyngeal carcinoma, maxillary sinus transferrin, 148P(ab) 3D, quantitative evaluation, brain involvement from sinusitis, 262P(ab) comparison with SPECT, myocardial uptake of imaging, 219P(ab) neurofibromatoses type 1, pediatrie "F-FDG, dyssynergic myocardium, 1631 abnormal cerebral glucose metabolism, patients, 265P(ab) comparisons of cocaine congeners for dopamine children, 286P(ab) nodal staging of non-small cell lung terminals, 1186 advanced primary and recurrent colorectal cancer, 121P(ab) complex and unresolved issues related to cancer, 132P(ab) noninvasive method for quantilating mice myocardial viability assessment, 794 after differentiated thyroid cancer, 134P(ab) input functions, 147P(ab) coronary flow and flow reserve, simplified appearance of Paget disease, 27P(ab) normal extracranial head and neck protocol using "Rb and "N- assessment of breast tumors, 254P(ab) structures, 251P(ab) ammonia, 1701 breast cancer response to tamoxifen, 99P(ab) Pagets disease or osteoblastic mÃ©tastasesof correction for attenuation, smoothing during breast cancer, staging of the axilla, 307P(ab) prostate, 27P(ab) transmission processing on cardiac breast imaging, prone and supine, 99P(ab) partial epilepsy with vascular scans, 690 breast, quantitative image analysis, 99P(ab) malformations, 100P(ab) cortical 5-HT2 serotonergic receptors, post- cancellous bone graft viability in total hip v% partial volume correction method for, MRI- stroke changes, 1976 replacements, 27P(ab) based, 42P(ab) CT comparison, mediastinal and extrathoracic cerebral metabolic correlates for depressive patient management of non-small-cell lung staging of non-small cell lung relapse, 80P(ab) cancer, 121P(ab) cancer, 260P(ab) classification of pancreatic tumors, 140P(ab) pediatrie neurology patients, 286P(ab) data fitting, parameter estimation, 304P(ab) colorectal cancer, hepatic, chemoembolization prediction of recovery in poststroke decarboxy lation of carbon-11 -DOPA, endocrine in, 132P(ab) aphasia, 122P(ab) pancreatic tumors, in vivo enzymatic correlation of GLUT-1 glucose transporters preliminary study, bladder cancer activity demonstration, 32 with FDG uptake in, 248P(ab) patients, 262P(ab) decision tree analysis, cost-effectiveness in detection and treatment of ocular preoperative nodal staging and detection of staging and management of non-small- melanoma, 137P(ab) non-small-cell lung cancer, 249P(ab) cell lung cancer, 1428 detection of lung cancer and mediastinal quantitation of cerebral glucose utilization decline in dopamine transporters with age, 554 lymph node mÃ©tastases,122P(ab) without blood sampling, 221P(ab) detector design, LSO scintillator crystals and detection of myocardial ischemia, 174P(ab) recurrent colorectal cancer, comparison with photodiode readout, 85P(ab) diagnosis of malignant melanoma, CT, 132P(ab) dichloracetate effects, myocardial glucose comparison with scintigraphy, 137P(ab) recurrent differentiated thyroid metabolism, 3P(ab) diagnostic accuracy and cost-effectiveness, cancer, 134P(ab) dopamine transporter occupancy, colorectal cancer, 132P(ab) recurrent malignant glioma from radiation methylphenidate induced high diagnostic evaluation of dementia, 270P(ab) necrosis, 157P(ab) and, 44P(ab) differentiating benign from malignant lesions, relation to local histology and prognostic dopamine transporter, cocaine binding sites lung, 121P(ab), 122P(ab) value, glioma, 2IP(ab) on, 65P(ab) differentiation of benign from malignant bone relationship between metabolism and function dual system, noninvasive quantification of "O and soft tissue lesions, 140P(ab) in coronary artery disease. 161P(ab) clinical studies, HOP(ab) evaluation of adrenal masses for metastatic renal cancer, correlation with dynamic disease, 141P(ab) histopalhological data, 64P(ab) estimation of serotonin synthesis rate, evaluation of renal cell carcinoma, 141P(ab) residual testicular cancer after F-Dopa and, Parkinson's disease, 271P(ab) brain, 145P(ab) chemotherapy, 256P(ab) kinetic modeling of, estimation of receptor for distinguishing between benign and respiratory gated, thoracic and upper concentration by, 146P(ab) malignant breast masses, 99P(ab) abdominal tumor imaging, 36P(ab) stochastic algorithm for parameter estimation gated, assessment of left ventricular sequential follow-up scanning, lung in, 222P(ab) function, 39P(ab) cancer, 261P(ab) earliest metabolic reduction, Alzheimer's glioma, clinical grading scale for, 263P(ab) SPECT and MRI comparison, pediatrie disease, 163P(ab) head and neck cancer epilepsy, 269P(ab) early detection of Alzheimer's disease, 79P(ab) head and neck tumor differentiation, 304P(ab) staging of colon cancer metastatic to ECAT EXACT HR+, performance identifying tumor hypoxia, *""TcHL91 liver, 131P(ab) characteristics, 221P(ab) and, 87P(ab) staging of esophageal cancer, 135P(ab) estimation of serotonin-2 receptor binding staging of high-risk cutaneous

Subject Index â€¢1996 2149 melanoma, 137P(ab) changes, 572 optimal sampling schedule, nuclear medicine staging of Hodgkin's disease, 139P(ab) image reconstruction, MRI- measurement, 227P(ab) staging of malignant melanoma, 138P(ab) constrained, 223P(ab) outcome of temporal lobe epilepsy staging of pulmonary neoplasms, 249P(ab) imaging agents of human multidrug resistance surgery, 1094 tumor glucose utilization, primary rectal P-glycoprotein, 51P(ab) parallel reconstruction tool for, penalized cancer, 54P(ab) imaging of P-glycoprotein in tumors, "C- weighted least square algorithms uptake in benign and normal breast daunorubicin and "C-verapamil, in, 154P(ab) tissue, 249P(ab) multidrug resistance, 1571 parathyroid L-"C-methionine accumulation, uptake, laryngeal muscles with in vivo quantification of pulmonary beta- hyperparathyroidism, 1766 speech, 282P(ab) adrenoceptor density, CGP-12177, 1275 Parkinson's disease validation with surgical pathology, colorectal infant, shielding to correct scatter from outside clinical significance of striatal DOPA cancer, 131P(ab) the field-of-view, 226P(ab) decarboxylase activity, 216 viable myocardium, diabetes mellitus labeling of angiotensin II receptors, "C-L- combined FDOPA and 3OMFD studies, 209 patients, 39P(ab) 159,884, 307 partial volume effects in, MRI-based correction white matter lesions, stable multiple ligands, antagonists for serotonin for, 154P(ab) sclerosis, 22P(ab) receptors, 204P(ab) phantom measurements, production of "St chemotherapy response in, 136P(ab) liver isotope, 166P(ab) value in preoperative workup, 136P(ab) protein synthesis, feasibility study on PET pharmacokinetic studies, measurement of whole-body staging, 136P(ab) tracers, 279 arterial input function, 266P(ab) discordance with MRI scans, 253P(ab) local statistics, analytic computation and sample potential use of "C-KF15372, adenosine Aj colorectal cancer recurrence, 258P(ab) estimation, 155P(ab) receptor ligand, 1203 detection of extent of malignant lossy compression, effects on parameter probability of malignancy in solitary pulmonary lymphoma, 262P(ab) estimation, 125P(ab) nodules, "F-FDG, 943 detection of recurrent or metastatic breast MacinPET, 303P(ab) quanlitation of cerebral perfusion with 62Cu- cancer, 99P(ab) maximum-likelihood image reconstruction, from PTSM and three-compartmental evaluation of suramin therapy, metastatic list-mode data, 124P(ab) model, 1089 prostate cancer, 267P(ab) McN5652, impulse response function and quantitative imaging expectation maximization with ordered kinetic modeling with, 33P(ab) '-'"I, 1557 subsets, 130P(ab) measurement of cell proliferation, methyl- "C- quantitative protein synthesis rate determination, recurrent breast cancer, 252P(ab) thymidine, 1048 without arterial sampling, 225P(ab) recurrent colorectal cancer, 26IP(ab) measurement of plasma volume and regional radiation dose estimates, primates, "C feasibility of scintillation detector distribution cerebral hematocrit, 6:Cu-HSA- arachidonic acid, 230P(ab) on a spheroidal surface, brain DTS, 1080 radiolabeled A | adenosine receptor antagonists imaging, 1219 measurement, nicotinic receptor as ligands for, 142P(ab) fluorine-18-6-fluorodopa, reproducibility and binding, HP(ab) reaction volume, in vivo ligand-receptor discriminating ability in Parkinson's measurements of cerebral hemodynamics and model, 118 disease, 421 metabolism in patients with severe receptor studies, tissue model for, 224P(ab) fluorocarazol, thoracic ÃŸ-adrenergicreceptors, diffuse brain injuries, 1166 regional differences in cerebral blood flow in heart, 71P(ab) medical insurance coverage policies for studies oxidative metabolism, 1086 fluorocarazolol, delineation of ÃŸ-adrenoceptors and for diagnostic use, 948(ed) reporter gene/reporter probe technology, in human brain, IlP(ab) metabolic consequences of acute brain imaging gene expression in living fluorouracil pharmacokinetics, liver mÃ©tastases trauma, 1170(ed) animals, 107P(ab) from colorectal carcinoma, 257P(ab) metabolism of "C-thymidine, tumor reproducibility of measurements of myocardial forward transport rates for F-Dopa and OMFD, imaging, 290 blood flow, resting and hyperemic compartmental analysis, 432 micropet, small animal imaging. 86P(ab) states, 1626 functional brain image database system, in monitoring response of soft-tissue and response to hyperthermic isolated limb dementia, 164P(ab) musculoskeletal sarcoma to neoadjuvant perfusion for soft-tissue sarcoma, "F- functional brain imaging, automated attenuation therapy, "F-FDG, 1438 FDG, 984 correction model for, 42P(ab) MRS and, evaluation of neural degeneration and retracted-SEPTA data, accurate 3D graft survival, Parkinson's disease functional brain mapping, signal-to-noise ratio reconstruction with, 225P(ab) in, 223P(ab) model, 66P(ab) scatter correction techniques, high-resolution gene therapy with cytosine deaminase, myocardial blood flow at rest and dipyridamole imaging, 2046 conversion of 5-FC to 5-FU, 87 loading, familial Sherbrooke avalanche photodiode PET scanner, glioblastoma multiforme, boron neutron capture hypercholesterolemia, 1937 performance of, 170P(ab) therapy in, 235P(ab) myocardial muscarinic receptors, up-regulation short-axis angle selection, effect on quantitation glucose metabolism of, heart denervation and, 70P(ab) of myocardial uptake, 160P(ab) Gertsmann-Straeussler-Scheinker disease myocardial perfusion tracers, 62Cu-PTSM simplified deoxyglucose utilization rate patients, 270P(ab) compared with "NH3, 729 analysis, 950 individual tissues, 68P(ab) myocardial perfusion, KC\Â¡PTSM complexes spontaneous regression of intracranial hepatoma cells produced by a generator for, 308P(ab) arteriovenous malformation, 1673 metabolic effects of gene therapy with HSV neural development studies, conscious infant squamous cell carcinoma mÃ©tastases,uptake of thymidine kinase, 234P(ab) primates, 55P(ab) L-l-"C-tyrosine, comparisons with other uptake of specific substrates for HSV neuroactivation studies, "O water and methods of evaluations, 897 thymidine kinase, 235P(ab) butanolkinetics in, 222P(ab) staging of small cell lung cancer, cost- high-resolution camera, transformable field of neurological FDG, postinjection transmission effectiveness of, 110P(ab) view, 85P(ab) measurements, attenuation slriatal dopamine system, acute high-resolution detectors, feasibility studies of, correction, 128 methamphetamine and amphetamine high magnetic field neuroreceptor occupancy, patterns in subjects effects, 163P(ab) environments, 85P(ab) treated with typical and atypical targeting glucose transport proteins for tumor high sensitivity/high spatial resolution scanner, antipsychotic drugs, 1122 imaging, 1031 small field of view, 86P(ab) nonpeptide angiotensin antagonist E-3174, three-dimensional correction for spillover and hyperperfusion and hypermetabolism in brain pharmacological potency, 288P(ab) recovery of myocardial images, 767 radiation necrosis, MET and FDG nonstationary scatter subtraction-restoration, time course of regional brain activation, uptake, 1174 reducing spillover effects in high- serotonin release, "O water use hypertrophie cardiomyopathy, metabolic resolution studies, 2040 in, 123P(ab)

2150 The Journalof Nuclear Medicine transmission measurements in, 19P(ab) SPECT, 1809 technetium, 28P(ab) transmission scans, image fusion method for localization of ectopie parathyroid adenomas, Protein leak, differentiatinghydrostatic adjustment of, 209P(ab) Tc-MIBI, 631 pulmonary edema from ARDS, transmission to emission transformation, in Primary sensorimotor cortex, regional noninvasive, bedside dual-radionuclide projection space, 155P(ab) functional differences in cerebral blood method, 1316 transport capacities and volumes of "C MHED, flow, oxidative metabolism, 1086 Protein synthesis, PETtracerassessmentin liver, during catecholamine Primary visual cortex, regionalfunctional L-I-"C Tyr and L-Me-"C Met, 279 stimulation, 70P(ab) differences in cerebral blood flow, Pseudomembranous colitis, abnormalcolonie trigeminal neuralgia, central processing of pain oxidative metabolism, 1086 accumulation of 18F-FDG, 1683 in, 278P(ab) Primitive neuroectodermal CNS tumors. Psychiatric illnesses, evaluationof thedopamine tumor tracers, normal and elevated media children, somatostatin receptor system of the human brain, PET, 1242 glucose levels, 64P(ab) scintigraphy in, 286P(ab) Puberty, delayed,testosteronetreatmentson bone visceral pain, normal and pathologic perception Probability of reversible myocardial ischemia, mineral density, l03P(ab) of, regional cerebral activity in, 123P(ab) myocardial perfusion imaging, diagnostic Pulmonary edema, '-''I-MIBGimagingin volume imaging scanner, ultra high and management strategy, 1618 pheochromocytoma, excessive resolution, 276P(ab) Procedureguidelines catecholamine effect on heart and lungs, whole body bone pain treatment, 881 cardiomyopathy. 1361 3D elastic transformation in registration bone scintigraphy, 1903 Pulmonary embolism of, 130P(ab) extended scintigraphy for differentiated thyroid acute, V/Q scans, chest radiographie findings attenuation correction using short cancer, 1269 and, 117P(ab) transmission scans, 172P(ab) general imaging, 2087 clinical diagnosis of, 295P(ab) attenuation correction with transmission imaging with radiopharmaceuticals,2092 companion leg Xenon imaging, part of routine image segmentation, 8P(ab) lung scintigraphy,pulmonary embolism, 1906 V/Q scanning, 302P(ab) distinguishing pathological from methodology for procedural directives in computer assisted V/Q assessment physiological and artifactual FDG nuclear medicine, 878 for directing pulmonary accumulations, 441 thyroid scintigraphy, 1264 angiography, 294P(ab) Positron volume imaging, singles-based, thyroid uptake measurement, 1266 prevalence of recurrence, 295P(ab) scatterin, 172P(ab) Prognosis, thyroglobulinas tumormarker,use criteria for diagnosis of, DTPAaerosol use Postconcussion syndrome, TcHMPAO SPECT after thyroidectomy and prior to ablative in, 295P(ab) use in, 278P(ab) radioiodine therapy, 1962 diagnostic value of small perfusion defects on Post-traumatic stress disorder, regionalcerebral Prolactin, levels measuredby scanfindings, ventilation/perfusion lung scans, 1313 blood HowSPECT activation study radioiodine breast uptake in non- DMP 444 as potential imaging agent, 119P(ab) in, 285P(ab) breastfeeding women, 26 evaluating criteria for low probability Posterior circulation, SPECTandMRI Prostate, "Tc-labeled antibodyCYT-351, interpretation of ventilation-perfusion evaluations of, moyamoya disease, 1613 conjugation, labeling and clinical scans, 577 Postinjection transmission, measurementfor studies, 96P(ab) imaging, Tc P748, 231P(ab) attenuation correction, neurological Prostate cancer low probability lung scans, review of six-month FDG-PET studies, 128 adenocarcinoma mortality in, 117P(ab) Postural cerebral hypoperfusion gemcitabine effects in, 265P(ab) lung scanning in diagnosis of pulmonary frontal area vascular rÃ©ponse,"MTc-HMPAO glucosylifosfamidebiodistribution in embolism, 165 SPECT, 1 rats, 264P(ab) lung scans for, pattern recognition systems with in patients with orthostatic hypotension, bone metastasis with superimposed synthetic discriminant function, 124P(ab) denervated myocardium, 1824 osteomyelitis, diagnostic difficulties, 999 massive, prognosis after, 117P(ab) Practice guidelines EDTAeffects on "'In KC-4G3, 198P(ab) matched ventilation, perfusion, and chest appropriateness of functional brain imaging, evaluation of 18Fandrogen receptor ligands in radiographie defects, detection of, 1636 1256 baboons, 1009 patient stratification by cardiopulmonary status, for bone pain treatment, 881 human dosimetry V/Q scan, 570 for bone scintigraphy, 1903 diagnostic doses of "'In-CYT-356 in prostate procedure guidelines for lung scintigraphy, 1906 for general imaging procedures cancer patients, 1583 pulmonary angiograms with and without lung nuclear medicine computer systems, 2087 marrow suppression as result of "Sr, scans, comparison of lung scan criteria scintillation cameras, 2087 DIC, 401(le) and, 118P(ab) SPECT imaging, 2089 metastatic venlilatory imaging, Tc pertechnegas and"'Xe for imaging with radiopharmaceuticals, 2092 patterns determined by "'In CYT356 comparison. 116P(ab) for lung scintigraphy, 1906 immunoscintigraphy, 10P(ab) Pulmonary embolus. pleuraleffusionand for thyroid scintigraphy, 1264 suramin therapy,evaluation with FDG- ventilation/perfusion scan for thyroid uptake measurement, 1266 PET, 267P(ab) interpretation, 1310 Prefrontal cortex, hypoperfusionin psychiatric pain relief of bone metastasis with '"Re- Pulmonary hypertension, myocardialimaging illness, SPECT,410 etidronate, pain assessment diary, 1511 with 121I-MIBG,right heart sympathetic Pregnancy outcome, exposureto "'Iin thyroid recurrent, monoclonal antibody imaging for neuronal function, 1343 cancer patients, 606 staging of, 10P(ab) Pulmonary leak index, noninvasive Pregnancy-relatedcomplications, radionuclide sigma receptor binding sites in tumor differentiation of hydrostatic pulmonary captopril renography, renal artery cells, 205P(ab) edema from ARDS, "Ga, 1316 aneurysms, 1368 simultaneous dual energy SPECT imaging Pulmonary scintiscans Preoperative chemotherapy of, 217P(ab) diagnosis of pulmonary embolism, patient assessment of effect on osteosarcoma using â„¢T1 staging with 18FFDHT, 87P(ab) stratification by cardiopulmonary scintigraphy, 1444 staging with monoclonal antibody scan, 11N(4) status, 570 evaluation of, using FDG-PET studies in breast Prostate-specificantigen, changinglevels, serial positive predictive value of triple-matched cancer patients, 931 bone scans, prostate cancer defects, detection of acute pulmonary Presynaptic neuron, use of "C-KFI5372in patients, 296P(ab) embolism, 1636 detecting degeneration of, adenosine A| Prostatectomy, transurethral, renal functional Pulmonary tuberculosis,detectionfollow-up, receptor ligand, 1203 changes after, Tc EC diagnosis Tc-MIBI scintigraphy, 233 Pretargeting, infectionimagingwithstreptavidin of, 289P(ab) Pure photosensitive epilepsy, brain SPECT and '"In-biotin, osteomyelitis, 1655 Prosthetic vascular graft infection, diagnosis Pyelonephritis Primary hyperparathyroidism with avidin/"'In-biotin imaging, 55 comparison of planar (pinhole) and SPECT comparison of FDG-PET and sestamibi- Protein, labelingwithcyclopentadienyltricarbonyl imaging in piglets, ""Tc-DMSA, 1731

Subject Index â€¢1996 2151 pediatrie, cortical lesions in, """Te MAG3 and SPECT/CT-guided biopsy after, 158P(ab) characterization, 78P(ab) "Te GH comparisonin, 287P(ab) organ S values for individual patients, 232P(ab) anti-CEA murine MN-14 F(ab)2 as potential Pyridinethiols, co-ligand forTc-labeled sequential pulmonary effects of, detection by agent for. tumor targeting, 169P(ab) hydrazinonicotinamide conjugated TcDTPA radioaerosol inhalation lung B-cell lymphoma, enhanced retention of peptides, l52P(ab) scintigraphy, 234P(ab) radionuclides by, "Y-labeled monoclonal Pyrimidinethiols, co-ligand for"*"Tc-labeled studies of "Cu TETA octreotide, tumor-bearing antibody, 151P(ab) hydrazinonicotinamide conjugated rats, 128P(ab) bifunctional chelating agent for, 167P(ab) peptides, 152P(ab) unsealed source, for solid tumors, 235P(ab) bispecific antibodies and n'I-labeled Radiation treatment planning, squamous head bivalenthaptens, BCL1 and neck cancer, immuno-SPECT, Tc- lymphoma, 129P(ab) labeled monoclonal antibodies, 1942 bone marrow dosimetry, regional Radioactive waste, possible low-level site in variability, 695 Quality assessment, interlaboratory program, Texas, 33N(5) CEA-expressing cancers '"I-labeled anti-CEA monoclonal Dept. of Veterans Affairs, Nuclear Radioaerosol Medicine Service, 306P(ab) Te DTPA inhalation lung scintigraphy, IgG, 168P(ab) tumor dosimetry with '"I-labeled CEA and Quality control, improved flood detection of pulmonary effects of sourceuniformity, chelation of '"In, radiation therapy, 234P(ab) anti-mucin monoclonal liquid-filled plexiglass tank, 21 IP(ab) Te DTPA lung scintigraphy antibodies, 231 P(ab) CEA-producing cancers, '"I-labeled anti-CEA Quantification acute inhalation injury in fire benzodiazepine receptor concentration and FMZ victims, 294P(ab) monoclonal antibody, 168P(ab) colon cancer, '"I-labeled MN-14 IgG anti-CEA affinity, partial saturation method, PET clearance, systemic lupus measurement in pons, 5 erythematosus, 295P(ab) MAb, 169P(ab) biodistribution of '"In-pentetreotide, endocrine criteria for diagnosis of pulmonary determination of radionuclide uptake, single tumors and lymphoma, 916 embolism, 295P(ab) projection method for, 209P(ab) dosimetrie evaluation of MCu in "Cu-2IT-BAT- comparison of planar and SPECT normal data Radiochemical yield, optimum pH for, from files, OTT1,Tc-sestamibi, Tc- stannylated precursors, 187P(ab) Lym-1, 146 tetrofosmin, and Tc-furifosmin, 1783 Radiocontaminant, assay calculation of ( u and dosimetrie potential, minimal residual disease, reappraisal of quantitative esophageal "Cu, ionization chamber dose radiolabeled antibodies, 44P(ab) generator produced ""Y,chemical form, scintigraphy, ROC analyses, 1799 calibrator, 302 Quantitation Radioimmunoassay clinically useful Metz intrinsic attenuation correction method, thyroid hormone binding ratio, free thyroxine radioconjugates, 195P(ab) intraperitoneal administration of '"Lu-CC49, performance in parameter estimation estimate and, 144P(ab) tasks. ISP(ab) VI-V3 specific antimyosin antibody, genetically ovarian cancer, 1491 nonlinear (asks, performance for, at low engineered single chain Fv of, loss of immunoreactivity during labeling, SNR. 124P(ab) mammalian system, l44P(ab) prevention of radiolysis of monoclonal parameter estimation tasks, evaluation of Radioimmunoconjugates. monoclonal antibody antibodies, 1384 CC49 labeled with "Sc, pre-clinical SPECT scatter compensation LYM-1 therapy, B-lymphocytic methods, 29P(ab) evaluation, 150P(ab) malignancies, 170P(ab) protein synthesis rate determination, PET Radioimmunodetection, therapy, CEA- micro and occult mÃ©tastases,SCID mouse without arterial sampling, 225P(ab) expressing tumors, 9P(ab) model, 44P(ab) ovarian cancer, '"I-labeled MN-14 IgG anti- regional radioactivity, spatial variability of, PET Radioimmunoscintigraphy brain scans, 222P(ab) CEA-scan, diagnosis and staging of breast CEA MAb, 168P(ab) single projection method, determination of cancer, 238P(ab) patient-specific dosimetry '"ln/"Â°Y-labeledmonoclonal radionuclide uptake, 209P(ab) NHS-BAT ester for antibody conjugation and time-activity curve slope, as a diagnostic Tc labeling, 362 antibodyCC49, 90P(ab) preparation of ""Re-MAGS-MAb conjugates, guide, 206P(ab) quantitative SPECT imaging and 3D-DFT Quantitative imaging. ';

2152 The Journal of Nuclear Medicine goiters, 2072 inhaled beclomelhasone, deposition of, Tc iterative prognostic value of thyroglobulin after labeling method for, 142P(ab) 180 degree data, 217P(ab) thyroidectomy, thyroid cancer, 1962 positron, radiation absorbed dose estimates 3D depth-dependent point response uptake enhanced by tumuricidal cytokines in for, 228P(ab) in. 153P(ab) cultured thyroid cancer cells, 646 prevalence of adverse reactions. 185 rapid 3D projection in, using Gaussian Radioisotope dilution technique, *""Tc-Q12and prior administration, effects on Schilling diffusion, 63P(ab) '"Tl extraction and retention, effects of test, l62P(ab) valid backprojection matrices, 206P(ab) ouabain, 752 rapid preparation method for Tc list-mode likelihood, 124P(ab) Radiolabeled aerosols, deposition and regional bicisate, 142P(ab) local statistics of PET, analytic computation and ventilation. Tc-DTPA, 239 receptor-binding, sentinel node sample estimation, 155P(ab) Radiolabeled antibody fragments, improved imaging. 118P(ab) maximum-likelihood image, from list-mode prospects for cancer therapy, Radiopharmacokinetic modeling, index of data, l24P(ab) peptides, 834(ed) hepatic function, Tc-NGA. receiver ML-EM algorithm, retracted-SPETA PET Radiolabeled biotin. imaging osteomyelitis, operating characteristics, 160 data, 225P(ab) streptavidin, 1655 Radiosurgery. stereotactic. hyperacute changesin MRI-constrained PET, newly- Radioligand binding, in vitro comparison with in tumor FDG uptake after, 257P(ab) developed, 223P(ab) vivo receptors, PET. 1275 Radiotherapy, evaluation of therapeutic effects multiple energy, MLEM use in, Radiolysis on VX2 liver tumor. FDG-PET, 296 SPECT. 17IP(ab) decomposition, "YDOTA-biolin. l66P(ab) Radiotoxicity, '"I-labeled ordered subset, elliptical orbits and, effects on prevention of, protection of monoclonal oligodeoxyribonucleotides, mammalian SPECT 3D spatial resolution. 63P(ab) antibodies during labeling, 1384 cells, 228P(ab) parallel tool for PET data, penalized weighted Radionuclide angiography. simultaneous Raise-up test, with Tc-HMPAO brain SPECT to least square algorithms in, l54P(ab) perfusion tomography during study cerebral perfusion in orthostatic phantom experiments, with rotating slant-hole dobutamine stress, 1306 patients. 1 SPECT camera, l20P(ab) Radionuclide clearance, formula to measure Rapid thyroidal iodine-131 turnover. spillover artifacts in PET, additive models and renal function in children and adults, hyperthyroidism, 1815 seeded region growth, 224P(ab) TC-MAG3, 588 Rat heart, kinetics of 18F-PFBG, catecholamine truncated projection data, L-shaped dual Radionuclide gastric emptying, lag phase uptake, 2011 detector system, myocardial quantification, time-activity curves, first rCBF, imaging during focal seizure activity, SPECT, 21OP(ab) appearance of bowel activity, modified HMPAO, 661 Recovery correction, suppression of spillover due power exponential, 1639 Reaction volume to limited resolution, myocardial Radionuclide imaging compartments, brain fluid spaces, I26(ed) PET. 767 :"T1 and Tc-letrofosmin uptake comparison, in vivo ligand-receptor interaction modeling, Recurrent tumor, comparison of "F-FDG and cardiac low flow state and systolic lipophilicity, 118 "C-METPET. 1472 dysfunction. 1398 Receiver operating characteristic analysis, Red blood cells investigations of breast tumors, '"F-FDG and effect on lesion detection, hepatic Tc-labeled, label stability over time. 199P(ab) SPECT, 615 SPECT, 30P(ab) Ultratag kit, splitting of, use in cardiac first pass morphine-augmentation in gallbladder reappraisal of quantitative esophageal studies, 83P(ab) nonvisualization. pericholecystic rim scintigraphy, motility disorders, 1799 Reference tissue model, PET receptor sign, 267 Receiver operating characteristics studies, 224P(ab) Radionuclide studies, monitoring of graft and kinetric analysis of Tc-NGA, detection of Region of interest native liver functions post hepatocellular disease, 160 nonstationary resolution recovery for, transplantation, 847 use of Tc-HMPAO SPECT and texture SPECT. 153P(ab) Radionuclide therapy analysis to detect decompression illness rough edges, approach to variance risk versus benefits in cancer therapy, '"I-MIBG in divers, 1154 reduction, l55P(ab) dosimetry, 1058 Receptor binding. Tc-labeled peptides, Regional cerebral blood flow use of *"Y-glass microspheres for liver somatostatin, 1016 comparison of Tc-HMPAO and '"Xe by malignancy, 958 Receptor-binding radiopharmaceuticals. SPECT, acetazolamide. 1735 Radionuclide venography. diagnosis and diagnostic performance in hepatocellular permeability-surface model, nonlinear functional assessment in superior vena disease, 160 correction of brain perfusion, cava syndrome, jugular venous Receptor-mediated endocytosis, SPECT, 1237 reflux, 1460 radiopharmaceutical targeting, "Ga-DF- predictive capacity of Tc-HMPAO SPECT, 12 Radionuclides Folate, 1003 months after mild head injury, 1605 combination therapy, bone mÃ©tastases,32P(ab) Receptors, free ligand concentration SPECT and MRI evaluation of posterior compartmental model for lung clearance, heterogeneity, reaction volume, 118 circulation in patients with moyamoya pertechnegas. 2066 Reconstruction disease. 1613 medical use discussed with SNM and ACNP 3D iterative filtered backprojection algorithm Regional cerebral metabolic rates of glucose. presidents, NRC chairman. 29N(5) for. SPECT with fan beam routine estimation. FDG-PET, 147P(ab) Regional hematocrit, measurement with ( 'u unauthorized use, new NRC rule, 15N(6) collimation, 214P(ab) Radiopharmaceutical synthesis, simple accelerated HSA-DTC, assessment of cerebral preparation of l-"C-acetate, 341 3D SPECT. dual matrix ordered circulation, 1080 Radiopharmaceutical therapy, pleuroperitoneal subsets. 62P(ab) Regional skeletal metabolism, sex specific and migration of i:P-chromic phosphate, SPECT, fast line search strategy, 62P(ab) age-related changes in bone metabolism, ovarian cancer, 636 Bayesian image, cardiac PET. 130P(ab) Tc-HMDP, 815 Radiopharmaceuticals brain SPECT, reconstruction of brain SPECT Regional ventricular function, correlation of 20-minute bacterial endotoxin test for, 305P(ab) Poisson noise, 218P(ab) MITIreverse redistribution with coronary chelating ligand in "*"Tc.solid phase chemistry decomposition of images, pinhole imaging lesion, wall motion abnormality, and method for removal of excess, 189P(ab) system, 63P(ab) tissue viability, 735 comparison of four, imaging of breast fast iterative algorithms, attenuation correction Renal artery aneurysms, radionuclide captopril cancer, 75P(ab) of cardiac SPECT, 63P(ab) renography, postpartum, 1368 distribution localization, high resolution fast iterative PET, performance Renal artery stenosis miniaturized gamma camera use evaluation. l54P(ab) ACE-inhibilion in, captopril renography in, 303P(ab) FBP and OS-EM comparison, signal-to-noise after, 46P(ab) effect of administration on Schilling test ratio in neurologic FDG-PET, 220P(ab) renographic characteristics in renovascular performance, 1995 disease. 594

Subject Index â€¢1996 2153 renography in diagnosis, aspirin versus captopril Reproducibility. myocardial edge detection for with high doses of "I, 246P(ab) renography, 289P(ab) gated-pool scintigraphy, 685 quantitative scintigraphies. patients with reflux Renal cell carcinoma Reproducibility studies esophagitis, 245P(ab) evaluation, whole-body FDG-PET. 14IP(ab) dopamine D2 receptor binding, with I!1IIBF Salivary glands, :'"TIimaging versus "Ga radioimmunotargeting, '"I-labeled chimeric SPECT. 281P(ab) imaging,-"'Te. 1819 G250 monoclonal antibody. 169P(ab) regional brain metabolic responses to Samarium-153 EDTMP. as palliative agent, bone Renal circulation, exercise renography in lorazepam, 76P(ab) mÃ©tastasespatients, 32P(ab) renal uptake of '""'Te MAG3 semiautomated untreated hypertensive patients, 838 Sarcoidosis Renal clearance and manual regions of interest, 293P(ab) lung and gastric uptake in bone scintigraphy, accuracy of measurements using precordial Research Tc-MDP uptake, hypercalcemia, 1530 gamma camera curve, Tc-MAG3, 1281 and education as investment in the Panda and Lambda signs om, 4P(ab) estimation, modified counlingmethod for future, I7N(7) Sarcoma estimation of Te MAG3. 291P(ab) future plans in nuclear medicine comparison of "F-FDG-PET and Tc-MlBI radionuclides in nephrourology. Committee on research. 16N(2) SPECT, diagnostic accuracy, 1476 Renal Clearance report, 1883 Residual disease. 20ITI and 99mTc-sestamibi FDG-PET evaluation, response to hyperthermic Renal cyst, febrile patient with polycystic kidney SPECT, nasopharyngeal carcinoma pre- isolated limb perfusion, 984 and liver disease, scintigraphic and post-therapy changes, 1956 monitoring neoadjuvant therapy response, "F- findings, 2062 Restenosis, detection after successful PTCA, FDG-PET. 1438 Renal failure, contrast-induced nephroloxicity, Tc-sestamibi SPECT, 1300 tumor glucose metabolic rate anddifferenlial role of radionuclide renal scan, vascular Retention index, differential diagnosis of uptake ratio, FDG use in, 140P(ab) occlusion versus ATN, 1828 loxoplasmosis and CNS lymphoma in Sarcoplasmic reticulum. calcium ATPase, Renal function patients with AIDS, -""TLSPECT, 1150 inhibition in cardiomyopathy, 144P(ab) biokinetics of Tc-DMSA, pediatrics, 1331 Retinal mÃ©tastases,somatostatin-receptor Scaled subprofile model, cerebral glucose noninvasive quantification using ""MTc-MAG3 scintigraphy, bronchial carcinoid, 1537 metabolism in HIV-1 seropositive and gamma camera in children. 71 Reverse redistribution, indications for thallium subjects, AIDS dementia complex, 1133 Renal hypertension, exercise renography in reinjection, 742(ed) Scandium-47, monoclonal antibody CC49 labeled untreated subjects, 838 Rhenium with, pre-clinical evaluation, 150P(ab) Renal imaging. """Tc-DMSASPECT, cortical detection with microelectrode sensors, 205P(ab) Scatter components scintigraphy in normal volunteers, 1346 peptide hormone, structure and Monte Carlo-based analysis of PET Renal plasma flow, gamma camera renography in function, 96P(ab) contributions, 2024 children, 71 Rhenium complexes, serotonin receptor binding, subtraction-restoration in high-resolution PET, Renal scintigraphy, baseline and after caplopril improvement of receptor selectivity and nonstationary, 2040 administration. Banter's syndrome, 1688 blood-brain transfer, 16P(ab) Scatter correction Renal tubular re-uptake, reduction with sodium Rhenium-186, rapid separation from Tungsten Monte Carlo-based calculations, PET, 2024 malÃ©ateor lysine administration, '"In- target, 196P(ab) scintillation camera imaging of 1311, window- DTPA-octreotide, 1388 Rhenium-186-HEDP based and spectrum-fitting Renal uptake reduction, effects of amino acid dose escalation in breast cancer patients, bone techniques, 2030 infusion on monoclonal antibody mÃ©tastases,244 subtraction-restoration in high-resolution PET, fragments, 829 efficacy in prostate cancer patients with nonstationary, 2040 Renogram. contrast-induced nephrotoxicity, metastatic bone pain, pain assessment Scatter correction techniques vascular occlusion versus ATN, 1828 diary, 1511 3D iterative, nonuniform attenuating media, Renography palliation of metastatic bone pain, 38 SPECT, 216P(ab) Tc EC. after transurethral Rhenium-186-labeled monoclonal antibody, 3D PET without, dynamic FDOPA scans prostatectomy, 289P(ab) clinical radioimmunotherapy. head and for, 73P(ab) aspirin versus captopril. diagnosis of renal neck cancer, 352 attenuation correction and, extra-cardiac activity artery stenosis. 289P(ab) Rhenium-188 on myocardialperfusion captopril, ACE-inhibition in renovascular direct labeling of proteins with, role of TIN- SPECT, 214P(ab) hypertension, 46P(ab) 117m in, l95P(ab) attenuation correction combined with characteristics in renovascular disease, RC-160 somatostatin analog labeled with, "Tl cardiac SPECT, 30P(ab) stenosis, 594 regional tumor radiotherapy, 236P(ab) simultaneous transmission/emission SPECT detection of renovascular hypertension, ACE Rhodium-105 system, 209P(ab) inhibition, consensus report, 1876 tetrathiamacrocycle conjugate, bombesin dual photopeak window method, digital diuresis analogue, 61P(ab) stationary dedicated brain 2-point postural drainage with, assessment of tetrathioether ligands with, 165P(ab) camera, 77P(ab) hydronephrosis, 46P(ab) Right ventricular hypertrophy, evaluation of effect on lesion detection, hepatic interpretation of, using feed forward neural sympathetic nervous system, 1!'I-M1BG SPECT, 30P(ab) network. **"Tc-MAG3 captopril cardiac imaging in pulmonary energy spectral deconvolution use in, Compton- investigations. 1649 hypertension, 1343 scatter correction, 171P(ab) suitability for deconvolution analysis, 403(le) ROC analysis. """TeMIB1 SPECT, coronary estimation method, fan-beam SPECT, 30P(ab) Renovascluar hypertension, baseline and artery disease, 160P(ab) invertibility and noise properties, multiple postcaptopril renal blood flow Rotor syndrome, kinetic cholescintigraphy in energy window projection data, measurements, essential evaluation of, 247P(ab) SPECT, 7P(ab) hypertension, 1652 Rubidium-82, simplified PET protocol for limitations of, 171P(ab) Renovascular hypertension determining coronary flow and flow models for high-resolution PET, 2046 ACE inhibitor renography, consensus reserve, "N-ammonia, 1701 outside the field-of-view, infant PET report, 1876 scans, 226P(ab) detection and therapy, meta-analysis of costs, shared charge collection effects, Complon sensitivities, specificities, 171 camera performance, 170P(ab) radionuclide captropril renography. postpartum signal and noise tradeoffs with renal artery aneurysms, 1368 S-values, revised adult head and brain model for 3D PET "O water brain activation Reperfusion, detection of """Tc-nitroimidazolein dosimetry, 1226 studies, 227P(ab) myocardial tissue, 761 Salivary gland singles-based PVI transmission Reperfusion injury, changes in function and absorbed dose of radioiodine, thyroid imaging, 172P(ab) regional glucose uptake, stunned porcine patients, l02P(ab) SPECT methods, evaluation by parameter myocardium, PET, 2006 function, parenchyma! damage after treatment estimation tasks, 29P(ab)

2154 The Journalof NuclearMedicine Scatter subtraction, '"In planarand SPECT background for, 78P(ab) Tc colloidal albumin, imaging, quadruple energy window use to diagnose and localize infected cysts, lymphoscintigraphy, 259P(ab) algorithm use in, 207P(ab) patient with polycystic kidney and liver early stage melanoma lymphoscintigraphy, SCH 23390, binding of dopamine Dl and D2 disease and hip prostheses, 2062 Tc sulfur colloid, 307P(ab) receptor radioligands, 203P(ab) using a radiolabeled somatostatin analog lymphoscintigraphy for lymphatic mapping in Schilling test compared with conventional imaging in cutaneous melanoma, 972 effect of radiopharmaceutical administration, medullary thyroid carcinoma, 912 receptor-binding radiopharmaceuticals analysis and recommendations, 1995 ventilation, '"Xe, tympanum and paranasal for, 118P(ab) performance, prior radiopharmaceutical sinuses, 4P(ab) Septal metabolic mismatch, left bundle branch administration on, 162P(ab) visualization of SP receptor-positive organs, block, 1918(le) Schizophrenia '"In-DTPA-Arg1, SP, 108 Septic arthritis, extensive photopenic dopamine transporter in, SPECT measurement whole-body osteomyelitis, bone scintigraphy, 1676 of, 33P(ab) differentiated thyroid carcinoma, follow-up Serotonin functional frontal eye field impairment, Tc evaluation, 446 "C MDL 100907 as a radiotracer, kinetic ECD SPECT study, 283P(ab) Scintillation camera, small, with analysis, 145P(ab) impaired Wisconsin card sorting, PET studies of photodiodereadout. imaging of breast diagnosis of normonally active carcinoid tumor, aging, 79P(ab) tumors, 52P(ab) paragangliomas, 270 Schwannoma, neuropeptide imaging of, 1272(le) energy-based scatter corrections, window-based dopamine interaction, |;'I ÃŸ-CITbinding Scintigraphy and spectrum-fitting techniques, instriatum with clomipramine, 66P(ab) '"In WBC, fever of unknown origin, 161P(ab) 1311,2030 release, "O water, time course of regional brain Tc sestamibi, detection of parathyroid Scintimammography activation, PET imaging of, 123P(ab) pathologyin Tc MDP(ab) synthesis hyperparathyroidism, 158P(ab) diagnostic accuracy in suspected breast brain, measured by PET and "C-a- achalasia, botulinum toxin effects, 57P(ab) cancer, 155P(ab) MT, 113P(ab) antral, gastric emptying, effects of gastric acid mammographie microcalcifications without reduction in plasma tryptophan and, males suppressant drugs on, 57P(ab) mass, 156P(ab) and females, 284P(ab) bone Tc MIBI, planning and monitoring treatment synthesis rate, estimation by "C-ot-methyl- diagnosis of prosthetic hip loosening, with forbreast cancer, 156P(ab) tryptophan kinetics, brain, 145P(ab) radiography, 62 Tc sestamibi Serotonin receptors effect of bisphosphonate, 401(le) histopathologic correlation in detection of "C MDL 100, 907 imaging, PET, 112P(ab) gallium bone scintigraphy, 193(le) breast cancer, 75P(ab) Tc-labeled, as imaging agents, 190P(ab) colon transit, subtypes of prolonged colonie palpable and nonpalpable breast antagonists for, 204P(ab) transit, 247P(ab) tumors, 259P(ab) binding studies, human brain, autoradiography direct puncture, flow characteristics of soft- Tc tetrofosmin, diagnosis of breast cancer and and PET in monkey brain, 112P(ab) tissue vascular anomalies, 183P(ab) lymph node mÃ©tastases,156P(ab) binding technetium and rhenium complexes, hepatobiliary accuracy, patient age and lesion histology improvement of receptor selectivity and after orthotopic liver transplant, 302P(ab) effects on, 254P(ab) blood-brain transfer, l6P(ab) comparison with """Te PMT and OSA, liver collimator design, imaging geometry occupancy cirrhosis with jaundice, 244P(ab) and, 78P(ab) after single dose of "C MDL histopathology and immunohistochemical cost-effectiveness of, breast cancer in dense 100,907, 112P(ab) correlation, abnormal parathyroid breasts after negative ziprasidone treatment effects, PET analysis pathology, 159P(ab) mammogram, 269P(ab) of, 33P(ab) homograft, pediatrie limb salvage detection of primary breast cancer, Tc- quantitative imaging, '"F altanserin use surgery, 286P(ab) MIBI, 626 in, 109P(ab) inhalation, '-''I interferon gamma in FDG-PET and, diagnosis of breast selective imaging, PET, "C MDL 100907 treatment, 5P(ab) cancer, 265P(ab) for, 108P(ab) leukocyte planar with sestamibi, SPECT improvement on Serotonin system, radioligand for, radiosymhesis disease activity in inflammatory bowel accuracy of, 252P(ab) binding affinity and biodistribution disease, 400(le) semiquantitative, or contrast-enhanced MRI, of, 40P(ab) lung, exercise, quantitative analysis of V/Q further evaluation ofindeterminate Serotonin transporters ratio, 296P(ab) mammograms, 156P(ab) fenfluramine and MDMA-induced loss of, PET lymphoma small scintillation camera, with photodiode visualization of, H2P(ab) comparison of "Ga and -""'TI,tumor grade, readout, imaging of breast impulse response function, kinetic model and, type, sensitivity of uptake, 46 tumors, 52P(ab) "CMcN5652, 33P(ab) MAG3 diuretic, acute renal Scleroderma, acetylcholine inhibition in, measures of in vivo binding to, INQUIP obstruction, 289P(ab) renalfunctional response to, 290P(ab) SPECT, 1207 MIBG Sebaceous cyst, false-positive '"I whole-body SPECT study using l;'I, 186P(ab) childhood tumors, 288P(ab) scans in patients with thyroid cancer, Serotonin-2 receptors, PET estimation of binding imaging in silent myocardial ischemia, cholecystitis, 1690 potential, F-setoperone, 95 evaluation of sympathetic Seizures, quantification of normal percent Shunt malfunction, radionuclide shuntogram, innervation, 712 variation, cerebral blood flow, 305P(ab) hydrocephalus, 406 MIDI, prognosis in pediatrie Semiconductor detectors Shutogram, reliability in management of lymphoma, 139P(ab) improvement of SPECT resolution, hydrocÃ©phaliepatients, 406 noninvasive detection of early tumor FASTSPECT concept, 301P(ab) Sigma receptors development, from pseudotumor into multiplexer readout for high-resolution binding sites lymphoma, "Ga-citrate, 1524 imaging, 53P(ab) biopsied solid breast tumors, 267P(ab) per-rectal portal Sensitivity analysis, cost-effectiveness of FDG- prostate tumor cells, 205P(ab) hepatic blood flow distribution, mesenteric PET in non-small-cell lung cancer probes, radioiodinated vein mapping, ':'I IMP scintigraphy to staging and management, decision tree arylethylenediamines, 7P(ab) detect portal streamlining, 51 analysis, 1428 Sigma-2 receptors, as biomarkers, breast perfusion, implantation of coronary Sentinel lymph nodes, drainage to triangular cancer, 87P(ab) stent, 126P(ab) intermuscular space nodes, melanoma on Signal augmentation, antibody-dependent in somatostatin receptor, staging of the back, 964 tumor xenografts, biolinylated melanoma, 138P(ab) Sentinel node monoclonal antibody, avidin, surgical beta ray camera, gamma-ray identification slreptavidin, 343

Subject Index â€¢1996 2155 Signal-to-noise ratio I!1IIBZM and, aging effects on amphetamine- striatal effects of antipsychotic agent effect of partition coefficient, permeability induced dopamine release, 33P(ab) RWJ-37796, 11 surface product, and radioisotope on, '-'I IPT dopamine transporter, Parkinson's Alzheimer's disease, automated neural PET, 223P(ab) disease, 273P(ab) networks, 195 tomographic region of interest, approach to |:'I IPT dosimelry, imaging dopamine astrocyloma visualized by Tc-ECD variance reduction, l55P(ab) transporters, 151 SPECT, 273 Silent myocardial ischemia, evaluationsof |;1I-IPTimaging of CNS dopamine transporters, dipyridamole stress in evaluation of cerebral sympathetic innervation. |:'I-MIBG, 712 effects of aging on striatal uptake blood flow reserve, carotid artery Simultaneous dual-isotope imaging, influenceof values, 1965 stenosis. 1595 '"'I-MIBG imaging of neuroblastoma, delayed downscatter, :"TI and Tc-PYP favorable review from neurology SPECT, 781 48-hour scans. 1464 panel, I4N(7) Single-blood sample method, estimating IJ'IQNB, imaging of muscarinic identification of epileptogenic foci in glomerular filtration rate, feasibility of receptors, 143P(ab) children, ictal and interictal studies with using adult technique in children, 1805 i:'I IPT measurement, dopamine transporter, Tc-bicisate, 1101 Single-chain Fv antibody fragments, nonhuman primates, 66P(ab) imaging of dopamine transporters, I!'I-B- radiolabeling with """Tcfor diagnostic "'Xe, motor task activation of cerebral CIT, 1129 imaging, 868 cortex, 273P(ab) limbic, paralimbic, and prefrontal Single-photon emission computed tomography 180degree data, use of iterative reconstruction hypoperlusion in depressive patients, 410 (SPECT) in, 217P(ab) measurement of dopamine transporters, '"I-B- "F-FDG and SPECT, investigations of breast -""Tl CIT, 222 tumors, 615 childhood brain tumors, 270P(ab) Slurge-Webersyndrome, "MTc-HMPAO Tc, brain, acquisition time in the performance interpretation, physician training level effects SPECT, 81 of, 273P(ab) on, 179P(ab) vascular response in frontal area of patients """Tc-DMSAscinligraphy, detection of lymphoma and infectious inlracranial lesions, with orlhostatic hypotension, I pyelonephritis in piglets, pinhole AIDS patient, 276P(ab) Bremsstrahlung magnification, 1731 â€¢'"'TIchloride or 99mTc sestamibi, inlracranial 3D quantitative dosimetry of colloidal Te DMSA uptake, kidneys, assessment of lesions in AIDS, 277P(ab) phosphorus-32, 90P(ab) reproducibilily, 290P(ab) J"T1imaging of astrocytoma, 273 cardiac TcECD MTIrest-redistribution, revascularization after attenuation correction of, short AsF brain images, mid-sagittal plane, 8P(ab) CAD, 178P(ab) transmission CT for, 2IOP(ab) localization of seizure foci, extratemporal 3D spatial resolution, ordered subset compensation for attenuation and 2D detector epilepsy, IOOP(ab) reconstruction effects. 63P(ab) response, ISP(ab) study of cerebral perfusion reserve. 88P(ab) accelerated image reconstruction compensation of attenuation map study of language processing, 280P(ab) dual matrix ordered subsets, 62P(ab) errors, 215P(ab) Tc-HMPAO fast line search strategy, 62P(ab) defect size, location, and contrast assessment of neurological deficits during accurate attenuation correction, without effects, 2IOP(ab) balloon test occlusion, 551 transmission measurements, 18P(ab) fan-beam, attenuation correction in, 18P(ab) detection of decompression illness in sports adenosine sestamibi. implications, fixed and kinetic parameters, input function shape and divers, 1154 reversible defects, prior MI, 181P(ab) image acquisition. 8P(ab) Tc HMPAO appropriateness of functional brain imaging, scatter and iterative attenuation correction brain, systemic lupus erylhematosus ethical clinical practice, 1256 in, 210P(ab) patients, 163P(ab) assessment of results, coronary stents, 126P(ab) CBF, cerebral dysautoregulation in chronic postconcussion syndrome, 278P(ab) attenuation artifacts, wrap-around lung effect in autonomie failure, 277P(ab) specific regions of left hemispheric cardiac imaging, 1891 cerebral arteriospasm, after subarachnoid dysfunction, 165P(ab) automated 3D registration algorithm, hemorrhage, 12P(ab) Tc-HMPAO, predictive capacity of scan 12 brain, 98P(ab) cerebral blood flow, dementias, 79P(ab) months after mild head injury, 1605 automated interstudy image, registration cerebrovascular stress tests, parenchymal versus """TeMAG3, evaluation of renal method, comparison of data sets with vascular cerebral disease, 88P(ab) parenchyma, 23P(ab) PET, 137 collimator design, influence on Tc-MIBI and 18F-FDG-PET,comparison of automated search for significant elements quantification, 1832 diagnostic accuracy in musculoskeletal in, 209P(ab) combination with FADS for detection of sarcoma, 1476 bone, 99mTc MDP,diagnosis of lumbar spine abnormal parathyroid glands, Tc- Tc-seslamibi, assessment of osseous tumor lesions, 127P(ab) sestamibi, 1773 mÃ©tastases,1526 bone comparative methods for quantifying thyroid Tc-sestamibi. bile reflux during myocardial mandibular invasion, squamous-cell volume, planar imaging, 1421 perfusion imaging, identifying carcinoma, 42 comparative nigrostriatal dopaminergic imaging noncardiac cause of chest pain, 1285 brain in Parkinson's disease, PET, 1760 Tc sestamibi Te ECD, patients with acute stroke, l3P(ab) comparison of Tc-HMPAO and Tc-ECD cardiac- 3D stereotactic surface projection, 215P(ab) images, 1749 reconstructions for. 81P(ab) accurate treatment of Poisson noise, 218P(ab) comparison with PET, myocardial uptake of "F- scatter, attenuation and resolution. 81P(ab) after traumatic injury, 275P(ab) FDG, dyssynergic myocardium, 1631 supine vs right lateral imaging, 48P(ab) automatic registration and intensity scaling complex and unresolved issues related to ""Tc sestamibi and 20ITI, quantifying perfusion in, 213P(ab) myocardial viability assessment, 794 defects, 178P(ab) comparison with MRI, brain tumor Compton camera performance, shared charge Tc with dipyridamole, early and delayed patients, 272P(ab) collection effects, 170P(ab) imaging comparison, 180P(ab) perfusion defect after synangiosis Compton-scatter correction in, energy spectral "'In-DTPA octreotide uptake, measurement in surgery,274P(ab) deconvolution, 171P(ab) normal and abnormal pituitary quantitative, transmission CT image quality concurrent changes in left ventricular function glands, 1449 for, 212P(ab) and volumes, perfusion tomography and 'â€¢''I-BM1PPmetabolism and kinetics in canine semi-quantitative analysis, pons as reference radionuclide angiography during myocardium, 757 point, 273P(ab) dobutamine stress, 1306 '-"IbCIT, dopamine transporter during cocaine use of 3D Kaiman filter for continuous step-and-shoot versus step-and-shoot abstinence, 44P(ab) evaluation, 208P(ab) acquisition, 2037 I!'I FP-CIT, striata! signal in Parkinson's brain depth-dependent response, recursive blur disease, l34P(ab) i:'I IBZM infusion, regional brain activity, models for, 153P(ab)

2156 The Journalof Nuclear Medicine detection of ventilatory abnormalities, improved accuracy of somatostatin receptor superimposed osteomyelitis, diagnostic distribution of "'Xe washout, 807 scintigraphy, abdominal carcinoid difficulties, 999 diagnosing and monitoring pediatrie acute tumors, 1452 quantitative improved method for radioiodination of 'â€¢'!- pyelonephritis, 1349 diagnostic accuracy, anti-ischemic diamox IQNB, 2021 medications in. 58P(ab) middle cerebral artery stenosis, 274P(ab) improvement on plantar scimimammography, errors due to partial volume effects, 215P(ab) surgical outcome, moyamoya disease in breast cancer. 252P(ab) iodine contrast media effects on transmission children, 89P(ab) inferior wall attenuation, scar, 81P(ab) data, 218P(ab) unilateral carotid stenosis patients, 274P(ab) interictal brain, value in extra-temporal lobe quantitative assessment of benzodiazepine dipyridamole thallium perfusion scintigraphy, epilepsy, 27!P(ab) receptors, 374 correlation with hemodynamic iterative reconstruction of, using Gaussian radiation treatment planning in squamous head indices, 723 diffusion, 63P(ab) and neck cancer, discordant MIBI and HMPAO uptake, recurrent kinetic behavior of Tc-ECD, regional cerebral radioimmunoscintigraphy. 1942 occipital meningioma, 1183 blood flow measured by "O-water radiolabeled A| adenosine receptor antagonists discriminant value in mild Alzheimer's PET, 1600 as ligands for, 142P(ab) disease, 404(le) knee, anterior cruciate ligament tears, 297P(ab) rCBF study, post-traumatic stress dobutamine stress !'"TI and echocardiography to left ventricular hypertrophy patients, coronary disorder. 285P(ab) assess ALCAPA syndrome, 748 artery disease in, 182P(ab) regional cerebral blood flow measurement. dopamine D2 receptor imaging in pituitary line source transmission data, correcting for scatter compensation for. 276P(ab) adenomas, '2'I-epidepride, 1931 emissioncontamination, 19P(ab) regional energy spectrum, in multispectral dopamine transporter, 1!'I IPT uptake values, localization of mediastinal parathyroid images, 171P(ab) primates, 201P(ab) adenoma, """Tc-sestamibi, 1535 regional radioactivity quanlitation based dopamine transporters and receptors, localization of partial seizures, on, 232P(ab) alcoholics, 33P(ab) epilepsy, 10IP(ab) renal function, pregnancy-induced hypertension dual energy, prostate cancer, 217P(ab) measurement of dopamine synaptic effects. 290P(ab) dual-headed system, practical method for concentration, resting state, 32P(ab) renal imaging with Tc-DMSA. normal attenuation correction, 30P(ab) measurement of dopamine transporter, in volunteers, 1346 dual-isotopic imaging, influence of schizophrenia, 33P(ab) resolution, improvement of, FASTSPECT downscatter, 781 measurements of regional cerebral blood flow. concept, 301P(ab) dual-isotope, single acquisition, correction for comparisons of ""Tc-HMPAO and "'Xe, ROI activity estimation in, nonstalionary downscatter, 31P(ab) acetazolamide, 1735 resolution recovery for, 153P(ab) dynamic functional, thorax phantom MIBI biodistribution, experimental phanton scatter correction, limitations of, 171P(ab) for, 219P(ab) based on, 154P(ab) semiquantitative diamox rCBF brain, carotid dynamic, estimation, sampling rate multi-modal coregistration, using external angioplasty. 89P(ab) effects. 98P(ab) fiducial markers, 219P(ab) semiquantitative rCBF. in narcolepsy. 165P(ab) ECG-gated, assessment of left ventricular multihead, motion correction for, 214P(ab) stereotactic biopsy guided by, after radiotherapy volume, 180P(ab) multiple energy reconstructions in, 171P(ab) for glioma, 158P(ab) evaluation of Tc-ECD as investigational tool multiple energy window projection data in, stress cerebral perfusion, image subtraction in childhood epilepsy, 1106 Â¡nvertibilityof. 7P(ab) in, 276P(ab) evaluation of posterior circulation in moyamoya myocardial summing rapid acquisitions, bladder filling disease, MRI, 1613 see also Myocardial perfusion imaging artifact and. 212P(ab) fan-beam, cardiac, scatter response function comparison of viability studies, 177P(ab) thallium, risk assessment, patients with for, 30P(ab) correction of photon attenuation in, 176P(ab) submaximal exercise, 182P(ab) FDG false positives in obese male three-dimensional bone scan images after glucose, myocardial viability, 60P(ab) patients, 178P(ab) usefulness and limitations, volume-rendering functional outcome after reconstruction of truncated projection technique, 1567 revascularization, 59P(ab) data. 210P(ab) transcranial Doppler combined with, assessment lung nodules, 36P(ab) rotating planar projection views, 149P(ab) of cerebrovascular reserve, 88P(ab) myocardial viability, 60P(ab) myocardial perfusion, typical angina and normal transmission imaging, multiple line sources prediction of function recovery, after bypass angiograms. women, 306P(ab) for, 120P(ab) surgery, l76P(ab) nonuniform attenuating media for transmission measurements in. l9P(ab) versus dobutamine stress echocardiography, 3D iterative scatter compensation, 2l6P(ab) tumor imaging, improper attenuation/emission after revascularization, 59P(ab) optimal number of views in 360-degree registration on, 21 IP(ab) frontal hypoperfusion in benign exertional imaging, decreasing artifacts, 1740 tumor pretargeting and direct antibody labeling headache, """Tc-HMPAO, 1172 OS-MLEM, reducing influence of partial in uveal melanoma, quantitative gated blood-pool imaging volume effect with, l53P(ab) comparison, 967 comparison with planar gated blood-pool P-glycoprolein overexpression, chemotherapy visual interpretation, statistical image analysis studies, left ventricular ejection failure, cancer patients, 7IP(ab) with, 275P(ab) Parkinson's disease fraction, 1795 with angiography and transcranial Doppler. left ventricular ejection fraction and '-'I-IBZM binding, reduction by dopamine vasospasm, l2P(ab) volume, 97P(ab) agonists but not L-Dopa, 1112 with pinhole collimator, myocardial infarction Parkinson's disease, i:'I iodolisuride, striatal quantitative analysis of, 93P(ab) in rats, l59P(ab) sensitivity dependence on region dopamine DI receptors, 22 with somatoslatin receptor scinligraphy, definition, 149P(ab) perfusion images, proportional stereotactic atlas gastroenteropancrealic tumors, 256P(ab) gated, measurement of left ventricular ejection for, 2l7P(ab) Skeletal muscle, interpreting myocardial FDG- fraction, l79P(ab), 21IP(ab) permeability-surface model, nonlinear PET images, influence of high-resolution thyroid pinhole tomography, correction of brain perfusion, 1237 hyperglycemia, 1713 thyroid gland, 2017 PET block detector technology for, 119P(ab) Small bowel transit, effects of opioid and opioid- hippocampus, blood flow decreases with pinhole like drugs measured by scinligraphy, 818 memory loss, 285P(ab) "F, brain, Monte Carlo study, 120P(ab) Small-cell lung cancer, bispecific antibody and hyperperfusion and hypermetabolism in brain brain tumor phantoms, '"I distributions '"[-labeled bivalent hapten dosimetry, radiation necrosis, â„¢T1chloride, 1174 in, 2l2P(ab) two-step targeting, medullary thyroid imaging of benzodiazepine receptors, in detection of breast tumors. 214P(ab) cancer, 1853 alcoholism, 285P(ab) high energy slit aperalure and, 7P(ab) Small-volume disease, radioimmunolherapy with '"I-NP4F(ab')2, 1504 imaging of dopamine receptors, 1591(ed) prostate cancer with bone metastasis.

Subject Index â€¢1996 2157 Sn-117m<4+) DTPA presence of "Cu impurity, 199P(ab) measurements and, 166P(ab) absorption, stannous diphosphonates to Spectrum-fitting technique, energy-based scatter Strontium-89 hydroxyapatite, 72P(ab) corrections for scintillation images of adriamycin toxicity and, treatment of androgen- correlation of marrow suppression with marrow 1311, window-based technique, 2030 dependent prostate cancer, 32P(ab) absorbed dose, bone pain, 102P(ab) Spherical geometry, PET cerebral imaging, GSO injected through implanted ports, 400(le) uptake and retention, bone pain, 72P(ab) scintillation detectors, 1219 procedure guideline for treatment of bone SNM, see Society of Nuclear Medicine Spillover artifacts, corrections for, PET pain, 881 Society of Nuclear Medicine withadditive models and seeded region therapy 43rd annual meeting, budget planning, 24N(4) growth, 224P(ab) skeletal melastatic disease, 31P(ab) annual meeting Spinal mÃ©tastases,diagnosis on routine symptomatic osseous mÃ©tastases, review of instrumentation developments, bonescintigraphy, in cancer pharmacoeconomic benefits of, 31P(ab) cameras, and computer systems, 25N(9) patients, 250P(ab) Sturge-Weber syndrome. *""Tc-HMPAO Denver 1996. features of 43rd annual meeting, Spontaneous regression, intracranial SPECT, 81 medical problem solving. 11N(8) arteriovenous malformation, 1673 Subacute thyroiditis, differential diagnosis, 1745 government relations update, 20N( 1) Squamous-cell carcinoma Subarachnoid hemorrhage strategic plan, 22N( 1) Tc-sestamtbi SPECT to assess osseous cerebral arteriospasm after, SPECT diagnosis Sodium, dietary, regulator of angiotensin tumor mÃ©tastases,1526 of, 12P(ab) receptors imaged with "C L-159, tumor cell line, uptake of 99mTc MIBI and cerebral infarction after, CBF with |:'I IMP 884,47P(ab) tetrofosmin comparison, 254P(ab) SPECT, 12P(ab) Sodium malÃ©ate,reduction of renal uptake of Standardized arterial input function, vasospasm after, brain SPECT with angiography '"In-DTPA-octreotide. lysine, 1388 quantitative assessment of and transcranial Doppler, 12P(ab) Soft tissue, benign and malignant masses, benzodiazepine receptors, SPECT, 374 Subcutaneous mÃ©tastases,somatostalin-receptor evaluation with FDG-PET. l40P(ab) Standardized uptake value, time-activity scintigraphy. bronchial carcinoid, 1537 soft-tissue sarcomas. PET imaging. '"FFDG, 257 curveslope, 206P(ab) Substance P receptor, in vitro and in vivo studies Solid-state detector, intraoperative probe, Standards, outcome and cost in nuclear with '"In-DTPA-Arg1, SP, 108 detection of beta emitters, 52P(ab) medicine, 1073(ed) Subtraction-restoration, nonstationary scatter Solitary pulmonary nodules, probability of Stannylated precursors, radioiodination kernels, high-resolution PET, 2040 malignancy and preoperative staging, "F- yieldsfrom, optimum pH for, 187P(ab) Sulfur colloid, filtered, bone marrow FDG-PET, 943 Statistical parameter mapping imagingproperties of Tc, 240P(ab) Somatostatin analogs brain activation/deactivation patterns, sensitivity Superior vena cava clot, lung scan detection of, oclreolide derivatives, labeled with of, 41P(ab) collateral flow to liver, 1826 Tc, 29P(ab) FDG-PET brain scans, clinical validation Superior vena cava syndrome, diagnosis and radiolabeled, comparative studies with of, 42P(ab) functional assessment, radionuclide six, 20P(ab) mu opioid receptor binding, analysis in cocaine venography, 1460 Somatostatin receptor imaging abusers, 45P(ab) Swallowing, medical conditions predisposing cost effective analysis, 886 Statistical parametric imaging, temporal lobe toaspiration, radionuclide salivagram, evaluation of "Tc-P587 and Tc-P829 in epilepsy, outcome of surgery, 1094 children, 22P(ab) detection of SSTR-expressing Statistics, analytic computation and sample Sympathetic innervation, imaging in silent tumors, 1016 estimation, local statistics of myocardial ischemia, 712 Somatostatin receptor scintigraphy. PET, 155P(ab) Sympathetic nerve activity, subclinical variants visualization of abdominal carcinoid Step-and-shoot, compared with continuous step- of, diagnostic pitfalls in interpreting tumors, "'In-pentetreotide SPECT, 1452 and-shoot mode, SPECT, 2037 myocardial MIBG images, 1686 Somatostatin receptors Stereoisomers, IQNPisomers, 186P(ab) Sympathetic nervous system Tc-labeled synthetic peptides with, staging of Stereotactic biopsy, radionuclide-guided, clinical evaluation of 11C-phenylephrine, melanoma. 138P(ab) coordinates from sinograms, breast MAO-sensitive marker of cardiac expression, clinical immunology, 24P(ab) cancer, 1562 neurons, 1923 imaging, clinico-pathologic Stereotaxy denervated ratheart, absence of uptake of correlation, 255P(ab) carbon dioxide responsiveness, comparison of MIBG, 106P(ab) overexpression of In-111 -octreolide in human normal and pathological aging, 165P(ab) Systemic lupus erythematosus neuroendocrine tumors, 2002 proportional atlas, interpretation of SPECT brain and CNS involvement, FDG-PET, 21P(ab) primitive ncuroectodermal CNS tumors, perfusion images, 217P(ab) lung clearance test in, Tc DTPA children, 286P(ab) Steroids, fluticasone propionate particles, labeling aerosol, 295P(ab) scinligraphy in FDG-PET studies, 14IP(ab) Systemic radionuclide therapy. "'In-DTPA-D- "Ga comparison, malignant Stochastic algorithm, parameter estimation, Phe'-octreolide, treatment in midgut lymphomas, 268P(ab) dynamic PET, 222P(ab) carcinoid syndrome. 1519 compared with MRI, suspected Stomach, concomitant lung and gastric uptake in meningioma, 257P(ab) bone scintigraphy, sarcoidosis. 1530 cost-effective analysis of. 19P(ab) Streptavidin diagnosis of small cell lung cancer and biochemical modification for two-step imaging mÃ©tastases,20P(ab) and therapeutic procedures, in vitro and Teaching files, internet for case-based gastrocnteropancreatic tumors, additional in vivo analysis, avidin, 1380 presentations, 178 value of SPECT in, 256P(ab) imaging osteomyelitis, '"In-biolin, 1655 Techetium-99m-HlVIPAO, ictal brain SPECT, gastroenteropanreatic tumors, 253P(ab) Striatum, dopamine D4 receptors in, crossed cerebellar hyperperfusion, 426 staging of non-Hodgkin lymphomas, l9P(ab) baboon, 113P(ab) Technegas, transition to pertechnegas, 1917(le) subcutaneous cavernous hemangioma, '"In- Stripe sign, differential diagnosis in perfusion Technetium complexes octreotide imaging, Beckwith- lung scan, lobar collapse. 1682 serotonin receptor binding, improvement of Wiedemann syndrome, 1516 Stroke, changes in cortical 5-HT2 serolonergic receptor selectivity and blood-brain tissues positive for, visualization by receptors, PET, 1976 transfer, 16P(ab) pentetreotide, rats, l41P(ab) Strontium-142. a positron emitter for technepine, labeling the dopamine transporter, uptakemonitoring, '"Sm EDTMP Specific binding, tissue distribution, metabolism brain, 17P(ab) of "'In-labeled analogs, gamma-camera therapy, 5IP(ab) Technetium-99m scintigraphy, 108 Strontium-153 EDTMP, therapy, l4;Smas a !'"T1 imaging versus "Ga imaging in salivary SPECT, see Single-photon emission computed positron emitter for uptake monitoring gland disorders, 1819 tomography of. 51P(ab) chelators Spectrometry, gamma, clinical doses of*'Cu, Strontium-83. production, PET phantom hydroxyamamide-based tetradentate, 189P(ab)

2158 The Journal of Nuclear Medicine N2S2 stroke, 272P(ab) dementia, 274P(ab) method for creating small ligands linked to Technetium-99m dextran 70, clinical grade, for SPECT images in Alzheimer's disease, targeting components, 190P(ab) lymphoscintigraphy, 143P(ab) comparison with 99mTc-HMPAO, 1749 small neutral, new one-step ligand synthesis Technetium-99m-diphosphonate, bone tumors, use as investigational tool in childhood biodistribution studies of '""Tc-labeled for preparation of, 191P(ab) epilepsy, 1106 synthesis by a simplified route and MTX-BP conjugate, 105 visualization of grade II astrocytoma, 273 evaluation of, 190P(ab) Technetium-99m disofenin, cholescintigraphy, Technetium-99m-furifosmin, quantitative solid phase chemistry method for removal of biliary atresia, 288P(ab) comparison of planar and SPECT normal excess, 189P(ab) Technetium-99m DMP 444, protein binding, data files, -'"TI, """Tc-sestamibi, and chemotactic peptides thrombosis imaging agent, 202P(ab) Tc-telrofosmin, 1783 accumulation in chronic intestinal Technetium-99m DMP-HSA, kit prepared, Technetium-99m-galactosyl-neoglycoalbumin, inflammation, 239P(ab) gatedblood pool imaging, 175P(ab) index of hepatic function, accumulation in lung, severe trauma Technetium-99m DMSA radiopharmacokinetic modeling, 160 effects, 240P(ab) assessment of renal function, pregnancy-induced Technetium-99m glucarate computational chemistry, local density hypertension effects, 290P(ab) evaluation of reperfusion damage, experimental functional methods in, 189P(ab) assessment of renal scarring ischemia, 119P(ab) correlation with cardiac serum markers, parenchyma! function and, 290P(ab) subnuclear localization, necrotic spontaneous angina, 58P(ab) reduction of functional renal mass myocardium, 175P(ab) ester-derivatized, brain imaging, 188P(ab) and, 290P(ab) uptake, swine model of demand labeled marker of solid tumor hypoxia, assessment of renal uptake, children, planar ischemia, 50P(ab) nitroimidazole, 1023 posterior-view method, 291 P(ab) Technetium-99m GSA labeled somatostatin receptor-binding biokinetic behavior of, effects of renal comparison with^Tc PMT, hepatobiliary peptides, 1016 pathology and age differences, 1331 scintigraphy, liver cirrhosis with labeling of bifunctional ligands, conjugation comparison with 201T1 and 99mTc MIBI, jaundice, 244P(ab) chemistry, immonoreactivity, kit solitary pulmonary lesion, 268P(ab) diagnosis and follow-up study of fulminant formulation, 362 detection of acute pyelonephritis in piglets, hepatic failure, 641 model chelators for, synthesis and SPECT versus pinhole DMSA Technetium-99m HIG, immunoscintigraphy, radiochemical studies of, 28P(ab) imaging, 1731 boneinfection after orthopedic surgery modeling, molecular mechanics investigation radiation dosimetry in children, body surface and bone trauma, l27P(ab) of, 16P(ab) area, 1336 Technetium-99m HL91, hypoxia avid new octreotide derivatives labeled with, 29P(ab) renal SPECT imaging in normal imagingagent, assessment of reperfused peptide conjugates, based on ternary ligand volunteers, 1346 myocardium, 94P(ab) system, 29P(ab) renal SPECT in diagnosing and monitoring Technetium-99m-HMDP, age-related changes in peptide labeled with, inflammation acute pyelonephritis, pediatrics, 1349 bone scintigraphy, 815 imaging, 152P(ab) SPECT, uptake, kidneys, assessment of Technetium-99m HMPAO peptides labeled with, comparison to challenge reproducibility, 290P(ab) absolute and relative quantitation with, Alzheimer's disease, 278P(ab) with cysteine, 150P(ab) studies in pediatrie urinary tract infection, 823 prostate antibody CYT-351, conjugation, Technetium-99m dsFv, biodistribution, favorable assessment of neurological deficits during labeling and clinical studies, 96P(ab) effects of lysine in, 129P(ab) balloon test occlusion, 551 protein labeling with Technetium-99m DTPA brain cyclopentadienyltricarbonyl determining regional ventilation, SPECT, vascular response in frontal area of technetium, 28P(ab) tracheostomized patients, 239 orthostatic patients with measure of BP, radiolabeled liposomes for tumor imaging, 326 lung scanning in diagnosis of pulmonary plasma norepinephrine during raise-up radiolabeling single chain Fv antibody embolism, 165 test, 1 fragments, 868 lung scintigraphy, assessment of carborundum brain SPECT red blood cell scan, clinical utility despite pneumoconiosis, 294P(ab) Alzheimer's disease, automated neural intestinal barium, 643 radioaerosol inhalation lung scintigraphy, networks, 195 renal tubular agents, renal extraction of, role of detection of pulmonary effects of detection of perfusion abnormalities in Lyme protein binding in, 47P(ab) radiation therapy, 234P(ab) disease, 270P(ab) serotonin receptors labeled with, as imaging radioaerosol, lung scintigraphy, acute inhalation evaluation of patients with pure agents, 190P(ab) injury, 294P(ab) photosensitive epilepsy, 1755 transmission source, MT1 myocardial Technetium-99m EC statistical parametric mapping and, 79P(ab) scintigraphy, 80P(ab) captopril scintigraphy, diagnosis of renovascular cellular basis of ECD, brain perfusion, 1694 Technetium-99m aerosol, labeling method, hypertension, 291P(ab) cerebral blood flow in depressed patients, inhaled beclomethasone, 142P(ab) simultaneous estimation, effective renal plasma electroconvulsive therapy. 1075 Technetium-99m alpha-fetoprotein flow and glomerular filtration, 91P(ab) cerebral blood flow, ischemie stroke, 13P(ab) blood pool activity subtraction and, diagnosis of Technetium-99m ECD cerebral hypoperfusion in orthostatic breast cancer, 148P(ab) brain SPECT hypotension, denervated recombinant, imaging of breast cancer acute stroke, 13P(ab) myocardium, 1824 xenografts, 87P(ab) high risk neonates, 22P(ab) compared with '"Xe measurements of regional Technetium-99m antibody conjugates, statistical parametric mapping and, 79P(ab) cerebral blood flow, Diamox, 1735 intracellular processing of, 239P(ab) cellular retention of, brain perfusion, 1694 detection, prosthetic vascular graft Technetium-99m-anti-NCA-95, bone marrow diamox SPECT, unilateral carotid stenosis infection, l63P(ab) scintigraphy in hÃ©matologiedisorders, patients, 274P(ab) discordant results compared with """Tc-MIBI '**"Tc-antigranulocyte antibody, 978 double-injection protocol for cerebral perfusion uptake, recurrent occipital Technetium-99m aprotinin, detection of amyloid reserve, Azetazolamide, 2057 meningioma, 1183 involvement, myocardial, 185P(ab) extraction and retention of, dynamic SPECT and fractionation, stannous ion augmentation Technetium-99m ATN-10, potential tumor ISO-water PET, 1600 technique, 84P(ab) imaging agent, 17P(ab) ictal SPECT, epileptogenic zones, 100P(ab) functional brain imaging, detection of cerebral Technetium-99m bicisate leukocyte labeling with, absence of plasma and radionecrosis. 259P(ab) ictal and interjetai brain SPECT, refractory erythrocytes, 84P(ab) ictal SPECT, epileptogenic zones, 100P(ab) epilepsy in children, 1101 neuroactivation studies, paradigm for smooth imaging cerebral blood flow at high flow levels, rapid preparation method for, 142P(ab) pursuit eye movement, 283P(ab) penicillin induced seizures in rats, 661 Technetium-99m BMS-181321, detection of properties of enzyme to catalyze, 189P(ab) labeled white blood cell scans, detection of cerebral ischemia, associated with acute SPECT, diagnosis orientation in appendicitis in women, 241P(ab)

Subject Index â€¢1996 2159 localization in brain tumors, 263P(ab) function agent, 17P(ab) brain SPECT, recurrent malignant low uptake, abnormal CSF substance P and, in accuracy of clearance measurements obtained glioma, 260P(ab) fibromyalgia syndrome, 276P(ab) with gamma camera heart curve, 1281 breast cancer, MRI comparison, 75P(ab) predictive capacity of SPECT, one-year follow- assessment of renal scarring, parenchyma! combined with parathyroid measurements as up after mild head injury, 1605 function and, 290P(ab) guide to parathyroidectomy, 798 preoperative brain perfusion imaging, calculation of split renal function with, using comparison with :'"T1 and Te DMSA, solitary identifying risk of infarction with patlak plot, 307P(ab) pulmonary lesion, 268P(ab) temporary occlusion of 1CA, 415 clearance discordant results compared with """Tc-HMPAO pyrophosphate-spiked, subdispensed, kinetic dual-headed gamma camera without plasma uptake, recurrent occipital and stability studies, 83P(ab) samples, 91 P(ab) meningioma, 1183 re-appraisal of quality control of labeled normal renal function, 293P(ab) dual versus single isotope imaging, parathyroid granulocytes, 863 renal allograft, 292P(ab) scintigraphy, 16P(ab) rest-stress SPECT. cerebral ischemia measured diagnosis of renal transplant rejection, ECG-gated SPECT, myocardial, ischemie heart by, 277P(ab) comparison with core needle disease patients, 304P(ab) scan abnormalities, cytarabine high dose, biopsy, 289P(ab) evaluation of multiple myeloma, diffuse marrow children, 35P(ab) dilated upper urinary tract, standardized increase in, 269P(ab) SPECT approach to diuresis renography. functional autonomy in secondary acetazolamide test and, evaluation of International Consensus hyperparathyroidism, 565 dementia, 273P(ab) Committee, 1872 gated, comparison with FDG, diagnosis of cerebral blood flow, systemic lupus exercise renography in untreated myocardial ischemia, 60P(ab) erylhematosus patients. 163P(ab) hypertension, 838 localization of ectopie parathyroid demonstration of frontal hypoperfusion in fractional renal uptake of, graphical adenoma, 631 benign exertional headache, 1172 analysis, 292P(ab) lung cancer images in Alzheimer's disease, comparison graphic (Patlak) method in, renal CT and FDG-PET comparison, 260P(ab) with "Tc-ECD, 1749 scintigraphy, 291P(ab) hilar and mediastinal lymph node mÃ©tastases MRI evaluation of posterior circulation, measurement of renal function in children and in, 263P(ab) moyamoya disease, 1613 adults, 588 preoperative assessment, hyperfunctional outcome after synangiosis surgery, 274P(ab) modified renal counting method in, estimation parathyroid glands, 15P(ab) oxido-reduclive state, cellular retention, 1413 of renal clearance, 291P(ab) scintigraphy in pulmonary tuberculosis, 233 perfusion images, proportional stereotactic radiolabeling of disulfide stabilized fragment, scintimammography, planning and monitoring atlas for, 217P(ab) effects on renal uptake, 29P(ab) treatment for breast cancer, l56P(ab) post concussion syndrome, 278P(ab) renal scintigraphic appearance in Banter's scintimammography in detection of primary regional brain function, pain and acupuncture syndrome, captopril administration, 1688 breast cancer, 626 effects, 278P(ab) renal uptake SPECT, primary and metastatic lung specific regions of left hemispheric gamma camera method, 293P(ab) cancer, 296P(ab) dysfunction, l65P(ab) semiautomated and manual regions of tetrofosmin and, thyroid and parathyroid Sturge-Weber syndrome, 81 interest, 293P(ab) nodules, 159P(ab) texture analysis to detect decompression renograms, living related donor and recipient uptake illness, 1154 kidney transplant evaluation, 292P(ab) in human breast cancer cell lines, 190P(ab) stabilized, radiolabeling leukocytes, 84P(ab) SPECT, evaluation of renal tumor cell line, comparison with use of Tc-labeled liposomes for blood pool parenchyma, 23P(ab) tetrofosmin, 254P(ab) imaging, compared with """Tc-red Technetium-99m MDP uptake mechanics, compared with ""Tc- cells, 1374 characteristics, multiple myeloma, 267P(ab) tetrofosmin. !'"TI in tumor cell while blood cell labeling, lymphocyte damages combined scintigraphy and radiography for lines, 1551 induced by, l01P(ab) detecting hip prosthesis loosening, 62 Technetium-99m-NGA, automatic preparation of Technetium-99m-HYNIC-IgG. biodislribution lung uptake on bone scan in Wegener's radiopharmacokinetic data, estimation of and dosimetry compared with "'In vasculitis, 857 receptor biochemistry, 1896 DTPA-lgG, 843 renal scinligraphy in evaluation of pediatrie Technetium-99m nitroimidazole Technetium-99m-IDA, hepatobiliary kinetics of, nephrourological disease, 71 cardiomyopathy, hypoxia effects, quantification by linear systems scintimammography, mammographie hamster, 175P(ab) theory, 1323 microcalcificalions without detection of ischemie and reperfused Technetium-99m-labeled monoclonal mass, 156P(ab) myocardium, 761 antibodies, radiation treatment planning SPECT bone scintigraphy of anterior cruciate Technetium-99m NOET in squamous head and neck cancer, ligament, knee injury, 1353 biodistribution and dosimetry, normal immuno-SPECT, 1942 unexpected intestinal leakage in primary humans, 229P(ab) Technetium-99m-labeled peptide, thrombus intestinal lymphangicctasia, 639 kinetics, gamma camera images, ischemie imaging, use of "*"Tc-P280, 775 Technetium-99m-mebrofenin. hepatic extraction myocardium at rest, 107P(ab) Technetium-99m-liposomes efficiency and excretion rate, Technetium-99m P280 blood-pool imaging, compared with '*â„¢Tc-red hepatobiliary study in dogs, 1846 activated platelet specific techtide, studies of cells, 1374 Technetium-99m-mÂ«o-hexamethyl carotid atherosclerosis, 272P(ab) scintigraphic detection of inflammation and propyleneamine oxime. imaging agent peptide imaging, deep vein thrombosis, 95P(ab), infection, """Tc-Steallh-liposomes, 1392 for glutathione localization in brain. 294P(ab) Technetium-99m LL-EC, comparison in rats and assessment of antioxidative ability, 1698 Technetium-99m-P483H. detection of occult healthy volunteers, 46P(ab) Technetium-99m MIBG, absence of uptake, infection and inflammation, platelet Technetium-99m LL1, potentially new bone denervated rat heart, 106P(ab) factor 4, 673 marrow imaging agent, 239P(ab) Technetium-99ni MIBI Technetium-99m P829, biodistribution Technetium-99m MAA :'"TI comparison, detection of viable anddosimetry, 230P(ab) lung perfusion scintigraphy, measurement of myocardium, 308P(ab) Technetium-99m pertechnegas, '"Xecomparison, focal pulmonary flow, 304P(ab) accumulation and modulation, multidrug ventilatory imaging in suspected lung scan detection of superior vena cava clot, resistant tumors, 118P(ab) pulmonary emboli, 116P(ab) collateral flow to liver. 1826 biodistribution, quantitative SPECT, Technetium-99m pertechnetate lung scanning in diagnosis of pulmonary experimental phantom based SPECT, smoking effects on lung embolism, 165 on, 154P(ab) permeability, 5P(ab) Technetium-99m MAG3 bone and soft tissue tumors, "Ga comparison uptake by parathyroid adenoma, 861 """Te EC combination, promising renal tubular within subject, 298P(ab) uptake mechanism, induced osteoarthritis,

2160 The Journalof Nuclear Medicine rat, 298P(ab) ""Tl, 1956 associated protein, 247P(ab) Technetium-99m phenylene Â¡minephenol, as evaluation of left ventricular function, uniformity, improved with attenuation aleukocyles labeling agent, 188P(ab) comparison with contrast correction, low likelihood tor coronary Technetium-99m PNA, hybridization ventriculography, 104P(ab), l05P(ab) artery disease, 148P(ab) of. 203P(ab) evaluation of thyroid cancer, comparison with uptake Technetium-99m polymer, synthetic radioiodine. 137P(ab) cancer cell lines resistant to chemotherapy. copolytnerkit, blood pool fractionation, stannous ion augmentation multidrug resistant associated imaging, 198P(ab) technique, 84P(ab) protein. 233P(ab) Technetium-99m-pyrophosphate, influence of gated imaging, automated method for cancer cell lines sensitive and resistant to downscatter in dual-isotope imaging . assessment of left ventricular chemotherapy. 189P(ab) -""TI,781 function, 179P(ab) correlation with pathologic features, breast lipid deposits in bone marrow, Gaucher's Technetium-99m Q complexes, cardiac cancer. 267P(ab) myocyteuptake, enhanced by ligand ester disease patients. 297P(ab) uptake in breast tumor and lymph nodes, 922 groups, 188P(ab) malignant melanoma, primary and uptake in myeloma, 1001 Technetium-99m Q12 recurrent, 266P(ab) utility of SPECT imaging with tumor-specific ;1IIT1extraction and retention, effects of mammoscintigraphy in suspected breast tracers, assessment of osseous tumor ouabain, 752 cancer, 926 spread, 1526 kinetics, hypoxia, acidosis, and ischemia parathyroid scintigraphy, evaluation of primary Technetium-99m sulfur colloid reperfusion, rat hearts, 49P(ab) and secondary assessment of gastric emptying in pediatrie Technetium-99m RBC hyperparathyroidism. 243P(ab) population, use of right lateral and diagnosis of gastric antral vascular ectasia, case position of photon-emitting objects in emission upright positioning. 1356 correlation with 111In-WBC uptake in Paget's report and ROL, 854 scanner, stereotactic coordinates. ECT hepatic hemangioma, 114P(ab) sinograms in breast biopsy, 1562 disease, 858 label stability over time, l99P(ab) pre and post therapy evaluation, nasopharyngeal lung uptake, microwave versus boiling Technetium-99m-rt-PA, detection of deep vein carcinoma, 257P(ab) preparations, l97P(ab) thrombosis, 744 prognostic value of stress in, gender preparation and evaluation, lymphoscintigraphy Technetium-99m sestamibi differences, 14P(ab) studies, 84P(ab) !'"T1comparison property of being a substrate for P-glycoprotein radiopharmaceulical for lymphoscintigraphy. acute coronary reperfusion, 160P(ab) similar to Tc-tetrofosmin, multidrug preparation parameters, particle size detectin of coronary artery disease in resistant breast cancer cells, 1578 distribution and stability, 1575 women, 69P(ab) pulmonary nodules, malignant or benign. reduced particle size, recognition of hibernating coccidioidotnycosis and, 35P(ab) lymphoscintigraphy, 30IP(ab) myocardium, 26P(ab) quantifying perfusion defects, single photon Technetium-99m TBIDA, adenosine stress, SPECT, early post-stress tomography, 178P(ab) hepatobiliaryscintigraphy, after auxiliary imaging, 59P(ab) quantitative comparison of planar and SPECT liver transplant, 113P(ab) anterior defect location with, l4P(ab) normal data files, -""Tl,"""Tc-tetrofosmin, Technetium-99m TcN-NOET arbutamine and dobutamine stress testing and """Tc-furifosmin, 1783 neutral, metabolite analysis, after injection in comparison, coronary artery recurrent hyperparalhyroidism after resection of rats, 188P(ab) disease, 177P(ab) parathyroid carcinoma, "F-FDG- uptake, cancer cell lines sensitive and resistant attenuated corrected stress, supine and prone PET, 2000 lo chemotherapy, 189P(ab) comparison, myocardial perfusion resting SPECT, postinjection times, 48P(ab) Technetium-99m tetrofosmin SPECT, 81P(ab) reverse redistribution, after coronary angioplasty â€¢""Tland, ECG-gated dual-isotope myocardial axillary node imaging, breast cancer, 251P(ab) in acute myocardial infarction, 181P(ab) SPECT, 308P(ab) bile reflux during cardiac imaging, identifying a reverse redistribution of, following PTCA in Tc sestamibi and MTI comparison, myocardial noncardiac cause of chest pain. 1285 acute myocardial infarction, 1289 viability assessment, 26P(ab) breast cancer scintimammography """Te sestamibi comparison, myocardial axillary lymphadenopathy and, 252P(ab) breast cancer response to uptake, 48P(ab) diagnostic accuracy of, 74P(ab) chemotherapy, 252P(ab) assessment of salvaged myocardium from onset scintimammography, histopathologic breast cancer, SPECT improvement to reperfusion, 126P(ab) correlation, 75P(ab) on, 252P(ab) early and delayed myocardial SPECT imaging, axillary lymph node involvement, 75P(ab) palpable and nonpalpable breast liver-heart artifact, 1622 breast density effects, 74P(ab) tumors, 259P(ab) dipyridamole and, early and delayed imaging clearance, hepatic, genetic factors in, 262P(ab) small-cell lung cancer, predictor of response to comparison, 180P(ab) combined with BMIPP to predict functional chemotherapy, 67P(ab) dipyridamole/rest, assessment of coronary artery outcome after myocardial infarction, 718 solid tumors, determination of P-glycoprotein disease, 58P(ab) compared to FDG-PET, localization of in, 67P(ab) during dobutamine administration, assessment parathyroid adenomas, SPECT of myocardial viability, 116P(ab) hyperparathyroidism, 1809 "F-FDG-PET, comparison of diagnostic functional risk area assessed by, infarcÃ¬size, comparisons with ;'"T1 imaging in evaluation of accuracy in musculoskeletal myocardial infarction, 58P(ab) thyroid tumors, 901 sarcomas, 1476 gated SPECT, measurement of left ventricular correlation with histologie characteristics, assessment of mediastinal involvement in ejection fraction. 179P(ab) benign breast tumor, 250P(ab) lung cancer, 938 MIBI and, thyroid and parathyroid detection of parathyroid pathology, detection of restenosis after successful nodules, 159P(ab) hyperparathyroidism, 158P(ab) PTCA, 1300 multicenter trial, myocardial viability, 26P(ab) diagnose multidrug resistance to chemotherapies imaging, preoperative parathyroid lesion multidrug resistant breast cancer cells, substrate in breast tumor cells, 286 localization, 242P(ab) for P-glycoprotein, Tc-MIBI, 1578 differentiated thyroid cancer, postoperative localization of mediastinal parathyroid primary lung cancer detection, 35P(ab) follow-up, 236P(ab) adenoma, 1535 quantitative comparison of planar and SPECT dipyridamole and, early and delayed imaging myocardial viability, 26P(ab) normal data files, a"Tl, Tc-sestamibi, comparison, 180P(ab) parathyroid scinligraphy, FADS. 1773 and Tc-furifosmin, 1783 dopamine stress, magnitude of ischemia, dogs subtraction, dual-phase, or SPECT, comparison scintimammography with coronary stenoses, 3P(ab) of parathyroid imaging, 15P(ab) diagnosis of breast cancer and lymph node evaluating primary disease and differentiating supine vs right lateral imaging, comparison with mÃ©tastases,l56P(ab) residual/recurrent disease from therapy coronary arteriography, 48P(ab) suspicion of breast cancer. 255P(ab) changes, nasopharyngeal carcinoma. transport substrate, human multidrug resistance- SPECT. primary lung tumor, 264P(ab)

Subject Index â€¢1996 2161 sublingual nitroglycerine plus, detection of thyroid tumors, 901 expression, 955 severely ischemie but viable dipyridamole, radiation exposure to OR staff stress-redistribution-reinjection, residual activity mycoardium, 302P(ab) after vascular surgery patients, 230P(ab) or defect reversibility, 179P(ab) uptake compared to :"T1, cardiac low flow state dipyridamole-thallium perfusion scintigraphy, stress reinjection, prediction of function and systolic dysfunction. 1398 correlation with hemodynamic indices of recovery, after bypass surgery, 176P(ab) uptake compared with Tc-MIBI and !"T1, myocardial dysfunction, 723 stress-induced reversible and mild-moderate tumor cell lines, 1551 discrepancy in dual-tracer autoradiography, irreversible defects, myocardial viability uptake, tumor cell line, comparison with comparisons with |:Ã•I-MIBGin and, 25P(ab) MIB1, 254P(ab) experimental myocardial infarctions, 680 timing of thallium injection during dobutamine utility, detection of small pulmonary dobutamine stress test and echocardiography to imaging, 193(le) nodules, lllP(ab) assess ALCAPA syndrome, 748 uptake and retention index, brain tumors after Technetium-99m trepanes, as dopamine evaluating primary disease and differentiating radiation therapy, 255P(ab) transponer imaging agents, 17P(ab) residual/recurrent disease from therapy uptake mechanisms, compared with Tc- Technetium-99m WBC, infection imaging, changes, nasopharyngeal carcinoma, tetrofosmin, Tc-MIBI in tumor cell comparison with "'IN WBC 99mTc-sestamibi SPECT, 1956 lines, 1551 imaging, 204P(ab) exercise-induced ischemia, viability patterns uptake, tumor cell line, 64P(ab) Technetium-99m-(V)DMSA, insular carcinoma and, chronic left ventricular dysfunction ventriculography, estimation of resting left of thyroid, 78 patients, 25P(ab) ventricular ejection fraction, 181P(ab) Technetium-labeled monoclonal antibody, gallium and, disseminated mycobacterium whole-body scan compared to '"I scintigraphy clinical radioimmunotherapy, head and avium complex. 242P(ab) in differentiated thyroid cancer, neck cancer, 352 influence of downscatter in dual-isotope concordance and discordance rates, 1487 Telemedicine, advantages and problems, age of imaging, Tc-PYP SPECT, 781 whole-body imaging, malignant melanoma filmless imaging departments, 19N(9) myocardial imaging, women with typical angina patients, 256P(ab) Temporal lobe epilepsy surgery, outcome and normal Thallium-201 scintigraphy, correlation with predicted by statistical parametric coronaryangiograms, 306P(ab) coronary lesion, wall motion abnormality imaging, PET, 1094 myocardial SPECT, phantom studies, small- and tissue viability, reverse Temporoparieto-occipital junction seizures, lesion detectability in, 213P(ab) redistribution, 735 ictal SPECT, cerebral blood flow, 1946 perfusion abnormalities in ischemie heart Thallium-201-chloride Test occlusion, preoperative prediction of ICA disease, detection of metabolic effect of chemotherapy in osteosarcoma, sacrifice, HMPAO SPECT, 415 abnormalities with 123I-BMIPP scintigraphic assessment, 1444 Testicular cancer, residual, afterchemotherapy. SPECT, 1981 high uptake in brain radiation necrosis, epileptic FDG-PET imaging of, 256P(ab) post-redistribution reinjection of, assessment of activity, 1174 Testis, radionuclide uptake, role of myocardial viability, 47P(ab) scintigraphy, low grade non-Hodgkin's transferrin, 336 pre and post therapy evaluation, nasopharyngeal lymphoma, 258P(ab) Testosterone, treatment, young males withdelayed carcinoma, 257P(ab) sequential thallium and gallium chest scans, puberty, effect on bone mineral prediction of outcome, recurrent thyroid differentiating kaposi sarcoma from density, l03P(ab) cancer, 16P(ab) lymphoma and opportunistic infections TFMPP, radiosynthesis binding affinity and proliferating cell nuclear antigen and Ki, in AIDS, 1662 biodistribution of, serotonin cellular localization. C6 visualization of grade II astrocytoma system, 40P(ab) gliomas, 65P(ab) SPECT, 273 Thallium-201 quantifying perfusion defects, SPECT, 178P(ab) Therapeutic monitoring, response of soft-tissue '"I scintigraphy comparison, differentiated quantitative comparison of planar and SPECT and musculoskeletal sarcoma to thyroid cancer, after surgery, 135P(ab) normal data files, Tc-sestamibi, Tc- neoadjuvants, I8F-FDG-PET, 1438 "Ga comparison, imaging of pediatrie tetrofosmin, and Tc-furifosmin, 1783 Therapeutic nuclear medicine, prediction of Hodgkin's disease, 285P(ab) quantitative SPECT, prediction of outcome in radiation doses, tracer studies with 1311- **Â°Tctetrofosmin and, ECG-galed dual- emory angioplasty versus surgery labeied antibodies, 1970 isotopemyocardial SPECT, 308P(ab) trial, 125P(ab) Three-compartment modeling, quantitation of Tc-Q12 and !"'TI extraction and retention, reinjection, after exercise-redistribution cerebral blood flow with "Cu-PTSM, effects of ouabain, 752 imaging, chronic ischemie left PET, 1089 Tc sestamibi comparative analysis, acute ventricular dysfunction, 13P(ab) Three-dimensional acquisition, nearly coronary reperfusion. l60P(ab) rest-redistribution SPECT isotropicspatial resolution and, new 24-hour images, functional outcome after positron camera, 170P(ab) redistribution/reinjection, 47P(ab) revascularization, 59P(ab) Three-dimensional analysis, description of brain SPECT prediction of functional improvement after pulmonary deposition of aerosols using differential diagnosis of toxoplasmosis and revascularization, 178P(ab) multimodality imaging, 873 CMS lymphoma in patients with rest-redistribution, Tc sestamibi comparison, Three-dimensional fusion imaging, "C-CHC AIDS, 1150 recognition of hibernating biodistribution, mullidrug resistant recurrent malignant glioma, 260P(ab) myocardium, 26P(ab) tumors, 312 cerebral hypoperfusion in orthostatic scintigraphic localization, proliferation markers Three-dimensional imaging hypotension, denervated and, glioma, 265P(ab) spheroid PET with GSO scintillation detectors, myocardium, 1824 scintigraphy, dobutamine echocardiography. cerebral studies, 1219 comparative assessment of four different uptake chronic left ventricular usefulness and limitations, bone scintigraphy indexes, brain tumor, 157P(ab) dysfunction, 126P(ab) with volume-rendering technique and comparative study of thallium versus gallium SPECT SPECT, 1567 scintigraphy in lymphoma subgroups, detection of brain lymphomas, AIDS I Inomlim.iiilmlic disease gallium uptake according to tumor grade, patients, 258P(ab) diagnostic value of small perfusion defects in type, 46 differentiation of benign and malignant suspected pulmonary embolism, compared to "Ga imaging in salivary gland solitary pulmonary lesion, 268P(ab) ventilation/perfusion scan, 1313 disorders, Tc, 1819 dobutamine stress test for assessment of peri- V/Q lung scan interpretation, patient comparison to Tc-tetrofosmin uptake, cardiac infarction and remote ischemia, stratification by cardiopulmonary low flow state and systolic myocardial infarction, 1951 status, 570 dysfunction, 1398 esophageal cancer, 248P(ab) Thromboembolism comparison with ""'Te MIBI and TcDMSA, relation of delayed scan uptake ratio and grade DMP444 as potential imaging agent. 129P(ab) solitary pulmonary lesion, 268P(ab) of histopathological differentiation in evaluating criteria for low probability comparisons with Tc-MIBI in evaluation of adenocarcinoma of lung, Na-K ATPase interpretation of ventilation-perfusion

2162 The Journal of Nuclear Medicine scans, 577 '"I, 1860 techniques, 92P(ab) matched ventilation, perfusion, and chest differentiated Tongue, glucose uptake in FDG-PET. 1918(le) radiographie defects, detection of after surgery, MT1 and '"I scintigraphy Total-body scanning, iodine concentration by the pulmonary embolism, 1636 comparison, 135P(ab) thymus, thyroid cancer, 1830 phase I trial of DMP 444, 117P(ab) comparison of two htG-IRMAs in, 144P(ab) Toxic nodular goiter, effective half-life Thrombolysis, clinical utilization of in acute FDG-PET as followup, 134P(ab) measurements of '"I, 228 ischemie stroke, brain SPECT, 1259 postoperative management, 236P(ab) Toxicity, platelet decrease, bone marrow absorbed Thrombosis imaging, evaluation of Tc-P280, in recurrent, FDG-PET for detection, 134P(ab) dose of ""Re-HEDP, bone metastasis, 38 vitro receptor-binding affinity and use of "'I in intraoperative detection Toxoplasmosis, differentiating from CNS clearance, 775 of, 52P(ab) lymphoma by !l"TL SPECT, AIDS, 1150 Thrombus imaging enhancement of radioiodine uptake by Trace metal analysis, isotope chetate "Te radiolabeling of r-annexin tumoricidal cytokines, 646 production, 195P(ab) V, 29P(ab) false-positive '"I whole-body scans, Tracers, PET quantitation of myocardial fatty DMP 444 as potential agent, 129P(ab) cholecystitis and sebaceous cyst, 1690 acid metabolism, l-"C-palmitale, 1723 plasma protein binding assay, ullrafiltration use histological differentiation, increased GLUT-1 Transarterial internal radiation therapy, in, 202P(ab) expression and, 248P(ab) biodistribution of "'Y-lipiodol in rats with potential imaging agent, DMP444, 151P(ab) isolated porta hepatis metastasis, 993 hepatoma, 332 radiolabeled peptides for, 152P(ab) locally recurrent and metastatic, FDG-PET Transcatheter arterial embolization, evaluation Thymic hyperplasia, '"Inpentetreotide and "Ga imaging of, 135P(ab) of therapy on VX2 liver tumor, FDG- citrate uptake in, after chemotherapy for medullary PET, 296 lymphoma, children, 256P(ab) detection with radiolabeled antibodies to Transferrin Thymidine carcinoembryonic antigen, 9P(ab) "F-labeled, iron metabolism in cell proliferation in vivo measurement of cell proliferation, radiolabeled monoclonal antibodies against and rapidly growing cancers, tumor- PET, 1048 CEA, 243P(ab) localization, 1408 marker of tumor proliferation, 262P(ab) prognostic value of thyroglobulin, use after "F-labeled, PET, biodistribution in nude mice metabolites in PET imaging, tumor, tissue thyroidectomy and prior to ablative models, 118P(ab) proliferation, 290 radioiodine therapy, 1962 receptor kinetics, measurement with dynamic uptake studies, preservation of hypoxic radiotoxicity after '"I therapy, micronucleus 3D-PET and'"F Tf, liver, 203P(ab) cardiomyocyte viability by antimyosin assay, 101P(ab) receptor mediated endocytosis, uptake of liposome membrane sealing, 106P(ab) recurrent, prediction of outcome with radionuclides by testis, 336 Thymus M1T1,16P(ab) Transjugular intrahepatic portosystemic shunt, '"I uptake in anterior mediastinum, 991 solid tumors, unsealed source radiation therapy liver perfusion scintigraphy before and iodine concentration in thyroid cancer, 1830 for, 235P(ab) after, portal hypertension, 243P(ab) Thyroglobin, comparison of two htG-IRMAs in, undifferentiated, accuracy of '"I and1" in Transmission computed tomography, image differentiated thyroid cancer, 144P(ab) diagnosis of, 236P(ab) qualilyfor quantitative SPECT, 212P(ab) Thyroglobulin Thyroid carcinoma Transmission smoothing, quantitative cardiac concordance and discordance between '"I and ^'Tl whole-body scintigraphy PET scans, effects of attenuation, 690 diagnostic '"I and !("T1scintigraphy, comparisons, distant mÃ©tastasesand Transmission/emission imaging differentiated thyroid cancer, 1487 residual activity, 1487 simultaneous, incorporating a scanning detection of recurrence or metastasis in alternating "F-FDG-PET and "'I whole-body transmission line source, performance differentiated thyroid carcinoma, 446 scanning, 1468 of, 210P(ab) prognostic value in thyroid cancer, use after effectiveness of combined diagnostic SPECT and PET comparison, 19P(ab) thyroidectomy and prior to ablation with modalities, 446 SPECT, multiple line sources for, 120P(ab) 1311, 1962 external radiation and radioactive iodine Transplant, interpretation of captopril renography Thyroid treatment for metastasis, 598 using a neural network, renal artery adenoma, nodular and extranodular tissue, thymic uptake of '"I in mediastinum, 991 stenosis, 1649 absorbed dose estimate by '"I imaging thyrotoxicosis induced by contrast media in Transplantation before radiotherapy, 230P(ab) metastatic thyroid carcinoma, abnormal bone marrow comparative methods for quantifying volume, ectopie thyroidal tissue, 1532 "*Ho DOTMP ablation trial, 234P(ab) planar imaging and SPECT, 1421 Thyroid diseases, '"I outpatienltherapy, NRC acute leukemia, '"I anti-CD45 antibody high-resolution pinhole tomography, regulations, 243P(ab) regimen priorto, 233P(ab) SPECT, 2017 Thyroid hormone binding ratio, correction heart metastatic insular carcinoma, Â°*MTc- of, 144P(ab) blood flow and coronary endothelial function (V)DMSA, 78 Thyroid malignancy, double-phase scanning, after, 83P(ab) nodules, "Te tetrofosmin and MIBI imaging Tc-sestamibi, 1919(le) cardiac PET with "C acetate, 161P(ab) of, 159P(ab) Thyroid scans, Tc-pertechnetate uptake by a incidence and time course of reinnervation somatostatin-receptor scintigraphy, bronchial parathyroid adenoma, 861 in, 70P(ab) carcinoid with mÃ©tastases,1537 Thyroid scintigraphy, procedure guideline sympathetic neuron effects on basal stability of thyroid radioiodine uptake for, 1264 myocardium blood flows and flow values, 805 Thyroid tumors, Tc-MIBI scintigraphy reserve, 4P(ab) uptake of radioiodide from sodium iodide compared with M'T1imaging, 901 kidney capsules, 197P(ab) Thyroid uptake measurement, procedure Te MAG3 clearance and delayed graft Thyroid cancer guideline for, 1266 function, 292P(ab) '"I- and '"I-labeled sodium iodidetotal body Thyroidectomy, comparison of '"I and !Â°'T1 living related donor and recipient renogram scan, comparison, 251P(ab) whole-body scintigraphy, detection of evaluation, 292P(ab) '" treatment, in children and distant mÃ©tastasesand residual rejection, Te MAG3 renogram or adolescents, 236P(ab) activity, 1487 coreneedle biopsy in diagnosis, 289P(ab) '"I and "1 sodium iodide comparison, total Thyrotoxicosis, induced by iodinated contrast Statistical Neurone! in evaluation, 92P(ab) body scanning, 301P(ab) media in metastatic thyroid carcinoma, kidney and pancreas, evaluation of renal '"I kinetics in, hypothyroidism, 15P(ab) abnormal ectopie tissue, 1532 function after, renal scan and ARM use Tc sestamibi evaluation, comparison with Time-activity curves, FDG-PET determination in, 293P(ab) radioiodine, 137P(ab) of, mice, 147P(ab) lymph-vessel, lymphoscintigraphy for non- absorbed dose of radioiodine, salivary Tomographie multigated analysis, leftventricular invasive long-term followup, 25P(ab) gland, 102P(ab) ejection fraction, comparison to planar monitoring of graft and native liver functions, biological dosimetry in patients treated with FAMIS, 847

Subject Index â€¢1996 2163 neural. Parkinson's disease, PET and MRS gastrointestinal adenocarcinomas, 1480 misdiagnosis of pulmonary embolism in evaluation of degeneration and graft Tumor-seeking agents, biochemical markers for complex congenital heart disease, 1359 survival, 66P(ah) cancer, 204P(ab) patient stratification by cardiopulmonary auxiliary. Te TBIDO hepatobiliary Two-dimensional echocardiography. complex status, 570 scintigraphy of, I l3P(ab) and unresolved issues related to revision of interpretive criteria for acute orthotopic, hepalohiliary scintigraphy myocardial viability assessment, 794 pulmonary embolus, pleural effusion after, 302P(ab) Two-step targeting, bispecific antibody and '"I- size, 1310 Treatment planning, prediction of radiation labeled bivalent hapten dosimetry, two- triple-matched defects in the detection of doses, tracer studies with 1311-labeled step targeting, small-cell lung acute pulmonary embolism, chest antibodies. 1970 cancer, 1853 radiographie abnormalities, 1636 Triangular intermuscular space, drainage of Tyrosine, potential as tracer for measuring liver patterns, pleural effusions, 296P(ab) lymph nodes on the back, protein synthesis, PET, 279 pulmonary embolism, prevalence of melanoma, 964 recurrence, 295P(ab) Tropane, derivatives, exclusive dopamine quantitative analysis of ratio, exercise lung transporter visualization agent. l86P(ab) scintigraphy, 296P(ab) Tubular reabsorption, *"Ga-labeled anti-TAC U Ventriculography dsFV, l52P(ab) Ultratag RBC kit, splitting of, use in cardiacfirst first-pass, estimation of resting left ventricular Tumor pass studies, 83P(ab) ejection fraction, l81P(ab) cell line. :'"TI uptake mechanisms in, 64P(ab) Uniformity flood, chelation oi In, liquid-filled radionuclide cells, hexokinase activity in, 18F Acetyl- plexiglass lank, 211 P(ab) evaluation in cardiomyoplasty, 93P(ab) FDG, l92P(ab) Upright test, see Raise-up test SPECT and, evaluation of left ventricular evaluation of '"'"Tc-labeled 2-nitroimidazole as Uremie secondary hyperparathyroidism, **Tc- hypertrophy. 93P(ab) marker of hypoxia. 1023 MIBI scintigraphy to identify functional treadmill exercise first-pass, normal limits grading, soft-tissue sarcomas, FDG-PET, 257 autonomy, 565 of, 93P(ab) use of **Tc-labeled liposomes for blood-pool hypoxia Urinary bladder, filling artifact, summing rapid '"I IETNIM as a marker for, predictor for SPECT acquisitions and, 212P(ab) imaging, compared with Tc-red radiosensilizing effect and. 253P(ab) Urinary tract infection cells, 1374 "F FMISO imaging of, 72P(ab) """Tc-DMSA imaging in pediatrie Vertebral metastasis, comparison of bone """Te HL9I for identification, correlation with population, 823 SPECT and MRI in detection of, 975 Vertebrobasilar insufficiency, """TeHMPAO FDGPET, 87P(ab) renal outcomes after, children, 46P(ab) imaging Urine pH, reduction of re-uptake of '"In-DTPA- brain perfusion SPECT, enhanced with '-''I-iodobenzamides as tracers for detection of octreotide, administration of lysine or acetazolamide, 88P(ab) melanolic melanoma, 1865 sodium malÃ©ate,1388 Vesamicol receptor '-'I MIV affinity for, Alzheimer's criteria for optimal results, radiolabeled Uveal melanoma, quantitative comparison of liposomes, 326 three-step pretargeting method with disease, 186P(ab) enhanced FDG-PET. 371 conventional binding, dopamine D2 receptor-sensitive, intact evaluation of '""Tc-labeled somatoslatin radioimmunoscintigraphy, 967 striatum, 280P(ab) receptor-binding peptides, 1016 Vesico-ureteric reflux, """Tc-DMSAimaging in fixai accumulation of '-''I-BMIPP in pediatrie urinary tract infection, 823 liposarcoma. 997 Vesicular internalization, enhancement of glucose transport proteins for targeting, radiation dose to nucleus, I3l-labeled- PET, 1031 Validation, test-retest differences in cerebral A33 monoclonal antibody, 1052 radiopharmaceutical targeting via receptor- glucose metabolism, FDG-PET, 1142 Vesicular monoamine transporter, assessment mediated endocylosis of "Ga-DF- Vascular graft, prosthetic, infection, Tc of. equilibrium versus compartmental Folate, 1003 HMPAO efficacy in, 163P(ab) analysis, 109P(ab) localization, biological disposition and imaging Vascular reserve, depletion of, oxygen Vestibular stimulation, differences in central of radioiodinated alkylphosphocholine in metabolism and, 277P(ab) processing, 122P(ab) rodents, breast tumors, 1540 Vasoactive drugs, blood pool changes in response Virtual surgery. Nuclear medicine lays the mandibular invasion, squamous-cell carcinoma, to, hepatic lobular dynamics, 244P(ab) groundwork for virtual surgery, 25N(2) bone SPECT, 42 Vasoactive intestinal peptide Visceral pain, normal and pathologic perception markers receptor antagonist, '-'I-labeled, binding, of, regional cerebral activity in, characterization of cancer, 204P(ab) adenocarcinomas, 25IP(ab) PET, 123P(ab) CYFRA 21.1, squamous cell carcinoma, head receptor scan sensitivity compared to "'In-CYT- Visual analysis, limits of. in image misregistration of brain '"F FDG-PET- and neck, l45P(ab) 103 immunoscintigraphy, gastrointestinal proliferation, :'"T1 scintigraphic localization of adenocarcinomas, 1480 MR1 study, 208P(ab) gliomas, 265P(ab) Vasomotor reserve, single day split dose Visual selective attention, orientation and spatial frequency, "O water PET, 306P(ab) thymidine as, 262P(ab) stresscerebral perfusion SPECT, image targeting subtraction in, 276P(ab) Volume estimation, quantification using planar antibody-dependent signal amplification, 343 Vasospasm, after subarachnoid hemorrhage, imaging and SPECT, thyroid xenogratted tumors, streptavidin and antibody brainSPECT with angiography and phantoms, 1421 fragment, 203P(ab) transcranial Doppler, 12P(ab) Volume rendering, three-dimensional bone therapy and diagnosis scintigraphy, usefulness and limitations, '-"MUdR and '"I-IUdR, preclinical animal Ventilation/perfusion detection of acute pulmonary embolism, chest SPECT, 1567 studies, 10S(4) radiographie findings and, 117P(ab) Vulvar cancer, groin mÃ©tastasesin, detection with "C tyrosine PET, 263P(ab) xenografts emphysema nude mice. Glut mRNA expression lung volume reduction surgery, 5P(ab) VX2 tumor. FDG-PET evaluation of therapy, 296 in, 254P(ab) preoperative assessment, 5P(ab) necrosis factor, response to hyperthermic endobronchial stem implantation by, isolated limb perfusion for soft-tissue quantification of, 36P(ab) W sarcoma, FDG-PET, 984 for directing pulmonary angiography, 294P(ab) proliferating, |;4I lUdR imaging of, 54P(ab) Wegener's vasculitis, lung uptake on "Tc-MDP lung scan Tumor-associated glycoprotein 72, '"I-VIP diagnostic value of small perfusion defects in bone scan, 857 receptor scinligraphy and '"In-CYT-103 suspected pulmonary embolism, 1313 Whole-body acquisition, combined scans and immunoscintigraphy comparisons. evaluating criteria for low probability FDG-SPECT in breast tumor interpretation, 577

2164 The Journalof Nuclear Medicine investigations. 615 Xenon-133 gas, washout, dynamic pulmonary colonie cancer xenograft Whole-body scan SPECT, 807 models, 168P(ab) false-positive findings due to cholecystitis and prevention of loss of immunoreactivity during sebaceous cyst in thyroid cancer patients, labeling, monoclonal antibodies, 1384 '"I, 1690 radiolabeled immunoglobulin therapy, role in radioiodine breast uptake in intraperitoncal administration in rodents nonbreastfeeding thyroid cancer YM-43611, "F fluorinated substituted benzamide with peritoneal carcinomalosis. 1545 patients. 26 analog of, radiotracer for dopamine D4 versus '"In, anti-tac monoclonal antibodies Whole-body skeletal uptake, age-related changes receptors, 50P(ab) labeled with, biodistribution of, 234P(ab) in bone metabolism, ""Tc-HMDP, 815 Yttrium-86 EDTMP, PET measurements of Yttrium-90 DOTA, therapeutic enhancement with Window-based technique, energy-based scatter uptake, calculation of radiation dose for taxol, treatment of human breast tumors corrections for scintillation images of '"I, '"Sm EDTMP based on, 227P(ab) in nude mice, 129P(ab) spectrum-fitting technique, 2030 Yttrium-90 Yttrium-90 DOTA-biotin World Wide Web immunoconjugates, autoradiolysis of, 143P(ab) high specific activity, radiolytic decomposition digital department moves to, 172P(ab) combined with anti-EGFr c225, nude mice with of, 166P(ab) internet for case-based teaching files, 178 human breast tumors, 167P(ab) therapy trial with, malignant glioma virtual reality markup language extensions and, '"In biotin and, dual isotope counting method, patients, 169P(ab) cardiac SPECT and PET, 172P(ab) X pretarged cancer therapy, 144P(ab) Yttrium-90-glass microspheres, ultrasound- "Sr and, proposed radioisotope generator based guided internal radiotherapy for liver onmicrofiltration, 194P(ab) malignancy, 958 chelation, preparation of radioimmunoconjugate, 167P(ab) Xenon-133 labeling of lipiodol, biodistribution in rats with compared with '""Tc-HMPAO measurements of hepatoma, 332 regional cerebral blood flow, labeling of monoclonal antibody macrocyclic Ziprasidone, serotonin receptor occupancy and, SPECT, 1735 chelalor conjugates, for PET analysis, 33P(ab) ventilation scintigraphy, tympanum and radioimmunolherapy, 62P(ab) paranasal sinuses, 4P(ab) myelosuppression and therapeutic potential.

April 13-15,1997 The Drake Hotelâ€”Chicago, IL Practitioners, ethÂ¡cists,medicalpolicymakers,and representatives of managedcareareinvitedto meettogetherto re-examinethe ethicof medicineas a professionandto considerchallengesto ethical practicethatphysiciansmay encounteras a resultof therapid changesin theorganizationandfinancingof healthcare.

â€¢^â€¢^â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢Â«â€¢^^^^^â€¢^^^^^^^â€¢^^^^^^â€¢^â€¢i^^^^^^HHB^^^^^B^B^^^^ Sponsoredby: The Councilor Medical Specialty Societies and theAmericanAcademyof Otolaryngologyâ€”Headand NeckSurgeryFoundation Confirmed Speakers: Saul Bellow,Roger J. Bulger, MD, Christine K. Cassel, MD, J. Lee Dockery, MD, John M. Eisenberg, MD, Jeremy Lazarus, MD, George D. Lundberg, MD, Mary H. McGrath, MD, MPH, Martin F. McKneally, MD, PhD, Lynn Peterson, MD, Edmund D. Pellegrino, MD, Raymond Scalettar,MD, and John Santa, MD CME Credit The American Academy of Otolaryngologyâ€”Head and Neck Surgery Foundation (AAO-HNSF) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The AAO-HNSF designates this educational activity for a maximum of 13 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. For more information or to request registration materials, call (847) 295-3456 or FAX (847)295-3759.

Subject Index â€¢1996 2165 Listed below are the companies that have advertised in this issue. Simply circle the numbers of those companies you are interested in, fill out the information below, and mail or FAX this to the Society of Nuclear Medicine, Advertising Department, 1850 Samuel Morse Drive, Reston, VA 20190, Fax 703-708-9015. We will forward this in JNM formation to the advertisers). DIRECT RESPONSE Advertisers for December 1996

Reader Svc.No.Advertiser1 No.800/538-8531 Laboratories10ADAC CAArlington Inc.23 Amersham,Medi-Physics, ILRamsey,Heights, 708/593-6300 Inc.31 Capintec, NJChapel 800/631-3826 Spectrum34Data NCNo.Hill, 919/732-6300 Company82DuPont Billerica,MA 800/343-7851 Immunomedics110 NJSt.Morris Plains, 800/327-7211 Inc.140 MallinckrodtMedical, MOGoffstown,Louis, 314/895-2000800/438-6637 Services145OnesMedical NHPeabody, Systems181ParkMedical MAHoffman 508/977-6868 CoverInsideBack Inc.192 SiemensMedicalSystems, ILTustin,Estates, 708/304-7252 FrontCoveMABack Coverj ToshibaMedicalSystemsMilpitas, CATelephone 800/521-1968Page(s)4A-5A15A-16A2A19A20A-22A13A9A-12A25AInside

InformationYOURInformationTITLEDEPTADDRESS:CITY:PHONE:PRIMARYSNMMeetings _j SNMMembership SNMBookOrder

NAME:INSTITUTION:fj

SPECIALTY:CHECK SPECIALTY:ZIP:ANSWER

ONEEmployer INCATEGORYPurchaseEACH

EmployerU AuthorityQ MemberQ Hospital Ã¼ Private Clinic Recommend Yesa Q 500 patients p,us g Se?"*' a Specify NOJNM/JNMT U 300-499 patients Q Government QPurchaseReason UotherÃ¼200-299 patients Q InquiryÃ¼for Subscriber3 100-199 patientsSTATE:FAX:SECONDARY PurchasenImmediate Yes~\ fÃ¬pnpralInfnrmatinnSNM Wn a BudgetingInformation

36A THE JOURNALOFNUCLEARMEDICINEâ€¢Vol. 37 â€¢No. 12 â€¢December 1996

------* :*Â¿-**-*â€”